

# ***Evidence Synthesis***

---

## **Number 163**

# **Screening for Cardiovascular Disease Risk With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
5600 Fishers Lane  
Rockville, MD 20857  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. HHSA-290-2015-00011-I, Task Order No. 5**

**Prepared by:**

RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center  
Research Triangle Park, NC

**Investigators:**

Daniel E. Jonas, MD, MPH  
Shivani Reddy, MD, MSc  
Jennifer Cook Middleton, PhD  
Colleen Barclay, MPH  
Joshua Green, BA  
Claire Baker  
Gary Asher, MD, MPH

**AHRQ Publication No. 17-05235-EF-1**

**June 2018**

This report is based on research conducted by the RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHS-290-2015-00011-I, Task Order No. 5). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

## **Acknowledgments**

The authors gratefully acknowledge the following individuals for their contributions to this project and deeply appreciate their considerable support, commitment, and contributions: Howard Tracer, MD, AHRQ Medical Officer, and Elisabeth Kato, MD, MRP, former AHRQ Medical Officer; Tracy Wolff, MD, MPH, AHRQ Associate Scientific Director; current and former members of the U.S. Preventive Services Task Force who contributed to topic deliberations; expert reviewers Joy Melnikow, MD, MPH, Amit Shah, MD, Fabrizio Turrini, MD, and Timothy Wilt, MD; federal partner reviewers at the National Institutes of Health; and RTI International–University of North Carolina EPC staff Carol Woodell, BSPH, Christiane Voisin, MSLS, Laurie Leadbetter, MSLS, Sharon Barrell, MA, and Loraine Monroe, publications specialist.

## **Suggested Citation**

Jonas DE, Reddy S, Middleton JC, Barclay C, Green J, Baker C, Asher G. Screening for Cardiovascular Disease Risk With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 163. AHRQ Publication No. 17-05235-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2018.

# Structured Abstract

**Purpose:** To systematically review the evidence on screening asymptomatic adults for cardiovascular disease (CVD) risk using resting or exercise electrocardiography (ECG) for populations and settings relevant to primary care in the United States.

**Data Sources:** PubMed/MEDLINE, the Cochrane Library, and trial registries through May 30, 2017; reference lists of retrieved articles; outside experts; and reviewers, with surveillance of the literature through April 4, 2018.

**Study Selection:** Two investigators selected English-language studies using a priori criteria. Eligible studies focused on the use of resting or exercise ECG for adults without symptoms or a diagnosis of CVD. Eligible designs included controlled trials comparing ECG screening with no ECG screening and prospective cohort studies reporting reclassification, calibration, or discrimination that compared risk assessment using ECG plus traditional risk factors versus traditional risk factors alone. For harms of ECG, prospective cohort studies, large retrospective cohort studies, and case-control studies were also eligible. For harms from exercise ECG or subsequent procedures/interventions, large registries or multicenter studies without a control group were also eligible.

**Data Extraction:** One investigator extracted data and a second checked accuracy. Two reviewers independently rated quality for all included studies using predefined criteria.

**Data Synthesis:** Sixteen studies (77,140 participants) were included. Two randomized, controlled trials (RCTs) (1,151 participants) found no significant improvement in all-cause mortality, cardiovascular-related mortality, myocardial infarction (MI), heart failure, or stroke for screening with exercise ECG in asymptomatic adults ages 50 to 75 years with diabetes compared with no screening. In addition, there was no significant improvement for their primary composite outcomes (hazard ratio [HR] 1.00 [95% confidence interval [CI], 0.59 to 1.71] for all-cause mortality, nonfatal MI, nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention, and HR 0.85 [95% CI, 0.39 to 1.84] for nonfatal MI or cardiac death). No controlled trials evaluated screening with resting ECG. Although potential harms of exercise or resting ECG include arrhythmias, acute MI, sudden cardiac death, and harms of subsequent angiography or revascularization procedures after an abnormal test, evidence on their frequency in asymptomatic persons was scant. Evidence from five cohort studies (9,582 participants; mean baseline Framingham Risk Score [FRS] 10.8 to 12.3 in studies reporting it) shows that the addition of exercise ECG abnormalities to traditional CVD risk factors results in small improvements in discrimination (absolute improvement in area under the curve [AUC] or C-statistics 0.02 to 0.03; 95% CIs rarely reported), but it is uncertain whether calibration or appropriate risk classification improves. Evidence from nine cohort studies (66,407 participants; mean baseline risk ranging from low to high across studies) shows that the addition of resting ECG findings to traditional CVD risk factors results in very small or small improvements in discrimination (absolute improvement in AUC or C-statistics 0.001 to 0.05) and improvements for calibration and appropriate risk classification for prediction of multiple outcomes (e.g., all-cause mortality, CVD mortality, CHD events). Total net reclassification improvements (event;

nonevent) ranged from 3.6 percent (2.7%; 0.6%) to 30 percent (17%; 19%) for studies using Framingham Risk Score (FRS) or pooled cohort equations (PCE) base models (95% CIs were rarely reported).

**Limitations:** The RCTs that evaluated exercise ECG in asymptomatic diabetic patients did not reach sample size targets and were stopped early because of trouble recruiting; both followed participants for about 3.5 years. For risk prediction with the addition of ECG, evidence was limited by imprecision, quality, and considerable heterogeneity. Consistency of findings for specific risk thresholds is unknown because all studies used different risk categories. About half of the included risk prediction studies did not use the published coefficients of externally validated base models such as FRS or PCE; only one used the PCE as a base model. For risk prediction with resting ECG, it is unclear what proportion of participants was truly asymptomatic because most studies did not report any assessment of symptoms.

**Conclusions:** The overall strength of evidence was low or insufficient for each of the questions and outcomes evaluated. RCTs of screening with exercise ECG in asymptomatic participants found no improvement in health outcomes despite focusing on higher risk populations with diabetes. For asymptomatic persons without a history of CVD, the harms of exercise or resting ECG can include arrhythmias, acute MI, sudden cardiac death, and harms of subsequent angiography or revascularization procedures after an abnormal test, but the frequency of these harms is uncertain. Evidence on whether the addition of exercise ECG to traditional CVD risk factors results in accurate reclassification is lacking. Cohort studies found that the addition of multiple resting ECG abnormalities to traditional CVD risk factors accurately reclassifies persons, and improves discrimination and calibration, but evidence was limited by imprecision, quality, considerable heterogeneity, and inconsistent use of risk thresholds that align with clinical decisions and recommendations.

# Table of Contents

<b>Chapter 1. Introduction.....</b>	<b>1</b>
Scope and Purpose.....	1
Condition Definition.....	1
Etiology and Natural History.....	1
Risk Factors.....	2
Prevalence and Burden.....	3
Rationale for Screening and Screening Strategies.....	3
Treatment Approaches.....	4
Recommendations and Clinical Practice in the United States.....	4
<b>Chapter 2. Methods.....</b>	<b>6</b>
Key Questions and Analytic Framework.....	6
Data Sources and Searches.....	6
Study Selection.....	7
Quality Assessment and Data Abstraction.....	8
Data Synthesis and Analysis.....	8
Expert Review and Public Comment.....	9
USPSTF Involvement.....	9
<b>Chapter 3. Results.....</b>	<b>10</b>
Literature Search.....	10
Results.....	10
KQ 1a. Does the Addition of Screening With Resting or Exercise ECG Improve Health Outcomes Compared With Traditional CVD Risk Factor Assessment Alone in Asymptomatic Adults? 1b. Does Improvement in Health Outcomes Vary for Subgroups Defined by Baseline CVD Risk, Age, Sex, or Race/Ethnicity?.....	10
KQ 2. Does the Addition of Screening With Resting or Exercise ECG to Traditional CVD Risk Factor Assessment Accurately Reclassify Persons Into Different Risk Groups or Improve Measures of Calibration and Discrimination?.....	12
KQ 3a. What Are the Harms of Screening With Resting or Exercise ECG, Including Harms of Subsequent Procedures or Interventions Initiated as a Result of Screening? 3b. Do the Harms of screening Vary for Subgroups Defined by Baseline CVD Risk, Age, Sex, or Race/Ethnicity?.....	21
<b>Chapter 4. Discussion.....</b>	<b>23</b>
Summary of Evidence.....	23
Evidence for the Benefits and Harms of Screening With Resting or Exercise ECG.....	23
Reclassification, Calibration, and Discrimination With the Addition of Resting or Exercise ECG to Traditional CVD Risk Factor Assessment.....	25
Limitations.....	27
Future Research Needs.....	28
Conclusion.....	28

## Figures

Figure 1. Analytic Framework

Figure 2. Summary of Evidence Search and Selection Diagram

Figure 3. Main Results of Included Randomized, Controlled Trials Reporting Health Outcomes (KQ1)

Figure 4. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score or Pooled Cohort Equation Base Models

Figure 5. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, Systemic Coronary Risk Evaluation, or Conventional Risk Factor Base Models

Figure 6. Effect on Reclassification of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, or Conventional Risk Factor Base Models

Figure 7. Effect on Reclassification of Adding Resting ECG Variables to Framingham Risk Score or Pooled Cohort Equation Base Models

## **Tables**

Table 1. Test Performance Measures for Comparing Risk Assessment or Prediction Models

Table 2. Characteristics of Included Randomized, Controlled Trials for KQ 1 and KQ 3

Table 3. Characteristics of Included Studies for KQ 2 That Evaluated Exercise ECG, Part 1

Table 4. Characteristics of Included Studies for KQ 2 That Evaluated Exercise ECG, Part 2

Table 5. Results of Included Studies for KQ 2 That Evaluated Exercise ECG

Table 6. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 1

Table 7. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 2

Table 8. Summary of Evidence for Screening With ECG

Table 9. Snapshot to Assess Net Benefit

## **Appendixes**

Appendix A. Additional Background, Summary of Recommendations From Other Groups, and Contextual Questions

Appendix B. Detailed Methods

Appendix C. Excluded Studies

Appendix D. Quality Assessments

Appendix E. Additional Tables and Results

# Chapter 1. Introduction

## Scope and Purpose

The U.S. Preventive Services Task Force (USPSTF) will use this report to inform an update of its 2012 recommendation on screening asymptomatic adults with electrocardiogram (ECG) for the prediction of cardiovascular disease (CVD) events.<sup>1</sup> In 2012, the USPSTF recommended against screening with resting or exercise ECG for the prediction of coronary heart disease (CHD) events in asymptomatic adults at low risk for CHD events (D recommendation). For asymptomatic adults at intermediate or high risk, the USPSTF concluded that evidence was insufficient to assess the balance of benefits and harms of screening (I statement). The purpose of this report is to systematically evaluate the current evidence on using resting or exercise ECG to screen asymptomatic adults for CVD risk for populations and settings relevant to primary care in the United States. This report summarizes the evidence on the benefits and harms of adding screening with resting or exercise ECG to traditional CVD risk factor assessments compared with using traditional CVD risk factor assessments alone. This report also summarizes the evidence on whether the addition of ECG accurately reclassifies persons into different risk groups or improves measures of calibration and discrimination.

## Condition Definition

CVD is a broad term encompassing atherosclerotic conditions that affect the heart and blood vessels.<sup>2-4</sup> CVD generally refers to atherosclerosis, including but not limited to CHD (also called ischemic heart disease), cerebrovascular disease, and peripheral artery disease (PAD). In patients with CVD, plaques form within the arteries, causing reduced blood flow and/or arterial blockage. Serious CVD events (sometimes described as hard outcomes) include myocardial infarction (MI), heart failure, stroke, and sudden cardiac death. Less severe CVD events (sometimes called soft outcomes) include angina, claudication, transient ischemic attack (TIA), and revascularization.

## Etiology and Natural History

In CVD, atherosclerotic plaque is deposited over many years within the endothelial lining of the coronary arteries, which provide oxygenated blood to the myocardium. The development of the plaque, containing not only lipids but other molecules secreted from various types of cells, is induced by a cascade of mechanisms including inflammatory processes.<sup>5, 6</sup> Some sites, such as branch points and the inner curves of arteries, are more susceptible to deposition of atherosclerotic plaque.<sup>7</sup> Sudden plaque rupture, or intra-luminal thrombosis related to the exposure of the ruptured plaque's thrombogenic core, is associated (though not invariably) with acute coronary syndrome, MI, and sudden cardiac death.<sup>7, 8</sup> Progression of atherosclerosis and of CVD is influenced by a variety of risk factors, some of them modifiable and thus targets for intervention.

Evidence of obstructive CHD, upon evaluation by coronary angiography, has been considered to be prognostic of significant morbidity and mortality; however, it has been demonstrated that culprit lesions, in patients who experience acute coronary events due to plaque rupture or acute thrombosis, may not be those angiographically observed to significantly occlude the vessel.<sup>8,9</sup> Some persons do not experience symptoms before major first CVD events<sup>10</sup> because major first events can result from plaque rupture in vessels without significant stenosis.

## Risk Factors

Traditional risk factors for CVD are male sex, older age, cigarette smoking, hypertension, dyslipidemia (high total or low-density lipoprotein cholesterol or low high-density lipoprotein [HDL] cholesterol), and diabetes. They are independently associated with risk of CVD and are included in the traditional Framingham risk assessment model.<sup>11, 12</sup> Some risk factors are modifiable and could be targets for treatment in patients identified as being at higher risk. Prevalence of risk factors is high in the United States: as of 2014, 16.9 percent of U.S. adults smoked cigarettes; as of 2012, 69 percent were overweight or obese, 13.1 percent had serum total cholesterol levels  $\geq 240$  mg/dL, 32.6 percent were hypertensive, and 8.5 percent of adults had diagnosed diabetes mellitus (another 3.3% had undiagnosed diabetes mellitus).<sup>13</sup> More than 90 percent of CVD events occur in persons with one or more risk factors.<sup>14</sup> Other factors, some behavioral and others biomarkers, are not included among the major independent traditional risk factors. Although they increase CVD risk to varying degrees, they have not been shown to consistently improve risk prediction in a clinically meaningful way beyond traditional risk factors; these include family history of early CVD, obesity, physical inactivity, atherogenic diet, and presence of prothrombotic and proinflammatory factors.<sup>12, 13, 15</sup>

To help providers operationalize the large number of factors that need to be considered, risk prediction equations that integrate and weight the traditional risk factors are used commonly in clinical practice to assess 10-year risk of CVD events and to guide treatment decisions. The USPSTF recommends using the American College of Cardiology/American Heart Association (ACC/AHA) pooled cohort equations (PCE) to calculate 10-year risk for adults ages 40 to 75 years to inform decisions about statin use for prevention of CVD and to inform decisions about aspirin use for primary prevention.<sup>2, 16, 17</sup> The USPSTF noted that concerns have been raised about the PCE's potential to overpredict risk and their moderate discrimination, but also that they are the only U.S.-based, externally validated equations that report risk as a combination of cerebrovascular and CHD events.<sup>2, 17</sup> The PCE approach takes into account age, sex, race, cholesterol levels, systolic blood pressure level, antihypertension treatment, presence of diabetes, and smoking status as risk factors and focuses on prediction of hard outcomes, specifically, heart attack and death from CHD, ischemic stroke, and stroke-related death.<sup>16</sup> Using the PCE and National Health and Nutrition Examination Survey data from 2011–2012, an estimated 9.4 percent of adults ages 40 to 79 years without a history of CVD have a 10-year risk greater than 20 percent.<sup>18</sup> Age has a large influence on the PCE's predicted risk, and it is estimated that 41 percent of men and 27 percent of women ages 60 to 69 years without a history of CVD will have a 10-year risk of at least 10 percent.<sup>19</sup>



## Prevalence and Burden

CVD is the leading cause of death in U.S. adults and causes about a third of all deaths.<sup>13, 18</sup> In the United States, an estimated 580,000 persons have a first MI each year and about 610,000 have a first stroke.<sup>20</sup> Adult CVD prevalence increases with each decade of life, with higher prevalence among men than women.<sup>13</sup> The average annual incidence of first major cardiovascular (CV) event increases from around 25 cases per 1,000 in men ages 35 to 44 years to 80 cases per 1,000 in men age 85 years or older. For women (compared with men), similar incidence rates are observed about 10 years later in life, although the gap narrows for women ages 75 to 84 years and is reversed by age 85 years or older. Prevalence of CHD and stroke were nearly 3 to 4 times greater for adults age 65 years or older than for those ages 45 to 64 years (19.8% vs. 7.1% and 8.3% vs. 2.9%, respectively).<sup>21, 22</sup> Disparities exist with regard to mortality from and prevalence of CVD. Mortality rates are lowest for white women and highest for black men, and prevalence is highest for American Indians/Alaska Natives and blacks.<sup>21, 22</sup> CVD is a major source of direct and indirect health care costs in the United States. The estimated total cost of CVD in 2015 was \$182 billion, which is predicted to double by 2030.<sup>13</sup>

## Rationale for Screening and Screening Strategies

Because many patients do not have any symptoms of CVD before a serious first event, such as MI or stroke, identifying asymptomatic individuals for treatment with preventive medications may reduce risk for future CVD morbidity and mortality. Approximately 30 percent of patients presenting with acute coronary syndromes do not have a prior diagnosis of CVD.<sup>10, 23</sup> For screening with resting or exercise ECG to be effective, it must be able to reclassify individuals in a manner that results in treatment changes that improve health outcomes. For example, screening with ECG might reclassify persons into higher or lower risk categories. Appropriately reclassifying such individuals could help target use of preventive interventions to those most likely to benefit or could reduce use of preventive interventions for those least likely to benefit. However, if reclassification was inappropriate, it could lead to an increase in overtreatment or undertreatment.

Potential screening strategies include both resting and exercise ECG. Resting ECG records cardiac electrical activity over a short time, typically 10 seconds. Clinicians interpret the recorded ECG waveforms to look for evidence of conduction problems and/or myocardial ischemia. Resting or exercise ECGs have long been used as tests for the diagnostic evaluation of suspected CVD, which has led to consideration of their use for screening asymptomatic individuals and risk prediction. Although the most common method of exercise testing is the exercise treadmill test, other methods include bicycles and ergometers. Both resting and exercise ECG may show markers of unrecognized previous MI, silent or inducible myocardial ischemia, and other cardiac abnormalities (such as left ventricular hypertrophy, bundle branch block, or arrhythmias) that may be associated with CVD or may predict future CVD events.

## Treatment Approaches

If screening for CVD risk results in appropriate risk reclassification, intensified preventive interventions focus on lipid-lowering therapy and aspirin, which have been demonstrated to reduce risk as assessed by a variety of outcomes.<sup>24-28</sup> Other preventive interventions (smoking cessation, blood pressure control, and weight management) would not be significantly affected by reclassification of risk (e.g., recommendations for smoking cessation are the same regardless of risk classification). Current USPSTF recommendations for statins and aspirin for primary prevention are based on the 10-year CVD risk as estimated by the PCE.<sup>2, 17</sup> The USPSTF recommends initiating use of low- to moderate-dose statins in adults ages 40 to 75 years without a history of CVD who have one or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD risk of 10 percent or greater (B recommendation) and selectively offering statins to adults ages 40 to 75 years without a history of CVD who have one or more CVD risk factors and a calculated 10-year risk of 7.5 percent to 10 percent (C recommendation). For aspirin, the USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and colorectal cancer in adults ages 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years (B recommendation). The USPSTF also has a C recommendation for initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults ages 60 to 69 years who have a 10 percent or greater 10-year CVD risk. The ACC and AHA jointly released guidelines (2014) recommending that moderate- to high-intensity statin therapy should be used in persons ages 40 to 75 years without a history of clinical CVD or diabetes and with an estimated 10-year risk of 7.5 percent or greater (Grade A, strong recommendation).<sup>29</sup> The ACC/AHA also recommended moderate-intensity statins when risk is 5 percent to less than 7.5 percent (Grade C, weak recommendation).

## Recommendations and Clinical Practice in the United States

Numerous organizations recommend against routine screening of asymptomatic adults for CVD with resting or exercise ECG, including the American College of Physicians,<sup>30</sup> the American Academy of Family Physicians,<sup>31</sup> and the American College of Preventive Medicine (**Appendix A Table 1**).<sup>32-34</sup> Screening of special populations is recommended by some groups. For example, the American Academy of Family Physicians recommends screening otherwise low-risk patients who have certain occupations in which undetected CVD could significantly affect the public (e.g., airline pilots),<sup>35</sup> and the American College of Sports Medicine recommends screening moderate-risk patients who are beginning a new exercise regimen.<sup>36</sup>

Many risk prediction equations (i.e., tools, models, scores, calculators) are available and have been recommended in various countries for use in clinical practice to guide treatment decisions (**Appendix A Table 2**). The USPSTF and the ACC/AHA recommend using the PCE to calculate 10-year risk. The existing equations that have been externally validated vary in the risk factors included and predicted outcomes (e.g., global CVD outcomes vs. mortality vs. CHD-specific outcomes). The Framingham Risk Score (FRS) was the first widely used multivariable risk assessment tool<sup>33, 34, 37</sup> and included sex, age, total and high-density lipoprotein cholesterol

(HDL-C), blood pressure, diabetes, and smoking. A variety of Framingham-based risk equations have been externally validated.<sup>27, 33, 34, 37-39</sup> One early Framingham model (1991)<sup>33</sup> included left ventricular hypertrophy (LVH) (determined by ECG) along with traditional risk factors, but it was dropped from later models. None of the currently recommended prediction equations include ECG.

Despite recommendations, use of risk assessment in clinical practice may be suboptimal. For example, a survey of over 900 U.S. physicians found that although more than 80 percent agreed that risk calculation is useful, only 41 percent reported that they use it in practice.<sup>40</sup> Among those who use it, the majority use it to guide lipid-lowering therapy recommendations (69%) and aspirin therapy recommendations (54%).<sup>40</sup> Limited data are available on using ECGs to assess CVD risk in asymptomatic persons, but a population-based retrospective cohort study of Canadian adults reported that 21.5 percent had an ECG within 30 days of an annual health exam.<sup>41</sup> The proportion varied widely across 679 primary care practices (from 1.8% to 76.1%).

# Chapter 2. Methods

## Key Questions and Analytic Framework

The Evidence-based Practice Center (EPC) investigators, USPSTF members, and Agency for Healthcare Research and Quality (AHRQ) Medical Officers developed the scope and key questions (KQs). **Figure 1** shows the analytic framework and KQs that guided the review. Three KQs were developed for this review:

- 1a. Does the addition of screening with resting or exercise electrocardiography (ECG) improve health outcomes compared with traditional CVD risk factor assessment alone in asymptomatic adults?
- 1b. Does improvement in health outcomes vary for subgroups defined by baseline CVD risk (e.g., low, intermediate, or high risk), age, sex, or race/ethnicity?
2. Does the addition of screening with resting or exercise ECG to traditional CVD risk factor assessment accurately reclassify persons into different risk groups (e.g., high-, intermediate-, and low-risk groups) or improve measures of calibration and discrimination?
- 3a. What are the harms of screening with resting or exercise ECG, including harms of subsequent procedures or interventions initiated as a result of screening?
- 3b. Do the harms of screening vary for subgroups defined by baseline CVD risk (e.g., low, intermediate, or high risk), age, sex, or race/ethnicity?

In addition to addressing our KQs, evidence related to two Contextual Questions was assessed. The first focused on what medications (i.e., aspirin, lipid-lowering therapy) are recommended for persons in each CVD risk category and the fidelity to prescribing and taking the recommended medications. The second focused on the harms and benefits of revascularization procedures in adults without symptoms or a prior diagnosis of CVD. These Contextual Questions were not a part of the systematic review. They are intended to provide additional background information. Literature addressing these questions is summarized in **Appendix A**.

## Data Sources and Searches

PubMed/MEDLINE and the Cochrane Library were searched for English-language articles published from January 2009 through May 30, 2017. Medical Subject Headings were used as search terms when available and keywords when appropriate, focusing on terms to describe relevant populations, tests, interventions, outcomes, and study designs. The search relied primarily on the 2011 systematic review for the USPSTF<sup>42</sup> to identify potentially relevant studies published before 2009 (we reassessed all articles included in that systematic review using the eligibility criteria). Complete search terms and limits are listed in **Appendix B1**. Targeted searches for unpublished literature were conducted by searching ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. To supplement electronic searches, the reference lists of pertinent review articles and studies that met the inclusion criteria were reviewed and all previously unidentified relevant articles were added. All

literature suggested by peer reviewers or public comment respondents was reviewed for eligibility. Since May 2017, ongoing surveillance was conducted through article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on April 4, 2018 and no additional studies meeting eligibility criteria were identified. All literature search results were managed using EndNote™ version 7.4 (Thomson Reuters, New York, NY).

## Study Selection

Inclusion and exclusion criteria were developed for populations, interventions, comparators, outcomes, settings, and study designs with input from the USPSTF (**Appendix B2**). English-language studies of adults age 18 years or older without symptoms or a diagnosis of CVD were included. Studies of children, adolescents, and persons with a history of CVD or symptoms suggesting CVD were excluded. Studies assessing resting ECG or exercise ECG were included and studies that assessed radiology tests, echocardiography, and vectorcardiography were excluded. Eligible studies recruited participants from primary care settings, occupational medicine settings, or the general population in countries categorized as “very high” on the Human Development Index.

For all KQs, controlled clinical trials and randomized, controlled trials (RCTs) comparing groups that were screened with groups that were not screened (i.e., comparing risk stratification using ECG plus traditional risk factors vs. risk stratification using traditional risk factors alone) were eligible. For KQ 1 (direct evidence that screening improves health outcomes), eligible outcomes included all-cause mortality, CV mortality, and CV events (MI, angina, stroke, congestive heart failure, composite CV outcomes).

For KQ 2 (calibration, discrimination, and reclassification), prospective cohort studies comparing CVD risk assessment models that included ECG findings with those that did not include ECG findings were also eligible. Studies were required to report reclassification (ability to correctly reassign persons into clinically meaningful risk categories), calibration (agreement between observed and predicted outcomes), or discrimination (ability to distinguish between persons who will vs. will not have an event). Detailed descriptions of the specific test performance measures are provided in **Table 1**. These measures assess performance of risk prediction models or the comparative performance of models. Studies that only assessed the association between ECG findings and outcomes (e.g., with adjusted hazard ratios) were excluded. The review focused on the benefits and harms of adding ECG to the current standard practice of CVD risk prediction using traditional risk factors: male sex, older age, cigarette smoking, hypertension, dyslipidemia (high total cholesterol, high low-density lipoprotein cholesterol, or low HDL-C), and diabetes. In current clinical practice, the PCE or FRS is typically used for risk prediction. Studies were not required to specifically use the PCE or FRS to be eligible, although such studies have greatest applicability to current practice. Eligible base models included age, sex, systolic blood pressure, antihypertensive medication use, total cholesterol, HDL, and current smoking or restricted samples to remove some of these variables. Models were not required to include diabetes or race/ethnicity, but models were eligible that

included them. Comparisons that would not allow us to isolate the effect attributable to ECG were not eligible.

For KQ 3 (harms), prospective cohort studies, large retrospective cohort studies, and well-designed case-control studies (only for rare events) were also eligible. Eligible harms included mortality, arrhythmia, CV events, or injuries from exercise ECG; anxiety; labeling; and harms of subsequent procedures or interventions initiated as a result of screening (e.g., subsequent angiography or revascularization procedures resulting in harm). For harms of subsequent procedures/interventions, studies that compare the procedure/intervention with no procedure/intervention were also eligible. For studies reporting rates of harms from exercise ECG or subsequent procedures/interventions, large registries or multicenter studies without a control group that report rates of harms for asymptomatic persons were also eligible. Two investigators independently reviewed titles and abstracts; those marked for potential inclusion by either reviewer were retrieved for evaluation of the full text. Two investigators independently reviewed the full text to determine final inclusion or exclusion. Disagreements were resolved by discussion and consensus.

## Quality Assessment and Data Abstraction

The quality of trials and cohort studies was assessed as good, fair, or poor, using predefined criteria developed by the USPSTF and adapted for this topic (**Appendix B3**). For risk prediction studies (KQ 2), predefined criteria from the Checklist for Critical Appraisal and Data Extraction for Systematic Review of Prediction Modelling Studies (CHARMS)<sup>43</sup> were used and adapted for this topic (**Appendix B3**). Two independent investigators assigned quality ratings for each study. Disagreements were resolved by discussion. Only studies rated as having good or fair quality were included.

For each included study, one investigator extracted pertinent information about the methods, populations, interventions, comparators, outcomes, timing, settings, and study designs. A second team member reviewed all data extractions for completeness and accuracy.

## Data Synthesis and Analysis

Findings for each KQ were qualitatively synthesized by summarizing the characteristics and results of included studies in tables, figures, and narrative format. To determine whether meta-analyses were appropriate, the clinical and methodological heterogeneity of the studies was assessed following established guidance.<sup>44</sup> The populations, tests, treatments, comparators, outcomes, and study designs were assessed qualitatively, looking for similarities and differences. At least three similar studies had to be available to estimate pooled effects. For KQ 1, pooled effects were not estimated because fewer than three similar studies were found, but risk ratios and 95 percent confidence intervals were calculated for binary outcomes reported by the included RCTs and a forest plot showing the results was created. For KQ 2, considerable heterogeneity of ECG findings assessed, base prediction models used, outcomes (e.g., all-cause mortality, CV mortality, CVD events, fatal ischemic heart disease), and duration of followup was

found; therefore, the results are presented in tabular format and in figures. Results were stratified by ECG findings evaluated, separating results for exercise ECG and resting ECG. Within the studies of resting ECG results were stratified to separate those that evaluated the addition of a constellation of ECG abnormalities from those that evaluated single/specific ECG changes. Results were categorized by the base models used as “published coefficient models,” meaning the model preserved the coefficients of original published models that have been externally validated (e.g., FRS or PCE), or as “model development.” For KQ 2, the C-statistic (Harrell’s C) and AUC were used as the primary measures of discrimination and were summarized together. Measures of overall performance were summarized with those of calibration. Net reclassification improvement (NRI) was the primary measure of reclassification, with event and nonevent NRIs reported separately when possible. There is no guidance in the literature about how to qualitatively characterize the magnitude or clinical meaning of changes in discrimination. To describe the magnitude of changes in discrimination, the following definitions were employed for practical reasons. For changes in the C-statistic, 0.1 or greater was considered large, 0.05-0.1 was considered to be moderate, 0.025-0.05 was considered small, and changes less than 0.025 were considered very small. C-statistics range from 0.5 to 1.0; the 0.1 cutpoint for large was set because it represents 20 percent of the possible range. A change in C-statistic of 0.025 approximates a 5 percent higher sensitivity when specificity is 50 percent. Analyses were conducted and figures were produced using Stata version 14 (StataCorp) and Microsoft Excel.

Two independent reviewers assessed the overall strength of the body of evidence for each KQ as high, moderate, low, or insufficient using methods developed for the USPSTF (based on methods of the EPC program<sup>45, 46</sup>), based on the overall quality of studies, consistency of results between studies, precision of findings, and risk of reporting bias. The applicability of the findings to U.S. primary care populations and settings was also assessed. Discrepancies were resolved through consensus discussion.

## **Expert Review and Public Comment**

A draft report was reviewed by content experts, representatives of federal partners, USPSTF members, and AHRQ Medical Officers and was revised based on comments, as appropriate. It was also posted for public comment. Based on the comments received we revised the report to add additional summary sections within the results; description and interpretation of measures for discrimination, calibration, and reclassification; description of prior USPSTF recommendations; and clarification that this review was limited to studies assessing resting or exercise ECG, along with discussion of the findings of another meta-analysis that evaluated any screening test for coronary artery disease in persons with type 2 diabetes.

## **USPSTF Involvement**

This review was funded by AHRQ. AHRQ staff and members of the USPSTF participated in developing the scope of work and reviewed draft reports, but the authors are solely responsible for the content.

# Chapter 3. Results

## Literature Search

In total, 4,595 unique records were identified and 524 full texts assessed for eligibility (**Figure 2**). In total, 507 articles were excluded for various reasons detailed in **Appendix C**, and 16 studies (described in 17 articles) of good or fair quality were included. Of the included studies, two were studies of the benefits of ECG screening (KQ 1); 14 were studies of reclassification, calibration, or discrimination; and one study was of harms of ECG screening (KQ 3, which was also included for KQ 1). Compared with the previous evidence review for the USPSTF,<sup>42</sup> the current review includes three studies<sup>47-49</sup> that were in both reviews and 13 studies that are only in the current review. The previous review included many additional studies reporting associations (e.g., adjusted hazard ratios) between ECG findings and outcomes that were not eligible for this review because they did not report discrimination, calibration, or reclassification. It also included two studies related to harms of exercise ECG that were not eligible for the current review (one was an uncontrolled single center report of military officers getting stress tests;<sup>50</sup> the other described survey data on harms, focusing on symptomatic participants<sup>51</sup>); both studies are described in the discussion of this report. Details of quality assessments of included studies and studies excluded because of poor quality are provided in **Appendix D**.

## Results

### **KQ 1a. Does the Addition of Screening With Resting or Exercise ECG Improve Health Outcomes Compared With Traditional CVD Risk Factor Assessment Alone in Asymptomatic Adults? 1b. Does Improvement in Health Outcomes Vary for Subgroups Defined by Baseline CVD Risk, Age, Sex, or Race/Ethnicity?**

#### **Summary**

No eligible studies compared screening with resting ECG and no screening, and none evaluated the use of screening with ECG for the purpose of risk reclassification to inform decisions about preventive medications. Two RCTs (DYNAMIT and DADDY-D) with a total of 1,151 participants evaluated screening with exercise ECG in high risk, asymptomatic adults ages 50 to 75 years with diabetes. Both RCTs reported no statistically significant improvement in health outcomes, but were limited by not reaching sample size targets.

#### **Detailed Results: Characteristics of Included Trials**

We included two fair-quality RCTs: Do You Need to Assess Myocardial Ischemia in Type-2 diabetes (DYNAMIT)<sup>52</sup> and Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients (DADDY-D).<sup>53</sup> The characteristics of the included studies are summarized in **Table 2**. Both trials compared screening with exercise ECG with no screening exercise ECG.



The DYNAMIT study was a multicenter randomized trial that randomized 631 ambulatory patients who consulted a diabetes specialist to screening versus no screening.<sup>52</sup> Those in the screening arm were referred for detection of silent ischemia using a bicycle exercise test or Dipyridamole Single Photon Emission Computed Tomography (SPECT). SPECT was used in patients unable to perform the exercise test, with a submaximal negative exercise test, or with ECG abnormalities impairing the interpretation of the exercise test (31% ultimately had SPECT). Those with positive exercise or SPECT tests were referred to cardiologists, and all subsequent investigations and treatments were left to the judgment of the cardiologists (i.e., no protocol for that part of the process related to angiography vs. no angiography; pragmatic approach). The DADDY-D trial randomized 520 participants from a single center (2 diabetes outpatient clinics) to screening or no screening.<sup>53</sup> Participants were required to have a normal ECG to get into the study. Those in the screening arm underwent maximal symptom-limited exercise treadmill test (ETT). Submaximal tests were considered not diagnostic and did not lead to any further investigations. Coronary angiography was proposed to all patients with positive ETTs, and choices to perform stenting or surgery were reportedly determined according to the European Guidelines by two interventional cardiologists and a cardiac surgeon after reviewing coronary anatomy.

DYNAMIT was conducted in France, and the DADDY-D trial was conducted in Italy. Mean duration of followup for both trials was 3.5 to 3.6 years. Both enrolled ambulatory patients with a clinical diagnosis of type 2 diabetes. Mean hemoglobin A1cs were 8.6 (DYNAMIT) and 7.7 (DADDY-D), respectively. DYNAMIT enrolled patients ages 55 to 75 years; mean age was 64. DADDY-D enrolled patients ages 50 to 70 years; mean age was 62. Less than half of the participants (20–45%) were women in both trials. Neither trial reported information about race or ethnicity of participants. DADDY-D did not report baseline prevalence of hypertension (but 74% were on antihypertensive medications) or PAD; they were 89 percent and 14 percent for DYNAMIT, respectively. The prevalence of heart failure in both trials was less than 1 percent. Less than half of the participants (17–39%) in both trials were smokers.

Both trials were rated as fair quality. Neither trial reached the sample size targets. DYNAMIT was stopped early because of trouble recruiting and a lower than expected event rate (it randomized 631 of the planned 3,000). DADDY-D aimed for 364 per group but enrolled about 260 per group; because the target number of participants could not be achieved, the followup period was extended from two years to 3.5 years for those who had been enrolled (the authors reported a power of 77%). For DADDY-D, masking of outcome assessors was not reported and amount of attrition was unclear.

## Results of Included Trials

The main results are shown in **Figure 3** and **Appendix E Table 1**. Overall, neither study found a statistically significant reduction in any category of events for screening compared with no screening, including their primary composite outcomes, all-cause mortality, CV-related mortality, MI, heart failure, or stroke, although findings were imprecise.

In the DYNAMIT trial, 28 participants in the screening group and 26 in the unscreened arm experienced at least one primary endpoint (composite of death from all causes, nonfatal MI,

nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention) (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.59 to 1.71). In the same trial, 13 in the screening arm and 15 in the unscreened arm experienced coronary events (fatal or nonfatal MI, hospitalized unstable angina, or heart failure requiring hospitalization or emergency service intervention) (HR, 0.77; 95% CI, 0.37 to 1.63). In the DADDY-D trial, 12 in the screened arm and 14 in the unscreened arm experienced a primary outcome, cardiac events defined as a composite of nonfatal MI or cardiac death (HR, 0.85; 95% CI, 0.39 to 1.84).

Subgroup analyses were performed by gender, age, and CV risk for multiple outcomes in the DADDY-D trial. No statistically significant differences were found between groups based on gender, age, or CV risk for the primary outcome of cardiac events. For heart failure, no significant differences were found between those screened and those not screened based on gender, age, or having a CV risk  $\geq 20$ , but a difference was found for those with a CV risk  $< 20$  (0 vs. 5 events,  $p=0.022$ ). For cardiac death, no significant differences were found between those screened and those not screened based on gender, CV risk, or being less than 60 years of age, but a difference was found for those  $\geq 60$  years of age. Fewer cardiac deaths were reported for those older than 60 years who were screened than those who were not screened (0 vs. 4 events,  $p=0.044$ ). No significant differences were found between those screened and not screened based on gender, age, or CV risk for nonfatal MI. The study did not report interaction tests for the subgroup analyses, no adjustments were made for multiple testing, and it is unclear whether the subgroup analyses were planned a priori. The positive subgroup analysis findings are likely due to chance.

## **KQ 2. Does the Addition of Screening With Resting or Exercise ECG to Traditional CVD Risk Factor Assessment Accurately Reclassify Persons Into Different Risk Groups or Improve Measures of Calibration and Discrimination?**

### **Summary**

Fourteen good- or fair-quality studies were included.<sup>47</sup> Five evaluated exercise ECG<sup>47, 48, 54-56</sup> and nine evaluated resting ECG.<sup>49, 57-64</sup> Of those nine, five evaluated multiple ECG changes (a group of major and minor changes)<sup>49, 57-60</sup> and four evaluated only single ECG changes.<sup>61-64</sup> Of the studies evaluating exercise ECG, three used published coefficient base models (2 FRS and 1 SCORE).<sup>47, 48, 55</sup> Of the studies evaluating resting ECG, five reported some analyses using published coefficient base models (5 FRS; 1 also used PCE).<sup>49, 57-59, 63</sup>

For exercise ECG, although evidence from five cohort studies (9,582 participants) shows that the addition of exercise ECG abnormalities to traditional CVD risk factors results in small improvements in discrimination (absolute improvement in AUC or C-statistics 0.02 to 0.03), it is uncertain whether calibration or appropriate risk classification improves. For resting ECG, evidence from nine cohort studies (66,407 participants) shows that the addition of ECG findings to traditional CVD risk factors results in very small or small improvements in discrimination (absolute improvement in AUC or C-statistics 0.001 to 0.05) and improvements for calibration and appropriate risk classification for prediction of multiple outcomes (e.g., all-cause mortality,

CVD mortality, CHD events, or CVD events), but evidence was limited by imprecision, quality, considerable heterogeneity, and the risk categories evaluated.

### **Characteristics of Studies Evaluating Exercise ECG**

Five cohort studies evaluated whether adding exercise ECG to traditional CVD risk prediction could improve discrimination, calibration, or risk reclassification (**Tables 3 and 4**).<sup>47, 48, 54-56</sup> The studies evaluated a total of 9,582 participants. Sample sizes ranged from 988<sup>54</sup> to 3,554.<sup>47</sup> One enrolled participants in the 1970s;<sup>56</sup> the other four enrolled participants in the 1990s. Two studies were conducted in the United States,<sup>47, 54</sup> two in France,<sup>48, 55</sup> and one in Norway.<sup>56</sup> Mean duration of followup ranged from 6 to 8 years in four studies; one had 26 years of followup.<sup>56</sup> The five studies used data from five different cohorts (although the 2 studies from France may have some overlap in a subset of the participants). For the base model, two used the FRS (with published coefficients of the original model),<sup>48, 55</sup> one used the European SCORE (with published coefficients),<sup>47</sup> one model development study used FRS variables,<sup>54</sup> and one model development study used some of the traditional risk factors (age, total cholesterol, systolic blood pressure, and smoking status) and restricted its sample to eliminate other risk factors (excluded women, those with prevalent diabetes, and those on blood pressure-lowering therapy at baseline) but did not account for HDL.<sup>56</sup>

All were prospective cohorts with participants from cardiology or prevention centers in urban hospitals. Participants were self-referred or referred by providers to a preventive cardiology unit in two studies,<sup>48, 55</sup> participants presented for executive physicals in one study,<sup>47</sup> participants were a subset of those from a study evaluating coronary artery calcium and SPECT in one study,<sup>54</sup> and participants were recruited from five governmental agencies in one study.<sup>56</sup> Four of the studies reported that all participants were asymptomatic. One study reported that 16.5 percent of participants had atypical chest pain symptoms and that the participants were a subset of persons having both coronary artery calcium score (CACs) and SPECT for “clinically indicated reasons”;<sup>54</sup> it is unclear what proportion of participants were truly asymptomatic and what the clinically indicated reasons for testing were. The mean age of participants ranged from 50 to 58 years. Most participants in all trials were men, with the proportion of female participants ranging from 0 to 38 percent. Four studies did not report information about race/ethnicity; one reported that 2 percent of participants were nonwhite.<sup>47</sup> The baseline prevalence of hypertension and diabetes ranged from 0 to 55 percent and 0 to 11 percent, respectively. The percentage of smokers ranged from 10 to 47 percent. Mean baseline FRS score was 10.8 to 12.3 in studies reporting it.<sup>48, 54, 55</sup>

Study end points included all-cause mortality,<sup>47</sup> coronary events (cardiac deaths, sudden deaths, acute MI, and stable or unstable angina),<sup>48, 55</sup> cardiac events (cardiac death, nonfatal MI, and the need for coronary revascularization following the development of symptomatic CAD),<sup>54</sup> and CHD mortality (deaths caused by ischemic heart disease and sudden, unexpected deaths).<sup>56</sup>

All five of the included studies received fair-quality ratings (**Appendix D**). The most common methodological concerns were not reporting CIs for calibration or discrimination (5/5), not reporting measures of reclassification (4/5), selective inclusion of participants in the model based on data availability (4/5), unknown masking of outcome assessors (4/5), unknown if predictors

were assessed masked for the outcome (4/5), not reporting both discrimination and calibration (3/5), unclear handling and amount of missing data (2/5), uncertain validity and reliability of method used for measuring outcomes (2/5), using base model equations that have not been externally validated (i.e., model development studies) (2/5), and mean duration of followup less than 10 years (4/5), despite the risk prediction being focused on 10 years. The study with the longest followup (26 years) did not account for one of the traditional risk factors (HDL).<sup>56</sup> In addition, the only study reporting reclassification did not use the risk categories commonly used in current practice for making treatment decisions (it used <6% vs. 6 to 20% vs. >20%) and may have included many symptomatic participants (16.5% had atypical chest pain and participants were a subset of those having CACS and SPECT for “clinically indicated reasons”).<sup>54</sup>

## Results of Studies Evaluating Exercise ECG

For the comparison of interest to this review, one model development study reported reclassification,<sup>54</sup> four reported calibration,<sup>48, 54-56</sup> and three reported discrimination.<sup>47, 54, 55</sup> Results of the included studies are shown in **Table 5** and **Figures 4–7**. The frequency of abnormal exercise tests across included studies ranged from 6.4 to 16.7 percent (**Appendix E Table 3**).

### *Discrimination*

Three studies reported discrimination for the addition of exercise ECG variables to traditional risk factors;<sup>47, 54, 55</sup> one of the three used FRS with published coefficients for the base model<sup>55</sup> and two were model development studies. Main results are shown in **Figures 4** and **5**, illustrating the AUC or C-statistic for the base model (black squares in the figures) and the AUC or C-statistic for the base model plus exercise ECG (white squares in the figures). Figure 4 is limited to the studies that used FRS or PCE with published coefficients for the base model whereas Figure 5 also shows model development studies. In addition to the AUC or C-statistic results, the columns of the figures show the outcome, ECG findings evaluated, base model used, sample size, and number of participants with an event. All three studies reported small absolute improvements in AUC or C-statistics (0.02 to 0.03), and none of them reported CIs for the discrimination data. One of the three reported a p-value indicating no statistically significant difference between a model with exercise testing variables and the base model with FRS variables ( $p=0.3$ ).<sup>54</sup>

### *Calibration or Overall Performance*

Four studies reported calibration or overall performance of models that added exercise ECG results to traditional risk factors (**Table 5**).<sup>48, 54-56</sup> Two of the studies used the FRS (with published coefficients) in base models<sup>48, 55</sup> and two were model development studies.<sup>54, 56</sup> None of the studies reported figures such as calibration plots, but one provided a table of predicted and observed events for quintiles of risk.<sup>56</sup> All four studies reported different measures: likelihood ratio test;<sup>48</sup> Akaike information criteria (AIC), Brier’s score, and Hosmer-Lemeshow  $\chi^2$ ;<sup>55</sup> global  $\chi^2$ ;<sup>54</sup> and numbers of predicted and observed events.<sup>56</sup>

The two studies that used the FRS were both conducted in France and focused on prediction of

coronary events.<sup>48,55</sup> One study (1,051 participants) reported that model performance was not improved for the full sample with the addition of symptom-limited exercise ECG to the model ( $p=0.13$ ).<sup>48</sup> For the subgroup with pretest Framingham risk of 10.4 percent or greater, the authors reported a statistically significant improvement for adding exercise ECG to some base models, but not when the base model was FRS ( $n=526$ ,  $p=0.06$ ). The other study (2,709 participants) reported improved goodness of fit with the addition of exercise ECG, indicated by lower AIC (748.9 vs. 727.8) and Brier's score (0.035 vs. 0.033); the Hosmer-Lemeshow test showed no difference between the models ( $p$ , 0.99 vs. 0.99).<sup>55</sup>

Two studies developed new models rather than using published coefficients of existing models (e.g., FRS and PCE). The study described below under Risk Reclassification (Chang et al, 2015<sup>54</sup>) reported better calibration for the model that included exercise testing results than for the base model (global chi-square 16.16 vs. 11.72,  $p=0.04$ ).<sup>54</sup> The study conducted in Norway (2,014 participants) reported numbers of predicted and observed events for models with and without exercise testing (**Table 5**).<sup>56</sup> Although both models (with and without exercise testing) show steep and similar gradients in age-adjusted CHD mortality (indicating good calibration), the model with exercise testing showed a slightly steeper gradient across quintiles of risk, with slightly better correspondence of predicted and observed events.

### *Risk Reclassification*

One study (Chang et al, 2015<sup>54</sup>; 988 participants) reported on the reclassification from adding exercise ECG to traditional CVD risk factor assessment for predicting cardiac events.<sup>54</sup> It did not use the current common clinical thresholds to reclassify risk; instead, it used categories defined by 10-year risk of <6 percent, 6 to 20 percent, and >20 percent. For the base model, the authors were not able to calculate the FRS as published because blood pressure and cholesterol measurements were not available (so these predictors were dichotomized based on history of hyperlipidemia and hypertension). Therefore, it was considered a model development study with FRS variables in the base model (i.e., rather than a study using the externally validated FRS coefficients in the base model). The study found that adding the presence or absence of stress-induced ischemia detected during symptom-limited exercise treadmill testing to the base model increased the total NRI in subjects overall (9.6%;  $p=0.007$ ) and in the intermediate risk group (18.9%;  $p=0.01$ ). It did not report event NRI and nonevent NRI. The study also reported absolute and relative integrated discrimination improvement (IDI). For all patients, the IDI was small but statistically significant (absolute IDI, 1.4%,  $p=0.006$ ; relative IDI, 110%,  $p<0.0001$ ). The IDI was also improved significantly for the intermediate risk category (absolute IDI%, 1.7 [ $p=0.01$ ]; relative IDI, 92% [ $p=0.004$ ]). The study authors also reported on calibration, finding better calibration for the model that included exercise testing results than for the base model (global chi-square 16.16 vs. 11.72,  $p=0.04$ ). However, adding exercise testing variables to the base model did not significantly improve discrimination (change in AUC, 0.02,  $p=0.3$ ).

### **Characteristics of Studies Evaluating Resting ECG**

Nine studies of resting ECG met inclusion criteria (**Tables 6 and 7**).<sup>49, 57-64</sup> Eight were cohort studies and one used data from an RCT.<sup>49</sup> Five evaluated multiple ECG changes: either a constellation of major and minor ECG changes based on the Minnesota code or an ECG risk

equation (that included multiple ECG changes).<sup>49, 57-60</sup> Four only evaluated single ECG changes.<sup>61-64</sup> Some studies that evaluated multiple ECG changes also reported findings for single/specific ECG changes. Three studies reported results from the National Health and Nutrition Examination Survey (NHANES),<sup>57, 59, 63</sup> two studies reported results from the Atherosclerosis Risk in Community study,<sup>62, 64</sup> and the remaining studies reported results from the Health, Aging, Body Composition Study,<sup>58</sup> the Women's Health Initiative,<sup>49</sup> the Jichi Medical School Cohort,<sup>61</sup> and the Copenhagen City Heart Study.<sup>60</sup> Excluding double-counted populations, the studies evaluated a total of 68,475 subjects. Sample sizes ranged from 1,264<sup>49</sup> to 15,375.<sup>62</sup> One study enrolled participants in the 1970s,<sup>60</sup> seven enrolled participants in the late 1980s and/or the 1990s, and one used a derivation cohort from the 1970s and a validation cohort from the 1980s and 1990s.<sup>59</sup> Seven studies were conducted in the United States, one in Japan,<sup>61</sup> and one in Denmark.<sup>60</sup> Duration of followup ranged from 6<sup>49</sup> to 19 years.<sup>59</sup>

For the base model, three studies used the FRS (with published coefficients of the original model),<sup>49, 57, 63</sup> one used the FRS and the PCE (with published coefficients; it also included model development analyses using FRS variables),<sup>59</sup> one focused on model development (with traditional risk factors) but also used FRS (with published coefficients) in some secondary analyses,<sup>58</sup> and four were model development studies using FRS variables (one of those also included alcohol intake and heart rate<sup>61</sup>).<sup>60-62, 64</sup>

All were population-based studies. Overall, the studies provided little or no information about any evaluation of whether participants had symptoms at baseline. It is unclear what proportion of participants were truly asymptomatic. One study reported excluding those with angina or claudication.<sup>57</sup> Another study included participants with symptoms of angina or claudication, counting them among the 5 percent with prevalent CHD enrolled in the study.<sup>62</sup> The studies either excluded those with a history of CVD or enrolled a small percentage of persons with a history of CVD. The mean age of participants ranged from 54 to 73 years. The majority of participants in all studies were women and one study enrolled only women.<sup>49</sup> Three studies did not report information about race/ethnicity; the range of nonwhite participants in those that did report race/ethnicity was 9 to 41 percent. The baseline prevalence of diabetes ranged from 0 to 13 percent. The percentage of smokers ranged from 22 to 54 percent. Mean baseline CVD risk was not reported by most studies.

Study end points included all-cause mortality,<sup>57, 59, 60</sup> CV mortality,<sup>57, 59, 60, 63</sup> CHD events,<sup>49, 58, 60, 64</sup> stroke events,<sup>61</sup> CVD events,<sup>49, 60</sup> sudden cardiac death,<sup>62</sup> and ischemic heart disease mortality.<sup>59</sup>

One study was rated as good quality,<sup>58</sup> and the others were rated as fair (**Appendix D**). The most common methodological concerns were selective inclusion of participants in the model based on data availability (9/9), unknown masking of outcome assessors (8/9), unknown if predictors were assessed masked for the outcome (7/9), not reporting CIs for either calibration or discrimination (5/9), not reporting calibration (5/9), using base model equations that have not been externally validated (i.e., model development studies) (4/9),<sup>58, 60, 61, 64</sup> not reporting the amount of missing data (2/9), and mean duration of followup less than 10 years (2/9).<sup>49, 58</sup> In addition, of the studies reporting reclassification, just three included a threshold between risk categories corresponding to the current USPSTF recommendations for initiating preventive medications (i.e., 7.5% or 10%

10-year risk).<sup>57-59</sup> Of the three, one reported using cut points between categories of 1, 5, and 10 percent;<sup>59</sup> one used <5, 5 to 9.9, 10 to 19.9, and 20 or greater;<sup>57</sup> and one used <7.5 percent, 7.5 percent to 15 percent, and >15 percent.<sup>58</sup> The study that used cut points of 1, 5 and 10 percent cited the European Society of Cardiology recommendations (from 2012) for lipid management as the rationale for the chosen cut points; those recommendations are based on SCORE (which predicts CVD death), and the recommendations describe that a 5 percent SCORE risk of CVD death equates to a 10 to 25 percent 10-year FRS risk of total CVD, depending on which of the several Framingham models is chosen.<sup>65</sup> One study based NRI cut points for risk categories on the distribution of the data rather than using a priori cut points.<sup>60</sup> One study included alcohol use and heart rate in addition to traditional risk factors in its base model.<sup>61</sup>

Among the five studies that evaluated multiple ECG changes, the most common methodological concerns (**Appendix D**) were selective inclusion of participants in the model based on data availability (5/5), unknown masking of outcome assessors (4/5), unknown if predictors were assessed masked for the outcome (4/5), not reporting CIs for either calibration or discrimination (3/5), not reporting the amount of missing data (2/5), not reporting calibration (2/5), using base model equations that have not been externally validated (i.e., model development studies) (2/5),<sup>58, 60</sup> and mean duration of followup less than 10 years (2/5).<sup>49, 58</sup> In addition, two studies reporting reclassification did not use the risk categories commonly used in current practice in the United States for making treatment decisions.<sup>59, 60</sup> One study based NRI cut points for risk categories based on the distribution of the data rather than using a priori cut points.<sup>60</sup>

## Results of Studies Evaluating Resting ECG: Multiple ECG Changes

Five studies evaluated the effect of adding major or minor ECG abnormalities or an ECG risk equation (that included multiple ECG abnormalities) to traditional risk factors.<sup>49, 57-60</sup> Four of the five evaluated the incremental improvement of adding major or minor ECG abnormalities to the FRS or PCE (with published coefficients) for some of the outcomes reported.<sup>49, 57-59</sup> Three studies evaluated CHD events,<sup>49, 58, 60</sup> two studies evaluated CVD events,<sup>49, 60</sup> three studies evaluated CVD mortality,<sup>57, 59, 60</sup> three studies evaluated all-cause mortality,<sup>57, 59, 60</sup> and one evaluated ischemic heart disease mortality.<sup>59</sup> The frequency of ECG abnormalities across these studies ranged from 31 to 55 percent (**Appendix E Table 4**).

### *Discrimination*

All five studies reported discrimination for the addition of ECG variables to traditional risk factors. Three of the five reported it using FRS or PCE with published coefficients.<sup>49, 57, 59</sup> Main results are shown in **Figure 4** and **Figure 5**, illustrating the AUC or C-statistic for the base model (black squares in the figures) and the AUC or C-statistic for the base model plus ECG changes (white squares in the figures). **Figure 4** is limited to the studies that used FRS or PCE with published coefficients for the base model whereas **Figure 5** also shows model development studies. In addition to the AUC or C-statistic results, the columns of the figures show the outcome, ECG findings evaluated, base model used, sample size, and number of participants with an event. All five studies reported very small<sup>57</sup> to small absolute improvements in AUC or C-statistics. Two studies reported p-values, with one study indicating statistically significant differences between models with ECG abnormalities and a base model with conventional risk

factors for outcomes of fatal CVD and combined fatal and nonfatal CVD ( $p < 0.001$ );<sup>60</sup> the other study approached statistical significance ( $p = 0.05$ ).<sup>57</sup>

### *Calibration or Overall Performance*

Three studies reported calibration or overall performance of models that added multiple changes from resting ECG to traditional risk factors (**Appendix E Table 2**).<sup>49, 57, 58</sup> Two of the studies used the FRS (with published coefficients) in base models,<sup>49, 57</sup> and one was a model development study (it reported reclassification for the addition of ECG variables to FRS, but only reported calibration for a model with ECG and FRS variables).<sup>58</sup> None of the studies reported figures such as calibration plots. The measures reported included likelihood ratio  $\chi^2$  test,<sup>49, 58</sup> Hosmer-Lemeshow  $\chi^2$ ,<sup>57, 58</sup> and Bayes information criterion (BIC).<sup>57</sup>

The two studies that used the FRS were both conducted in the United States and focused on prediction of CV mortality<sup>57</sup> or CHD events and CVD events.<sup>49</sup> One study (6,025 participants) using NHANES data reported that the addition of major and minor ECG changes improved calibration and performance for predicting CV mortality (Hosmer-Lemeshow  $\chi^2$  decreased from 15.14 to 10.98,  $p$ -values 0.05 and 0.2, respectively; BIC decreased from 3,360.54 to 3,358.28).<sup>57</sup> The other study (1,264 participants) reported that the addition of major and minor ECG abnormalities to FRS improved model performance for predicting both CHD and CVD events (likelihood ratio chi square test:  $p = 0.004$  and  $p = 0.02$ , respectively).

The one model development study that reported calibration for a model with ECG and FRS variables was conducted in the United States and used the Health ABC Study cohort of 2,192 adults ages 70 to 79 years.<sup>58</sup> The study reported that a model with traditional risk factors (FRS variables) did not show a good calibration and was not improved by the addition of ECG abnormalities (Hosmer-Lemeshow  $\chi^2$  increased with the addition of ECG abnormalities from 67.6 to 87.9, likelihood ratio  $p < 0.00005$ , goodness of fit  $p$ -values 0.03 for FRS variables vs. 0.01 for FRS variables plus ECG).<sup>58</sup>

### *Risk Reclassification*

Four of the five studies evaluating multiple ECG changes reported results on reclassification when adding resting ECG to traditional risk factors (**Appendix E Table 2; Figures 6 and 7**).<sup>57-60</sup> **Figures 6 and 7** show the NRI results, with black squares indicating the total NRI (sum of the event NRI and nonevent NRI), gray squares indicating the event NRI (net upward reclassification among persons who had an event), and white squares representing nonevent NRI (net downward reclassification among persons who did not have an event). For some studies, only the total NRI (black square) is provided because the data for event and nonevent NRI were not reported. Figure 6 shows model development studies and studies that used FRS or PCE with published coefficients for the base model, whereas Figure 7 is limited to studies that used FRS or PCE with published coefficients for the base model. In addition to the NRI results, the columns of the figures show the outcome, ECG findings evaluated, base model used, sample size, number of participants with an event, and the risk categories used for analyses. Three of the studies used the FRS (with published coefficients) in base models,<sup>57-59</sup> one also used PCE (with published coefficients) and a model with FRS variables (not using published coefficients),<sup>59</sup> and one was a



model development study.<sup>60</sup> All four studies reported NRI and all but one<sup>60</sup> provided event NRI or nonevent NRI data (or the table to allow us to calculate it) for some models. Two studies reported IDI (**Appendix E Table 2**).<sup>58, 59</sup>

For studies using published coefficient models, **Figure 7** shows the net reclassification results. Three studies reported outcomes of reclassification and IDI. One study of adults in the NHANES population used four risk categories (<5%, 5 to 10%, 10 to 20%, and >20%) to calculate reclassification indices.<sup>57</sup> Investigators reported an overall NRI of 3.6 percent, where the NRI for those with events was 3 percent and the NRI for those without events was 0.6 percent, indicating a net appropriate reclassification of those with CVD mortality upward into higher risk categories. This study also reported a clinical NRI for intermediate risk patients of 13.6 percent, although this estimate was not corrected for bias.<sup>66</sup> The absolute value of the IDI was low, although statistically significant. (0.0001,  $p < 0.001$ ). A study of older adults in the Healthy Aging and Body Composition (Healthy ABC) study also reported an improved overall NRI and IDI when ECG abnormalities were added to FRS (NRI 5.7% [95% CI, -0.4 to 11.6], IDI, 1.03% [95% CI, 0.56% to 1.50%]), although specific NRIs for events and nonevents were not provided for the comparison with FRS.<sup>58</sup> The third study evaluated the addition of an ECG risk equation (that included frontal T axis, QT interval, and heart rate) to FRS, PCE, or a model with traditional risk factors.<sup>59</sup> It used NHANES I data to derive the risk equation and validated the model with NHANES III.<sup>59</sup> The clinical risk thresholds were based on the European Society of Cardiology (1%, 5%, and 10%). Adding the ECG risk equation to the FRS, PCE, or conventional risk factors resulted in improved classification. Categorical NRIs ranged from 4 to 30 percent, and continuous NRI ranged from 33 to 57 percent. Absolute IDI ranged from 0.2 to 2.6 percent, and relative IDIs ranged from 7 percent to 47 percent.

Three model development studies examined improvement in CV risk prediction when any ECG abnormality was added to conventional CV risk factors, which included diabetes in addition to the risk factors of the FRS variables.<sup>58-60</sup> Two of them also evaluated published coefficient models (FRS or PCE) as described in the previous paragraph.<sup>58, 59</sup> Two studies were conducted in older adult populations with mean age ranging from 70 to 74 years. The Healthy ABC study looked at the outcome of CHD,<sup>58</sup> while a study of the Copenhagen City Heart Study examined outcomes of fatal CVD events, fatal and nonfatal CVD events, and all-cause mortality.<sup>60</sup> The third study used NHANES cohorts to evaluate the addition of an ECG risk score to several base models.<sup>59</sup> All three studies reported improvements in discrimination and reclassification for all outcomes examined.

The models using the Healthy ABC cohort reported an NRI for those with events of -0.9 percent, indicating inappropriate reclassification of patients with CHD events to lower risk categories. The NRI for persons without events was 8.3 percent, indicating appropriate reclassification of patients without CHD events to lower risk categories. The study authors reported on reclassification of intermediate risk participants using an unadjusted and adjusted clinical NRI (13.6% and 6.7%, respectively). The Copenhagen City Heart Study reported improved categorical NRIs and continuous NRIs, although event and nonevent component NRIs were not reported for the former (**Appendix E Table 2** and **Figure 6**).<sup>60</sup> The study that evaluated the addition of an ECG risk equation (that included frontal T axis, QT interval, heart rate, age, and sex) to a model with traditional risk factors used NHANES I data to derive the risk equation and

validated the model with NHANES III.<sup>59</sup> The clinical risk thresholds were based on the European Society of Cardiology (1%, 5%, and 10%). Adding the ECG risk equation to conventional risk factors resulted in improved classification. Categorical NRIs ranged from 4 percent (for fatal ischemic heart disease) to 11 percent (for all-cause mortality), with reclassification to higher categories for persons with events accounting for most of the total NRI (i.e., event NRIs were greater than nonevent NRIs).

## **Results of Studies Evaluating Resting ECG: Single ECG Changes**

Five studies evaluated the effect of adding a single ECG abnormality to traditional risk factors. Studies evaluated a range of outcomes including CVD events,<sup>60</sup> CHD events,<sup>64</sup> stroke,<sup>61</sup> CVD mortality,<sup>60, 63</sup> sudden cardiac death,<sup>62</sup> and all-cause mortality.<sup>60</sup> Three studies evaluated T wave changes and other ventricular repolarization abnormalities, three studies examined LVH, and the remaining two studies looked at a variety of ECG changes. The frequency of ECG abnormalities across the studies that evaluated single ECG changes ranged from 1 to 24 percent (**Appendix E Table 4**).

### *T Wave Changes and Other Ventricular Repolarization Abnormalities*

One study using NHANES III data examined the effect of adding observed T wave amplitude greater than -0.2 mV in lead aVR to the FRS on risk prediction of CV mortality.<sup>63</sup> Investigators observed an improvement in discrimination (C-statistic 0.812 to 0.820), good calibration, and overall categorical NRI of 0.07 using clinical risk categories of <5 percent, 5 to 10 percent, 10 to 20 percent, and >20 percent. Net reclassification of subjects with events was 2.7 percent, and net reclassification of subjects without events was 2.3 percent, indicating participants were appropriately reclassified to higher or lower risk categories. IDI was reported as 0.012 ( $p<0.01$ ).

The Copenhagen City Heart study examined the addition of any T wave changes or ventricular conduction delay (VCD) to conventional CV risk factors. For both repolarization abnormalities, the C-statistic improved from 0.705 to 0.716 (T wave) or 0.706 (VCD) for the outcome of fatal CVD events. For the combined outcome of nonfatal and fatal CVD events, discrimination improved from 0.651 to 0.658 for any T wave abnormality, but there was no change for VCD. Calibration results were not reported. Different risk thresholds were used for outcomes of fatal CVD events and fatal and nonfatal CVD events (**Appendix E Table 2** and **Figure 6**) when calculating categorical NRIs, and separate event and nonevent NRIs were not reported. Adding T wave changes to conventional risk factors resulted in an overall continuous NRI of 29.2 percent and a categorical NRI of 5.4 percent for fatal CVD events and 20.3 percent and 2.7 percent for fatal and nonfatal CVD events, respectively. Addition of VCD to conventional risk factors resulted in small but significant NRIs for fatal CVD events (overall continuous NRI of 12.1% and categorical NRI of 1.1%) but nonsignificant or no change for fatal and nonfatal CVD events.

Finally, prolonged QTc interval was added to conventional risk factors to participants in the Jichi Medical School Cohort. Discrimination and calibration results were not reported. Adding prolonged QTc to conventional risk factors resulted in a categorical NRI of 0.026 (event NRI, 1.35%; nonevent NRI, 1.22%) and nonsignificant IDI (0.291;  $p=0.80$ ).<sup>61</sup>

### *Left Ventricular Hypertrophy*

Three studies added LVH to conventional risk factors.<sup>60, 61, 64</sup> In the Copenhagen City Heart study, the addition of LVH to conventional risk factors resulted in increased discrimination of fatal CVD events and continuous and categorical NRIs of 2.8 percent and 1.1 percent, respectively.<sup>60</sup> There was no improvement in discrimination or significant NRI findings for fatal or nonfatal CVD events. Calibration and IDI results were not reported for this study. In a study of the Atherosclerosis Risk in Communities (ARIC) cohort, LVH was examined as a continuous measure using the Cornell score, as well as a categorical variable, by gender and diabetes subgroups.<sup>64</sup> For women, adding continuous or categorical LVH ECG findings to conventional risk factors worsened discrimination of CHD events (0.707 and 0.709, respectively vs 0.711) among those with diabetes and did not change discrimination in those without diabetes (0.777 for all models). For men, there was no or minimal improvement in discrimination. Calibration, reclassification, and IDI outcomes were not reported. The Jichi Medical School Cohort did not report discrimination or calibration outcomes but did report a categorical NRI of 0.020 (event NRI, 1.01%; nonevent NRI, 1.01%) and IDI of 0.004 (p=0.75) for a model that included LVH.<sup>61</sup>

### *Other ECG Changes*

The remaining studies evaluated different individual ECG changes combined with conventional risk factors.<sup>60, 62</sup> One study examined the effect of adding the finding of a deep terminal negativity of the P wave in lead V1 to conventional risk factors and reported a categorical NRI of 0.028 for clinical risk thresholds of 5 percent and 15 percent.<sup>62</sup> Event NRI was 0.028, indicating participants who had events were primarily reclassified to higher risk categories. Discrimination, calibration, and IDI were not reported.

In the Copenhagen City Heart Study, Q waves, ST segment depressions, and resting heart rate were added to conventional risk factors with improvements in discrimination compared with conventional risk factors alone for fatal CVD events and fatal or nonfatal CVD events<sup>60</sup> (**Appendix E Table 2**). However, categorical NRIs were only significant for ST segment depressions (3.1% for fatal CVD, 2.2% for all CVD events), and event and nonevent NRIs were not reported separately. Calibration and IDI were also not reported.

## **KQ 3a. What Are the Harms of Screening With Resting or Exercise ECG, Including Harms of Subsequent Procedures or Interventions Initiated as a Result of Screening? 3b. Do the Harms of Screening Vary for Subgroups Defined by Baseline CVD Risk, Age, Sex, or Race/Ethnicity?**

### **Summary**

One eligible study reported on harms from subsequent procedures or interventions initiated as a result of screening. It reported that one person out of 12 undergoing revascularization had a nonfatal MI. No other eligible studies reported rates of harms from screening asymptomatic adults with resting or exercise ECG. We searched for, but did not find, other studies evaluating

potential harms such as mortality, arrhythmia, CV events, injuries, anxiety, labeling, and harms of subsequent procedures or interventions initiated as a result of screening.

### **Detailed Results**

One of the fair-quality RCTs described in KQ 1, the DADDY-D trial, reported some results eligible for this KQ.<sup>53</sup> Twenty out of 262 participants (7.6%) in the screened group had positive ETTs. Of those 20, 17 underwent coronary angiography (6.5% of the 262 in the screened group). Angiography revealed critical stenosis (not defined) in 71 percent (12/17), and all patients with critical stenosis underwent revascularization procedures (7 percutaneous and 5 surgical). One patient having percutaneous revascularization had a nonfatal acute MI 3 days after the procedure and underwent a second percutaneous angioplasty. His ejection fraction was reported to be normal 6 months after the event.

The other trial described in KQ 1 (DYNAMIT) reported the number of some subsequent tests but did not report whether any of the tests or interventions resulted in harms; adverse events that occurred during followup were not recorded.<sup>52</sup> Sixty-eight of the 316 participants (21.5%) in the screened group had a definitely abnormal or an uncertain screening test (exercise test or SPECT) result. Of those, 38 underwent coronary angiography (12% of the 316 in the screened group) and nine subsequently underwent coronary angioplasty (7 of those 9 received stents) and three had coronary artery bypass graft.

# Chapter 4. Discussion

## Summary of Evidence

**Tables 8 and 9** provide a summary of findings in this evidence review. **Table 8** is organized by KQ and provides a summary of the main findings along with a description of consistency, precision, quality, limitations, strength of evidence, and applicability. For KQ 2, the summary of evidence for exercise ECG and resting ECG was separated. The overall strength of evidence was low or insufficient for each of the questions and outcomes evaluated. No RCTs of screening with resting ECG were found; RCTs of exercise ECG in asymptomatic participants found no improvement in health outcomes despite focusing on higher risk populations with diabetes, although they were limited by not reaching sample size targets. Scant direct evidence on harms of screening asymptomatic persons with ECG was found. Evidence on whether the addition of exercise ECG to traditional CVD risk factors results in accurate reclassification is lacking. Cohort studies found that the addition of multiple resting ECG abnormalities to traditional CVD risk factors accurately reclassifies persons, and improves discrimination and calibration, but evidence was limited by imprecision, quality, considerable heterogeneity, and inconsistent use of risk thresholds that align with clinical decisions and recommendations.

### Evidence for the Benefits and Harms of Screening With Resting or Exercise ECG

No eligible studies compared screening with resting ECG and no screening, and none evaluated the use of screening with ECG for the purpose of risk reclassification to inform decisions about whether to initiate preventive medications. Two RCTs (DYNAMIT and DADDY-D, total of 1,151 participants) evaluated screening with exercise ECG in asymptomatic adults ages 50 to 75 years with diabetes compared with no screening and found no statistically significant improvement in health outcomes, including their primary composite outcomes, all-cause mortality, CV-related mortality, MI, heart failure, or stroke. Findings from the two studies were consistent but imprecise. For the primary composite outcomes, HRs were 1.00 (95% CI, 0.59 to 1.71) for a composite of death from all causes, nonfatal MI, nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention and 0.85 (95% CI, 0.39 to 1.84) for a composite of nonfatal MI or cardiac death. Some key limitations of the trials include not reaching sample size targets and stopping early because of trouble recruiting. Both trials followed participants for about 3.5 years, and longer followup may be needed to adequately evaluate screening with exercise ECG. The overall strength of evidence for whether screening with exercise ECG improves health outcomes was low (for no benefit) because of imprecision and risk of bias.

The participants in the included trials were higher risk groups that would be, in theory, more likely to benefit from screening with exercise ECG to identify silent ischemia. For example, in DYNAMIT, participants had diabetes plus two of the following additional risk factors: urinary albumin excretion above a threshold, hypertension, hyperlipidemia, history of PAD (14%), history of TIA (4 to 5%), tobacco consumption, or family history of premature CVD. However,

even among these higher risk groups of asymptomatic diabetics, screening with exercise ECG (followed by referral to cardiology [DYNAMIT] or recommendation for coronary angiography [DADDY-D] for those with abnormal exercise ECGs) did not improve health outcomes.

Potential harms of screening asymptomatic adults with resting or exercise ECG include mortality, arrhythmia, CV events, injuries, anxiety, labeling, and harms of subsequent procedures or interventions initiated as a result of screening (e.g., subsequent angiography or revascularization procedures resulting in harm). Both DYNAMIT and DADDY-D reported numbers of subsequent tests and interventions after abnormal exercise tests, but just one (DADDY-D) reported whether any of the tests or interventions resulted in harms (1/12 [8.3%] undergoing percutaneous revascularization had a nonfatal acute MI 3 days later). Among asymptomatic diabetics, DADDY-D and DYNAMIT reported that 7.6 percent (20/262 screened) had abnormal ETTs and 21.5 percent (68/316 screened) had definitely abnormal or uncertain bicycle exercise or SPECT results, respectively. Most of those with abnormal screening tests underwent coronary angiography (DADDY-D: 17/262, 6.5%; DYNAMIT 38/316, 12%), and some had revascularization procedures (12/262, 4.6% and 12/316, 3.8%, respectively).

No other eligible studies reported rates of harms for asymptomatic adults. Studies without control groups were eligible if they were multicenter studies or registries that reported rates of harms from exercise ECG or subsequent procedures/interventions specifically for asymptomatic persons. A single site study of 377 asymptomatic military officers (mean age 37) at one station in the Midwestern United States reported that none had complications during exercise testing.<sup>50</sup> Of the 377, 45 (11.9%) had abnormal exercise test results and 10 (2.7%) underwent coronary angiography. Of those, one was reported to have “mild CAD.” Many other studies have reported rates of angiography (but no information on harms) for asymptomatic persons after exercise ECG; rates have ranged from 0.6 percent to 13 percent, although most reported rates less than 3 percent.<sup>47, 48, 50, 67-74</sup> Rates of subsequent revascularization have also been reported by some, with those studies estimating lower rates than reported by DADDY-D and DYNAMIT. For example, two studies (with 3,554 and 1,051 participants, respectively) reported rates of 0.1 percent to 0.5 percent undergoing revascularization after screening exercise ECG.<sup>47, 48</sup> Little is known about the harms of revascularization procedures for adults without symptoms or a prior diagnosis of CVD (**Appendix A**). Regardless of symptom status, some tests that follow an abnormal ECG expose patients to radiation, including coronary angiography, computed tomography angiography, and myocardial perfusion imaging.<sup>75</sup> Coronary angiography can expose patients to as much radiation as 600 to 800 chest X-rays.<sup>76</sup>

Studies that focused on *symptomatic* adults have reported rates of harms of exercise ECG and harms of subsequent procedures/interventions. The scientific statement from the AHA with recommendations for clinical exercise laboratories reports that the complication rate is usually considered to be approximately 1 in 10,000<sup>51</sup> (0.01%). It references a review of eight studies estimating sudden cardiac death during exercise testing that reported rates from zero to 0.005 percent (5 per 100,000 tests).<sup>51, 77</sup> The statement also notes that survey data provide estimates of rates for complications: hospitalization including serious arrhythmias (0.2% or less), acute MI (0.04%), or sudden cardiac death during or immediately after an exercise test (0.01%).<sup>51, 78</sup>

## Reclassification, Calibration, and Discrimination With the Addition of Resting or Exercise ECG to Traditional CVD Risk Factor Assessment

No consensus exists for the thresholds that should be considered clinically significant changes in discrimination (e.g., AUC, C-statistic), calibration, or reclassification (e.g., NRI). Changes in these measures are important to evaluate in the context of each other, but appropriate reclassification (NRI) has the most direct clinical meaning. Nevertheless, studies must use clinically meaningful risk categories (i.e., that correspond to clinical decisions, such as 7.5% or 10% 10-year risk) to allow for the potential clinical significance of NRI results to be assessed. Further, interpreting NRI is not simple because it is unfamiliar to many and it is calculated from four proportions. For more clear interpretation, focusing on the event NRI and nonevent NRI components may help. For example, nonevent NRI is the net downward reclassification (i.e., appropriate reclassification) among persons who did not have an event; it is calculated as the proportion of persons without an event who were appropriately reclassified into a lower risk group minus the proportion of those without an event who were inappropriately reclassified into a higher risk group.

For exercise ECG, although evidence from five cohort studies (9,582 participants) shows that the addition of exercise ECG results to traditional CVD risk factors results in small improvements in discrimination (absolute improvement in AUC or C-statistics 0.02 to 0.03), it is uncertain whether calibration or appropriate risk classification improves. Evidence was limited by imprecision and risk of bias for all outcomes and by inconsistency or unknown consistency for calibration and reclassification outcomes. Some important limitations of the evidence include that CIs for calibration or discrimination were not reported; mean duration of followup was less than 10 years in four of the five studies; reclassification was only reported by one study; unknown masking of outcome assessors in four studies; and not reporting both discrimination and calibration in three studies. The only study reporting reclassification was a model development study (i.e., used FRS variables but did not use published coefficients) that used risk categories of <6 percent, 6 to 20 percent, and >20 percent and may have included many symptomatic participants (because 16.5% had atypical chest pain and participants were a subset of those having CACS and SPECT for “clinically indicated reasons”).<sup>54</sup> Also, we found an absence of evidence related to exercise ECG for healthy, low risk persons (e.g., mean age was 50 to 58 and mean baseline FRS score was 10.8 to 12.3 in studies reporting it).

For resting ECG, evidence from nine cohort studies (66,407 participants) shows that the addition of ECG findings to traditional CVD risk factors results in very small or small improvements in discrimination (absolute improvement in AUC or C-statistics 0.001 to 0.05) and in improvements for calibration and appropriate risk classification for prediction of all-cause mortality, CVD mortality, CHD events, or CVD events. Total NRIs (event; nonevent) range from 3.6 percent (2.7%; 0.6%) to 30 percent (17%; 19%) for studies using FRS or PCE base models (95% CIs were rarely reported). However, evidence was limited by imprecision and risk of bias for all outcomes and by incomplete and inconsistent reporting of discrimination, calibration, and reclassification measures. For reclassification, although evidence consistently showed improved NRI, the estimates of NRI and the outcomes assessed were inconsistent, and the consistency of findings is unknown for specific risk thresholds because all studies used different risk categories. The body of evidence also had considerable heterogeneity in baseline prediction models used,

type of ECG abnormalities added to base models, and outcomes assessed (e.g., all-cause mortality, CVD mortality, CHD events). The reported discrimination of base models varied widely, ranging from inadequate to excellent (AUC or C-statistics from 0.58 to 0.85) likely because of the different outcomes, different patient populations, and different base models used. Only one study used the base model for risk prediction (i.e., the PCE) that the USPSTF and ACC/AHA currently recommend to inform clinical decisions about preventive medications.

An important limitation of the evidence was a lack of reporting on any assessment of symptoms; it is unclear what proportion of participants was truly asymptomatic in most of the studies of resting ECG. Perhaps the proportion with symptoms is likely to be relatively low given that the studies were population based and most of them excluded persons with a history of CVD, but it is uncertain whether enrolling even a small percentage of symptomatic participants could artificially inflate estimates of appropriate reclassification. Other important limitations included unknown masking of outcome assessors in eight studies, CIs for calibration or discrimination were not reported in five studies, calibration or overall performance was not reported in five studies, and not using established risk prediction models with published coefficients in four studies (i.e., model development studies).

For NRI, event and nonevent NRI components were often not reported as recommended. Although an overall positive value of NRI indicates net appropriate reclassification into appropriate risk strata, the clinical implications can be very different if the majority of patients are those with events being shifted into higher risk categories (event NRI) as opposed to those without events being shifted into lower risk categories (nonevent NRI). Although the addition of ECG abnormalities to conventional risk factors improves total NRI in both cases, one might lead to an increase in preventive medications, while the other suggests a possible reduction in the use of preventive medications.

For reclassification with resting ECG, few studies included a threshold between risk categories corresponding to the USPSTF recommendations for preventive medications (i.e., 7.5% or 10% 10-year risk). The potential for appropriate reclassification based on the addition of major and minor ECG changes to existing models (PCE or FRS) initially looks promising when viewing **Figure 7** because studies reported increases in total appropriate reclassification (total NRI), appropriate reclassification of persons with events to higher risk categories (event NRI), and appropriate reclassification of persons without events to lower risk categories (nonevent NRI). However, several cautions should be noted: (1) no two studies evaluated the same model, risk category thresholds, and outcome. Therefore, none of the models that included ECG variables have been validated in more than one study; (2) no CIs were provided for most of that data; (3) NRI is highly dependent on risk category thresholds, which varied widely across these studies; (4) evaluating risk reclassification using four categories to determine NRI is potentially not clinically meaningful (or is less clinically meaningful than using fewer categories) and may artificially make the reclassification look better because each reclassification counts as a positive move for the NRI if someone with an event moves from any lower to any higher category regardless of whether the change would correspond to different treatment decisions (likewise for someone without an event who moves into any lower risk category); (5) a single study<sup>59</sup> accounts for six of the nine rows in **Figure 7**. It reported NRI for three different base models for prediction of several mortality outcomes but did not evaluate prediction of CHD or CVD events



because it used NHANES data that do not have that capability. The study is limited by using risk category thresholds of 1, 5, and 10 percent and not reporting the full reclassification table to allow determination of how much of the NRI was accounted for by reclassification that should change clinical decisions (e.g., from 5 to 9.9% to 10% or greater risk for persons with events) versus how much was accounted for by reclassification that would have no effect on clinical decisions and outcomes (e.g., from 1 to 4.9% to <1% for persons without events). The study<sup>59</sup> is also the only study that evaluated adding an ECG risk equation to base models; (6) another study<sup>58</sup> in **Figure 7** is limited by only having 7.5 years of followup. It also focused on elderly participants ages 70 to 79 years and did not report event NRI or nonevent NRI (or the data to calculate those) for the addition of ECG changes to the FRS base model (those were reported for a model development part of the study and showed net inappropriate reclassification for persons who had events, event NRI -0.9%). It is uncertain whether risk reclassification could provide clinically useful information for this population given recent evidence on lack of benefit of statins for primary prevention in elderly persons of similar age<sup>79</sup> and given the USPSTF I statement on initiation of aspirin for primary prevention in adults age 70 years or older.

## Limitations

This review did not evaluate the evidence on preventive medications (i.e., aspirin and lipid lowering therapy) that could be initiated based on risk reclassification or the evidence on benefits and harms of lifestyle counseling to reduce CV risk. Other systematic reviews for the USPSTF have evaluated that evidence. But one of the contextual questions (**Appendix A**) summarizes what medications (i.e., aspirin, lipid-lowering therapy) are recommended for persons in various CVD risk categories. This review did not systematically review the benefits and harms of revascularization procedures; contextual question 2 (**Appendix A**) summarizes information on the harms and benefits of revascularization procedures for adults without symptoms or a prior diagnosis of CVD.

For KQ 2 (reclassification, calibration, and discrimination), it was sometimes challenging to determine whether studies used published coefficients (e.g., used the FRS or PCE) or whether they were model development studies that used the FRS variables. Study authors were contacted to clarify the uncertainty, but some did not respond. Therefore, some studies could be misclassified (regarding model development vs. published coefficients). For KQ 2, we used qualitative terms (e.g., very small, small, moderate) to describe the magnitude of changes in discrimination. These qualitative terms are meant only to be descriptive of specific numeric ranges and are not intended to indicate a corresponding clinically meaningful benefit for health outcomes. No consensus exists for the thresholds that should be considered clinically meaningful changes in the AUC/C-statistic or NRI.

For KQ 3 (harms of screening), for studies without control groups to be eligible for this review, studies were required to be multicenter studies or from large registries. This approach excluded a single center study of 377 asymptomatic military officers<sup>50</sup>; that study is described above in the Discussion. This review did not evaluate harms from ECG or subsequent procedures/interventions for symptomatic populations.

This review was limited to studies assessing resting ECG or exercise ECG. A previously published meta-analysis evaluated any screening test for coronary artery disease in persons with type 2 diabetes.<sup>80</sup> It identified five trials (including DYNAMIT and DADDY-D) with a total of 3,315 participants. The trials that were not eligible for our review evaluated stress scintigraphy, coronary CT angiography, or stress echocardiography with exercise ECG. Pooled analyses found no statistically significant association with all-cause mortality (RR, 0.95; 95% CI, 0.66 to 1.35) or cardiac events (RR, 0.72; 95% CI, 0.49 to 1.06).

## Future Research Needs

To better understand whether risk classification is improved in a clinically useful way that is likely to improve health outcomes, risk prediction studies that evaluate the addition of ECG abnormalities to the PCE (as the base model) would be most useful because the PCE is the approach currently recommended by the USPSTF and ACC/AHA to assess 10-year risk and to inform decisions about preventive medications. Only one included study used the PCE as the base model. Studies of a constellation of resting ECG changes (e.g., major and minor changes based on the Minnesota code) show greater promise than those of single ECG changes and should likely be the focus of future research. Future risk studies should use clinically meaningful risk categories that correspond to recommendations about preventive medications to determine how many persons are appropriately reclassified in a manner that would lead to additional or fewer preventive medication treatments. Specifically, when considering the USPSTF recommendations for statins and aspirin, evaluating NRI related to the 10% 10-year risk threshold is of great interest. Future studies should evaluate asymptomatic populations (with some assessment of symptom status to avoid enrolling those with angina, atypical chest pain, or dyspnea, for example) and should exclude those with a history of CVD. Measures of discrimination, calibration, and reclassification (including total NRI, event NRI, and nonevent NRI) and their corresponding CIs should be reported.

## Conclusion

The overall strength of evidence was low or insufficient for each of the questions and outcomes evaluated. Controlled trials of screening with exercise ECG in asymptomatic diabetic patients found no improvement in health outcomes over about 3.5 years but were limited by not reaching sample size targets and stopping early because of trouble recruiting. No controlled trials evaluated screening with resting ECG for asymptomatic adults. Potential harms of exercise ECG include arrhythmias, acute MI, and sudden cardiac death. Potential harms of both exercise and resting ECG include harms of subsequent angiography or revascularization procedures after an abnormal test, but little evidence exists to determine their frequency in asymptomatic persons. Some evidence suggests that the addition of exercise ECG to traditional risk factors results in small improvements in discrimination, but it is uncertain whether calibration or appropriate risk classification improves. Cohort studies found that the addition of multiple resting ECG findings to traditional risk factors improves discrimination (small absolute improvement in AUC or C-statistics), calibration, and appropriate risk classification, but evidence was limited by

imprecision, quality, considerable heterogeneity, and unknown consistency for specific risk thresholds because studies used different risk categories.

## References

1. Moyer VA. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012 Oct 2;157(7):512-8. doi: 10.7326/0003-4819-157-7-201210020-00514. PMID: 22847227.
2. U. S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2016 Nov 15;316(19):1997-2007. doi: 10.1001/jama.2016.15450. PMID: 27838723.
3. World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.
4. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: World Health Organization; 1992.
5. Abbate R, Cioni G, Ricci I, et al. Thrombosis and acute coronary syndrome. *Thromb Res.* 2012 Mar;129(3):235-40. doi: 10.1016/j.thromres.2011.12.026. PMID: 22281070.
6. Moreira DM, da Silva RL, Vieira JL, et al. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. *Am J Cardiovasc Drugs.* 2015 Feb;15(1):1-11. doi: 10.1007/s40256-014-0094-z. PMID: 25369900.
7. Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. *Circ Res.* 2014 Jun 6;114(12):1852-66. doi: 10.1161/CIRCRESAHA.114.302721. PMID: 24902970.
8. Santos-Gallego CG, Picatoste B, Badimon JJ. Pathophysiology of acute coronary syndrome. *Curr Atheroscler Rep.* 2014 Apr;16(4):401. doi: 10.1007/s11883-014-0401-9. PMID: 24504549.
9. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med.* 2011 Jan 20;364(3):226-35. doi: 10.1056/NEJMoa1002358. PMID: 21247313.
10. Saab F, Mukherjee D, Gurm H, et al. Risk Factors in first presentation acute coronary syndromes (ACS): how do we move from population to individualized risk prediction? *Angiology.* 2009 Dec-2010 Jan;60(6):663-7. doi: 10.1177/0003319709333870. PMID: 19729368.
11. D'Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA.* 2001 Jul 11;286(2):180-7. PMID: 11448281.
12. Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA.* 2001 May 16;285(19):2486-97. PMID: 11368702.
13. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation.* 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.000000000000152. PMID: 25520374.

14. Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Ann Intern Med.* 2005 Mar 15;142(6):393-402. PMID: 15767617.
15. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009 Oct 06;151(7):496-507. PMID: 19805772.
16. American Heart Association, American College of Cardiology. Pooled Cohort Equations Cardiovascular Risk Calculator. 2014. <http://tools.acc.org/ASCVD-Risk-Estimator/>. Accessed May 19, 2017.
17. Bibbins-Domingo K, U. S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med.* 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577. PMID: 27064677.
18. Ford ES, Will JC, Mercado CI, et al. Trends in predicted risk for atherosclerotic cardiovascular disease using the pooled cohort risk equations among US adults from 1999 to 2012. *JAMA Intern Med.* 2015 Feb;175(2):299-302. doi: 10.1001/jamainternmed.2014.6403. PMID: 25485596.
19. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Cancer: A Decision Analysis. AHRQ Publication 15-05229-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
20. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation.* 2017 Mar 07;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. PMID: 28122885.
21. Fang J, Shaw KM, Keenan NL. Prevalence of coronary heart disease--United States, 2006-2010. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 14;60(40):1377-81. PMID: 21993341.
22. Fang J, Shaw KM, George M. Prevalence of stroke--United States, 2006-2010. *MMWR Morb Mortal Wkly Rep.* 2012 May 25;61(20):379-82. PMID: 22622094.
23. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemost.* 2013 Aug;110(2):213-22. doi: 10.1160/th13-02-0165. PMID: 23595785.
24. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. PMID: 21067804.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002 Jul 06;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. PMID: 12114036.
26. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005 Apr 07;352(14):1425-35. doi: 10.1056/NEJMoa050461. PMID: 15755765.
27. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of

- High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002 Dec 17;106(25):3143-421. PMID: 12485966.
28. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. *J Am Coll Cardiol*. 2009 Jan 27;53(4):316-22. doi: 10.1016/j.jacc.2008.10.024. PMID: 19161879.
  29. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. PMID: 24222016.
  30. Chou R, High Value Care Task Force of the American College of Physicians. Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians. *Ann Intern Med*. 2015 Mar 17;162(6):438-47. doi: 10.7326/M14-1225. PMID: 25775317.
  31. American Academy of Family Physicians. Annual EKGs for Low-risk Patients. 2012. <http://www.aafp.org/patient-care/clinical-recommendations/all/cw-ekg.html>. Accessed 18 Nov, 2015.
  32. Lim LS, Haq N, Mahmood S, et al. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. *Am J Prev Med*. 2011 Mar;40(3):381 e1-10. doi: 10.1016/j.amepre.2010.11.021. PMID: 21335273.
  33. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. *Am Heart J*. 1991 Jan;121(1 Pt 2):293-8. PMID: 1985385.
  34. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. *Circulation*. 1991 Jan;83(1):356-62. PMID: 1984895.
  35. American Academy of Family Physicians. Family physician interpretation of electrocardiograms. Leawood, KS: American Academy of Family Physicians; 2007.
  36. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
  37. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998 May 12;97(18):1837-47. PMID: 9603539.
  38. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. PMID: 18212285.
  39. National Heart, Lung, and Blood Institute. 2013 Report on the Assessment of Cardiovascular Risk: Full Work Group Report Supplement: National Heart, Lung, and Blood Institute; 2013.
  40. Shillinglaw B, Viera AJ, Edwards T, et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. *BMC Health Serv Res*. 2012 Jan 24;12:20. doi: 10.1186/1472-6963-12-20. PMID: 22273080.
  41. Bhatia RS, Bouck Z, Ivers NM, et al. Electrocardiograms in Low-Risk Patients Undergoing An Annual Health Examination. *JAMA Intern Med*. 2017 Jul 10doi: 10.1001/jamainternmed.2017.2649. PMID: 28692719.
  42. Chou R, Arora B, Dana T, et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task


- Force. *Ann Intern Med.* 2011 Sep 20;155(6):375-85. doi: 10.7326/0003-4819-155-6-201109200-00006. PMID: 21930855.
43. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med.* 2014 Oct;11(10):e1001744. doi: 10.1371/journal.pmed.1001744. PMID: 25314315.
  44. West SL, Gartlehner G, Mansfield AJ, et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity Methods Research Paper. AHRQ Publication No. 10-EHC070-EF. Rockville, MD: Agency for Healthcare Research and Quality; September 2010. <http://effectivehealthcare.ahrq.gov/>
  45. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol.* 2010 May;63(5):513-23. doi: 10.1016/j.jclinepi.2009.03.009. PMID: 19595577.
  46. Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. *J Clin Epidemiol.* 2015 Nov;68(11):1312-24. doi: 10.1016/j.jclinepi.2014.11.023. PMID: 25721570.
  47. Aktas MK, Ozduran V, Pothier CE, et al. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. *JAMA.* 2004 Sep 22;292(12):1462-8. doi: 10.1001/jama.292.12.1462. PMID: 15383517.
  48. Cournot M, Taraszkiwicz D, Galinier M, et al. Is exercise testing useful to improve the prediction of coronary events in asymptomatic subjects? *Eur J Cardiovasc Prev Rehabil.* 2006 Feb;13(1):37-44. PMID: 16449862.
  49. Denes P, Larson JC, Lloyd-Jones DM, et al. Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. *JAMA.* 2007 Mar 7;297(9):978-85. doi: 10.1001/jama.297.9.978. PMID: 17341712.
  50. Hollenberg M, Zoltick JM, Go M, et al. Comparison of a quantitative treadmill exercise score with standard electrocardiographic criteria in screening asymptomatic young men for coronary artery disease. *N Engl J Med.* 1985 Sep 5;313(10):600-6. doi: 10.1056/NEJM198509053131003. PMID: 4022047.
  51. Myers J, Arena R, Franklin B, et al. Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association. *Circulation.* 2009 Jun 23;119(24):3144-61. doi: 10.1161/CIRCULATIONAHA.109.192520. PMID: 19487589.
  52. Lievre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. *Trials.* 2011;12:23. doi: 10.1186/1745-6215-12-23. PMID: 21269454.
  53. Turrini F, Scarlini S, Mannucci C, et al. Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease. *Eur J Intern Med.* 2015 Jul;26(6):407-13. doi: 10.1016/j.ejim.2015.05.006. PMID: 26058988.
  54. Chang SM, Nabi F, Xu J, et al. Value of CACS compared with ETT and myocardial perfusion imaging for predicting long-term cardiac outcome in asymptomatic and symptomatic patients at low risk for coronary disease: clinical implications in a multimodality imaging world. *JACC Cardiovasc Imaging.* 2015 Feb;8(2):134-44. doi: 10.1016/j.jcmg.2014.11.008. PMID: 25677886.

55. Cournot M, Taraszkievicz D, Cambou JP, et al. Additional prognostic value of physical examination, exercise testing, and arterial ultrasonography for coronary risk assessment in primary prevention. *Am Heart J.* 2009 Nov;158(5):845-51. doi: 10.1016/j.ahj.2009.08.017. PMID: 19853707.
56. Erikssen G, Bodegard J, Bjornholt JV, et al. Exercise testing of healthy men in a new perspective: from diagnosis to prognosis. *Eur Heart J.* 2004 Jun;25(11):978-86. doi: 10.1016/j.ehj.2004.04.009. PMID: 15172470.
57. Badheka AO, Patel N, Tuliani TA, et al. Electrocardiographic abnormalities and reclassification of cardiovascular risk: insights from NHANES-III. *Am J Med.* 2013 Apr;126(4):319-26.e2. doi: 10.1016/j.amjmed.2012.10.020. PMID: 23415052.
58. Auer R, Bauer DC, Marques-Vidal P, et al. Association of major and minor ECG abnormalities with coronary heart disease events. *JAMA.* 2012 Apr 11;307(14):1497-505. doi: 10.1001/jama.2012.434. PMID: 22496264.
59. Shah AJ, Vaccarino V, Janssens AC, et al. An electrocardiogram-based risk equation for incident cardiovascular disease from the National Health and Nutrition Examination Survey. *JAMA Cardiol.* 2016 Aug 3doi: 10.1001/jamacardio.2016.2173. PMID: 27487404.
60. Jorgensen PG, Jensen JS, Marott JL, et al. Electrocardiographic changes improve risk prediction in asymptomatic persons age 65 years or above without cardiovascular disease. *J Am Coll Cardiol.* 2014 Sep 2;64(9):898-906. doi: 10.1016/j.jacc.2014.05.050. PMID: 25169175.
61. Ishikawa J, Ishikawa S, Kario K. Prolonged corrected QT interval is predictive of future stroke events even in subjects without ECG-diagnosed left ventricular hypertrophy. *Hypertension.* 2015 Mar;65(3):554-60. doi: 10.1161/hypertensionaha.114.04722. PMID: 25534703.
62. Tereshchenko LG, Henrikson CA, Sotoodehnia N, et al. Electrocardiographic deep terminal negativity of the P wave in V(1) and risk of sudden cardiac death: the Atherosclerosis Risk in Communities (ARIC) study. *J Am Heart Assoc.* 2014 Dec;3(6):e001387. doi: 10.1161/jaha.114.001387. PMID: 25416036.
63. Badheka AO, Patel NJ, Grover PM, et al. ST-T wave abnormality in lead aVR and reclassification of cardiovascular risk (from the National Health and Nutrition Examination Survey-III). *Am J Cardiol.* 2013 Sep 15;112(6):805-10. doi: 10.1016/j.amjcard.2013.04.058. PMID: 23764245.
64. Folsom AR, Chambless LE, Duncan BB, et al. Prediction of coronary heart disease in middle-aged adults with diabetes. *Diabetes Care.* 2003 Oct;26(10):2777-84. PMID: 14514579.
65. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J.* 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. PMID: 22555213.
66. Paynter NP, Cook NR. A bias-corrected net reclassification improvement for clinical subgroups. *Med Decis Making.* 2013 Feb;33(2):154-62. doi: 10.1177/0272989X12461856. PMID: 23042826.



67. Blumenthal RS, Becker DM, Yanek LR, et al. Detecting occult coronary disease in a high-risk asymptomatic population. *Circulation*. 2003 Feb 11;107(5):702-7. PMID: 12578872.
68. Boyle RM, Adlakha HL, Mary DA. Diagnostic value of the maximal ST segment/heart rate slope in asymptomatic factory populations. *J Electrocardiol*. 1987 Oct;20 Suppl:128-34. PMID: 3320257.
69. Davies B, Ashton WD, Rowlands DJ, et al. Association of conventional and exertional coronary heart disease risk factors in 5,000 apparently healthy men. *Clin Cardiol*. 1996 Apr;19(4):303-8. PMID: 8706370.
70. Dunn RL, Matzen RN, VanderBrug-Medendorp S. Screening for the detection of coronary artery disease by using the exercise tolerance test in a preventive medicine population. *Am J Prev Med*. 1991 Sep-Oct;7(5):255-62. PMID: 1790029.
71. Livschitz S, Sharabi Y, Yushin J, et al. Limited clinical value of exercise stress test for the screening of coronary artery disease in young, asymptomatic adult men. *Am J Cardiol*. 2000 Aug 15;86(4):462-4. PMID: 10946046.
72. Massie BM, Szlachcic Y, Tubau JF, et al. Scintigraphic and electrocardiographic evidence of silent coronary artery disease in asymptomatic hypertension: a case-control study. *J Am Coll Cardiol*. 1993 Nov 15;22(6):1598-606. PMID: 8227826.
73. Piegrass SR, Uhl GS, Hickman JR, Jr., et al. Limitations of the exercise stress test in the detection of coronary artery disease in apparently healthy men. *Aviat Space Environ Med*. 1982 Apr;53(4):379-82. PMID: 7082255.
74. Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. *Am J Cardiol*. 1998 Jan 15;81(2):219-24. PMID: 9591907.
75. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. *N Engl J Med*. 2009 Aug 27;361(9):849-57. doi: 10.1056/NEJMoa0901249. PMID: 19710483.
76. Choosing Wisely. EKGs and exercise stress tests When you need them-and when you don't. Philadelphia, PA: Choosing Wisely® is an initiative of the ABIM Foundation©. All rights reserved; 2017. <http://www.choosingwisely.org/patient-resources/ekgs-and-exercise-stress-tests/>. Accessed November 13, 2017.
77. Gordon NF, Kohl HW. Exercise testing and sudden cardiac death. *J Cardiopulm Rehabil Prev*. 1993;13:381-6.
78. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
79. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT Randomized Clinical Trial. *JAMA Intern Med*. 2017 May 22;doi: 10.1001/jamainternmed.2017.1442. PMID: 28531241.
80. Rados DV, Pinto LC, Leitao CB, et al. Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis. *BMJ Open*. 2017 May 09;7(5):e015089. doi: 10.1136/bmjopen-2016-015089. PMID: 28490559.

**Figure 1. Analytic Framework**



\* Includes adults regardless of their CVD risk (those with low, intermediate, or high risk are eligible) as assessed by traditional risk factors (those included in Framingham risk models): male sex, older age, cigarette smoking, hypertension, dyslipidemia (high total cholesterol, high low-density lipoprotein cholesterol, or low high-density lipoprotein cholesterol), and diabetes.


† This systematic review does not include key questions about the benefits and harms of preventive medications to reduce cardiovascular risk (i.e., aspirin and lipid-lowering therapy) or the benefits and harms of lifestyle counseling, because those have been addressed by other systematic reviews for the USPSTF.

**Abbreviations:** CVD = cardiovascular disease; ECG = electrocardiography; KQ – key question.

### Key Questions to Be Systematically Reviewed

- 1a. Does the addition of screening with resting or exercise electrocardiography (ECG) improve health outcomes compared with traditional cardiovascular disease (CVD) risk factor assessment alone in asymptomatic adults?
- 1b. Does improvement in health outcomes vary for subgroups defined by baseline CVD risk (e.g., low, intermediate, or high risk), age, sex, or race/ethnicity?
2. Does the addition of screening with resting or exercise ECG to traditional CVD risk factor assessment accurately reclassify persons into different risk groups (e.g., high-, intermediate-, and low-risk groups) or improve measures of calibration and discrimination?
- 3a. What are the harms of screening with resting or exercise ECG, including harms of subsequent procedures or interventions initiated as a result of screening?
- 3b. Do the harms vary for subgroups defined by baseline CVD risk (e.g., low, intermediate, or high risk), age, sex, or race/ethnicity?


**Figure 2. Summary of Evidence Search and Selection Diagram**



Note: The sum of the number of studies per KQ exceeds the total number of studies because some studies were applicable to multiple KQs.

**Abbreviations:** ICTRP=International Clinical Trials Registry Platform; KQ=key question; USPSTF=U.S. Preventive Services Task Force; WHO=World Health Organization.

**Figure 3. Main Results of Included Randomized, Controlled Trials Reporting Health Outcomes (KQ 1)**



DYNAMIT, primary composite outcome was defined as death from all causes, nonfatal MI, nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention.


DADDY-D, primary composite outcome was defined as first cardiac event, specifically nonfatal MI or cardiac death.

DYNAMIT did not report data for CV-related deaths. For other CV events, the DYNAMIT trial reported no significant differences between arms for revascularization (18 vs. 21, p=0.61).

The DADDY-D trial reported 19 total deaths (6 cardiac and 13 noncardiac) and seven total strokes but did not report which group those occurred in.

**Abbreviations:** CV=cardiovascular; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; MI=myocardial infarction.


**Figure 4. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score or Pooled Cohort Equation Base Models**




<sup>a</sup> Study reported c-statistic rather than AUC.

**Abbreviations:** AUC=area under the curve; CHD=coronary heart disease; CI=confidence interval; CVD=cardiovascular disease; ECG=electrocardiography; FRS=Framingham Risk Score; LVH=left ventricular hypertrophy; NR=not reported; PCE=pooled cohort equations.


**Figure 5. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, Systemic Coronary Risk Evaluation, or Conventional Risk Factor Base Models**



**Figure 5. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, Systemic Coronary Risk Evaluation, or Conventional Risk Factor Base Models**



**Figure 5. Effect on Discrimination of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, Systemic Coronary Risk Evaluation, or Conventional Risk Factor Base Models**



<sup>a</sup> Model also included metabolic equivalent (MET) and Duke treadmill score (DTS).

<sup>b</sup> Study reported c-statistic rather than AUC.


<sup>c</sup> In women without diabetes mellitus.

<sup>d</sup> In men without diabetes mellitus.


**Abbreviations:** AUC=area under the curve; CHD=coronary heart disease; CI=confidence interval; CRF=conventional risk factors; CVD=cardiovascular disease; ECG=electrocardiography; FRS=Framingham Risk Score; IHD=ischemic heart disease; LVH=left ventricular hypertrophy; NR=not reported; PCE=pooled cohort equations; SCORE=Systemic Coronary Risk Evaluation.




**Figure 6. Effect on Reclassification of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, or Conventional Risk Factor Base Models**




**Figure 6. Effect on Reclassification of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, or Conventional Risk Factor Base Models**



**Figure 6. Effect on Reclassification of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, or Conventional Risk Factor Base Models**




**Figure 6. Effect on Reclassification of Adding Exercise or Resting ECG Variables to Framingham Risk Score, Pooled Cohort Equation, or Conventional Risk Factor Base Models**



<sup>a</sup> Model also included metabolic equivalent (MET) and Duke treadmill score (DTS).

**Abbreviations:** CHD=coronary heart disease; CI=confidence interval; CRF=conventional risk factors; CVD=cardiovascular disease; ECG=electrocardiography; FRS=Framingham Risk Score; LVH=left ventricular hypertrophy; NR=not reported; NRI=net reclassification index; PCE=pooled cohort equations.

**Figure 7. Effect on Reclassification of Adding Resting ECG Variables to Framingham Risk Score or Pooled Cohort Equation Base Models**



**Abbreviations:** CHD=coronary heart disease; CI=confidence interval; CVD=cardiovascular disease; ECG=electrocardiography; FRS=Framingham Risk Score; NR=not reported; NRI=net reclassification index; PCE=pooled cohort equations.

**Table 1. Test Performance Measures for Comparing Risk Assessment or Prediction Models**

Purpose of Outcome Measure	Example Measures of Test Performance	Description
Discrimination	c-statistic or AUC; change in c-statistic or AUC	The probability that, for a randomly selected pair of individuals, one with disease and the other without, that the person with disease will have the higher estimated disease probability according to the model. The C-statistic can be conceptualized as the area under the ROC curve (plots sensitivity against 1-specificity); as a rank order statistic, it is insensitive to systematic errors in calibration. The Harrell's C-statistic is an extension of the AUC for survival analysis allowing for right-censored data and variable time to follow up. The change in c-statistic or AUC can be insensitive in assessing the impact of adding new predictors to a model, and the impact of a new predictor on c-statistics is lower when other strong predictors are in the model.
Calibration	Calibration plot	Graphical assessment of calibration with predictions on the x-axis and outcome on the y-axis. Calibration in the large and calibration slope can be derived from calibration plots.
	O:E	The ratio of observed to expected events.
	Hosmer-Lemeshow $\chi^2$	Calculated by summing differences between observed and predicted probabilities in each group (e.g., groups defined by deciles or risk strata); a significant p-value signals poor fit. The test is sensitive to how groups are constructed and sensitive to sample size, often being nonsignificant for small N and significant for large N.
Overall performance (captures both calibration and discrimination aspects)	Akaike information criterion (AIC) and Bayes information criterion (BIC)	Measures used during model development to aid in inclusion or exclusion of predictors in a model. The AIC is a function of log likelihood that adds a penalty for each added predictor. The BIC is similar, though imposes a greater penalty than the AIC for added variables. Lower values of both measures indicate better model fit. A change of >10 in the AIC has been proposed to indicate strong evidence for a difference in models.
	Likelihood ratio $\chi^2$	Likelihood ratio $\chi^2$ is a global test of model fit and is a function of the number of terms in the model. Higher values for the ratio, or difference between models, indicate better fit (as do lower absolute log-likelihood values). A global $\chi^2$ is generally the same as a likelihood $\chi^2$ (twice the log likelihood ratio).
	R <sup>2</sup>	There are a number of ways to calculate an R <sup>2</sup> for a logistic regression. Nagelkerke's generalized R <sup>2</sup> is generally analogous to the percentage of variance explained in a linear model and is adjusted to a range of 0 to 1. Higher values indicate better fit. The R <sup>2</sup> is more helpful than the Brier score because it can be compared across models/studies.
	Brier score	The Brier score computes the sum of squared differences between observed outcomes and fitted probability, where lower values indicate that predicted probabilities are closer to observed outcomes.
Risk reclassification	Net reclassification index or improvement (NRI)	The sum of differences in proportions of individuals moving up (a risk category) minus those moving down with a cardiovascular disease outcome, plus the proportion moving down minus those moving up without an outcome. NRI can be considered separately as the sum of the event NRI (P(up event) - P(down event)) and nonevent NRI (P(down nonevent) - P(up nonevent)). The NRI is of limited value in comparing models with different risk categories.
	Integrated discrimination improvement (IDI)	Integrates the NRI over all possible cut-offs; equivalent to difference in discrimination slopes of the two models and to the difference in R <sup>2</sup> .

Note: Table was modified with permission of the authors from the Kaiser Permanente Evidence-based Practice Center; from a table in their report on nontraditional risk factors.

**Abbreviations:** AIC=Akaike information criterion; AUC=area under the curve; BIC=Bayes information criterion; FRS=Framingham risk score; IDI=integrated discrimination improvement; N=sample size; NRI=net reclassification index or improvement; PCE=pooled cohort equations; ROC=receiver operating characteristic.

**Table 2. Characteristics of Included Randomized, Controlled Trials for KQ 1 and KQ 3**

First Author, Year Trial Name	G1 (N) G2 (N)	Screening Approach	Source of Patients	Country	Years of Follow-up	Mean Age (SD)	% F	% Non-white	Mean CV Risk (SD)	Mean A1c (SD)	Mean BMI (SD)	% HTN % HF % TIA % PAD % PVD % Smokers	Quality
Lievre et al, 2011 <sup>52</sup> DYNAMIT	Screened (316) Not screened (315)	Exercise ECG, bicycle exercise test (or dipyridamole SPECT, 31%) <sup>a</sup>	45 hospitals, ambulatory patients who consulted a diabetes specialist	France	Mean 3.5	63.9 (5.1)	45	NR	NR	8.6 (2.1)	30.6 (5)	88.8 0.5 4.6 14.1 NR 16.6 <sup>b</sup>	Fair
Turrini et al, 2015 <sup>53</sup> DADDY-D	Screened (262) Not screened (258)	Exercise ECG <sup>c</sup>	2 diabetes outpatient clinics	Italy	Mean 3.6	61.9 (5)	20	NR	20 (9) <sup>d</sup>	7.7 (2)	30.1 (6)	NR <sup>e</sup> 0 (excluded) NR NR 6 38.7	Fair

<sup>a</sup> SPECT was used in patients unable to perform the exercise test, with a submaximal negative exercise test, or with ECG abnormalities impairing the interpretation of the exercise test. Those with positive tests were referred to cardiologists, and all subsequent investigations and treatments were left at the cardiologist's discretion.

<sup>b</sup> Tobacco consumption

<sup>c</sup> Maximal symptom-limited exercise treadmill test (ETT) performed following American Heart Association guidelines. Submaximal tests were considered not diagnostic and did not lead to any further investigations. Coronary angiography was proposed to all patients with positive ETT; choices to perform stenting or surgery were determined according to the European Guidelines by two interventional cardiologists and a cardiac surgeon after reviewing coronary anatomy.

<sup>d</sup> Required CV risk score  $\geq 10\%$  for eligibility, risk determined according to Italian risk chart (includes gender, diabetic status, age, cigarette smoking status, systolic blood pressure, serum cholesterol).

<sup>e</sup> 74.3% on antihypertensive treatment; mean SBP 140.

**Abbreviations:** A1c=glycosylated hemoglobin; BMI=body mass index; CV=cardiovascular; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; ECG=electrocardiogram; ETT=exercise treadmill test; F=female; HF=heart failure; HTN=hypertension; KQ=key question; G=group; N=sample size; NR=not reported; PAD=peripheral artery disease; PVD=peripheral vascular disease; SBP=systolic blood pressure; SD=standard deviation; SPECT=Single Photon Emission Computed Tomography; TIA=transient ischemic attack.

**Table 3. Characteristics of Included Studies for KQ 2 That Evaluated Exercise ECG, Part 1**

First Author, Year Quality	ECG Findings Evaluated	Model Type: Base Model	Cohort	Source of Patients	Country	Sample Size	Years of Follow up
Aktas, 2004 <sup>47</sup> Fair	Exercise ECG according to Bruce (or modified Bruce) protocol; ischemic ST abnormality <sup>a</sup> using a 12-lead, symptom-limited exercise ECG	Published coefficient: European SCORE <sup>b</sup>	From Preventive Medicine Section of Cleveland Clinic (1990–2002)	Consecutive participants presenting for an executive physical. Self-referred.	US	3,554	Mean: 8
Chang, 2015 <sup>54</sup> Fair	Exercise ECG according to Bruce protocol; stress-induced ischemia <sup>c</sup> identified via ECG during symptom-limited exercise treadmill testing; METS and DTS	Model development: FRS <sup>d</sup> variables	From the Methodist Hospital, Houston Texas (1995–2006)	Persons who had both CACS and stress SPECT for clinically indicated reasons at the Heart and Vascular Center	US	988	Median: 6.9
Cournot, 2006 <sup>48</sup> Fair	Symptom-limited exercise ECG <sup>e</sup>	Published coefficient: FRS <sup>f</sup>	From the preventive cardiology unit of a teaching hospital (1995–1999)	Consecutive asymptomatic persons self-referred or referred by PCPs and cardiologists for evaluation of risk factors and routine screening	France	1,051	Mean: 6
Cournot, 2009 <sup>55</sup> Fair	A positive exercise test <sup>g</sup> during a symptom-limited exercise ECG with orthogonal and V <sub>1</sub> to V <sub>6</sub> leads	Published coefficient: FRS <sup>f</sup>	From the preventive cardiology unit of a teaching hospital (1996–2004)	Apparently healthy asymptomatic persons self-referred (20%) or referred by PCPs (27%) or other providers to a preventive cardiology unit	France	2,709	Median: 6
Erikssen, 2004 <sup>56</sup> Fair	Resting ECG and a symptom-limited bicycle exercise ECG test <sup>h</sup>	Model development: Classical Risk Factor (CRF) regression model <sup>i</sup>	From the University Hospital of Oslo (1972–1975)	Apparently healthy males ages 40–60 years recruited from five governmental agencies who participated in a cardiovascular risk assessment	Norway	Assessment 1 (1972–1975): 2,014 Assessment 2 (1980–1982): 1,428	26

<sup>a</sup> An ischemic ST abnormality, which was assessed visually by two independent readers, was defined as a 1-mm horizontal or downsloping ST-segment depression occurring 80 ms after the J-point; ST-segment depression had to be noted in at least three consecutive beats in at least two contiguous leads.

<sup>b</sup> SCORE includes age, sex, total cholesterol, systolic blood pressure, and smoking status (this study used the high-risk coefficients from it).

<sup>c</sup> Ischemia was defined as  $\geq 1$  mm of ST-segment depression occurring  $>80$  ms after the J-point. High and low risk were defined as the presence and absence of ischemia, respectively.

<sup>d</sup> Authors attempted to calculate FRS as published, but continuous BP and cholesterol measurements were not available, so these predictors were dichotomized (hyperlipidemia defined as total cholesterol 200–239 mg/dL and HTN defined as SBP 140–159 mm Hg).

<sup>e</sup> Positive ET was defined as a horizontal or downsloping ST-segment depression  $\geq 1.0$  mm at 80 ms after the J-point, in at least two contiguous leads, occurring at any time of exercise or recovery period.

<sup>f</sup> Used Anderson 1991: 10-year FRS function that includes age, sex, current smoking, diabetes, total cholesterol, and HDL-C.

<sup>g</sup> Positive exercise testing was defined as a horizontal or downsloping ST-segment depression  $\geq 1.0$  mm at 80 ms after the J-point, in at least two contiguous leads, occurring at any time during exercise or the recovery period.

<sup>h</sup> Exercise predictors were physical fitness (cumulative work during exercise divided by body weight), maximal heart rate, systolic blood pressure at the end of the first exercise load, and exercise ECG interpretation (ST-segment depression  $\geq 1.0$  mm at 0.08 s after the J-point regardless of ST-segment morphology).

<sup>i</sup> CRF model included age, total cholesterol, systolic blood pressure, and smoking status. The study included men only; therefore, sex was not needed in the model; the study also excluded persons with prevalent diabetes and persons on blood pressure-lowering therapy at baseline. High-density lipoprotein cholesterol was not accounted for in the model.



### Table 3. Characteristics of Included Studies for KQ 2 That Evaluated Exercise ECG, Part 1

**Abbreviations:** BP=blood pressure; CACS=coronary artery calcium score; CRF=Classical Risk Factor; DTS=Duke treadmill score; ECG=electrocardiogram; ET=exercise test; FRS=Framingham Risk Score; HDL-C=high-density lipoprotein cholesterol; HTN=hypertension; METS=metabolic equivalents of task; KQ=key question; PCP=primary care physicians and cardiologists; SCORE=Systematic Coronary Risk Evaluation; SPECT=single-photon emission computed tomography; U.S.=United States.

**Table 4. Characteristics of Included Studies for KQ 2 That Evaluated Exercise ECG, Part 2**

First Author, Year	% CVD	% With Symptoms	Mean Age (SD)	% F	% Non-white	CV Risk	Mean BMI (SD)	% HTN	% DM	% Smokers
Aktas, 2004 <sup>47</sup>	0	0	57 (4)	19	2	SCORE, <sup>a</sup> median (25 <sup>th</sup> –75 <sup>th</sup> percentile) 1 <sup>st</sup> tertile: 0.14 (0.87–1.8) 2 <sup>nd</sup> tertile: 3.0 (2.5–3.5) 3 <sup>rd</sup> tertile: 6.6 (5.2–9.2)	28 (4)	NR (mean SBP 128)	3	10
Chang, 2015 <sup>54</sup>	0 (for CAD; NR for CVD)	16.5 <sup>b</sup>	57.5 (9.3)	25	NR	FRS, mean (SD): 11.1 (6.5) Low risk (<6%): 16.9% Intermediate risk (6%–20%): 69.2% High risk (>20%): 13.9%	NR	49.6	9.6	46.5
Cournot, 2006 <sup>48</sup>	0	0	Total: 51.6 (10.3)	36	NR	Mean (median) FRS All: 12.3 (10.4) Negative ET, n=962: 12.1 (10.4) Positive ET, n=89: 14.7 (11.4)	Total: 26.1 (4.5)	≥160/95 mm Hg: 33.0 ≥140/90 mm Hg: 54.8	11.0	24.3
Cournot, 2009 <sup>55</sup>	0	0	Median: 51.6 (10.5)	38	NR	FRS, mean (SD): 10.8 (7.8)	26.0 (4.4)	48.2	6.8	23.9
Erikssen, 2004 <sup>56</sup>	0	0	Assessment 1: 49.8 (5.5) Assessment 2: 56.6 (5.4)	0	NR	NR	NR	0 (treated HTN)	0	Assessment 1: 43.8 (NR) Assessment 2: 32.8 (NR)

<sup>a</sup> SCORE provides 10-year risk for cardiovascular mortality and includes age, sex, total cholesterol, systolic blood pressure, and smoking status (this study used the high-risk coefficients from it).

<sup>b</sup> Study reported 16.5% had atypical chest pain symptoms but does not report indications for other tests beyond stating that they were “clinically indicated reasons.”

**Abbreviations:** BMI=body mass index; CAD=coronary artery disease; CV=cardiovascular; CVD=cardiovascular disease; DM=diabetes mellitus; ECG=electrocardiogram; ET=exercise testing; F= female; FRS=Framingham Risk Score; HTN=hypertension; KQ=key question; n=sample size; NR=not reported; SBP=systolic blood pressure; SCORE=Systematic COronary Risk Evaluation; SD=standard deviation.

**Table 5. Results of Included Studies for KQ 2 That Evaluated Exercise ECG**

First Author, Year Quality	Outcome	N (%) With Outcome	Discrimination	Calibration	Reclassification
Aktas, 2004 <sup>47</sup> Fair	All-cause mortality	114 (3)	C-statistic (95% CI): SCORE: 0.73 (NR) SCORE + exercise test: 0.76 (NR), p NR	NR	NR
Chang, 2015 <sup>54</sup> Fair	Cardiac events <sup>a</sup>	106 (11) <sup>p</sup>	AUC FRS variables: 0.63 (NR) FRS variables + ETT: NR FRS variables + DTS: NR FRS variables + METS: NR FRS variables + ETT + MET <sup>c</sup> + DTS <sup>d</sup> : 0.65 (NR) p=0.3 (FRS variables + ETT + MET + DTS vs. FRS variables)	Global $\chi^2$ FRS variables: 11.72 FRS variables + ETT <sup>e</sup> : 16.16 p=0.04 (FRS + ETT vs. FRS) FRS variables + DTS: 14.59 p=0.24 (FRS + DTS vs. FRS) FRS variables + METS: 14.68 p=0.03 (FRS + METS vs. FRS)	<b>NRI % for FRS variables + ETT (p Value vs FRS variables)</b> All patients: 9.6 (0.007); Appropriate Use Cohort <sup>f</sup> : 11.1 (0.005) Low risk: 0 (1.0); Intermediate risk: 18.9 (0.01); High risk: 8.1 (0.38) <b>Absolute IDI % for FRS variables + ETT (p Value vs FRS variables)</b> All patients: 1.4 (0.006); Appropriate Use Cohort: 1.6 (0.006) Low risk: 0.1 (0.75); Intermediate risk: 1.7 (0.01); High risk: 0.88 (0.39) <b>Relative IDI % for FRS variables + ETT (p Value vs FRS variables)</b> All patients: 110 (<0.0001); Appropriate Use Cohort: 128 (<0.0001) Low risk: 591 (0.35); Intermediate risk: 92 (0.004); High risk: 522 (0.19)
Cournot, 2006 <sup>48</sup> Fair	Total coronary events <sup>g</sup> (CE)	34 (3) <sup>h</sup>	NR	FRS Model vs. FRS Model + exercise test (ET) results Likelihood ratio test: <i>Whole sample (n=1051) p=0.13<sup>i</sup></i> <i>Subgroup with pre-test Framingham risk <math>\geq</math>10.4% (n=526): p=0.06<sup>j</sup></i>	NR
Cournot, 2009 <sup>55</sup> Fair	Definite coronary events <sup>k</sup>	94 (4) <sup>l</sup>	FRS vs. FRS + femoral bruit + positive exercise test <sup>m</sup> <i>AUROC (95% CI): 0.732 (NR) vs. 0.762 (NR), p NR</i> <i>Sensitivity, %: 3.2 vs. 8.5</i> <i>Specificity, %: 99.4 vs. 98.6</i> <i>Positive predictive value, %: 15.8 vs. 19.1</i> <i>Negative predictive value, %: 96.4 vs. 96.6</i>	FRS vs. FRS + femoral bruit + positive exercise test <sup>m</sup> <i>Hosmer-Lemeshow chi-square: P=0.99 vs. P=0.99</i> <i>Akaike information criterion: 748.9 vs. 727.8</i> <i>Brier's score: 0.035 vs. 0.033</i>	NR

**Table 5. Results of Included Studies for KQ 2 That Evaluated Exercise ECG**

First Author, Year Quality	Outcome	N (%) With Outcome	Discrimination	Calibration	Reclassification
Erikssen, 2004 <sup>56</sup> Fair	CHD Mortality <sup>n</sup>	300 (15)	NR	<p>CRF vs. CRF+X models<sup>o</sup>, Predicted (observed) events:</p> <p><i>CRF, Assessment 1, 26-year follow-up</i>            &lt;8.9%: 30.1 (37)            8.9–11.3%: 41.3 (44)            1.4–15.2%: 54.2 (52)            15.3–20.0%: 70.4 (65)            &gt;20.0%: 104.1 (102)            Total: 300.1 (300)</p> <p><i>CRF+X, Assessment 1, 26-year follow-up</i>            &lt;7.2%: 24.8 (27)            7.2–10.2%: 37.2 (37)            10.3–14.1%: 49.2 (47)            14.2–20.8%: 67.8 (69)            &gt;20.8%: 121.2 (120)            Total: 300.2 (300)</p> <p><i>CRF, Assessment 2, 19-year follow-up</i>            &lt;8.9%: 14.7 (16)            8.9–11.3%: 19.9 (19)            1.4–15.2%: 24.9 (21)            15.3–20.0%: 32.4 (38)            &gt;20.0%: 51.0 (49)            Total: 142.9 (143)</p> <p><i>CRF+X, Assessment 2, 19-year follow-up</i>            &lt;7.2%: 10.7 (10)            7.2–10.2%: 15.9 (18)            10.3–14.1%: 21.8 (27)            14.2–20.8%: 30.6 (23)            &gt;20.8%: 64.0 (65)            Total: 142.9 (143)</p> <p><i>CRF, Assessment 1 with Insertion of Assessment 2 data for those who remained healthy (at 2), 19-year follow-up</i>            &lt;8.9%: 15.8 (18)            8.9–11.3%: 21.4 (20)            1.4–15.2%: 27.1 (25)            15.3–20.0%: 36.0 (32)            &gt;20.0%: 58.6 (48)            Total: 158.9 (143)</p>	NR

**Table 5. Results of Included Studies for KQ 2 That Evaluated Exercise ECG**

First Author, Year Quality	Outcome	N (%) With Outcome	Discrimination	Calibration	Reclassification
Erikssen, 2004 <sup>56</sup> Fair (cont'd)				<i>CRF+X, Assessment 1 with Insertion of Assessment 2 data for those who remained healthy (at 2), 19-year follow-up</i> <7.2%: 8.0 (12) 7.2–10.2%: 14.9 (15) 10.3–14.1%: 23.3 (30) 14.2–20.8%: 35.6 (31) >20.8%: 76.5 (55) Total: 158.3 (143)	

<sup>a</sup> Cardiac events were defined as a composite of cardiac death, nonfatal MI, and the need for coronary revascularization following the development of symptomatic CAD.

<sup>b</sup> The 106 events included 17 cardiac death, 16 nonfatal MIs, and 73 coronary revascularizations.

<sup>c</sup> Metabolic equivalents of task (peak exercise capacity was determined from the ETT to determine METs, and it was categorized as >8, 5 to 8, or <5).

<sup>d</sup> Duke treadmill score (it was categorized as low, 5 or more, intermediate, 4 to -10, or high, -11 or less)

<sup>e</sup> ETT is based on criteria for determining ischemia (separate from DTS or METs from the exercise test)

<sup>f</sup> Appropriate use cohort was 824 patients (87% of the total cohort) considered acceptable candidates for functional testing on the basis of recent appropriate use criteria (i.e., intermediate to high FRS risk and/or chest pain symptoms).

<sup>g</sup> Total coronary events included cardiac deaths, sudden deaths, acute MI, and stable or unstable angina.

<sup>h</sup> Including 6 cardiac deaths, 13 stable or unstable angina events, and 15 nonfatal MI. Number of sudden deaths NR.

<sup>i</sup> When adjusting for age, sex, current tobacco consumption, systolic blood pressure, total cholesterol, HDL cholesterol and diabetes (instead of 10-year Framingham risk of CHD), reported p was 0.10.

<sup>j</sup> When adjusting for age, sex, current tobacco consumption, systolic blood pressure, total cholesterol, HDL cholesterol and diabetes (instead of 10-year Framingham risk of CHD), reported p was 0.03.

<sup>k</sup> Definite coronary events included cardiac deaths, sudden deaths, acute MI, and stable or unstable angina. Revascularization (coronary artery bypass surgery or percutaneous coronary intervention) without clinical symptom was not considered as a coronary event.

<sup>l</sup> Study reported 8 with sudden death or fatal MI, 24 with nonfatal MI, 15 with acute coronary syndromes, and 47 with stable angina.

<sup>m</sup> All of the models considering the exercise test variable also included femoral bruit because it had been significant in adjusted HRs. The article provides data for FRS + femoral bruit also, showing that there was little to no change with its addition, e.g., AUROC 0.732 (same as for the model with FRS only).

<sup>n</sup> Deaths caused by ischemic heart disease and sudden, unexpected deaths were classified as coronary deaths. Cardiovascular deaths also include deaths caused by stroke and ruptured aortic aneurysms.

<sup>o</sup> Exercise predictors: Physical fitness (cumulative work during exercise divided by body weight), maximal heart rate, systolic blood pressure at end of the first exercise load (100 W), and exercise ECG interpretation (ST-depression of at least 1.0 mm 0.08 s after the J-point regardless of ST-segment morphology)

**Abbreviations:** AUC=area under the curve; AUROC=area under the receiver operating characteristic curve; CHD=coronary heart disease; CRF=classical risk factors; DTS=Duke treadmill score; ECG=electrocardiogram; ETT=exercise treadmill testing; MET=metabolic equivalents of task; FRS=Framingham Risk Score; IDI=integrated discrimination improvement; KQ=key question; N=sample; NR=not reported; NRI=net reclassification improvement; SCORE=Systematic COronary Risk Evaluation.

**Table 6. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 1**

First Author, Year Quality	ECG Findings Evaluated	Model Type: Base model	Cohort	Source of Patients	Country
Auer et al, 2012 <sup>58</sup> Good	Major <sup>a</sup> and minor <sup>b</sup> 12-lead ECG abnormalities classified using the Minnesota Coding System	Both types evaluated Model development: (1) FRS variables <sup>c</sup> and diabetes (2) FRS variables only Published coefficient: FRS	Health, Aging, and Body Composition Study (Health ABC Study)	Population-based cohort assessing body composition, long-term conditions, and incident mobility limitation in an older adult cohort (1997–98)	U.S.
Badheka et al, 2013 <sup>57</sup> Fair	Major and Minor 12-lead ECG abnormalities classified using the Minnesota Coding System <sup>d</sup>	Published coefficient: FRS	NHANES-III	Population-based survey to collect information on the health and nutrition of U.S. households (1988–1994).	U.S.
Badheka et al, 2013 <sup>63</sup> Fair	12-lead ECG ST-T wave abnormalities in lead aVR classified by the Minnesota Code	Published coefficient: FRS	NHANES-III	Population-based survey to collect information on the health and nutrition of U.S. households (1988–1994).	U.S.
Denes 2007 <sup>49</sup> Fair	Major, <sup>e</sup> minor, <sup>f</sup> and incident <sup>g</sup> 12-lead ECG changes using the Novacode criteria	Published coefficient: FRS	WHI Study (estrogen + progestin trial)	Population-based study on common causes of morbidity/mortality among postmenopausal women (1993–1998).	U.S.
Folsom 2003 <sup>64</sup> Fair	LVH using a 12-lead ECG and the Cornell score	Model development: FRS variables <sup>h</sup>	ARIC	Population-based study of 4 U.S. communities (1987–1989)	U.S.
Ishikawa 2015 <sup>61</sup> Fair	Prolonged corrected QT (QTc) intervals <sup>i</sup> and LVH <sup>j</sup> on 12-lead ECG	Model development: FRS variables plus alcohol intake and heart rate <sup>k</sup>	The Jichi Medical School Cohort	Government-sponsored screening to clarify the risk factors for cardio/cerebrovascular diseases in the general population (1992-1995)	Japan
Jorgensen 2014 <sup>60</sup> Fair	Major and Minor 12-lead ECG abnormalities classified using Minnesota Code; also reported outcomes for some single ECG changes <sup>m</sup>	Model development: FRS variables <sup>l</sup>	The Copenhagen City Heart Study	The Copenhagen City Heart Study (1976–1978)	Denmark
Shah, 2016 <sup>59</sup> Fair	ECG Risk Score including frontal T axis, corrected QT interval, T axis, heart rate, age, sex, age*sex interaction term (selected from major <sup>o</sup> and minor <sup>p</sup> abnormalities)	Both types evaluated  Published coefficient: FRS <sup>n</sup> and PCE  Model development: FRS variables	NHANES I (development cohort) and NHANES III (validation cohort)	Population-based survey to collect information on the health and nutrition; NHANES I (1971–1975) and NHANES III (1988–1994)	U.S.
Tereshchenko, 2014 <sup>62</sup> Fair	Resting 12-lead, P wave morphology (specifically DTNPV1 <sup>1</sup> )	Model development: FRS variables <sup>q</sup>	ARIC	Population-based study of 4 U.S. communities (1987–1989)	U.S.

<sup>a</sup> Criteria for major prevalent ECG abnormalities were any of the following: Q-QS wave abnormalities (MC 1-1 to 1-2-8); left ventricular hypertrophy (MC 3–1); Wolff-Parkinson-White syndrome (MC 6-4-1 or 6-4-2); complete bundle branch block or intraventricular block (MC 7-1-1, 7-2-1, 7–4, or 7–8); atrial fibrillation or atrial flutter (MC 8–3); or major ST-T changes (MC 4–1, 4–2, 5–1, and 5–2).

**Table 6. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 1**

<sup>b</sup> Criteria for minor prevalent ECG abnormalities were minor ST-T changes (MC 4–3, 4-4, 5–3, and 5–4). Participants with both major and minor abnormalities were classified as having major abnormalities. Participants without minor or major ECG abnormalities were classified as having marginal or no abnormalities and their ECG was considered normal.

<sup>c</sup> FRS variables were age, sex, total and HDL-C systolic blood pressure, and smoking.

<sup>d</sup> Individuals with any of the following at baseline were considered to have ECG abnormalities: possible or probably MI, cardiac infarction/injury score of  $\geq 10$ , possible or probably left ventricular hypertrophy, any axis deviation, and any rhythm abnormalities other than sinus.

<sup>e</sup> Criteria for major prevalent ECG abnormalities were any of the following: (1) atrial fibrillation or atrial flutter; (2) high-degree atrioventricular dissociation; (3) left bundle-branch block; (4) right bundle-branch block; (5) indeterminate conduction delay; (6) Q-wave MI; (7) isolated ischemic abnormalities; (8) left ventricular hypertrophy with ST-T abnormalities; and (9) miscellaneous arrhythmias (e.g., supraventricular tachycardia, ventricular preexcitation, ventricular tachycardia) with less than 5 participants being included in the analysis and not listed individually. Women with both major and minor abnormalities were classified as having major abnormalities.

<sup>f</sup> Criteria for minor prevalent ECG abnormalities were any of the following: (1) first- and second-degree atrioventricular block; (2) borderline prolonged ventricular excitation; (3) prolonged ventricular repolarization; (4) isolated minor Q and ST-T abnormalities; (5) left ventricular hypertrophy without ST-T abnormalities; (6) left atrial enlargement; (7) frequent atrial or ventricular premature beats; and (8) fascicular blocks.

<sup>g</sup> Criteria for incident ECG abnormalities were any of the following: (1) new atrial fibrillation or flutter; (2) new prolonged ventricular excitation; (3) new prolonged ventricular repolarization; (4) new left ventricular hypertrophy; (5) new Q-wave MI; and (6) new ischemic ST-T evolution.

<sup>h</sup> model included age, race, total & HDL cholesterol, systolic blood pressure, use of antihypertensive medication, and smoking status

<sup>i</sup> QTc determined by Bazett QTc intervals of  $\geq 440$  ms in men and  $\geq 460$  ms in women on a 12-lead ECG

<sup>j</sup> LVH diagnosed with Cornell product of  $\geq 244$  mVxms

<sup>k</sup> model included age, sex, body mass index, current smoking, alcohol intake  $>20$  g/d, systolic blood pressure, antihypertensive medication use, diabetes mellitus, hyperlipidemia, and heart rate.

<sup>l</sup> Model included age, systolic blood pressure, total cholesterol, sex, current smoking, and diabetes

<sup>m</sup> Reported outcomes for major or minor ECG changes, T wave changes, ventricular conduction delay, LVH, Q waves, ST depressions, resting heart rate

<sup>n</sup> FRS model includes age, sex, systolic and diastolic blood pressure, diabetes, tobacco use, total and HDL-C levels, and use of antihypertensives

<sup>o</sup> Major ECG abnormalities were defined based on Minnesota codes as follows: Major Q/QS waves (1.1, 1.2), ST depression (4.1, 4.2), negative T waves (5.1, 5.2), ventricular conduction defect (7.1, 7.2, or 7.4), atrial fibrillation/flutter (8.3), or ST elevation (9.2).

<sup>p</sup> Minor ECG abnormalities were defined as having Minnesota codes for Minor Q waves (1.2.8 or 1.3), high R waves (3.1 or 3.3), minor ST changes (4.3 or 4.4), minor T wave changes (5.3 or 5.4), prolonged PR interval (6.3), RR' in V1 or V2 (7.3 or 7.5), or left anterior fascicular block (7.7).

<sup>q</sup> FRS components: age, gender, systolic blood pressure, diabetes, HDL and total cholesterol, smoking, and blood pressure-lowering therapy)

<sup>r</sup> Deep terminal negativity of P wave in V1

**Abbreviations:** ARIC=Atherosclerosis Risk in Communities; ECG=electrocardiogram; FRS=Framingham Risk Score; HDL-C= high-density lipoprotein cholesterol; LVH=Left ventricular hypertrophy; NHANES-I= National Health and Nutrition Examination Survey-i; NHANES-III= National Health and Nutrition Examination Survey-III; PCE=pooled cohort equations; U.S.=United States; WHI=Women's Health Initiative.

**Table 7. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 2**

First Author, Year Quality	Sample Size	Years of Follow-up	% CVD	% With Symptoms	Mean Age (SD)	% F	% Non- white	CV Risk	Mean BMI (SD)	% HTN	% DM	% Smokers
Auer et al, 2012 <sup>58</sup> Good	2192	Median: 8.2	0	NR	73.5 (2.8)	55	41	FRS mean (SD): 12.6 (7.3 <sup>a</sup> ) Mean intermediate risk	27.4 (4.9)	57.3	13.3	Current: 10.1 Former: 43.6
Badheka et al, 2013 <sup>57</sup> Fair	6025	Mean 13	0	NR <sup>b</sup>	58.7 (13)	54	12	<5: 3391 (59%) 5-10: 987 (17%) 10-20: 854 (15%) >20: 497 (9%) Most low risk	27.2 (5)	40	0	24
Badheka et al, 2013 <sup>63</sup> Fair	7928	Mean 13.5	CAD: 9.8 MI: 5.4 HF: 2.8 Stroke: 2.9 Total: 15.4	NR	59.9 (13.4)	55	9.2	<5: 2625 (35%) 5-10: 1221 (16%) 10-20: 1487 (20%) >20: 2176 (29%) Most low risk	27.6 (5.5)	43.8	10.9	23.1
Denes 2007 <sup>49</sup> Fair	1,264 <sup>c</sup>	Mean 5.6	0	NR	63	100	16	NR	28-29 <sup>d</sup> (5.6-6.2)	55-75	4	Past: 40 Current: 10
Folsom 2003 <sup>64</sup> Fair	14,054	Median: 10.2	0 with history of CHD	NR	Median: 55 (range 45-64)	57	NR <sup>e</sup>	NR	NR	NR	10.7	NR
Ishikawa 2015 <sup>61</sup> Fair	10,643	Mean 10.7	Unclear, but likely small % <sup>f</sup>	NR	55.4 (11.2)	62	NR	<2.5: 4648 (55%) 2.5-5: 1819 (22%) >5: 1986 (23%) Most low stroke risk	23.1 (3.1)	33.9	3.6	22.6
Jorgensen 2014 <sup>60</sup> Fair	6991 <sup>9i</sup>	Median 11.9 <sup>h</sup>	0	NR	70 (4)	59	NR	FRS <sup>i</sup> 25.9-33.4 Mean high risk	26 (4.3)	NR	5	47
Shah, 2016 <sup>59</sup> Fair	9969 (derivation: 3640, validation: 6329)	Median: 18.8 (derivation), 10 (validation)	0	NR	Total: 55.3 (10.1)	53	Derivation: 11 Validation: 26.6	NHANES ECG risk equation scores: 9.02 (0.79); 8.96 (0.86) Possibly low risk	NR	Anti- hypertensive use: 7.5; 20.4	4.9; 16.6	34.3; 25.5 <sup>j</sup>
Tereshchenko, 2014 <sup>62</sup> Fair	15,375 <sup>k</sup>	Median 14	CHD: 5% HF: 5% MI: 4% Stroke: 2%	NR <sup>l</sup>	54 (5.8)	55	27	<5: 12,463 (96%) 5-20: 565 (4%) >20: 21 (0.2%) Most low SCD risk	28 (5.5)	25	10	26

<sup>a</sup> Breakdown by FRS Categories by % 10-year risk was as follows: <5.0: 297 (13.6); 5.0-9.9: 525 (23.9); 10.0-19.9: 853 (38.9); ≥20.0: 517 (23.6)

<sup>b</sup> Study excluded those with self-reported chest pain suggestive of angina or leg pain suggestive of claudication

<sup>c</sup> The number of participants shown here is the number in analyses eligible for our review. The authors used the 1,264 participants in the WHI blood subsample for the eligible analyses (the larger study included 14,749 participants, 7593 from the estrogen + progestin group and 7,156 from the placebo group).

<sup>d</sup> When this table includes a range, it means that the data were not reported for the full sample, but were reported separately for subgroups



## Table 7. Characteristics of Included Studies for KQ 2 That Evaluated Resting ECG, Part 2

<sup>e</sup> % nonwhite was NR for full sample, but the authors reported that 45% of diabetic participants were black.

<sup>f</sup> Exclusion criteria listed pacemaker implantation, atrial fibrillation, advanced or complete atrioventricular block, dextrocardia, complete left or right bundle block, heart rate over 150 bpm, and history of stroke or MI, but did not address history of CHD, TIA, angina, or PAD.

<sup>g</sup> For sample with  $\geq 10$  years follow-up (sample used to calculate discrimination and reclassification outcomes): 4923 had  $\geq 10$  years of follow-up for the endpoint of fatal CVD, 5418 had  $\geq 10$  years of follow-up for the endpoint of fatal and nonfatal CVD, and 6907 had  $\geq 10$  years of follow-up for the endpoint of all-cause mortality.

<sup>h</sup> Median for fatal CVD (primary outcome was 10.9); median for fatal or nonfatal CVD combined (secondary endpoint) was 9.8 years, and median for all-cause mortality was 11.9 years.

<sup>i</sup> Baseline risk from the SCORE Risk Model: For participants with no ECG Changes: 13.1 (8.0–21.1); for those with ECG Changes: 18.3 (10.7–29.6)

<sup>j</sup> When 2 numbers are present in these, they are for derivation cohort and the validation cohort

<sup>k</sup> 13,049 CVD-free persons were in the reclassification analyses

<sup>l</sup> The study defined prevalent CHD to include those with symptoms of angina or claudication as well as those with diagnoses of CHD.

**Abbreviations:** AUC=area under the curve; CAD=coronary artery disease; CHD=coronary heart disease; CV=cardiovascular; CVD=cardiovascular disease; DM=diabetes mellitus; FRS=Framingham Risk Score; HF=heart failure; HTN=hypertension; MI=myocardial infarction; NHANES=National Health and Nutrition Examination Survey; NR=not reported; SCD=spontaneous cardiac death; SD=standard deviation.

**Table 8. Summary of Evidence for Screening With ECG**

Key Question and Topic	No. of Studies, Study Design	N	Summary of Main Findings (Including Consistency and Precision)	Quality	Limitations (Including Reporting Bias)	Strength of Evidence	Applicability
1: Benefits of screening with ECG	2 RCTs	1,151	Neither study found a statistically significant reduction in events, including their primary outcomes, <sup>a</sup> all-cause mortality, cardiovascular-related mortality, MI, heart failure, or stroke. Findings were consistent and imprecise.	2 Fair	Neither trial reached sample size targets; stopped early because of trouble recruiting. Not clear that 3.5 years of follow up is sufficient. Masking of outcome assessors and amount of missing data NR in 1. <sup>53</sup> Reporting bias not detected.	Low for no benefit of screening with exercise ECG  Insufficient for resting ECG; no studies	Asymptomatic adults ages 50 to 75 years with diabetes undergoing exercise ECG; both trials enrolled high risk populations
2: Reclassification, calibration, and discrimination for exercise ECG	5 cohort studies	9,582	Discrimination (k=3): small absolute improvement in AUC or C-statistics (0.02–0.03); none reported 95% CIs; 1 reported p=0.3 (no significant difference between models). Consistent; imprecise.  Calibration or performance (k=4 total; k=2 FRS base model): all 4 used different metrics; <sup>b</sup> none reported figures such as calibration plots; <sup>c</sup> k=3 reported improvement with addition of exercise ECG variables; mixed results for the 2 with FRS base models. Inconsistent; imprecise.  Reclassification (k=1 model development study, 988 participants): Total NRI 9.6% (p=0.007); intermediate risk group NRI 18.9% (p=0.01). Consistency unknown; imprecise.	5 Fair	Confidence intervals for calibration or discrimination NR (k=5); mean duration of follow up <10 years <sup>d</sup> (k=4), reclassification NR (k=4); unknown masking of outcome assessors (k=4); not reporting both discrimination and calibration (k=3); model development studies (k=2); unclear handling and amount of missing data (k=2); the 1 study reporting NRI was a model development study, used risk categories of <6% vs. 6–20% vs. >20% and may have included many symptomatic participants. <sup>e</sup> Reporting bias not detected.	Discrimination: Low for small improvement  Calibration: Insufficient  Reclassification: Insufficient	Adults without a history of CVD; mean age of participants 50–58 years; range of females was 0–38%; race/ethnicity NR in most (k=4); mean baseline FRS score was 10.8–12.3 in studies reporting it (k=3); intermediate risk, on average
2: Reclassification, calibration, and discrimination for resting ECG	9 cohort studies	66,407	Discrimination (k=7 total; k=4 FRS or PCE base model; k=4 multiple ECG changes): very small to small absolute improvement in AUC or C-statistics (0.001–0.05); Few (k=3) reported whether differences were statistically significant. Consistent; imprecise.	8 Fair; 1 Good	Limited reporting on assessment of symptoms; unclear what proportion of participants were truly asymptomatic.	Discrimination: Low for very small to small improvement  Calibration: Low for improvement	Adults without a history of CVD; mean age of participants 54–73; majority were women in all studies.

**Table 8. Summary of Evidence for Screening With ECG**

Key Question and Topic	No. of Studies, Study Design	N	Summary of Main Findings (Including Consistency and Precision)	Quality	Limitations (Including Reporting Bias)	Strength of Evidence	Applicability
2: Reclassification, calibration, and discrimination for resting ECG (continued)			<p>Calibration or performance (k=4 total; k=2 FRS + major/minor ECG changes; k=1 FRS + specific T wave change): none reported calibration plots; variety of metrics used; good calibration with addition of major/minor changes (k=2) or T wave amplitude in lead aVR (k=1) to FRS. Poor calibration with addition of major/minor changes to FRS variables (k=1 model development of older adults 70–79). Consistent among studies using published coefficients (k=3); imprecise.</p> <p>Reclassification (k=7 total with 59,123 participants; k=3 FRS or PCE + multiple ECG changes; k=1 FRS + specific T wave change). Overall, total NRIs (event; nonevent) range from 3.6% (2.7%; 0.6%) to 30% (17%; 19%) for studies using FRS or PCE base models (95% CIs rarely reported [Figure 7]).<sup>f</sup></p> <p>Consistent in all showing improved NRI, but inconsistent for estimates of NRI and outcomes assessed; consistency unknown for specific risk categories because all studies used different risk categories; imprecise.</p>		Masking of outcome assessors NR (k=8), confidence intervals for calibration or discrimination NR (k=5), not reporting calibration (k=5), model development studies (k=4), amount of missing data NR (k=2), and mean duration of follow up less than 10 years (k=2). For reclassification, few studies (k=3) included a threshold between risk categories corresponding to the recommendations for preventive medications (i.e., 7.5% or 10% 10-year risk).	Reclassification: Low for improvement	Range of nonwhite participants in those that reported race/ethnicity (k=6) was 9–41%. Mean baseline risk ranging from low to high across studies
3: Harms of screening with ECG	1 RCT	520	One patient out of 12 (8.3%) undergoing revascularization procedures after positive exercise treadmill tests in the DADDY-D trial had a nonfatal acute MI 3 days after percutaneous revascularization and underwent a second percutaneous angioplasty. <sup>9</sup> Consistency unknown (single study); imprecise.	1 Fair	Trial focused on assessing benefits; did not reach sample size target; not clear that mean of 3.6 years of follow up is sufficient; masking of outcome assessors NR and amount of missing data NR. Reporting bias not detected.	Insufficient	Asymptomatic adults ages 55 to 75 years with diabetes undergoing screening with exercise ECG

<sup>a</sup> For the primary composite outcomes, HRs were 1.00 (0.59 to 1.71) for a composite of death from all causes, nonfatal MI, nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention, and 0.85 (0.39 to 1.84) for a composite of nonfatal MI or cardiac death.

<sup>b</sup> Metrics included likelihood ratio test; Akaike information criteria (AIC), Brier’s score, and Hosmer-Lemeshow  $\chi^2$ ; global  $\chi^2$ ; and numbers of predicted and observed events.

<sup>c</sup> One model development study provided a table of predicted and observed events for quintiles of risk.<sup>56</sup>

<sup>d</sup> The only study reporting longer followup covered 26 years, but it did not account for HDL in analyses.<sup>56</sup>

<sup>e</sup> 16.5% had atypical chest pain and participants were a subset of those having CACS and SPECT for “clinically indicated reasons.”<sup>54</sup>

## Table 8. Summary of Evidence for Screening With ECG

<sup>f</sup> For multiple ECG changes (on resting 12-lead ECG), total NRIs (event NRIs; nonevent NRIs) for studies using any base model ranged from 1.9% (-0.2%; 0.6%) to 30% (17%; 19%).

<sup>g</sup> The DADDY-D trial reported that 20/262 participants (7.6%) in the screened group had positive ETTs. Of those 20, 17 underwent coronary angiography (6.5% of the 262). Angiography revealed critical stenosis (not defined) in 71% (12/17), and all patients with critical stenosis underwent revascularization procedures (7 percutaneous, 5 surgical). The DYNAMIT trial (included in KQ 1) reported the number of some subsequent tests but did not report whether any of the tests or interventions resulted in harms; adverse events that occurred during followup were not recorded.<sup>52</sup> Sixty eight of the 316 participants (21.5%) in the screened group had a definitely abnormal or an uncertain screening test (exercise test or SPECT) result. Of those, 38 underwent coronary angiography (12% of the 316 in the screened group) and 9 subsequently underwent coronary angioplasty (7/9 received stents) and 3 had coronary artery bypass graft.

**Abbreviations:** AIC=Akaike information criteria; AUC=area under the curve; CACS=coronary artery calcium score; CI=confidence interval; CVD=cardiovascular disease; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; ECG=electrocardiogram; FRS=Framingham Risk Score; HDL=high-density lipoprotein; HR=hazard ratio; k=number of studies; KQ=key question; MI=myocardial infarction; N=number; NR=not reported; NRI=net reclassification improvement; PCE=pooled cohort equations; RCT=randomized, controlled trial; SPECT=single-photon emission computed tomography.

**Table 9. Snapshot to Assess Net Benefit**

Key Question	Exercise ECG	Resting ECG	Considerations
<b>Benefits</b>			
KQ 1: Benefits of screening	k=2; n=1,151 <b>No statistically significant difference</b> in primary composite outcomes, all-cause mortality, CV-related mortality, MI, heart failure, or stroke at 3.5 years	No evidence	Despite enrolling high-risk persons with diabetes, neither trial found benefit. But neither reached sample size targets; stopped early because of trouble recruiting. Findings were imprecise. Not clear that 3.5 years of follow up is sufficient. Masking of outcome assessors and amount of missing data not reported in 1 trial.
KQ 2: Calibration	k=4; n=6,762 <b>Mixed results</b> (and all 4 used different metrics)	k=4; n=17,409 <b>Improved calibration</b> among studies using published coefficients of FRS (k=3). Poor calibration in 1 model development of older adults ages 70–79 years.	Preferred measures rarely reported. <b>For resting ECG:</b> none reported calibration plots; limited reported on assessment of symptoms; unclear what proportion of participants were truly asymptomatic; majority of the resting ECG studies did not report calibration (k=5 out of 9); imprecise.
KQ 2: Discrimination	k=3; n=7,251 <b>Small improvement</b>	k=7; n=44,699 <b>Very small to small improvement</b>	Overall, results were consistent but imprecise. <b>For exercise ECG:</b> 95% CIs were not reported (1 reported p=0.3, no significant difference between models). <b>For resting ECG:</b> k=4 FRS or PCE base model; few (k=3) reported whether differences were statistically significant.
KQ 2: Reclassification	k=1; n=988 <b>Improvement</b> (total NRI 9.6%, p=0.007; intermediate risk group NRI 18.9%, p=0.01)	k=7; n=59,123 <b>Improvement</b> for studies using FRS or PCE base models (k=4): total NRIs (event; nonevent) range from 3.6% (2.7%; 0.6%) to 30% (17%; 19%)	Heterogeneity and applicability of risk thresholds; 95% CIs rarely reported. <b>For exercise ECG:</b> 1 model development study that used risk categories of <6% vs. 6–20% vs. >20% and may have included many symptomatic participants. <b>For resting ECG:</b> consistent in all showing improved NRI but inconsistent for estimates of NRI and outcomes assessed; consistency unknown for specific risk categories because all studies used different risk categories.
<b>Harms</b>			
KQ 3: Screening	k=1; n=520 1/12 persons (8.3%) undergoing revascularization after positive exercise tests had a nonfatal acute MI 3 days after the procedure	No evidence	Only 1 study eligible with 1 event reported. More information about potential harms is in the Discussion and contextual question 2.

**Abbreviations:** CI=confidence interval; CV=cardiovascular; ECG=electrocardiogram; FRS=Framingham Risk Score; KQ=key question; MI=myocardial infarction; NRI=net reclassification improvement; PCE=pooled cohort equations.

**Appendix A Table 1. Recent Recommendations on Screening for CVD Using ECG**

<b>Organization</b>	<b>Population</b>	<b>Recommendation</b>
ACP, 2015 <sup>1</sup>	Asymptomatic low-risk adults	Do not screen for cardiac disease in asymptomatic, low-risk adults with resting or stress ECG.
ACC Foundation/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS, 2014 <sup>2</sup>	Low global risk; regardless of ECG interpretability and ability to exercise  Intermediate global risk; ECG interpretable and able to exercise	Exercise ECG is rarely an appropriate option because of the lack of a clear benefit/risk advantage.  Exercise ECG may be an appropriate option because of variable evidence or agreement regarding the benefit/risk ratio, potential benefit based on practice experience in the absence of evidence, and/or variability in the population.
AAFP, 2012 <sup>3</sup>	Asymptomatic low-risk adults	Do not order annual ECGs or any other cardiac screening.
ACPM, 2011 <sup>4</sup>	General adult population	Do not routinely screen the general adult population using resting or exercise ECG.
ACC/AHA, 2010 <sup>5</sup>	Asymptomatic adults <b>with</b> hypertension or diabetes  Asymptomatic adults <b>without</b> hypertension or diabetes  Intermediate-risk asymptomatic adults (including sedentary adults considering starting a vigorous exercise program)	A resting ECG is reasonable for cardiovascular risk assessment.  A resting ECG may be considered for cardiovascular risk assessment.  An exercise ECG may be considered for cardiovascular risk assessment, particularly when attention is paid to non-ECG markers such as exercise capacity.
AHA, 2005 <sup>6</sup>	Asymptomatic adults	There is insufficient evidence to recommend exercise testing as a routine screening modality.

**Abbreviations:** AAFP=American Academy of Family Physicians; ACC=American College of Cardiology; ACP=American College of Physicians; ACPM=American College of Preventive Medicine; AHA=American Heart Association; ASA=American Stroke Association; ASE=American Society of Echocardiography; ASNC=American Society of Nuclear Cardiology; CVD=cardiovascular disease; ECG=electrocardiogram; HFSA=Heart Failure Society of America; HRS=Heart Rhythm Society; Royal College of Physicians of Edinburgh; SCAI=Society for Cardiovascular Angiography and Interventions; SCCT=Society of Cardiovascular Computed Tomography; SCMR=Society for Cardiovascular Magnetic Resonance; STS=Society of Thoracic Surgeons.

**Appendix A Table 2. Characteristics of Available and Recommended Cardiovascular and Coronary Risk Assessment Models**

Risk Score and Recommending Body	Risk Factors Included in the Model	Time Horizon and Outcome	Derivation and External Validation Cohorts	Limitations
ACC/AHA Pooled Cohort Equation, 2013 <sup>7</sup>  ACC/AHA <sup>8</sup>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Sex</li> <li>• Race/ethnicity</li> <li>• Treated or untreated SBP</li> <li>• TC</li> <li>• HDL-C</li> <li>• Current smoking</li> <li>• Diabetes</li> </ul> <p>Other CVD risk factors evaluated but not included<sup>a</sup></p>	10-year risk  First hard CVD event (nonfatal MI, CHD death, fatal or nonfatal stroke)	<p><u>Derivation Cohorts:</u> ARIC, CHS, CARDIA, Framingham/Framingham Offspring</p> <p><u>External Validation Cohorts:</u> REGARDS, MESA, Contemporary Cohort (ARIC, Framingham/Framingham Offspring), Rotterdam Study, WHS, PHS, WHI Observational Study</p>	Baseline exams for source cohorts conducted >25 years ago No equations for Hispanics or Asians; lack of large external datasets with needed covariate data to validate in these subpopulations Small numbers of events in validation cohorts, particularly in lower-risk groups Possible overprediction across risk strata
Framingham CVD, 2008 <sup>9</sup>  Canadian Cardiovascular Society <sup>10</sup>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Sex</li> <li>• TC</li> <li>• HDL-C</li> <li>• SBP</li> <li>• Antihypertensive medication use</li> <li>• Smoking</li> <li>• Diabetes</li> <li>• (Family history)<sup>b</sup></li> </ul>	10-year risk  Any CVD event (coronary death, MI, coronary insufficiency, angina), cerebrovascular events, peripheral artery disease (intermittent claudication), and congestive heart failure	<p><u>Derivation Cohort:</u> Framingham</p> <p><u>External Validation Cohorts:</u> MESA, WHI Observational Study</p>	Not limited to “hard” outcomes Baseline exams for source cohorts conducted >40 years ago Derivation cohort predominately white with high proportion of smokers (~40%) Possible overprediction, potentially higher among men
QRISK2, 2008 <sup>11</sup>  NICE <sup>12</sup>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Sex</li> <li>• Race/ethnicity</li> <li>• Smoking status</li> <li>• SBP</li> <li>• TC:HDL-C ratio</li> <li>• Body mass index</li> <li>• Family history of CHD in first-degree relative age &lt;60 years</li> <li>• Townsend deprivation score</li> <li>• Treated hypertension</li> <li>• Rheumatoid arthritis</li> <li>• Chronic kidney disease</li> <li>• Diabetes</li> <li>• Atrial fibrillation</li> </ul>	10-year risk  CVD event (angina, MI, stroke, TIA)	<p><u>Derivation Cohort:</u> U.K. primary care database; 2/3 of participants randomly allocated to derivation dataset and 1/3 assigned to validation dataset</p> <p><u>External Validation Cohort:</u> N/A</p>	Not externally validated Derivation cohort predominantly white Recording of family history of CHD possibly not systematic Townsend deprivation score specific to the United Kingdom

**Appendix A Table 2. Characteristics of Available and Recommended Cardiovascular and Coronary Risk Assessment Models**

Risk Score and Recommending Body	Risk Factors Included in the Model	Time Horizon and Outcome	Derivation and External Validation Cohorts	Limitations
Reynolds, men, 2008 <sup>13</sup>  N/A	<ul style="list-style-type: none"> <li>• Age</li> <li>• SBP</li> <li>• Smoking</li> <li>• TC</li> <li>• HDL-C</li> <li>• hs-CRP</li> <li>• Parental history of MI at &lt;60 years of age</li> </ul>	10-year risk  CVD event (CVD death, MI, stroke, coronary revascularization)	<u>Derivation Cohort:</u> PHS  <u>External Validation Cohort:</u> MESA	Derivation cohort predominately white Derivation cohort health professionals; health behaviors, access to health care, and SES may not be generalizable Data on blood pressure, obesity, and family history based on self-report Uncertain applicability in men <50 years old and those with diabetes
Reynolds, women, 2007 <sup>14</sup>  N/A	<ul style="list-style-type: none"> <li>• Age</li> <li>• SBP</li> <li>• Smoking</li> <li>• TC</li> <li>• HDL-C</li> <li>• hs-CRP</li> <li>• Parental history of MI at &lt;60 years of age</li> <li>• HbA1c if diabetic</li> </ul>	10-year risk  CVD events (CVD death, MI, stroke, coronary revascularization)	<u>Derivation Cohort:</u> WHS; 2/3 of participants assigned to model derivation dataset and 1/3 assigned to validation dataset  <u>External Validation Cohorts:</u> MESA, WHI Observational Study	Derivation cohort predominately white Derivation cohort health professionals; health behaviors, access to health care, and SES may not be generalizable Data on blood pressure, obesity, and family history based on self-report Possible underprediction
ASSIGN, 2007 <sup>15</sup>  SIGN <sup>16</sup>	<ul style="list-style-type: none"> <li>• TC</li> <li>• HDL-C</li> <li>• SBP</li> <li>• Smoking</li> <li>• Cigarettes per day</li> <li>• Family history</li> <li>• Diabetes</li> <li>• Index of social status/ deprivation</li> </ul>	10-year risk  CVD events (CVD death, hospitalization for CHD or cerebrovascular disease, revascularization)	<u>Derivation Cohort:</u> SHHEC  <u>External Validation Cohort:</u> U.K. general practice database	Not externally validated in the United States Baseline exams for source cohort conducted >30 years ago Social deprivation index specific to Scotland High prevalence of smoking (~40%) and family history (~20%) in source cohort
ARIC, 2003 <sup>17</sup>  N/A	<ul style="list-style-type: none"> <li>• Sex</li> <li>• Race</li> <li>• Cigarette smoking</li> <li>• TC</li> <li>• HDL-C</li> <li>• SBP</li> <li>• Antihypertensive medication use</li> <li>• Diabetes</li> </ul> <p>Other CVD risk factors evaluated but not included<sup>c</sup></p>	10-year risk  CHD event (CHD death, MI, unrecognized MI defined by electrocardiogram readings, or coronary revascularization)	<u>Derivation Cohort:</u> ARIC  <u>External Validation Cohort:</u> N/A	Not externally validated Baseline exams for source cohorts conducted >25 years ago Not limited to “hard” outcomes Race/ethnicity limited to blacks and whites Source cohort not inclusive of age <45 or >65 years



**Appendix A Table 2. Characteristics of Available and Recommended Cardiovascular and Coronary Risk Assessment Models**

Risk Score and Recommending Body	Risk Factors Included in the Model	Time Horizon and Outcome	Derivation and External Validation Cohorts	Limitations
SCORE, 2003 <sup>18</sup> European Society of Cardiology <sup>19</sup>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Sex</li> <li>• Smoking</li> <li>• TC or TC:HDL ratio</li> <li>• SBP</li> <li>• Smoking</li> <li>• High- and low-risk regions of Europe</li> </ul>	<p>10-year risk</p> <p>Fatal CVD event (MI, stroke, aortic aneurysm)</p>	<p><u>Derivation Cohort:</u> Pooled dataset of population-based and occupational cohort studies from 12 European countries</p> <p><u>External Validation Cohorts:</u> Externally validated in European cohorts (11 evaluation studies)</p>	<p>Not externally validated in the United States</p> <p>Baseline exams for source cohorts conducted &gt;25 years ago</p> <p>Diabetes not included as a risk factor because it was not uniformly collected in source cohort</p>
PROCAM, 2002 <sup>20</sup> N/A	<ul style="list-style-type: none"> <li>• Age</li> <li>• LDL-C</li> <li>• HDL-C</li> <li>• Triglycerides</li> <li>• Smoking</li> <li>• Diabetes</li> <li>• Family history of MI at age &lt;60 years</li> <li>• SBP</li> </ul>	<p>10-year risk</p> <p>CHD event (sudden cardiac death, definite MI)</p>	<p><u>Derivation Cohort:</u> Prospective German cohort of men</p> <p><u>External Validation Cohorts:</u> Externally validated in several European cohorts</p>	<p>Not externally validated in the United States</p> <p>Baseline exams for source cohort conducted &gt;30 years ago</p> <p>Excludes women and adults &gt;65 years old</p> <p>Source cohort ~30% smokers</p>
ATP III modification of Wilson Framingham model, 2002 <sup>21d</sup> ATP III <sup>21e</sup>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Sex</li> <li>• TC</li> <li>• HDL-C</li> <li>• SBP</li> <li>• Treatment for hypertension</li> <li>• Smoking</li> </ul>	<p>10-year risk</p> <p>Hard CHD (MI death, CHD death)</p>	<p><u>Derivation Cohort:</u> Framingham</p> <p><u>External Validation Cohorts:</u> ATP III: MESA, WHI Observational Study</p> <p>Wilson: wide range of cohorts in United States, Europe, and Australia, including ARIC, PHS, HHP, PR, SHS, CHS</p>	<p>Baseline exams for source cohorts conducted &gt;40 years ago</p> <p>Derivation cohort predominately white with high proportion of smokers (~40%)</p> <p>Most validation cohorts have an upper age range of ages 64 or 74 years</p> <p>Recent external validations of ATP III model suggest substantial overestimation, particularly among men</p> <p>Older validations of the Wilson model show underprediction in high-risk groups (people who have diabetes, have a strong family history of premature CVD, reside in regions with high incidence, have low SES) and overprediction in low-risk groups (Japanese American men, Hispanic men, Native American women)</p>

<sup>a</sup> ACC/AHA recommends that if risk based treatment is uncertain using this tool, then consider one or more of the following: family history, hs-CRP, coronary artery calcium score, or ankle-brachial index. Do not use carotid intima-media thickness for risk assessment. No recommendation for or against use of chronic kidney disease, apolipoprotein B, microalbuminuria, and cardiorespiratory fitness.

<sup>b</sup> Canadian Cardiovascular Society recommends a modified version of the model that includes family history of premature CHD.<sup>10</sup>

<sup>c</sup> Other CVD risk factors explored: age, body mass index, waist-to-hip ratio, sport activity index, forced expiratory volume, plasma fibrinogen, factor VII, factor VIII, von Willebrand factor, lipoprotein a, heart rate, Keys score, pack-years smoking, carotid intima-media thickness, fasting triglycerides, apolipoprotein A, apolipoprotein B, albumin, white blood cell count, and creatinine.

## Appendix A Table 2. Characteristics of Available and Recommended Cardiovascular and Coronary Risk Assessment Models

<sup>d</sup> There are additional Framingham-based risk assessment models with variations in outcomes predicted and risk factors included.<sup>22-25</sup> In this table we focused on models recommended by guideline bodies.<sup>9, 21</sup>

<sup>e</sup> Replaced by 2014 recommendations from the ACC/AHA.<sup>8</sup>

**Abbreviations:** ACC=American College of Cardiology; AHA=American Heart Association; ARIC=Atherosclerosis Risk in Communities Study; ATP III=Adult Treatment Panel III; CARDIA=Coronary Artery Risk Development in Young Adults; CHD=coronary heart disease; CHS=Cardiovascular Health Study; CVD=cardiovascular disease; HbA1c=glycated hemoglobin; HDL-C=low-density lipoprotein cholesterol; HHP=Honolulu Heart Program; hs-CRP=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol; MESA=Multi-Ethnic Study of Atherosclerosis; MI=myocardial infarction; N/A=not applicable; NICE=National Institute for Health and Care Excellence; PHS=Physician's Health Study; PR=Puerto Rico Heart Health Program; PROCAM=Prospective Cardiovascular Münster; REGARDS=Reasons for Geographic and Racial Differences in Stroke; SBP=systolic blood pressure; SCORE=Systematic Coronary Risk Evaluation; SES=socioeconomic status; SHHEC=Scottish Heart Health Extended Cohort; SHS=Strong Heart Study; SIGN=Scottish Intercollegiate Guidelines Network; TC=total cholesterol; TIA=transient ischemic attack; UK=United Kingdom; U.S.=United States; WHI=Women's Health Initiative Observational Study; WHS=Women's Health Study.

### **CQ 1a. For People in Each CVD Risk Category (or Strata), What Medications (i.e., Aspirin, Lipid-Lowering Therapy) Are Recommended?**

Several organizations have recommendations for primary prevention of CVD, including the USPSTF, the ACC/AHA, and the American Academy of Family Physicians. European organizations have also weighed in on the subject. Most organizations consider aspirin and statin therapy for primary prevention, while some groups have also considered dietary supplement use.

#### **Aspirin**

The USPSTF released their recommendation<sup>26</sup> for the use of aspirin to prevent CVD in April 2016. They recommended initiating low-dose aspirin for adults ages 50 to 59 years with a 10-year CVD risk of 10 percent or greater and who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take daily aspirin for at least 10 years (B recommendation). The USPSTF recommended using the PCE for determination of 10-year risk. The USPSTF also has a C recommendation for adults ages 60 to 69 years (i.e., C recommendation indicating selectively offering this service based on professional judgment and patient preferences; at least moderate certainty that the net benefit is small). For adults less than age 50 years or 70 years or older, the USPSTF concluded there was insufficient evidence to assess the balance of benefits and harms (I statement).

Recommendations from the American Academy of Family Physicians about aspirin use for primary prevention have been consistent with those of the USPSTF. The American College of Chest Physicians suggests that patients older than 50 years without symptomatic CVD use low-dose aspirin for primary CVD prevention.<sup>27</sup> Both the ACC/AHA and the American Stroke Association recommend low-dose aspirin for adults with 10-year CVD risk greater than 6 percent,<sup>28</sup> while the American Diabetes Association<sup>29</sup> recommends low-dose aspirin in patients with both type 1 and 2 diabetes who have 10-year CVD risk greater than 10 percent and are not at increased risk for bleeding. The ADA does not recommend aspirin therapy in men younger than 50 years or most women younger than 60 years who have low CVD risk because the risk for bleeding outweighs the potential benefits of aspirin treatment.

#### **Statins**

In December 2016, the USPSTF<sup>30</sup> recommended low- to moderate-dose statins for primary prevention for adults ages 40 to 75 years with one or more CVD risk factors and a 10-year CVD risk of 10 percent or greater (B recommendation). For adults with 10-year CVD risk between 7.5 and 10 percent, the USPSTF made a C recommendation, noting that the likelihood of benefit within this risk category was smaller but some adults might benefit. For adults older than 75 years, the USPSTF concluded the evidence was insufficient to assess the balance of benefits and harms (I statement).

The 2013 ACC/AHA guidelines<sup>31</sup> recommend moderate- to high-intensity statin therapy for adults ages 40 to 75 years with LDL-C 70 to 189 mg/dL with a 10-year CVD risk greater than 7.5 percent as calculated by the PCE (strong recommendation) or if they have diabetes. For those with 10-year CVD risk of 5 percent to 7.5 percent, the ACC/AHA made a “weak recommendation” for using statins for primary prevention. For adults age 21 years or older with LDL-C greater than 190, they recommend statin therapy regardless of CVD risk (moderate recommendation).

## Appendix A. Contextual Questions

The Canadian Cardiovascular Society recommends statins plus behavior modification for men age 40 years or older and women age 50 years or older without CVD risk factors and adults of any age with CVD risk factors who also have a 20 percent or greater 10-year CVD event risk (using FRS) or an LDL-C level of 135 to 190 mg/dL and a 10 percent to 20 percent CVD event risk (based on the FRS).<sup>10</sup> The recommended treatment strategy is treatment-to-target rather than by therapy dose (e.g., 50% reduction in LDL-C level).<sup>10</sup>

The UK National Institute for Health and Care Excellence (NICE) recommends atorvastatin (20 mg) for primary prevention in adults (with or without type 2 diabetes) age 40 years or older with 10 percent or greater 10-year CVD risk (based on the QRISK2 tool).<sup>12,32</sup> They note that for adults age 85 years or older, statins may reduce the risk of nonfatal MI. They recommend statin treatment for adults with type 1 diabetes who are older than 40 years, have had diabetes more than 10 years, have nephropathy, or have other CVD risk factors.

## Vitamin Supplements

The USPSTF recommends against the use of beta-carotene and vitamin E supplementation for CVD prevention (D recommendation). For multivitamin, single-, or paired-nutrient supplements, the USPSTF concluded there was insufficient evidence to assess the balance of benefits and harms for CVD prevention (I statement). In addition to beta-carotene and vitamin E, the AHA<sup>33</sup> recommends against the use of antioxidant vitamin supplements (e.g., vitamin C) and folic acid for primary CVD prevention.

## Omega-3 Fatty Acids

The AHA<sup>34</sup> reported there were no RCTs to guide recommendations for the use of omega-3 fatty acids for primary CVD prevention in the general population. However, they found evidence there was no benefit for patients with or at risk for diabetes mellitus to prevent CVD. For patients with high CVD risk, the expert panel was split between recommending against omega-3 fatty acids use versus a weak recommendation that treatment in high-risk patients may be reasonable. NICE<sup>35</sup> recommends against use of omega-3 fatty acids for primary CVD prevention.

## CQ 1b. What Is the Fidelity to Prescribing and Taking the Recommended Medications?

According to the National Ambulatory and National Hospital Ambulatory Medical Care Surveys from 2005 to 2008,<sup>36</sup> few patients were recommended to take aspirin in concordance with guideline recommendations. For example, in 2007 to 2008, among the population identified by the USPSTF to receive aspirin for prevention of CVD and stroke, it was recommended at only 16 percent of visits for males and 22 percent of visits for females.

In an analysis of the National Health and Nutrition Examination Survey (NHANES), 2011–2012,<sup>37</sup> patients without CVD were classified into high and low risk based on FRSs. Approximately 40 percent of the high-risk group and 26 percent of the low-risk group reported being told by their physician to take aspirin. Between 76 percent and 79 percent of patients advised to take aspirin reported complying. Using the same dataset, Malayala et al<sup>38</sup> reported that about 35 percent of men ages 45 to 79 years who met USPSTF guideline recommendations for aspirin for primary prevention were advised by their providers to take aspirin and about 70 percent of that group reported compliance with the recommendation. Also using

## Appendix A. Contextual Questions

the 2011–2012 NHANES dataset, Fiscella et al<sup>39</sup> reported a slightly higher rate of aspirin recommendations for eligible women (i.e., ages 55 to 79 years), 42 percent, for primary CVD prevention.

The Reduction of Atherothrombosis for Continued Health (REACH)<sup>40</sup> Registry compiled data on over 25,000 U.S. outpatients with atherothrombosis or atherosclerotic risk factors between 2003–2004. Approximately 25 percent of the registry enrollees were asymptomatic and comprised the primary prevention cohort (n=6,600). For primary CVD prevention, 62 percent of the cohort were taking at least one antiplatelet agent, most often aspirin, and 77 percent were receiving a statin.

### **CQ 2. What Are the Harms and Benefits of Revascularization Procedures for Adults Without Symptoms or a Prior Diagnosis of CVD?**

Precise estimates of benefits and harms of revascularization for asymptomatic adults were not available. Available data come from studies with mostly symptomatic people. For example, population-based registries including people with symptoms estimate that the risk for any serious harms from angiography (which is often done at the same time as revascularization) is about 1.7 percent, including arrhythmia (0.4%), death (0.1%), stroke (0.07%), or MI (0.05%).<sup>41</sup> After an abnormal screening ECG that is concerning for ischemia, some people without CHD would be sent for angiography without the possibility of benefit but would be subjected to potential harms. Even among a large sample undergoing elective angiography (about 400,000 participants) that was mostly symptomatic (70%), an estimated 39 percent had no CHD on angiography.<sup>42</sup>

One registry study published in *JAMA Internal Medicine*'s Less is More series reported data from a preoperative referral population (for noncardiac surgery) that describes data for a sample with a majority of asymptomatic participants (60%): the National Cardiovascular Data Registry CathPCI Registry. It is a large, national registry of patients undergoing diagnostic cardiac catheterizations and/or percutaneous coronary interventions (PCI) that captures about 85 percent of PCI procedures from approximately 1,400 U.S. hospitals. The registry<sup>43</sup> contains data on nearly 195,000 patients who underwent preoperative evaluation prior to noncardiac surgery between July 2009 and December 2014. Approximately 60 percent of this cohort was reported to be clinically asymptomatic, although 58 percent had been taking antianginal medications within 2 weeks of the procedure; about 20 percent had atypical chest pain considered unlikely to be ischemic, and another 20 percent had stable angina. The sample excluded patients undergoing catheterization with suspected acute coronary syndrome, those who had unstable angina symptoms, and patients undergoing catheterization as part of a cardiac transplant evaluation.

The authors concluded that most patients undergoing diagnostic catheterization before noncardiac surgery are asymptomatic; the discovery of obstructive coronary artery disease is common; and although randomized, clinical trials have found no benefit in outcomes, revascularization is recommended in nearly half of these patients.

Obstructive disease was identified in 48 percent of the cohort overall, 40 percent of those who underwent diagnostic catheterization only, and 97 percent of those receiving PCI. Of patients with asymptomatic presentations, 48 percent were found to have obstructive disease. Approximately 16 percent of the cohort underwent PCI, and an additional 8 percent received CABG; revascularization was recommended in 23 percent of asymptomatic patients.

## Appendix A. Contextual Questions

For the overall cohort, complications related to PCI were uncommon, including coronary artery dissection (1.3%), periprocedural MI (1.7%), vascular complications (0.4%), stroke (0.1%), and renal failure (0.4%). Death occurred in 14 patients on the same day as the procedure, eight of which occurred in the catheterization lab. Bleeding events within 72 hours of the procedure occurred in 371 patients (1.3%), primarily at the procedure access site. Adverse events for asymptomatic patients were not separately reported.

Benefits of revascularization in asymptomatic adults is uncommonly reported. McFalls et al<sup>44</sup> randomized patients scheduled for vascular surgery at 18 Veterans Affairs medical centers to receive preoperative coronary artery revascularization or no revascularization. Of these, 510 participants were randomized, and 240 participants underwent either PCI (n=141) or CABG (n=99). Notably, about half of all participants had prior CAD. After 2.7 years of followup, mortality was no different between groups (RR, 0.97; 95% CI, 0.69 to 1.36). In high-risk subgroups of participants, CABG did not confer a survival benefit. The vast majority of participants were taking beta-blockers, aspirin, ACE inhibitors, and statins up to 24 months after randomization, and their use did not differ between groups.

## Appendix B1. Search Strategies

### PubMed, 7/13/16

Search	Query	Items found
#1	Search ("Electrocardiography"[Mesh] OR electrocardiography OR EKG OR ECG OR "Exercise Test"[Mesh] OR (treadmill AND test) OR (treadmill AND ett))	256656
#2	Search ("Myocardial Ischemia"[Mesh] OR "coronary heart disease"[tiab] OR "coronary disease"[tiab] OR "coronary disease"[mh] OR "coronary artery disease"[tiab] OR "Atherosclerosis"[Mesh] OR atherosclerosis[tiab])	500580
#3	Search (#1 and #2)	67866
#4	Search (("Mass Screening"[Mesh] OR screen*[tiab]))	591681
#5	Search (#3 and #4)	1397
#6	Search (#3 and #4) Filters: Humans	1347
#7	Search (#3 and #4) Filters: Humans; English	1115
#8	Search (#3 and #4) Filters: Humans; English; Adult: 19+ years	843
#9	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	642180
#10	Search (#8 and #9)	81
#11	Search (#8 and #9) Filters: Humans	81
#12	Search (#8 and #9) Filters: Humans; English	81
#13	Search (#8 and #9) Filters: Publication date from 2009/01/01 to 2016/12/31; Humans; English	13
#14	Search (#3 and #4) Filters: Systematic Review s; Humans; English; Adult: 19+ years	18
#15	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Humans; English; Adult: 19+ years	18
#16	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	10
#17	Search ("adverse effects"[Subheading] OR "Long Term Adverse Effects"[Mesh] OR "Patient Harm"[Mesh] OR "Mortality"[Mesh] OR "mortality" [Subheading] OR death[tiab] OR mortality[tiab] OR "medical errors"[mh] OR "iatrogenic disease"[mh] OR "false positive reactions"[mh] OR "Syncope"[Mesh] OR "Arrhythmias, Cardiac"[Mesh] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Anxiety"[Mesh] OR labeling[tiab] OR labelling[tiab] OR "Coronary Angiography"[Mesh] OR "Myocardial Revascularization"[Mesh])	3631548
#18	Search (#8 and #17)	560
#19	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields]))	1903256
#20	Search (#18 and #19) Publication date from 2009/01/01 to 2016/12/31	92
#21	Search (#8 and #17) Filters: Systematic Review s	13
#22	Search (#8 and #17) Filters: Systematic Review s; Meta-Analysis	13
#23	Search (#8 and #17) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31	8
#24	Search ("Coronary Angiography"[Mesh] OR "Myocardial Revascularization"[Mesh])	121744
#25	Search (#2 and #24)	86047
#26	Search ("adverse effects"[Subheading] OR "Long Term Adverse Effects"[Mesh] OR "Patient Harm"[Mesh] OR "Mortality"[Mesh] OR "mortality" [Subheading] OR death[tiab] OR mortality[tiab] OR "medical errors"[mh] OR "iatrogenic disease"[mh] OR "false positive reactions"[mh] OR "Syncope"[Mesh] OR "Arrhythmias, Cardiac"[Mesh] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Anxiety"[Mesh] OR labeling[tiab] OR labelling[tiab])	3574617
#27	Search (#25 and #26)	49909
#28	Search (#25 and #26) Filters: Humans	49313
#29	Search (#25 and #26) Filters: Humans; English	42245
#30	Search (#25 and #26) Filters: Humans; English; Adult: 19+ years	32017
#31	Search (#25 and #26) Filters: Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	11463
#32	Search (#25 and #26) Filters: Systematic Review s; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	266
#33	Search (#25 and #26) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	267
#34	Search (letter[pt] OR new spaper article[pt] OR editorial[pt] OR comment[pt])	1511006
#35	Search (#33 not #34)	266

## Appendix B1. Search Strategies

### PubMed KQ 2 – Risk/Harms search, 7/13/16

Search	Query	Items found
#1	Search ("Electrocardiography"[Mesh] OR electrocardiography OR EKG OR ECG OR "Exercise Test"[Mesh] OR (treadmill AND test) OR (treadmill AND ett))	256656
#2	Search ("Mortality"[Mesh] OR "mortality"[Subheading] OR death[tiab] OR mortality[tiab] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Myocardial Ischemia"[Mesh] OR "Cardiovascular Diseases"[Mesh:NoExp] OR "Coronary Disease"[MeSH] OR "Coronary Disease"[mh] OR "coronary heart disease"[tiab] OR "coronary artery disease"[tiab] OR "coronary disease"[tiab] OR "Heart Failure"[Mesh] OR "heart failure"[tiab] OR "Stroke"[Mesh])	1944815
#3	Search (#1 and #2)	95297
#4	Search ("Risk"[Mesh:NoExp] OR "Logistic Models"[Mesh] OR "Risk Assessment"[Mesh] OR "Risk Factors"[Mesh] OR "Predictive Value of Tests"[Mesh] OR "Kaplan-Meier Estimate"[Mesh] OR "risk prediction"[tiab] OR reclass*[tiab] OR Framingham[tiab] OR "risk score"[tiab] OR "risk scores"[tiab])	1099100
#5	Search (#3 and #4)	17436
#6	Search (#3 and #4) Filters: Humans	17238
#7	Search (#3 and #4) Filters: Humans; English	15162
#8	Search (#3 and #4) Filters: Humans; English; Adult: 19+ years	12007
#9	Search (#3 and #4) Filters: Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	4971
#10	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	642180
#11	Search (#9 and #10)	496
#12	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))	1903256
#13	Search (#9 and #12)	3135
#14	Search (#3 and #4) Filters: Systematic Review s; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	81
#15	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	81



## Appendix B1. Search Strategies

### Cochrane Library Searches KQ 1 and KQ 3, 7/13/16

ID	Search	Hits
#1	[mh Electrocardiography] or electrocardiography or EKG or ECG or [mh "Exercise Test"] or (treadmill and test) or (treadmill and ett)	20976
#2	[mh "Myocardial Ischemia"] or "coronary heart disease":ti,ab or "coronary disease":ti,ab or "coronary disease":kw or "coronary artery disease":ti,ab or [mh Atherosclerosis] or atherosclerosis:ti,ab	32974
#3	#1 and #2	5808
#4	[mh "Mass Screening"] or screen*:ti,ab	26321
#5	#3 and #4 Publication Year from 2009 to 2016, in Cochrane Review s (Review s and Protocols) and Other Review s	13
#6	((controlled:ti or controlled:ab) and (trial:ti or trial:ab)) or "controlled clinical trial" or "randomized controlled trial":pt or "randomized controlled trial as topic":pt or "single-blind method":pt or "double-blind method":pt or "random allocation":pt	574189
#7	#5 and #6	9
#8	[mh /AE] or [mh "Long Term Adverse Effects"] or [mh "Patient Harm"] or [mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or "medical errors":kw or "iatrogenic disease":kw or "false positive reactions":kw or [mh Syncope] or [mh "Arrhythmias, Cardiac"] or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh Anxiety] or labeling:ti,ab or labelling:ti,ab or [mh "Coronary Angiography"] or [mh "Myocardial Revascularization"]	184054
#9	#5 and #8	12
#10	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	139076
#11	#9 and #10	9
#12	[mh "Coronary Angiography"] or [mh "Myocardial Revascularization"]	11381
#13	#2 and #12	7785
#14	[mh /AE] or [mh "Long Term Adverse Effects"] or [mh "Patient Harm"] or [mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or "medical errors":kw or "iatrogenic disease":kw or "false positive reactions":kw or [mh Syncope] or [mh "Arrhythmias, Cardiac"] or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh Anxiety] or labeling:ti,ab or labelling:ti,ab	179573
#15	#13 and #14 Publication Year from 2009 to 2016, in Cochrane Review s (Review s and Protocols) and Other Review s	215

### Cochrane Library Searches KQ 2, Risk, 7/13/16

ID	Search	Hits
#1	[mh Electrocardiography] or electrocardiography or EKG or ECG or [mh "Exercise Test"] or (treadmill and test) or (treadmill and ett)	20976
#2	[mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh "Myocardial Ischemia"] or [mh ^"Cardiovascular Diseases"] or [mh "Coronary Disease"] or "Coronary Disease":kw or "coronary heart disease":ti,ab or "coronary artery disease":ti,ab or "coronary disease":ti,ab or [mh "Heart Failure"] or "heart failure":ti,ab or [mh Stroke]	101003
#3	#1 and #2	8278
#4	[mh ^Risk] or [mh "Logistic Models"] or [mh "Risk Assessment"] or [mh "Risk Factors"] or [mh "Predictive Value of Tests"] or [mh "Kaplan-Meier Estimate"] or "risk prediction":ti,ab or reclass*:ti,ab or Framingham:ti,ab or "risk score":ti,ab or "risk scores":ti,ab	44070
#5	#3 and #4	1239
#6	#3 and #4 Publication Year from 2009 to 2016	539
#7	#6 in Cochrane Review s (Review s and Protocols) and Other Review s	33
#8	((controlled:ti or controlled:ab) and (trial:ti or trial:ab)) or "controlled clinical trial" or "randomized controlled trial":pt or "randomized controlled trial as topic":pt or "single-blind method":pt or "double-blind method":pt or "random allocation":pt	574189
#9	#6 and #8	493
#10	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	139076
#11	#6 and #10	281
#12	#9 or #11 Publication Year from 2009 to 2016	209

## Appendix B1. Search Strategies

### PubMed KQ 1 and KQ 3, 5/30/17

Search	Query	Items Found
#1	Search ("Electrocardiography"[Mesh] OR electrocardiography OR EKG OR ECG OR "Exercise Test"[Mesh] OR (treadmill AND test) OR (treadmill AND ett))	264065
#2	Search ("Myocardial Ischemia"[Mesh] OR "coronary heart disease"[tiab] OR "coronary disease"[tiab] OR "coronary disease"[mh] OR "coronary artery disease"[tiab] OR "Atherosclerosis"[Mesh] OR atherosclerosis[tiab])	518274
#3	Search (#1 and #2)	69195
#4	Search (("Mass Screening"[Mesh] OR screen*[tiab]))	630082
#5	Search (#3 and #4)	1445
#6	Search (#3 and #4) Filters: Humans	1390
#7	Search (#3 and #4) Filters: Humans; English	1156
#8	Search (#3 and #4) Filters: Humans; English; Adult: 19+ years	875
#9	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	672674
#10	Search (#8 and #9)	84
#11	Search (#8 and #9) Filters: Humans	84
#12	Search (#8 and #9) Filters: Humans; English	84
#13	Search (#8 and #9) Filters: Publication date from 2016/01/01 to 2017/12/31; Humans; English	4
#14	Search (#3 and #4) Filters: Systematic Review s; Humans; English; Adult: 19+ years	19
#15	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Humans; English; Adult: 19+ years	19
#16	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	1
#17	Search ("adverse effects"[Subheading] OR "Long Term Adverse Effects"[Mesh] OR "Patient Harm"[Mesh] OR "Mortality"[Mesh] OR "mortality" [Subheading] OR death[tiab] OR mortality[tiab] OR "medical errors"[mh] OR "iatrogenic disease"[mh] OR "false positive reactions"[mh] OR "Syncope"[Mesh] OR "Arrhythmias, Cardiac"[Mesh] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Anxiety"[Mesh] OR labeling[tiab] OR labelling[tiab] OR "Coronary Angiography"[Mesh] OR "Myocardial Revascularization"[Mesh])	3790291
#18	Search (#8 and #17)	577
#19	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields]))	2023668
#20	Search (#18 and #19) Publication date from 2016/01/01 to 2017/12/31	14
#21	Search (#8 and #17) Filters: Systematic Review s	13
#22	Search (#8 and #17) Filters: Systematic Review s; Meta-Analysis	13
#23	Search (#8 and #17) Filters: Systematic Review s; Meta-Analysis; Publication date from 2009/01/01 to 2016/12/31	0
#24	Search ("Coronary Angiography"[Mesh] OR "Myocardial Revascularization"[Mesh])	125817
#25	Search (#2 and #24)	89049
#26	Search ("adverse effects"[Subheading] OR "Long Term Adverse Effects"[Mesh] OR "Patient Harm"[Mesh] OR "Mortality"[Mesh] OR "mortality" [Subheading] OR death[tiab] OR mortality[tiab] OR "medical errors"[mh] OR "iatrogenic disease"[mh] OR "false positive reactions"[mh] OR "Syncope"[Mesh] OR "Arrhythmias, Cardiac"[Mesh] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Anxiety"[Mesh] OR labeling[tiab] OR labelling[tiab])	3731590
#27	Search (#25 and #26)	51715
#28	Search (#25 and #26) Filters: Humans	51104
#29	Search (#25 and #26) Filters: Humans; English	43976
#30	Search (#25 and #26) Filters: Humans; English; Adult: 19+ years	33495
#31	Search (#25 and #26) Filters: Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	1221
#32	Search (#25 and #26) Filters: Systematic Review s; Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	22
#33	Search (#25 and #26) Filters: Systematic Review s; Meta-Analysis; Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	22
#34	Search (letter[pt] OR new spaper article[pt] OR editorial[pt] OR comment[pt])	1566106
#35	Search (#33 not #34)	22

## Appendix B1. Search Strategies

### PubMed KQ 2 – Risk/Harms, 5/30/17

Search	Query	Items Found
#1	Search ("Electrocardiography"[Mesh] OR electrocardiography OR EKG OR ECG OR "Exercise Test"[Mesh] OR (treadmill AND test) OR (treadmill AND ett))	264065
#2	Search ("Mortality"[Mesh] OR "mortality"[Subheading] OR death[tiab] OR mortality[tiab] OR "Myocardial Infarction"[Mesh] OR "heart attack"[tiab] OR "Myocardial Ischemia"[Mesh] OR "Cardiovascular Diseases"[Mesh:NoExp] OR "Coronary Disease"[MeSH] OR "Coronary Disease"[mh] OR "coronary heart disease"[tiab] OR "coronary artery disease"[tiab] OR "coronary disease"[tiab] OR "Heart Failure"[Mesh] OR "heart failure"[tiab] OR "Stroke"[Mesh])	2043386
#3	Search (#1 and #2)	97776
#4	Search ("Risk"[Mesh:NoExp] OR "Logistic Models"[Mesh] OR "Risk Assessment"[Mesh] OR "Risk Factors"[Mesh] OR "Predictive Value of Tests"[Mesh] OR "Kaplan-Meier Estimate"[Mesh] OR "risk prediction"[tiab] OR reclass*[tiab] OR Framingham[tiab] OR "risk score"[tiab] OR "risk scores"[tiab])	1099100
#5	Search (#3 and #4)	18197
#6	Search (#3 and #4) Filters: Humans	17983
#7	Search (#3 and #4) Filters: Humans; English	15883
#8	Search (#3 and #4) Filters: Humans; English; Adult: 19+ years	12604
#9	Search (#3 and #4) Filters: Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	509
#10	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	672674
#11	Search (#9 and #10)	51
#12	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))	2023668
#13	Search (#9 and #12)	334
#14	Search (#3 and #4) Filters: Systematic Review s; Publication date from 2009/01/01 to 2016/12/31; Humans; English; Adult: 19+ years	8
#15	Search (#3 and #4) Filters: Systematic Review s; Meta-Analysis; Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	8

## Appendix B1. Search Strategies

### Cochrane Library Searches KQ 1 and KQ 3, 5/30/17

ID	Search	Hits
#1	[mh Electrocardiography] or electrocardiography or EKG or ECG or [mh "Exercise Test"] or (treadmill and test) or (treadmill and ett)	22891
#2	[mh "Myocardial Ischemia"] or "coronary heart disease":ti,ab or "coronary disease":ti,ab or "coronary disease":kw or "coronary artery disease":ti,ab or [mh Atherosclerosis] or atherosclerosis:ti,ab	35404
#3	#1 and #2	6048
#4	[mh "Mass Screening"] or screen*:ti,ab	31391
#5	#3 and #4 Publication Year from 2016 to 2017, in Cochrane Review s (Review s and Protocols) and Other Review s	7
#6	((controlled:ti or controlled:ab) and (trial:ti or trial:ab)) or "controlled clinical trial" or "randomized controlled trial":pt or "randomized controlled trial as topic":pt or "single-blind method":pt or "double-blind method":pt or "random allocation":pt	663873
#7	#5 and #6	6
#8	[mh /AE] or [mh "Long Term Adverse Effects"] or [mh "Patient Harm"] or [mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or "medical errors":kw or "iatrogenic disease":kw or "false positive reactions":kw or [mh Syncope] or [mh "Arrhythmias, Cardiac"] or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh Anxiety] or labeling:ti,ab or labelling:ti,ab or [mh "Coronary Angiography"] or [mh "Myocardial Revascularization"]	201669
#9	#5 and #8	6
#10	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	150064
#11	#9 and #10	4
#12	[mh "Coronary Angiography"] or [mh "Myocardial Revascularization"]	11848
#13	#2 and #12	8118
#14	[mh /AE] or [mh "Long Term Adverse Effects"] or [mh "Patient Harm"] or [mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or "medical errors":kw or "iatrogenic disease":kw or "false positive reactions":kw or [mh Syncope] or [mh "Arrhythmias, Cardiac"] or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh Anxiety] or labeling:ti,ab or labelling:ti,ab	197054
#15	#13 and #14 Publication Year from 2016 to 2017, in Cochrane Review s (Review s and Protocols) and Other Review s	4

### Cochrane Library Searches KQ 2, Risk, 5/30/17

ID	Search	Hits
#1	[mh Electrocardiography] or electrocardiography or EKG or ECG or [mh "Exercise Test"] or (treadmill and test) or (treadmill and ett)	22891
#2	[mh Mortality] or [mh /MO] or death:ti,ab or mortality:ti,ab or [mh "Myocardial Infarction"] or "heart attack":ti,ab or [mh "Myocardial Ischemia"] or [mh ^"Cardiovascular Diseases"] or [mh "Coronary Disease"] or "Coronary Disease":kw or "coronary heart disease":ti,ab or "coronary artery disease":ti,ab or "coronary disease":ti,ab or [mh "Heart Failure"] or "heart failure":ti,ab or [mh Stroke]	115133
#3	#1 and #2	8800
#4	[mh ^Risk] or [mh "Logistic Models"] or [mh "Risk Assessment"] or [mh "Risk Factors"] or [mh "Predictive Value of Tests"] or [mh "Kaplan-Meier Estimate"] or "risk prediction":ti,ab or reclass*:ti,ab or Framingham:ti,ab or "risk score":ti,ab or "risk scores":ti,ab	47503
#5	#3 and #4	1334
#6	#3 and #4 Publication Year from 2009 to 2016	55
#7	#6 in Cochrane Review s (Review s and Protocols) and Other Review s	2
#8	((controlled:ti or controlled:ab) and (trial:ti or trial:ab)) or "controlled clinical trial" or "randomized controlled trial":pt or "randomized controlled trial as topic":pt or "single-blind method":pt or "double-blind method":pt or "random allocation":pt	663874
#9	#6 and #8	54
#10	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	150064
#11	#6 and #10	27
#12	#9 or #11 Publication Year from 2016 to 2017	54

## Appendix B2. Eligibility Criteria

	Include	Exclude
Populations	Adults age $\geq 18$ years without symptoms or a diagnosis of CVD; studies of mixed populations of asymptomatic and symptomatic persons are eligible if results are reported separately for asymptomatic persons or $< 20\%$ of the sample is symptomatic <sup>a</sup>	Persons with a history of atherosclerotic disease or symptoms suggesting coronary heart disease; children and adolescents
Screening tests	Resting ECG, exercise ECG	Radiology tests (e.g., thallium scan, scintigraphy, computed tomography), echocardiography, and vectorcardiography <sup>b</sup>
Comparisons	All KQs: Screened vs. nonscreened groups (i.e., risk stratification using ECG plus traditional risk factors vs. risk stratification using traditional risk factors alone) KQ 2: CVD risk assessment models that include ECG findings compared with those that do not KQ 3: For harms of subsequent procedures/interventions, studies that compare the procedure/intervention to no procedure/intervention are also eligible. For studies reporting rates of harms from exercise ECG or subsequent procedures/interventions, large registries or multicenter studies without a control group that report rates of harms for asymptomatic persons are also eligible.	No comparison, nonconcordant historical control, comparative studies with other novel risk factors (e.g., comparing ECG vs. C-reactive protein); studies that compare the risk for subsequent events between persons with and without ECG abnormalities and report associations (e.g., prospective cohort studies that report hazard ratios for outcomes associated with baseline T-wave abnormalities)
Outcomes	KQ 1: All-cause mortality, cardiovascular mortality, and cardiovascular events (myocardial infarction, angina, stroke, congestive heart failure, composite cardiovascular outcomes) KQ 2: Reclassification, calibration (the degree to which predicted and observed risk estimates agree, goodness-of-fit statistics), and discrimination (C-statistic/area under the curve) KQ 3: Mortality, arrhythmia, cardiovascular events, or injuries from exercise ECG; anxiety; labeling; harms of subsequent procedures or interventions initiated as a result of screening (e.g., subsequent angiography or revascularization procedures resulting in harm)	KQ 2: Studies assessing the association between ECG findings and outcomes (e.g., with adjusted hazard ratios)
Study designs	All KQs: Randomized, controlled trials or controlled clinical trials KQs 2, 3: Prospective cohort studies are also eligible KQ 3: Well-designed large retrospective cohort studies and well-designed case-control studies (only for rare events) are also eligible	All other designs, narrative reviews, systematic reviews <sup>c</sup> case reports, case series, editorials, letters, cross-sectional studies
Setting	Studies performed in primary care or occupational medicine settings, studies that recruit participants from the general population	Studies performed in specialty settings, studies of patients undergoing preoperative evaluation
Country	Studies conducted in countries categorized as "Very High" on the 2014 Human Development Index (as defined by the United Nations Development Program)	
Language	English	Non-English
Study quality	Good or fair	Poor (according to design-specific USPSTF criteria)

<sup>a</sup> The a priori plan for mixed populations was to include studies if the results were reported separately for asymptomatic persons or if less than 10 percent of the sample was symptomatic, and to systematically determine whether that approach would result in the exclusion of any studies in which 10 to 50 percent of the population was symptomatic that should be considered for inclusion. We only identified one such study (16.5% of participants had atypical chest pain<sup>45</sup>) and decided to include the study because of the uncertainty around the appropriate threshold (for proportion of symptomatic patients that would alter study findings and substantially limit their applicability for the review questions).

<sup>b</sup> Vectorcardiography is a method of recording the magnitude and direction of the electrical forces that are generated by the heart by means of a continuous series of vectors that form curving lines around a central point.

<sup>c</sup> We will not abstract data from systematic reviews and will not include them in the results, but we will conduct separate searches for systematic reviews and search the references lists of all potentially relevant systematic reviews to identify relevant primary studies that our electronic searches did not identify.

## Randomized, Controlled Trials and Cohort Studies

### Criteria

- Initial assembly of comparable groups
- Randomized, controlled trials (RCTs)—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, crossovers, adherence, and contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements: Equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: Adjustment for potential confounders for cohort studies or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

### Definition of Ratings Based on Above Criteria

**Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup  $\geq 80$  percent); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention is given to confounders in analysis. In addition, intention-to-treat analysis is used for RCTs.

**Fair:** Studies will be graded “fair” if any or all of the following problems occur, without the important limitations noted in the “poor” category below: Generally comparable groups are assembled initially but some question remains on whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is lacking for RCTs.

**Poor:** Studies will be graded “poor” if any of the following major limitations exist: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. Intention-to-treat analysis is lacking for RCTs.

**Sources:** U.S. Preventive Services Task Force, Procedure Manual, Appendix VI  
<https://www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes>  
Harris et al, 2001<sup>46</sup>

## **Specific Questions Used to Guide Assessment of Included Studies**

Items used to assess quality of RCTs for KQs 1 and 3

1. Was randomization adequate?
2. Was allocation concealment adequate?
3. Were groups similar at baseline?
4. Was intervention fidelity adequate?
5. What was the reported adherence to the intervention?
6. What was the overall attrition?
7. What was the differential attrition?
8. Did the study have differential attrition or overall high attrition raising concern for bias?
9. Did the study have cross-overs or contamination raising concern for bias?
10. Were outcome measurements equal, valid, and reliable?
11. Were patients masked?
12. Were providers masked?
13. Were outcome assessors masked?
14. Was the duration of follow up adequate to assess the outcome?
15. What was the method used to handle missing data?
16. Did the study use acceptable statistical methods?
17. Quality Rating

Additional Items used to assess quality of RCTs that address harms, KQ3

1. Were harms prespecified and defined?
2. Were ascertainment techniques for harms adequately described?
3. Were ascertainment techniques for harms equal, valid, and reliable?
4. Was duration of follow-up adequate for harms assessment?
5. Quality Rating

Items used to assess quality of relevant studies reporting reclassification, calibration, and discrimination, KQ 2

1. Does study sample adequately capture the population of interest (participant eligibility and recruitment)?
2. Was there selective inclusion of participants in the model based on data availability?
3. If participants are from a treatment RCT, is treatment accounted for?
4. Enrolled consecutive patients or a random sample?
5. Were selection criteria clearly described?
6. Is a valid and reliable definition and method for measurement of the outcomes reported?
7. Was the same outcome definition (and method for measurement) used in all patients?
8. Were the outcomes assessed without knowledge of the candidate predictors (i.e., blinded)?
9. Is a valid and reliable definition and method for measurement and classification of candidate predictor(s) (ECG and risk factors) reported?
10. Were predictors assessed blinded for the outcome, and for each other (if relevant)?
11. How was the predictor of interest (ECG) handled in the modelling?
12. Number (%) participants with missing data (include predictors and outcomes)
13. Did the study have high attrition raising concern for bias?
14. How was missing data handled?
15. Were multiple measures of performance used (e.g., global fit, discrimination, calibration, net reclassification)?
16. Were both calibration and discrimination measures reported? Were confidence intervals reported?
17. Were a priori cut points used for classification measures (e.g., sensitivity, specificity, predictive values, NRI)?
18. Was a bias-corrected NRI used?
19. If net reclassification was assessed, were appropriate clinical thresholds used to reclassify risk?
20. Method used for testing model performance: development dataset only or separate external validation?
21. In what way was the population a separate external validation from the FRS or PCE?
22. Was the FRS or PCE recalibrated in the population before ECG was added to the model?
23. Quality

## Appendix C. Excluded Studies

- X1: Non-English
- X2: Ineligible population
- X3: Ineligible/no screening/treatment
- X4: Ineligible/no comparison
- X5: Ineligible/no outcome
- X6: Ineligible setting
- X7: Ineligible study design
- X8: Appears to meet all criteria but ineligible country
- X9: Appears to meet all criteria but abstract only
- X10: Poor quality

1. Summaries for patients. Adding electrocardiography to medical history and physical examination for evaluation before sports participation in college athletes. *Ann Intern Med.* 2010 Mar 2;152(5):I13. doi: 10.7326/0003-4819-152-5-201003020-00001. PMID: 20194228. Exclusion Code: X7.
2. Abudiab M, Aijaz B, Konecny T, et al. Use of functional aerobic capacity based on stress testing to predict outcomes in normal, overweight, and obese patients. *Mayo Clin Proc.* 2013 Dec;88(12):1427-34. doi: 10.1016/j.mayocp.2013.10.013. PMID: 24290116. Exclusion Code: X2.
3. Acampa W, Petretta M, Evangelista L, et al. Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial. *Eur J Nucl Med Mol Imaging.* 2012 Mar;39(3):387-95. doi: 10.1007/s00259-011-1983-x. PMID: 22109666. Exclusion Code: X3.
4. Adabag AS, Grandits GA, Prineas RJ, et al. Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men. *Am J Cardiol.* 2008 May 15;101(10):1437-43. doi: 10.1016/j.amjcard.2008.01.021. PMID: 18471455. Exclusion Code: X5.
5. Agarwal SK, Chao J, Peace F, et al. Premature ventricular complexes on screening electrocardiogram and risk of ischemic stroke. *Stroke.* 2015 May;46(5):1365-7. doi: 10.1161/strokeaha.114.008447. PMID: 25873602. Exclusion Code: X5.
6. Agarwal SK, Heiss G, Rautaharju PM, et al. Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study. *Stroke.* 2010 Apr;41(4):588-93. doi: 10.1161/strokeaha.109.567800. PMID: 20167922. Exclusion Code: X5.
7. Agarwal SK, Simpson RJ, Jr., Rautaharju P, et al. Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk In Communities [ARIC] Study). *Am J Cardiol.* 2012 Jan 1;109(1):105-9. doi: 10.1016/j.amjcard.2011.08.009. PMID: 21945138. Exclusion Code: X5.
8. Ahmed HM, Al-Mallah MH, McEvoy JW, et al. Maximal exercise testing variables and 10-year survival: fitness risk score derivation from the FIT Project. *Mayo Clin Proc.* 2015 Mar;90(3):346-55. doi: 10.1016/j.mayocp.2014.12.013. PMID: 25744114. Exclusion Code: X2.
9. Ahmed T, Steward JA, O'Mahony MS. Dyspnoea and mortality in older people in the community: a 10-year follow-up. *Age Ageing.* 2012 Jul;41(4):545-9. doi: 10.1093/ageing/afs049. PMID: 22522776. Exclusion Code: X2.
10. Al Rifai M, Patel J, Hung RK, et al. Higher Fitness Is Strongly Protective in Patients with Family History of Heart Disease: The FIT Project. *Am J Med.* 2017 Mar;130(3):367-71. doi: 10.1016/j.amjmed.2016.09.026. PMID: 27751899. Exclusion Code: X4.
11. Al Rifai M, Schneider AL, Alonso A, et al. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. *J Diabetes Complications.* 2015 Mar;29(2):180-5. doi: 10.1016/j.jdiacomp.2014.11.008. PMID: 25499973. Exclusion Code: X3.
12. Aladin AI, Whelton SP, Al-Mallah MH, et al. Relation of resting heart rate to risk for all-cause mortality by gender after considering exercise capacity (the Henry



## Appendix C. Excluded Studies

- Ford exercise testing project). *Am J Cardiol.* 2014 Dec 1;114(11):1701-6. doi: 10.1016/j.amjcard.2014.08.042. PMID: 25439450. Exclusion Code: X2.
13. Albayrak S, Ozhan H, Aslantas Y, et al. Predictors of major adverse cardiovascular events; results of population based MELEN study with prospective follow-up. *Eur Rev Med Pharmacol Sci.* 2015 Apr;19(8):1446-51. PMID: 25967720. Exclusion Code: X5.
  14. Al-Mallah MH, Keteyian SJ, Brawner CA, et al. Rationale and design of the Henry Ford Exercise Testing Project (the FIT project). *Clin Cardiol.* 2014 Aug;37(8):456-61. doi: 10.1002/clc.22302. PMID: 25138770. Exclusion Code: X2.
  15. Al-Zaiti SS, Carey MG. The Prevalence of Clinical and Electrocardiographic Risk Factors of Cardiovascular Death Among On-duty Professional Firefighters. *J Cardiovasc Nurs.* 2015 Sep-Oct;30(5):440-6. doi: 10.1097/jcn.000000000000165. PMID: 24874885. Exclusion Code: X7.
  16. Al-Zaiti SS, Fallavollita JA, Wu YW, et al. Electrocardiogram-based predictors of clinical outcomes: a meta-analysis of the prognostic value of ventricular repolarization. *Heart Lung.* 2014 Nov-Dec;43(6):516-26. doi: 10.1016/j.hrtlng.2014.05.004. PMID: 24988910. Exclusion Code: X7.
  17. Andersen K, Rasmussen F, Held C, et al. Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study. *Bmj.* 2015;351:h4543. doi: 10.1136/bmj.h4543. PMID: 26378015. Exclusion Code: X5.
  18. Anttila I, Nikus K, Nieminen T, et al. Prevalence and prognostic value of poor R-wave progression in standard resting electrocardiogram in a general adult population. The Health 2000 Survey. *Ann Med.* 2010 Mar;42(2):123-30. doi: 10.3109/07853890903555334. PMID: 20166814. Exclusion Code: X5.
  19. Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. *J Am Coll Cardiol.* 2005 Jul 5;46(1):158-65. doi: 10.1016/j.jacc.2005.02.088. PMID: 15992651. Exclusion Code: X3.
  20. Arbel Y, Birati EY, Shapira I, et al. T-wave amplitude is related to physical fitness status. *Ann Noninvasive Electrocardiol.* 2012 Jul;17(3):214-8. doi: 10.1111/j.1542-474X.2012.00512.x. PMID: 22816540. Exclusion Code: X7.
  21. Armstrong AW, Azizi S, Wu J, et al. Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. *Arch Dermatol Res.* 2013 Dec;305(10):891-7. doi: 10.1007/s00403-013-1419-5. PMID: 24166719. Exclusion Code: X4.
  22. Aro AL, Anttonen O, Tikkanen JT, et al. Intraventricular conduction delay in a standard 12-lead electrocardiogram as a predictor of mortality in the general population. *Circ Arrhythm Electrophysiol.* 2011 Oct;4(5):704-10. doi: 10.1161/circep.111.963561. PMID: 21841194. Exclusion Code: X5.
  23. Aro AL, Anttonen O, Tikkanen JT, et al. Prevalence and prognostic significance of T-wave inversions in right precordial leads of a 12-lead electrocardiogram in the middle-aged subjects. *Circulation.* 2012 May 29;125(21):2572-7. doi: 10.1161/circulationaha.112.098681. PMID: 22576982. Exclusion Code: X4.
  24. Aro AL, Huikuri HV. Electrocardiographic predictors of sudden cardiac death from a large Finnish general population cohort. *J Electrocardiol.* 2013 Sep-Oct;46(5):434-8. doi: 10.1016/j.jelectrocard.2013.06.016. PMID: 23871401. Exclusion Code: X7.
  25. Aro AL, Huikuri HV, Tikkanen JT, et al. QRS-T angle as a predictor of sudden cardiac death in a middle-aged general population. *Europace.* 2012 Jun;14(6):872-6. doi: 10.1093/europace/eur393. PMID: 22183749. Exclusion Code: X4.
  26. Artero EG, Jackson AS, Sui X, et al. Longitudinal algorithms to estimate cardiorespiratory fitness: associations with nonfatal cardiovascular disease and disease-specific mortality. *J Am Coll Cardiol.* 2014 Jun 3;63(21):2289-96. doi: 10.1016/j.jacc.2014.03.008. PMID: 24703924. Exclusion Code: X3.
  27. Asia Pacific Cohort Studies C, Barzi F, Patel A, et al. Cardiovascular risk prediction tools for populations in Asia. *J Epidemiol Community Health.* 2007 Feb;61(2):115-21. doi: 10.1136/jech.2005.044842. PMID: 17234869. Exclusion Code: X3.
  28. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year

## Appendix C. Excluded Studies

- follow-up of the prospective cardiovascular Munster (PROCAM) study. *Circulation*. 2002 Jan 22;105(3):310-5. PMID: 11804985. Exclusion Code: X3.
29. Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. *Eur J Clin Invest*. 2007 Dec;37(12):925-32. doi: 10.1111/j.1365-2362.2007.01888.x. PMID: 18036028. Exclusion Code: X3.
30. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. *Int J Obes (Lond)*. 2008 May;32 Suppl 2:S11-6. doi: 10.1038/ijo.2008.29. PMID: 18469834. Exclusion Code: X3.
31. Bachmann TN, Skov MW, Rasmussen PV, et al. Electrocardiographic Tpeak-Tend interval and risk of cardiovascular morbidity and mortality: Results from the Copenhagen ECG study. *Heart Rhythm*. 2016 Apr;13(4):915-24. doi: 10.1016/j.hrthm.2015.12.027. PMID: 26707793. Exclusion Code: X5.
32. Badheka AO, Rathod A, Marzouka GR, et al. Isolated nonspecific ST-segment and T-wave abnormalities in a cross-sectional United States population and Mortality (from NHANES III). *Am J Cardiol*. 2012 Aug 15;110(4):521-5. doi: 10.1016/j.amjcard.2012.04.023. PMID: 22608358. Exclusion Code: X4.
33. Badheka AO, Singh V, Patel NJ, et al. QRS duration on electrocardiography and cardiovascular mortality (from the National Health and Nutrition Examination Survey-III). *Am J Cardiol*. 2013 Sep 1;112(5):671-7. doi: 10.1016/j.amjcard.2013.04.040. PMID: 23726176. Exclusion Code: X2.
34. Bakhoya VN, Kurl S, Laukkanen JA. T-wave inversion on electrocardiogram is related to the risk of acute coronary syndrome in the general population. *Eur J Prev Cardiol*. 2014 Apr;21(4):500-6. doi: 10.1177/2047487312460022. PMID: 22952285. Exclusion Code: X2.
35. Balady GJ, Larson MG, Vasan RS, et al. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. *Circulation*. 2004 Oct 5;110(14):1920-5. doi: 10.1161/01.CIR.0000143226.40607.71. PMID: 15451778. Exclusion Code: X5.
36. Bandorski D, Bogossian H, Ecke A, et al. Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. *Cardiol J*. 2016;23(4):465-72. doi: 10.5603/CJ.a2016.0044. PMID: 27367480. Exclusion Code: X5.
37. Barmpouletos D, Stavens G, Ahlberg AW, et al. Duration and type of therapy for diabetes: impact on cardiac risk stratification with stress electrocardiographic-gated SPECT myocardial perfusion imaging. *J Nucl Cardiol*. 2010 Dec;17(6):1041-9. doi: 10.1007/s12350-010-9293-4. PMID: 20963539. Exclusion Code: X3.
38. Bastuji-Garin S, Deverly A, Moyses D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. *J Hypertens*. 2002 Oct;20(10):1973-80. PMID: 12359975. Exclusion Code: X3.
39. Bates RE, Omer M, Abdelmoneim SS, et al. Impact of Stress Testing for Coronary Artery Disease Screening in Asymptomatic Patients With Diabetes Mellitus: A Community-Based Study in Olmsted County, Minnesota. *Mayo Clin Proc*. 2016 Nov;91(11):1535-44. doi: 10.1016/j.mayocp.2016.07.013. PMID: 27720456. Exclusion Code: X4.
40. Bauters C, Lemesle G. Screening for asymptomatic coronary artery disease in patients with diabetes mellitus: A systematic review and meta-analysis of randomized trials. *BMC Cardiovasc Disord*. 2016 May 10;16:90. doi: 10.1186/s12872-016-0256-9. PMID: 27165687. Exclusion Code: X7.
41. Becker A, Leber A, Becker C, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. *Am Heart J*. 2008 Jan;155(1):154-60. doi: 10.1016/j.ahj.2007.08.024. PMID: 18082507. Exclusion Code: X3.
42. Becker A, Leber AW, Becker C, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. *BMC Cardiovasc Disord*. 2008 Oct 10;8:27. doi: 10.1186/1471-2261-8-27. PMID: 18847481. Exclusion Code: X3.
43. Bem D, Lordkipanidze M, Hodgkinson J, et al. The Effects of Different Aspirin Dosing

## Appendix C. Excluded Studies

- Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. *Clin Pharmacol Ther.* 2016 Nov;100(5):500-12. doi: 10.1002/cpt.438. PMID: 27449968. Exclusion Code: X2.
44. Bernard S, Serusclat A, Targe F, et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. *Diabetes Care.* 2005 May;28(5):1158-62. PMID: 15855582. Exclusion Code: X3.
45. Berry JD, Lloyd-Jones DM, Garside DB, et al. Framingham risk score and prediction of coronary heart disease death in young men. *Am Heart J.* 2007 Jul;154(1):80-6. doi: 10.1016/j.ahj.2007.03.042. PMID: 17584558. Exclusion Code: X3.
46. Berry JD, Willis B, Gupta S, et al. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study. *J Am Coll Cardiol.* 2011 Apr 12;57(15):1604-10. doi: 10.1016/j.jacc.2010.10.056. PMID: 21474041. Exclusion Code: X5.
47. Bhatia RS, Bouck Z, Ivers NM, et al. Electrocardiograms in Low-Risk Patients Undergoing An Annual Health Examination. *JAMA Intern Med.* 2017 Jul 10;doi: 10.1001/jamainternmed.2017.2649. PMID: 28692719. Exclusion Code: X5.
48. Bhopal R, Fischbacher C, Vartiainen E, et al. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. *J Public Health (Oxf).* 2005 Mar;27(1):93-100. doi: 10.1093/pubmed/fdh202. PMID: 15749725. Exclusion Code: X3.
49. Bianco HT, Izar MC, Fonseca HA, et al. Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. *Arq Bras Cardiol.* 2014 Oct;103(4):272-81. PMID: 25098376. Exclusion Code: X5.
50. Binici Z, Intzilakis T, Nielsen OW, et al. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. *Circulation.* 2010 May 4;121(17):1904-11. doi: 10.1161/circulationaha.109.874982. PMID: 20404258. Exclusion Code: X3.
51. Binici Z, Mouridsen MR, Kober L, et al. Decreased nighttime heart rate variability is associated with increased stroke risk. *Stroke.* 2011 Nov;42(11):3196-201. doi: 10.1161/strokeaha.110.607697. PMID: 21921280. Exclusion Code: X3.
52. Blair SN, Kampert JB, Kohl HW, 3rd, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA.* 1996 Jul 17;276(3):205-10. PMID: 8667564. Exclusion Code: X5.
53. Bodegard J, Erikssen G, Bjornholt JV, et al. Symptom-limited exercise testing, ST depressions and long-term coronary heart disease mortality in apparently healthy middle-aged men. *Eur J Cardiovasc Prev Rehabil.* 2004 Aug;11(4):320-7. PMID: 15292766. Exclusion Code: X5.
54. Boman K, Gerdt E, Wachtell K, et al. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. *Eur J Cardiovasc Prev Rehabil.* 2009 Apr;16(2):242-8. doi: 10.1097/HJR.0b013e328329560e. PMID: 19369828. Exclusion Code: X2.
55. Bouzas-Mosquera A, Peteiro J, Alvarez-Garcia N, et al. Prediction of mortality and major cardiac events by exercise echocardiography in patients with normal exercise electrocardiographic testing. *J Am Coll Cardiol.* 2009 May 26;53(21):1981-90. doi: 10.1016/j.jacc.2009.01.067. PMID: 19460612. Exclusion Code: X2.
56. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. *BMJ.* 2003 Nov 29;327(7426):1267. doi: 10.1136/bmj.327.7426.1267. PMID: 14644971. Exclusion Code: X3.
57. Brindle PM, McConnachie A, Upton MN, et al. The accuracy of the Framingham risk score in different socioeconomic groups: a prospective study. *Br J Gen Pract.* 2005 Nov;55(520):838-45. PMID: 16281999. Exclusion Code: X3.
58. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. *Am Heart J.* 2000 Dec;140(6):848-56. doi: 10.1067/mhj.2000.111112. PMID: 11099987. Exclusion Code: X5.
59. Buonacera A, Boukhris M, Tomasello SD, et al. Impact of left ventricular remodeling and renal function on 24h-ECG recordings

## Appendix C. Excluded Studies

- and cardiovascular outcome in elderly hypertensive patients. *Eur J Intern Med*. 2016 Apr;29:71-7. doi: 10.1016/j.ejim.2016.01.001. PMID: 26781517. Exclusion Code: X2.
60. Buyken AE, von Eckardstein A, Schulte H, et al. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. *Eur J Cardiovasc Prev Rehabil*. 2007 Apr;14(2):230-6. doi: 10.1097/HJR.0b013e3280142037. PMID: 17446801. Exclusion Code: X4.
61. Camhi SM, Katzmarzyk PT, Broyles S, et al. Association of metabolic risk with longitudinal physical activity and fitness: coronary artery risk development in young adults (CARDIA). *Metab Syndr Relat Disord*. 2013 Jun;11(3):195-204. doi: 10.1089/met.2012.0120. PMID: 23438155. Exclusion Code: X3.
62. Cardoso CR, Leite NC, Salles GF. Factors associated with abnormal T-wave axis and increased QRS-T angle in type 2 diabetes. *Acta Diabetol*. 2013 Dec;50(6):919-25. doi: 10.1007/s00592-013-0483-9. PMID: 23744129. Exclusion Code: X2.
63. Carlson N, Dixen U, Marott JL, et al. Predictive value of casual ECG-based resting heart rate compared with resting heart rate obtained from Holter recording. *Scand J Clin Lab Invest*. 2014 Mar;74(2):163-9. doi: 10.3109/00365513.2013.867531. PMID: 24329133. Exclusion Code: X2.
64. Carrington MJ, Jennings GL, Clark RA, et al. Assessing cardiovascular risk in regional areas: the Healthy Hearts Beyond City Limits program. *BMC Health Serv Res*. 2012;12:296. doi: 10.1186/1472-6963-12-296. PMID: 22943553. Exclusion Code: X2.
65. Cederholm J, Eeg-Olofsson K, Eliasson B, et al. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. *Diabetes Care*. 2008 Oct;31(10):2038-43. doi: 10.2337/dc08-0662. PMID: 18591403. Exclusion Code: X3.
66. Chambless LE, Heiss G, Shahar E, et al. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. *Am J Epidemiol*. 2004 Aug 1;160(3):259-69. doi: 10.1093/aje/kwh189. PMID: 15257999. Exclusion Code: X4.
67. Chan AK, Ilias-Khan NA, Xian H, et al. Arm exercise stress perfusion imaging predicts clinical outcome. *J Appl Physiol (1985)*. 2011 Dec;111(6):1546-53. doi: 10.1152/jappphysiol.00725.2011. PMID: 21852405. Exclusion Code: X2.
68. Chauhan K, Ackerman MJ, Crows on CS, et al. Population-based study of QT interval prolongation in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2015 Jan-Feb;33(1):84-9. PMID: 25572282. Exclusion Code: X5.
69. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. *Jama*. 2009 Jun 24;301(24):2571-7. doi: 10.1001/jama.2009.888. PMID: 19549974. Exclusion Code: X5.
70. Cheng S, Larson MG, Keyes MJ, et al. Relation of QRS width in healthy persons to risk of future permanent pacemaker implantation. *Am J Cardiol*. 2010 Sep 1;106(5):668-72. doi: 10.1016/j.amjcard.2010.04.021. PMID: 20723643. Exclusion Code: X5.
71. Cheriath P, He F, Peters I, et al. Relation of atrial and/or ventricular premature complexes on a two-minute rhythm strip to the risk of sudden cardiac death (the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol*. 2011 Jan 15;107(2):151-5. doi: 10.1016/j.amjcard.2010.09.002. PMID: 21211594. Exclusion Code: X5.
72. Chisalita SI, Dahlstrom U, Arnqvist HJ, et al. Proinsulin and IGFBP-1 predicts mortality in an elderly population. *Int J Cardiol*. 2014 Jun 15;174(2):260-7. doi: 10.1016/j.ijcard.2014.03.171. PMID: 24794551. Exclusion Code: X3.
73. Chou R, Arora B, Dana T, et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2011 Sep 20;155(6):375-85. doi: 10.7326/0003-4819-155-6-201109200-00006. PMID: 21930855. Exclusion Code: X7.
74. Cicero AF, Rosticci M, Tocci G, et al. Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. *Eur J Intern Med*. 2015 May;26(4):255-8. doi: 10.1016/j.ejim.2015.02.007. PMID: 25708168. Exclusion Code: X5.

## Appendix C. Excluded Studies

75. Cilli A, Batmaz F, Demir I, et al. The diagnostic yield of exercise stress testing as a screening tool for subclinical coronary artery disease in patients with moderate to severe obstructive sleep apnea. *J Clin Sleep Med*. 2011 Feb 15;7(1):25-9. PMID: 21344047. Exclusion Code: X7.
76. Cintra FD, Tufik S, Paola A, et al. Cardiovascular profile in patients with obstructive sleep apnea. *Arq Bras Cardiol*. 2011 Apr;96(4):293-9. PMID: 21437515. Exclusion Code: X5.
77. Cirillo M, Terradura-Vagnarelli O, Mancini M, et al. Cohort profile: The Gubbio Population Study. *Int J Epidemiol*. 2014 Jun;43(3):713-20. doi: 10.1093/ije/dyt025. PMID: 23543599. Exclusion Code: X5.
78. Cole CR, Foody JM, Blackstone EH, et al. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. *Ann Intern Med*. 2000 Apr 4;132(7):552-5. PMID: 10744592. Exclusion Code: X4.
79. Conen D, Schon T, Aeschbacher S, et al. Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP). *Swiss Med Wkly*. 2013;143:w13728. doi: 10.4414/smw.2013.13728. PMID: 23299990. Exclusion Code: X3.
80. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. *Ann Intern Med*. 2006 Jul 4;145(1):21-9. PMID: 16818925. Exclusion Code: X3.
81. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. *Atherosclerosis*. 2005 Jul;181(1):93-100. doi: 10.1016/j.atherosclerosis.2004.12.026. PMID: 15939059. Exclusion Code: X3.
82. Courand PY, Jenck S, Bricca G, et al. R wave in a VL lead: an outstanding ECG index in hypertension. *J Hypertens*. 2014 Jun;32(6):1317-25. doi: 10.1097/hjh.000000000000181. PMID: 24751594. Exclusion Code: X4.
83. Crow RS, Hannan PJ, Folsom AR. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up. *Circulation*. 2003 Oct 21;108(16):1985-9. doi: 10.1161/01.CIR.0000095027.28753.9D. PMID: 14517173. Exclusion Code: X5.
84. Cuddy TE, Tate RB. Sudden unexpected cardiac death as a function of time since the detection of electrocardiographic and clinical risk factors in apparently healthy men: the Manitoba Follow-Up Study, 1948 to 2004. *Can J Cardiol*. 2006 Mar 1;22(3):205-11. PMID: 16520850. Exclusion Code: X5.
85. D'Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. 2001 Jul 11;286(2):180-7. PMID: 11448281. Exclusion Code: X3.
86. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. PMID: 18212285. Exclusion Code: X3.
87. Danzi G, Giordano A, Biondi-Zoccai G, et al. [The DANAMI-3-PRIMULTI study]. *Giornale italiano di cardiologia* (2006); 2016. p. 171-5. Exclusion Code: X1.
88. Darabont R, Tautu OF, Pop D, et al. Visit-to-Visit Blood Pressure Variability and Arterial Stiffness Independently Predict Cardiovascular Risk Category in a General Population: Results from the SEPHAR II Study. *Hellenic J Cardiol*. 2015 May-Jun;56(3):208-16. PMID: 26021242. Exclusion Code: X3.
89. Daugherty SL, Magid DJ, Kikla JR, et al. Gender differences in the prognostic value of exercise treadmill test characteristics. *Am Heart J*. 2011 May;161(5):908-14. doi: 10.1016/j.ahj.2011.01.021. PMID: 21570521. Exclusion Code: X2.
90. Daviglus ML, Liao Y, Greenland P, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. *JAMA*. 1999 Feb 10;281(6):530-6. PMID: 10022109. Exclusion Code: X5.
91. De Bacquer D, De Backer G, Kornitzer M, et al. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women.

## Appendix C. Excluded Studies

- Heart. 1998 Dec;80(6):570-7. PMID: 10065025. Exclusion Code: X5.
92. de Groot JR, Krul SP, Kroon S, et al. Unidentified candidates for cardiac resynchronization therapy: guideline adherence in a large academic outpatient clinic in the Netherlands. *Pacing Clin Electrophysiol*. 2013 Jan;36(1):69-75. doi: 10.1111/pace.12021. PMID: 23078171. Exclusion Code: X2.
93. de L, II, Verhagen HJ, Stolker RJ, et al. The value of treadmill exercise test parameters together in patients with known or suspected peripheral arterial disease. *Eur J Prev Cardiol*. 2012 Apr;19(2):192-8. doi: 10.1177/1741826711399986. PMID: 21450584. Exclusion Code: X2.
94. de Lemos JA, Ayers CR, Levine B, et al. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. *Circulation*. 2017 May 30;135(22):2119-32. doi: 10.1161/CIRCULATIONAHA.117.027272. PMID: 28360032. Exclusion Code: X4.
95. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. *BMJ*. 2009 Jan 08;338:a3083. doi: 10.1136/bmj.a3083. PMID: 19131384. Exclusion Code: X3.
96. DeFina L, Radford N, Leonard D, et al. Cardiorespiratory fitness and coronary artery calcification in women. *Atherosclerosis*. 2014 Apr;233(2):648-53. doi: 10.1016/j.atherosclerosis.2014.01.016. PMID: 24561492. Exclusion Code: X7.
97. Denes P, Garside DB, Lloyd-Jones D, et al. Major and minor electrocardiographic abnormalities and their association with underlying cardiovascular disease and risk factors in Hispanics/Latinos (from the Hispanic Community Health Study/Study of Latinos). *Am J Cardiol*. 2013 Nov 15;112(10):1667-75. doi: 10.1016/j.amjcard.2013.08.004. PMID: 24055066. Exclusion Code: X4.
98. Detrano RC, Wong ND, Doherty TM, et al. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. *Circulation*. 1999 May 25;99(20):2633-8. PMID: 10338455. Exclusion Code: X3.
99. Dhingra R, Pencina MJ, Wang TJ, et al. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. *Hypertension*. 2006 May;47(5):861-7. doi: 10.1161/01.HYP.0000217141.20163.23. PMID: 16585411. Exclusion Code: X5.
100. Dhoble A, Lahr BD, Allison TG, et al. Predicting long-term cardiovascular risk using the mayo clinic cardiovascular risk score in a referral population. *Am J Cardiol*. 2014 Sep 1;114(5):704-10. doi: 10.1016/j.amjcard.2014.05.061. PMID: 25052544. Exclusion Code: X2.
101. Dhoble A, Lahr BD, Allison TG, et al. Cardiopulmonary fitness and heart rate recovery as predictors of mortality in a referral population. *J Am Heart Assoc*. 2014;3(2):e000559. doi: 10.1161/jaha.113.000559. PMID: 24663334. Exclusion Code: X7.
102. Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk as associated with electrocardiographic ST-T segment changes. *J Am Coll Cardiol*. 2002 Oct 16;40(8):1401. PMID: 12392828. Exclusion Code: X5.
103. Donnan PT, Donnelly L, New JP, et al. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. *Diabetes Care*. 2006 Jun;29(6):1231-6. doi: 10.2337/dc05-1911. PMID: 16732001. Exclusion Code: X3.
104. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. *Kidney Int*. 2004 Jul;66(1):441-7. doi: 10.1111/j.1523-1755.2004.00751.x. PMID: 15200454. Exclusion Code: X2.
105. Dunder K, Lind L, Zethelius B, et al. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A I ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). *Am Heart J*. 2004 Oct;148(4):596-601. doi: 10.1016/j.ahj.2004.03.021. PMID: 15459588. Exclusion Code: X3.
106. Dyakova M, Shantikumar S, Colquitt Jill L, et al. Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews*. 2016(1)doi: 10.1002/14651858.CD010411.pub2. PMID: CD010411. Exclusion Code: X7.
107. Ekelund LG, Suchindran CM, McMahan RP, et al. Coronary heart disease morbidity

## Appendix C. Excluded Studies

- and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. *J Am Coll Cardiol*. 1989 Sep;14(3):556-63. PMID: 2768706. Exclusion Code: X4.
108. Elkeles RS, Godsland IF, Feher MD, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. *Eur Heart J*. 2008 Sep;29(18):2244-51. doi: 10.1093/eurheartj/ehn279. PMID: 18573867. Exclusion Code: X3.
109. Elsharawy MA, Al-Elq AH, Alkhadra AH, et al. Screening for asymptomatic cardiovascular disease in Arab patients with diabetes. *Int Angiol*. 2011 Feb;30(1):52-7. PMID: 21248673. Exclusion Code: X4.
110. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. *Eur Heart J*. 2003 Nov;24(21):1903-11. PMID: 14585248. Exclusion Code: X3.
111. Engeseth K, Hodnesdal C, Grundvold I, et al. Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study. *Eur J Prev Cardiol*. 2016 Jan;23(1):59-66. doi: 10.1177/2047487314553202. PMID: 25281482. Exclusion Code: X5.
112. Eranti A, Aro AL, Kerola T, et al. Prevalence and prognostic significance of abnormal P terminal force in lead V1 of the ECG in the general population. *Circ Arrhythm Electrophysiol*. 2014 Dec;7(6):1116-21. doi: 10.1161/circep.114.001557. PMID: 25381332. Exclusion Code: X4.
113. Erdem A, Uenishi M, Kucukdurmaz Z, et al. The effect of metabolic syndrome on heart rate turbulence in non-diabetic patients. *Cardiol J*. 2012;19(5):507-12. PMID: 23042315. Exclusion Code: X5.
114. Erez A, Kivity S, Berkovitch A, et al. The association between cardiorespiratory fitness and cardiovascular risk may be modulated by known cardiovascular risk factors. *Am Heart J*. 2015 Jun;169(6):916-23.e1. doi: 10.1016/j.ahj.2015.02.023. PMID: 26027631. Exclusion Code: X5.
115. Eriksen BO, Lochen ML, Arntzen KA, et al. Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population. *Kidney Int*. 2014 Jul;86(1):146-53. doi: 10.1038/ki.2013.470. PMID: 24304885. Exclusion Code: X5.
116. Eriksen G, Liestol K, Gullestad L, et al. The terminal part of the QT interval (T peak to T end): a predictor of mortality after acute myocardial infarction. *Ann Noninvasive Electrocardiol*. 2012 Apr;17(2):85-94. doi: 10.1111/j.1542-474X.2012.00493.x. PMID: 22537325. Exclusion Code: X2.
117. Estes EH, Zhang ZM, Li Y, et al. The Romhilt-Estes left ventricular hypertrophy score and its components predict all-cause mortality in the general population. *Am Heart J*. 2015 Jul;170(1):104-9. doi: 10.1016/j.ahj.2015.04.004. PMID: 26093870. Exclusion Code: X5.
118. Fagher K, Nilsson A, Londahl M. Heart rate-corrected QT interval prolongation as a prognostic marker for 3-year survival in people with Type 2 diabetes undergoing above-ankle amputation. *Diabet Med*. 2015 May;32(5):679-85. doi: 10.1111/dme.12632. PMID: 25388827. Exclusion Code: X5.
119. Faramawi MF, Caffrey JL, Amanzadeh J, et al. Cystatin C estimated renal dysfunction predicts T wave axis deviation in US adults: results from NHANES III. *Eur J Epidemiol*. 2011 Feb;26(2):101-7. doi: 10.1007/s10654-010-9534-5. PMID: 21184143. Exclusion Code: X2.
120. Farrell SW, Finley CE, Haskell WL, et al. Is There a Gradient of Mortality Risk among Men with Low Cardiorespiratory Fitness? *Med Sci Sports Exerc*. 2015 Sep;47(9):1825-32. doi: 10.1249/mss.0000000000000608. PMID: 25551401. Exclusion Code: X5.
121. Farrell SW, Finley CE, McAuley PA, et al. Cardiorespiratory fitness, different measures of adiposity, and total cancer mortality in women. *Obesity (Silver Spring)*. 2011 Nov;19(11):2261-7. doi: 10.1038/oby.2010.345. PMID: 21293448. Exclusion Code: X5.
122. Farrell SW, Finley CE, Radford NB, et al. Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study. *Circ Heart Fail*. 2013 Sep 1;6(5):898-905. doi: 10.1161/circheartfailure.112.000088. PMID: 23873472. Exclusion Code: X4.
123. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and as associated

## Appendix C. Excluded Studies

- cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). *Am J Cardiol*. 2014 Oct 15;114(8):1217-22. doi: 10.1016/j.amjcard.2014.07.045. PMID: 25159234. Exclusion Code: X3.
124. Ferrario M, Chiodini P, Chambless LE, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. *Int J Epidemiol*. 2005 Apr;34(2):413-21. doi: 10.1093/ije/dyh405. PMID: 15659467. Exclusion Code: X3.
125. Ferrie JE, Singh-Manoux A, Kivimaki M, et al. Cardiorespiratory risk factors as predictors of 40-year mortality in women and men. *Heart*. 2009 Aug;95(15):1250-7. doi: 10.1136/hrt.2008.164251. PMID: 19389720. Exclusion Code: X5.
126. Fitzmaurice DA, McCahon D, Baker J, et al. Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. *Fam Pract*. 2014 Jun;31(3):298-302. doi: 10.1093/fampra/cmu011. PMID: 24728774. Exclusion Code: X4.
127. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. *Circulation*. 1990 Feb;81(2):428-36. PMID: 2297853. Exclusion Code: X4.
128. Floyd JS, Sitlani CM, Wiggins KL, et al. Variation in resting heart rate over 4 years and the risks of myocardial infarction and death among older adults. *Heart*. 2015 Jan;101(2):132-8. doi: 10.1136/heartjnl-2014-306046. PMID: 25214500. Exclusion Code: X5.
129. Fuchs T, Torjman A, Galitzkaya L, et al. The clinical significance of ventricular arrhythmias during an exercise test in non-competitive and competitive athletes. *Isr Med Assoc J*. 2011 Dec;13(12):735-9. PMID: 22332442. Exclusion Code: X5.
130. Fyfe-Johnson AL, Muller CJ, Alonso A, et al. Heart Rate Variability and Incident Stroke: The Atherosclerosis Risk in Communities Study. *Stroke*. 2016 Jun;47(6):1452-8. doi: 10.1161/strokeaha.116.012662. PMID: 27217501. Exclusion Code: X5.
131. Garcia MN, Murray KO, Hotez PJ, et al. Development of chagas cardiac manifestations among Texas blood donors. *Am J Cardiol*. 2015 Jan 1;115(1):113-7. doi: 10.1016/j.amjcard.2014.09.050. PMID: 25456877. Exclusion Code: X7.
132. Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. *Lancet*. 2008 Mar 15;371(9616):923-31. doi: 10.1016/S0140-6736(08)60418-3. PMID: 18342687. Exclusion Code: X3.
133. Gencer B, Butler J, Bauer DC, et al. Association of electrocardiogram abnormalities and incident heart failure events. *Am Heart J*. 2014 Jun;167(6):869-75.e3. doi: 10.1016/j.ahj.2014.03.020. PMID: 24890537. Exclusion Code: X4.
134. Georgoulas P, Demakopoulos N, Valotasios V, et al. Long-term prognostic value of heart-rate recovery after treadmill testing in patients with diabetes mellitus. *Int J Cardiol*. 2009 May 1;134(1):67-74. doi: 10.1016/j.ijcard.2008.01.036. PMID: 18499284. Exclusion Code: X3.
135. Ghaffari S, Kazemi B, Aliakbarzadeh P. Abnormal heart rate recovery after exercise predicts coronary artery disease severity. *Cardiol J*. 2011;18(1):47-54. PMID: 21305485. Exclusion Code: X7.
136. Giagnoni E, Secchi MB, Wu SC, et al. Prognostic value of exercise EKG testing in asymptomatic normotensive subjects. A prospective matched study. *N Engl J Med*. 1983 Nov 3;309(18):1085-9. doi: 10.1056/NEJM198311033091803. PMID: 6621650. Exclusion Code: X5.
137. Giustetto C, Drago S, Demarchi PG, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. *Europace*. 2009 Apr;11(4):507-13. doi: 10.1093/europace/eup006. PMID: 19193676. Exclusion Code: X2.
138. Gordon DJ, Ekelund LG, Karon JM, et al. Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study. *Circulation*. 1986 Aug;74(2):252-61. PMID: 3731417. Exclusion Code: X5.
139. Gorodeski EZ, Ishwaran H, Blackstone EH, et al. Quantitative electrocardiographic measures and long-term mortality in exercise test patients with clinically normal resting electrocardiograms. *Am Heart J*.



## Appendix C. Excluded Studies

- 2009 Jul;158(1):61-70.e1. doi: 10.1016/j.ahj.2009.04.015. PMID: 19540393. Exclusion Code: X2.
140. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. *J Am Coll Cardiol*. 2000 May;35(6):1628-37. PMID: 10807470. Exclusion Code: X5.
141. Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. *Eur Heart J*. 2011 Jan;32(2):218-25. doi: 10.1093/eurheartj/ehq394. PMID: 21047877. Exclusion Code: X6.
142. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA*. 2004 Jan 14;291(2):210-5. doi: 10.1001/jama.291.2.210. PMID: 14722147. Exclusion Code: X3.
143. Greenland P, Xie X, Liu K, et al. Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up. *Am J Cardiol*. 2003 May 1;91(9):1068-74. PMID: 12714148. Exclusion Code: X5.
144. Greiser KH, Kluttig A, Schumann B, et al. Cardiovascular diseases, risk factors and short-term heart rate variability in an elderly general population: the CARLA study 2002-2006. *Eur J Epidemiol*. 2009;24(3):123-42. doi: 10.1007/s10654-009-9317-z. PMID: 19199053. Exclusion Code: X7.
145. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. *PLoS One*. 2013;8(9):e72013. doi: 10.1371/journal.pone.0072013. PMID: 24039732. Exclusion Code: X3.
146. Grossman C, Ehrlich S, Shemesh J, et al. Coronary artery calcium and exercise electrocardiogram as predictors of coronary events in asymptomatic adults. *Am J Cardiol*. 2015 Mar 15;115(6):745-50. doi: 10.1016/j.amjcard.2014.12.039. PMID: 25616536. Exclusion Code: X4.
147. Grover SA, Dorais M, Paradis G, et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. *CMAJ*. 2000 Nov 14;163(10):1263-9. PMID: 11107461. Exclusion Code: X3.
148. Grundy SM, Barlow CE, Farrell SW, et al. Cardiorespiratory fitness and metabolic risk. *Am J Cardiol*. 2012 Apr 1;109(7):988-93. doi: 10.1016/j.amjcard.2011.11.031. PMID: 22221951. Exclusion Code: X4.
149. Gulati M, Arnsdorf MF, Shaw LJ, et al. Prognostic value of the duke treadmill score in asymptomatic women. *Am J Cardiol*. 2005 Aug 1;96(3):369-75. doi: 10.1016/j.amjcard.2005.03.078. PMID: 16054460. Exclusion Code: X4.
150. Gulati M, Black HR, Arnsdorf MF, et al. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. *J Womens Health (Larchmt)*. 2012 Sep;21(9):917-24. doi: 10.1089/jwh.2011.3406. PMID: 22480201. Exclusion Code: X4.
151. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. *Circulation*. 2003 Sep 30;108(13):1554-9. doi: 10.1161/01.CIR.0000091080.57509.E9. PMID: 12975254. Exclusion Code: X5.
152. Gulati M, Shaw LJ, Thisted RA, et al. Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. *Circulation*. 2010 Jul 13;122(2):130-7. doi: 10.1161/circulationaha.110.939249. PMID: 20585008. Exclusion Code: X5.
153. Gupta S, Rohatgi A, Ayers CR, et al. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. *Circulation*. 2011 Apr 5;123(13):1377-83. doi: 10.1161/circulationaha.110.003236. PMID: 21422392. Exclusion Code: X3.
154. Guzder RN, Gatling W, Mullee MA, et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. *Diabet Med*. 2005 May;22(5):554-62. doi: 10.1111/j.1464-5491.2005.01494.x. PMID: 15842509. Exclusion Code: X3.
155. Haataja P, Anttila I, Nikus K, et al. Prognostic implications of intraventricular conduction delays in a general population: the Health 2000 Survey. *Ann Med*. 2015 Feb;47(1):74-80. doi: 10.3109/07853890.2014.985704. PMID: 25613171. Exclusion Code: X5.

## Appendix C. Excluded Studies

156. Hadaegh F, Ehteshami-Afshar S, Hajebrahimi MA, et al. Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up. *Int J Cardiol.* 2015 Mar 1;182:334-9. doi: 10.1016/j.ijcard.2015.01.017. PMID: 25585379. Exclusion Code: X5.
157. Hadaegh F, Hatami M, Mohebi R, et al. Electrocardiography-defined silent CHD and risk of cardiovascular events among diabetic patients in a Middle Eastern population. *Eur J Prev Cardiol.* 2012 Dec;19(6):1227-33. doi: 10.1177/1741826711428065. PMID: 22013153. Exclusion Code: X2.
158. Hage FG, Lusa L, Dondi M, et al. Exercise stress tests for detecting myocardial ischemia in asymptomatic patients with diabetes mellitus. *Am J Cardiol.* 2013 Jul 1;112(1):14-20. doi: 10.1016/j.amjcard.2013.02.047. PMID: 23578350. Exclusion Code: X4.
159. Halon DA, Dobrecky-Mery I, Gaspar T, et al. Heart rate recovery after exercise and coronary atheroma in asymptomatic individuals with type 2 diabetes mellitus: a study using 64-slice coronary CT angiography. *Int J Cardiol.* 2010 Nov 5;145(1):102-3. doi: 10.1016/j.ijcard.2009.05.045. PMID: 19540605. Exclusion Code: X5.
160. Hankil Kim J, Dooley P, Smith R. Clinical Inquiry: Do asymptomatic adults need screening EKGs? *J Fam Pract.* 2013 Aug;62(8):438-50. PMID: 24143339. Exclusion Code: X7.
161. Hartaigh B, Allore HG, Trentalange M, et al. Elevations in time-varying resting heart rate predict subsequent all-cause mortality in older adults. *Eur J Prev Cardiol.* 2015 Apr;22(4):527-34. doi: 10.1177/2047487313519932. PMID: 24445263. Exclusion Code: X2.
162. Hense HW, Schulte H, Lowel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. *Eur Heart J.* 2003 May;24(10):937-45. PMID: 12714025. Exclusion Code: X3.
163. Heston TF. Standardizing predictive values in diagnostic imaging research. *J Magn Reson Imaging.* 2011 Feb;33(2):505; author reply 6-7. doi: 10.1002/jmri.22466. PMID: 21274995. Exclusion Code: X7.
164. Hillebrand S, Gast KB, de Mutsert R, et al. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. *Europace.* 2013 May;15(5):742-9. doi: 10.1093/europace/eus341. PMID: 23370966. Exclusion Code: X7.
165. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. *Heart.* 2008 Jan;94(1):34-9. doi: 10.1136/hrt.2007.134890. PMID: 17916661. Exclusion Code: X3.
166. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ.* 2007 Jul 21;335(7611):136. doi: 10.1136/bmj.39261.471806.55. PMID: 17615182. Exclusion Code: X3.
167. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ.* 2008 Jun 28;336(7659):1475-82. doi: 10.1136/bmj.39609.449676.25. PMID: 18573856. Exclusion Code: X3.
168. Hisamatsu T, Miura K, Ohkubo T, et al. Interaction between dietary marine-derived n-3 fatty acids intake and J-point elevation on the risk of cardiac death: a 24-year follow-up of Japanese men. *Heart.* 2013 Jul;99(14):1024-9. doi: 10.1136/heartjnl-2012-303496. PMID: 23666393. Exclusion Code: X4.
169. Hisamatsu T, Ohkubo T, Miura K, et al. Association between J-point elevation and death from coronary artery disease--15-year follow up of the NIPPON DATA90. *Circ J.* 2013;77(5):1260-6. PMID: 23358431. Exclusion Code: X4.
170. Ho JS, Fitzgerald SJ, Barlow CE, et al. Risk of mortality increases with increasing number of abnormal non-ST parameters recorded during exercise testing. *Eur J Cardiovasc Prev Rehabil.* 2010 Aug;17(4):462-8. doi: 10.1097/HJR.0b013e3283336a10d. PMID: 20084008. Exclusion Code: X5.
171. Hodnesdal C, Prestgaard E, Eriksen G, et al. Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary

## Appendix C. Excluded Studies

- heart disease mortality risk. *Eur J Prev Cardiol*. 2013 Aug;20(4):541-8. doi: 10.1177/2047487312444370. PMID: 22492865. Exclusion Code: X4.
172. Hollenberg M, Zoltick JM, Go M, et al. Comparison of a quantitative treadmill exercise score with standard electrocardiographic criteria in screening asymptomatic young men for coronary artery disease. *N Engl J Med*. 1985 Sep 5;313(10):600-6. doi: 10.1056/NEJM198509053131003. PMID: 4022047. Exclusion Code: X4.
173. Holtermann A, Mortensen OS, Burr H, et al. Long work hours and physical fitness: 30-year risk of ischaemic heart disease and all-cause mortality among middle-aged Caucasian men. *Heart*. 2010 Oct;96(20):1638-44. doi: 10.1136/hrt.2010.197145. PMID: 20820054. Exclusion Code: X3.
174. Holtermann A, Mortensen OS, Burr H, et al. Physical work demands and physical fitness in low social classes--30-year ischemic heart disease and all-cause mortality in the Copenhagen Male Study. *J Occup Environ Med*. 2011 Nov;53(11):1221-7. doi: 10.1097/JOM.0b013e318233865f. PMID: 22015549. Exclusion Code: X3.
175. Hung RK, Al-Mallah MH, McEvoy JW, et al. Prognostic value of exercise capacity in patients with coronary artery disease: the FIT (Henry Ford Exercise Testing) project. *Mayo Clin Proc*. 2014 Dec;89(12):1644-54. doi: 10.1016/j.mayocp.2014.07.011. PMID: 25440889. Exclusion Code: X2.
176. Hung RK, Al-Mallah MH, Qadi MA, et al. Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford Exercise Testing Project. *Am Heart J*. 2015 Aug;170(2):390-9. doi: 10.1016/j.ahj.2015.04.030. PMID: 26299238. Exclusion Code: X2.
177. Ilias NA, Xian H, Inman C, et al. Arm exercise testing predicts clinical outcome. *Am Heart J*. 2009 Jan;157(1):69-76. doi: 10.1016/j.ahj.2008.09.007. PMID: 19081399. Exclusion Code: X2.
178. Ilkhanoff L, Liu K, Ning H, et al. Association of QRS duration with left ventricular structure and function and risk of heart failure in middle-aged and older adults: the Multi-Ethnic Study of Atherosclerosis (MESA). *Eur J Heart Fail*. 2012 Nov;14(11):1285-92. doi: 10.1093/eurjhf/hfs112. PMID: 22791081. Exclusion Code: X5.
179. Ilkhanoff L, Soliman EZ, Prineas RJ, et al. Clinical characteristics and outcomes associated with the natural history of early repolarization in a young, biracial cohort followed to middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Circ Arrhythm Electrophysiol*. 2014 Jun;7(3):392-9. doi: 10.1161/circep.113.000874. PMID: 24759868. Exclusion Code: X3.
180. Inama G, Pedrinazzi C. T-wave alternans and ventricular arrhythmias in athletes: usefulness of follow-up updates. *Ann Noninvasive Electrocardiol*. 2009 Jan;14(1):99. doi: 10.1111/j.1542-474X.2008.00280.x. PMID: 19149801. Exclusion Code: X7.
181. Inohara T, Kohsaka S, Okamura T, et al. Cumulative impact of axial, structural, and repolarization ECG findings on long-term cardiovascular mortality among healthy individuals in Japan: National Integrated Project for Prospective Observation of Non-Communicable Disease and its Trends in the Aged, 1980 and 1990. *Eur J Prev Cardiol*. 2014 Dec;21(12):1501-8. doi: 10.1177/2047487313500568. PMID: 23918839. Exclusion Code: X4.
182. Inohara T, Kohsaka S, Okamura T, et al. Long-term outcome of healthy participants with atrial premature complex: a 15-year follow-up of the NIPPON DATA 90 cohort. *PLoS One*. 2013;8(11):e80853. doi: 10.1371/journal.pone.0080853. PMID: 24260495. Exclusion Code: X4.
183. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. *Ann Noninvasive Electrocardiol*. 2014 Sep;19(5):490-500. doi: 10.1111/anec.12157. PMID: 24829126. Exclusion Code: X7.
184. Ishikawa J, Ishikawa S, Kario K. Levels of cornell voltage and cornell product for predicting cardiovascular and stroke mortality and morbidity in the general Japanese population. *Circ J*. 2014;78(2):465-75. PMID: 24284883. Exclusion Code: X4.
185. Jacob MJ. Evaluation of TMT abnormalities in asymptomatic persons using myocardial perfusion study. *J Assoc Physicians India*.

## Appendix C. Excluded Studies

- 2011 Mar;59:155-6, 61-3. PMID: 21751624. Exclusion Code: X5.
186. Jee SH, Park JW, Lee SY, et al. Stroke risk prediction model: a risk profile from the Korean study. *Atherosclerosis*. 2008 Mar;197(1):318-25. doi: 10.1016/j.atherosclerosis.2007.05.014. PMID: 17586511. Exclusion Code: X3.
187. Jensen MT, Suadicani P, Hein HO, et al. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. *Heart*. 2013 Jun;99(12):882-7. doi: 10.1136/heartjnl-2012-303375. PMID: 23595657. Exclusion Code: X4.
188. Jeong HC, Kim I, Park KH, et al. New strategy for detection of subclinical coronary atherosclerosis in asymptomatic patients with type 2 diabetes based on cardiac multi-detector computed tomography and treadmill test. *Circ J*. 2014;78(3):671-8. PMID: 24401570. Exclusion Code: X4.
189. Jimenez-Pavon D, Artero EG, Lee DC, et al. Cardiorespiratory Fitness and Risk of Sudden Cardiac Death in Men and Women in the United States: A Prospective Evaluation From the Aerobics Center Longitudinal Study. *Mayo Clin Proc*. 2016 Jul;91(7):849-57. doi: 10.1016/j.mayocp.2016.04.025. PMID: 27378037. Exclusion Code: X5.
190. Jissho S, Shimada K, Taguchi H, et al. Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients. - The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Circ J*. 2010 May;74(5):938-45. PMID: 20339195. Exclusion Code: X2.
191. Johnson NP, Goldberger JJ. Prognostic value of late heart rate recovery after treadmill exercise. *Am J Cardiol*. 2012 Jul 1;110(1):45-9. doi: 10.1016/j.amjcard.2012.02.046. PMID: 22463837. Exclusion Code: X2.
192. Josephson RA, Shefrin E, Lakatta EG, et al. Can serial exercise testing improve the prediction of coronary events in asymptomatic individuals? *Circulation*. 1990 Jan;81(1):20-4. PMID: 2297826. Exclusion Code: X4.
193. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. *N Engl J Med*. 2005 May 12;352(19):1951-8. doi: 10.1056/NEJMoa043012. PMID: 15888695. Exclusion Code: X5.
194. Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. *N Engl J Med*. 2000 Sep 21;343(12):826-33. doi: 10.1056/NEJM200009213431201. PMID: 10995861. Exclusion Code: X4.
195. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. *Am J Cardiol*. 2012 Mar 1;109(5):685-92. doi: 10.1016/j.amjcard.2011.10.025. PMID: 22169130. Exclusion Code: X2.
196. Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects. *Heart Rhythm*. 2014 Oct;11(10):1701-6. doi: 10.1016/j.hrthm.2014.05.024. PMID: 24858812. Exclusion Code: X5.
197. Kabutoya T, Ishikawa S, Ishikawa J, et al. P-wave morphologic characteristics predict cardiovascular events in a community-dwelling population. *Ann Noninvasive Electrocardiol*. 2012 Jul;17(3):252-9. doi: 10.1111/j.1542-474X.2012.00529.x. PMID: 22816544. Exclusion Code: X7.
198. Kahn S, Frishman WH, Weissman S, et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. *J Am Geriatr Soc*. 1996 May;44(5):524-9. PMID: 8617900. Exclusion Code: X5.
199. Kamel H, Bartz TM, Longstreth WT, Jr., et al. Association between left atrial abnormality on ECG and vascular brain injury on MRI in the Cardiovascular Health Study. *Stroke*. 2015 Mar;46(3):711-6. doi: 10.1161/strokeaha.114.007762. PMID: 25677594. Exclusion Code: X5.
200. Kamel H, Hunter M, Moon YP, et al. Electrocardiographic Left Atrial Abnormality and Risk of Stroke: Northern Manhattan Study. *Stroke*. 2015 Nov;46(11):3208-12. doi: 10.1161/strokeaha.115.009989. PMID: 26396031. Exclusion Code: X5.
201. Kamel H, O'Neal WT, Okin PM, et al. Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. *Ann Neurol*. 2015

## Appendix C. Excluded Studies

- Nov;78(5):670-8. doi: 10.1002/ana.24482. PMID: 26179566. Exclusion Code: X5.
202. Kamel H, Soliman EZ, Heckbert SR, et al. P-wave morphology and the risk of incident ischemic stroke in the Multi-Ethnic Study of Atherosclerosis. *Stroke*. 2014 Sep;45(9):2786-8. doi: 10.1161/strokeaha.114.006364. PMID: 25052322. Exclusion Code: X5.
203. Kanaya AM, Kandula N, Herrington D, et al. Mediators of Atherosclerosis in South Asians Living in America (MASALA) study: objectives, methods, and cohort description. *Clin Cardiol*. 2013 Dec;36(12):713-20. doi: 10.1002/clc.22219. PMID: 24194499. Exclusion Code: X5.
204. Katsikis A, Theodorakos A, Kouzoumi A, et al. Prognostic value of the Duke treadmill score in octogenarians undergoing myocardial perfusion imaging. *Atherosclerosis*. 2014 Oct;236(2):373-80. doi: 10.1016/j.atherosclerosis.2014.07.028. PMID: 25133351. Exclusion Code: X2.
205. Katsikis A, Theodorakos A, Papaioannou S, et al. Long-term prognostic value of myocardial perfusion imaging in octogenarians able to undergo treadmill exercise stress testing. *J Nucl Cardiol*. 2014 Dec;21(6):1213-22. doi: 10.1007/s12350-014-9991-4. PMID: 25189145. Exclusion Code: X2.
206. Kawasaki-Ogita Y, Hamamoto Y, Honjo S, et al. The limited usefulness of the treadmill test or a risk-guided approach in screening for asymptomatic coronary heart disease in Japanese patients with type 2 diabetes. *Intern Med*. 2012;51(24):3337-42. PMID: 23257517. Exclusion Code: X5.
207. Kellett J, Rasool S, McLoughlin B. Prediction of mortality 1 year after hospital admission. *Qjm*. 2012 Sep;105(9):847-53. doi: 10.1093/qjmed/hcs099. PMID: 22690010. Exclusion Code: X2.
208. Kentta T, Karsikas M, Junttila MJ, et al. QRS-T morphology measured from exercise electrocardiogram as a predictor of cardiac mortality. *Europace*. 2011 May;13(5):701-7. doi: 10.1093/europace/euq461. PMID: 21186225. Exclusion Code: X5.
209. Khan H, Kunutsor S, Rauramaa R, et al. Cardiorespiratory fitness and risk of heart failure: a population-based follow-up study. *Eur J Heart Fail*. 2014 Feb;16(2):180-8. doi: 10.1111/ejhf.37. PMID: 24464981. Exclusion Code: X2.
210. Khan HS, Iftikhar I, Khan Q. Validity of Electrocardiographic QT Interval in Predicting Left Ventricular Diastolic Dysfunction in Patients with Suspected Heart Failure. *J Coll Physicians Surg Pak*. 2016 May;26(5):353-6. doi: 2313. PMID: 27225136. Exclusion Code: X2.
211. Khan R, Jang IK. Evaluation of coronary allograft vasculopathy using multi-detector row computed tomography: a systematic review (Provisional abstract). *European Journal of Cardio-Thoracic Surgery*. 2012;41(2):415-22. PMID: DARE-12012022142. Exclusion Code: X2.
212. Kim JH, Baggish AL. Electrocardiographic right and left bundle branch block patterns in athletes: prevalence, pathology, and clinical significance. *J Electrocardiol*. 2015 May-Jun;48(3):380-4. doi: 10.1016/j.jelectrocard.2015.03.015. PMID: 25836379. Exclusion Code: X7.
213. Kobal SL, Wilkof-Segev R, Patchett MS, et al. Prognostic value of myocardial ischemic electrocardiographic response in patients with normal stress echocardiographic study. *Am J Cardiol*. 2014 Mar 15;113(6):945-9. doi: 10.1016/j.amjcard.2013.11.051. PMID: 24440328. Exclusion Code: X2.
214. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. *Circulation*. 2004 Mar 23;109(11):1349-53. doi: 10.1161/01.CIR.0000120707.98922.E3. PMID: 15023871. Exclusion Code: X3.
215. Kokkinos P, Doumas M, Myers J, et al. A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. *Blood Press*. 2009;18(5):261-7. doi: 10.3109/08037050903272859. PMID: 19919397. Exclusion Code: X4.
216. Kokkinos P, Faselis C, Myers J, et al. Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. *Am J Hypertens*. 2014 Mar;27(3):422-30. doi: 10.1093/ajh/hpt241. PMID: 24436326. Exclusion Code: X2.
217. Kokkinos P, Myers J, Doumas M, et al. Heart rate recovery, exercise capacity, and mortality risk in male veterans. *Eur J Prev Cardiol*. 2012 Apr;19(2):177-84. doi: 10.1177/1741826711398432. PMID: 21450594. Exclusion Code: X4.

## Appendix C. Excluded Studies

218. Kokkinos PF, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. *Lancet*. 2013 Feb 2;381(9864):394-9. doi: 10.1016/s0140-6736(12)61426-3. PMID: 23199849. Exclusion Code: X2.
219. Koller MT, Steyerberg EW, Wolbers M, et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. *Am Heart J*. 2007 Jul;154(1):87-93. doi: 10.1016/j.ahj.2007.03.022. PMID: 17584559. Exclusion Code: X3.
220. Kook HY, Jeong MH, Oh S, et al. Current trend of acute myocardial infarction in Korea (from the Korea Acute Myocardial Infarction Registry from 2006 to 2013). *Am J Cardiol*. 2014 Dec 15;114(12):1817-22. doi: 10.1016/j.amjcard.2014.09.019. PMID: 25438907. Exclusion Code: X2.
221. Kop WJ, Stein PK, Tracy RP, et al. Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression. *Psychosom Med*. 2010 Sep;72(7):626-35. doi: 10.1097/PSY.0b013e3181eadd2b. PMID: 20639389. Exclusion Code: X3.
222. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. *Stroke*. 2002 Jul;33(7):1776-81. PMID: 12105351. Exclusion Code: X3.
223. Krepp JM, Lin F, Min JK, et al. Relationship of electrocardiographic left ventricular hypertrophy to the presence of diastolic dysfunction. *Ann Noninvasive Electrocardiol*. 2014 Nov;19(6):552-60. doi: 10.1111/anec.12166. PMID: 24750238. Exclusion Code: X4.
224. Krijthe BP, Leening MJ, Heeringa J, et al. Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. *Int J Cardiol*. 2013 Sep 30;168(2):1453-7. doi: 10.1016/j.ijcard.2012.12.057. PMID: 23332895. Exclusion Code: X5.
225. Kurl S, Laukkanen JA, Tuomainen TP, et al. Association of exercise-induced, silent ST-segment depression with the risk of stroke and cardiovascular diseases in men. *Stroke*. 2003 Jul;34(7):1760-5. doi: 10.1161/01.STR.0000078564.46376.0A. PMID: 12829872. Exclusion Code: X5.
226. Kurl S, Makikallio TH, Laukkanen JA. T-wave inversion and mortality risk. *Ann Med*. 2015 Feb;47(1):69-73. doi: 10.3109/07853890.2014.985703. PMID: 25613172. Exclusion Code: X5.
227. Kurl S, Makikallio TH, Rautaharju P, et al. Duration of QRS complex in resting electrocardiogram is a predictor of sudden cardiac death in men. *Circulation*. 2012 May 29;125(21):2588-94. doi: 10.1161/circulationaha.111.025577. PMID: 22615341. Exclusion Code: X2.
228. Kurl S, Sivenius J, Makikallio TH, et al. Exercise workload, cardiovascular risk factor evaluation and the risk of stroke in middle-aged men. *J Intern Med*. 2009 Feb;265(2):229-37. doi: 10.1111/j.1365-2796.2008.02006.x. PMID: 18793247. Exclusion Code: X5.
229. Ladapo JA, Blecker S, Douglas PS. Physician decision making and trends in the use of cardiac stress testing in the United States: an analysis of repeated cross-sectional data. *Ann Intern Med*. 2014 Oct 7;161(7):482-90. doi: 10.7326/m14-0296. PMID: 25285541. Exclusion Code: X7.
230. Ladapo JA, Blecker S, Elashoff MR, et al. Clinical implications of referral bias in the diagnostic performance of exercise testing for coronary artery disease (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2013(2):e000505. PMID: DARE-12014040303. Exclusion Code: X3.
231. Lakoski SG, Barlow CE, Farrell SW, et al. Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center longitudinal study). *Am J Cardiol*. 2011 Jul 1;108(1):34-9. doi: 10.1016/j.amjcard.2011.02.338. PMID: 21529738. Exclusion Code: X5.
232. Lakoski SG, Willis BL, Barlow CE, et al. Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. *JAMA Oncol*. 2015 May;1(2):231-7. doi: 10.1001/jamaoncol.2015.0226. PMID: 26181028. Exclusion Code: X5.
233. Larsen BS, Kumarathurai P, Falkenberg J, et al. Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. *J Am Coll Cardiol*. 2015 Jul 21;66(3):232-41. doi: 10.1016/j.jacc.2015.05.018. PMID: 26184616. Exclusion Code: X5.
234. Larsen CT, Dahlin J, Blackburn H, et al. Prevalence and prognosis of electrocardiographic left ventricular

## Appendix C. Excluded Studies

- hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study. *Eur Heart J*. 2002 Feb;23(4):315-24. doi: 10.1053/euhj.2001.2774. PMID: 11812068. Exclusion Code: X5.
235. Larstorp AC, Okin PM, Devereux RB, et al. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. *J Hum Hypertens*. 2011 Mar;25(3):178-85. doi: 10.1038/jhh.2010.52. PMID: 20505749. Exclusion Code: X5.
236. Lauer MS, Okin PM, Larson MG, et al. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. *Circulation*. 1996 Apr 15;93(8):1520-6. PMID: 8608620. Exclusion Code: X5.
237. Laukkanen JA, Di Angelantonio E, Khan H, et al. T-wave inversion, QRS duration, and QRS/T angle as electrocardiographic predictors of the risk for sudden cardiac death. *Am J Cardiol*. 2014 Apr 1;113(7):1178-83. doi: 10.1016/j.amjcard.2013.12.026. PMID: 24513474. Exclusion Code: X2.
238. Laukkanen JA, Kurl S, Lakka TA, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. *J Am Coll Cardiol*. 2001 Jul;38(1):72-9. PMID: 11451298. Exclusion Code: X5.
239. Laukkanen JA, Kurl S, Rauramaa R, et al. Systolic blood pressure response to exercise testing is related to the risk of acute myocardial infarction in middle-aged men. *Eur J Cardiovasc Prev Rehabil*. 2006 Jun;13(3):421-8. PMID: 16926673. Exclusion Code: X5.
240. Laukkanen JA, Rauramaa R, Kurl S. Exercise workload, coronary risk evaluation and the risk of cardiovascular and all-cause death in middle-aged men. *Eur J Cardiovasc Prev Rehabil*. 2008 Jun;15(3):285-92. doi: 10.1097/HJR.0b013e3282f37a33. PMID: 18525382. Exclusion Code: X5.
241. Laukkanen JA, Willeit P, Kurl S, et al. Elevated systolic blood pressure during recovery from exercise and the risk of sudden cardiac death. *J Hypertens*. 2014 Mar;32(3):659-66. doi: 10.1097/hjh.000000000000066. PMID: 24317550. Exclusion Code: X2.
242. Lee CD, Sui X, Blair SN. Combined effects of cardiorespiratory fitness, not smoking, and normal waist girth on morbidity and mortality in men. *Arch Intern Med*. 2009 Dec 14;169(22):2096-101. doi: 10.1001/archinternmed.2009.414. PMID: 20008693. Exclusion Code: X5.
243. Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. *Circulation*. 2011 Dec 6;124(23):2483-90. doi: 10.1161/circulationaha.111.038422. PMID: 22144631. Exclusion Code: X3.
244. Lee DC, Sui X, Ortega FB, et al. Comparisons of leisure-time physical activity and cardiorespiratory fitness as predictors of all-cause mortality in men and women. *Br J Sports Med*. 2011 May;45(6):504-10. doi: 10.1136/bjsm.2009.066209. PMID: 20418526. Exclusion Code: X5.
245. Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. *Circulation*. 2006 Jun 27;113(25):2897-905. doi: 10.1161/CIRCULATIONAHA.105.593178. PMID: 16769914. Exclusion Code: X4.
246. Lee JM, Yoo KD, Oh YS, et al. Relationship between resting electrocardiographic parameters and estimated 10-year risk for coronary heart disease in healthy adults in the USA. *Ann Noninvasive Electrocardiol*. 2010 Oct;15(4):315-20. doi: 10.1111/j.1542-474X.2010.00386.x. PMID: 20946553. Exclusion Code: X5.
247. Lee V, Hemingway H, Harb R, et al. The prognostic significance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review. *Heart*. 2012 Sep;98(17):1290-8. doi: 10.1136/heartjnl-2012-302005. PMID: 22781425. Exclusion Code: X7.
248. Leigh JA, O'Neal WT, Soliman EZ. Electrocardiographic Left Ventricular Hypertrophy as a Predictor of Cardiovascular Disease Independent of Left Ventricular Anatomy in Subjects Aged  $\geq$ 65 Years. *Am J Cardiol*. 2016 Jun 01;117(11):1831-5. doi: 10.1016/j.amjcard.2016.03.020. PMID: 27067620. Exclusion Code: X4.

## Appendix C. Excluded Studies

249. Leo T, Uberoi A, Jain NA, et al. The impact of ST elevation on athletic screening. *Clin J Sport Med*. 2011 Sep;21(5):433-40. doi: 10.1097/jsm.0b013e31822cf105. PMID: 21892017. Exclusion Code: X7.
250. Levitt K, Aves T, Dorian P, et al. Lack of difference in T wave variability between patients at risk of sudden cardiac death and healthy subjects. *J Electrocardiol*. 2014 Mar-Apr;47(2):251-6. doi: 10.1016/j.jelectrocard.2013.12.007. PMID: 24456792. Exclusion Code: X4.
251. Li Y, Dawood FZ, Chen H, et al. Minor isolated Q waves and cardiovascular events in the MESA study. *Am J Med*. 2013 May;126(5):450.e9-.e16. doi: 10.1016/j.amjmed.2012.10.030. PMID: 23582938. Exclusion Code: X4.
252. Li Y, Shah AJ, Soliman EZ. Effect of electrocardiographic P-wave axis on mortality. *Am J Cardiol*. 2014 Jan 15;113(2):372-6. doi: 10.1016/j.amjcard.2013.08.050. PMID: 24176072. Exclusion Code: X2.
253. Liao Y, McGee DL, Cooper RS. Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. *Am J Cardiol*. 1999 Jul 1;84(1):31-6. PMID: 10404847. Exclusion Code: X3.
254. Liao Y, McGee DL, Cooper RS, et al. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. *Am Heart J*. 1999 May;137(5):837-45. PMID: 10220632. Exclusion Code: X3.
255. Liao YL, Liu KA, Dyer A, et al. Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women. *J Am Coll Cardiol*. 1988 Dec;12(6):1494-500. PMID: 3192848. Exclusion Code: X5.
256. Lindekleiv H, Wilsgaard T, Macfarlane PW, et al. QT interval and the risk of myocardial infarction and all-cause death: a cohort study. *J Cardiovasc Electrophysiol*. 2012 Aug;23(8):846-52. doi: 10.1111/j.1540-8167.2012.02308.x. PMID: 22509793. Exclusion Code: X4.
257. Lindman AS, Veierod MB, Pedersen JI, et al. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. *Eur J Cardiovasc Prev Rehabil*. 2007 Aug;14(4):501-7. doi: 10.1097/HJR.0b013e328011490a. PMID: 17667638. Exclusion Code: X3.
258. Liu J, Hong Y, D'Agostino RB, Sr., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. *JAMA*. 2004 Jun 2;291(21):2591-9. doi: 10.1001/jama.291.21.2591. PMID: 15173150. Exclusion Code: X3.
259. Liu R, Sui X, Laditka JN, et al. Cardiorespiratory fitness as a predictor of dementia mortality in men and women. *Med Sci Sports Exerc*. 2012 Feb;44(2):253-9. doi: 10.1249/MSS.0b013e31822cf717. PMID: 21796048. Exclusion Code: X5.
260. Lovett KM, Liang BA. Direct-to-consumer cardiac screening and suspect risk evaluation. *Jama*. 2011 Jun 22;305(24):2567-8. doi: 10.1001/jama.2011.865. PMID: 21693746. Exclusion Code: X7.
261. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemost*. 2013 Aug;110(2):213-22. doi: 10.1160/th13-02-0165. PMID: 23595785. Exclusion Code: X7.
262. Lysterly GW, Sui X, Church TS, et al. Maximal exercise electrocardiography responses and coronary heart disease mortality among men with diabetes mellitus. *Circulation*. 2008 May 27;117(21):2734-42. doi: 10.1161/CIRCULATIONAHA.107.729277. PMID: 18490521. Exclusion Code: X5.
263. Lysterly GW, Sui X, Church TS, et al. Maximal exercise electrocardiographic responses and coronary heart disease mortality among men with metabolic syndrome. *Mayo Clin Proc*. 2010 Mar;85(3):239-46. doi: 10.4065/mcp.2009.0509. PMID: 20160139. Exclusion Code: X5.
264. Lysterly GW, Sui X, Lavie CJ, et al. The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus. *Mayo Clin Proc*. 2009 Sep;84(9):780-6. doi: 10.1016/s0025-6196(11)60487-4. PMID: 19720775. Exclusion Code: X5.
265. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. *Europace*. 2011 May;13(5):634-9. doi:



## Appendix C. Excluded Studies

- 10.1093/europace/eur016. PMID: 21325345. Exclusion Code: X2.
266. Macfarlane PW, Norrie J, Committee WE. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. *J Electrocardiol.* 2007 Jan;40(1):101-9. doi: 10.1016/j.jelectrocard.2006.05.003. PMID: 17069838. Exclusion Code: X4.
267. Machado DB, Crow RS, Boland LL, et al. Electrocardiographic findings and incident coronary heart disease among participants in the Atherosclerosis Risk in Communities (ARIC) study. *Am J Cardiol.* 2006 Apr 15;97(8):1176-81. doi: 10.1016/j.amjcard.2005.11.036. PMID: 16616022. Exclusion Code: X5.
268. Magnani JW, Johnson VM, Sullivan LM, et al. P wave duration and risk of longitudinal atrial fibrillation in persons  $\geq 60$  years old (from the Framingham Heart Study). *Am J Cardiol.* 2011 Mar 15;107(6):917-21.e1. doi: 10.1016/j.amjcard.2010.10.075. PMID: 21255761. Exclusion Code: X5.
269. Magnani JW, Wang N, Nelson KP, et al. Electrocardiographic PR interval and adverse outcomes in older adults: the Health, Aging, and Body Composition study. *Circ Arrhythm Electrophysiol.* 2013 Feb;6(1):84-90. doi: 10.1161/circep.112.975342. PMID: 23243193. Exclusion Code: X2.
270. Maheshwari A, Norby FL, Soliman EZ, et al. Relation of Prolonged P-Wave Duration to Risk of Sudden Cardiac Death in the General Population (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol.* 2017 May 01;119(9):1302-6. doi: 10.1016/j.amjcard.2017.01.012. PMID: 28267962. Exclusion Code: X2.
271. Mainous AG, 3rd, Everett CJ, Player MS, et al. Importance of a patient's personal health history on assessments of future risk of coronary heart disease. *J Am Board Fam Med.* 2008 Sep-Oct;21(5):408-13. doi: 10.3122/jabfm.2008.05.080046. PMID: 18772295. Exclusion Code: X3.
272. Mainous AG, 3rd, Koopman RJ, Diaz VA, et al. A coronary heart disease risk score based on patient-reported information. *Am J Cardiol.* 2007 May 1;99(9):1236-41. doi: 10.1016/j.amjcard.2006.12.035. PMID: 17478150. Exclusion Code: X3.
273. Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. *J Am Coll Cardiol.* 2010 Nov 2;56(19):1576-84. doi: 10.1016/j.jacc.2010.06.033. PMID: 21029874. Exclusion Code: X2.
274. Mandyam MC, Soliman EZ, Alonso A, et al. The QT interval and risk of incident atrial fibrillation. *Heart Rhythm.* 2013 Oct;10(10):1562-8. doi: 10.1016/j.hrthm.2013.07.023. PMID: 23872693. Exclusion Code: X2.
275. Mandyam MC, Soliman EZ, Heckbert SR, et al. Long-term outcomes of left anterior fascicular block in the absence of overt cardiovascular disease. *Jama.* 2013 Apr 17;309(15):1587-8. doi: 10.1001/jama.2013.2729. PMID: 23592102. Exclusion Code: X4.
276. Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. *J Am Coll Cardiol.* 2013 Aug 6;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091. PMID: 23684685. Exclusion Code: X4.
277. Marine JE, Shetty V, Chow GV, et al. Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging). *J Am Coll Cardiol.* 2013 Aug 13;62(7):595-600. doi: 10.1016/j.jacc.2013.05.026. PMID: 23747767. Exclusion Code: X4.
278. Marrugat J, Subirana I, Comin E, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. *J Epidemiol Community Health.* 2007 Jan;61(1):40-7. doi: 10.1136/jech.2005.038505. PMID: 17183014. Exclusion Code: X4.
279. Martin WH, 3rd, Xian H, Chandiramani P, et al. Cardiovascular mortality prediction in veterans with arm exercise vs pharmacologic myocardial perfusion imaging. *Am Heart J.* 2015 Aug;170(2):362-70. doi: 10.1016/j.ahj.2015.05.004. PMID: 26299235. Exclusion Code: X2.
280. Massing MW, Simpson RJ, Jr., Rautaharju PM, et al. Usefulness of ventricular premature complexes to predict coronary heart disease events and mortality (from the Atherosclerosis Risk In Communities cohort). *Am J Cardiol.* 2006 Dec

## Appendix C. Excluded Studies

- 15;98(12):1609-12. doi: 10.1016/j.amjcard.2006.06.061. PMID: 17145219. Exclusion Code: X5.
281. May M, Lawlor DA, Brindle P, et al. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. *Heart*. 2006 Oct;92(10):1396-401. doi: 10.1136/hrt.2005.085381. PMID: 16547204. Exclusion Code: X3.
282. McAuley P, Pittsley J, Myers J, et al. Fitness and fatness as mortality predictors in healthy older men: the veterans exercise testing study. *J Gerontol A Biol Sci Med Sci*. 2009 Jun;64(6):695-9. doi: 10.1093/gerona/gln039. PMID: 19196639. Exclusion Code: X5.
283. McAuley PA, Sui X, Church TS, et al. The joint effects of cardiorespiratory fitness and adiposity on mortality risk in men with hypertension. *Am J Hypertens*. 2009 Oct;22(10):1062-9. doi: 10.1038/ajh.2009.122. PMID: 19617881. Exclusion Code: X5.
284. McEwan P, Williams JE, Griffiths JD, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. *Diabet Med*. 2004 Apr;21(4):318-23. doi: 10.1111/j.1464-5491.2004.01139.x. PMID: 15049932. Exclusion Code: X3.
285. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabetes Care*. 2005 Feb;28(2):385-90. PMID: 15677797. Exclusion Code: X3.
286. Menotti A, Mulder I, Kromhout D, et al. The association of silent electrocardiographic findings with coronary deaths among elderly men in three European countries. The FINE study. *Acta Cardiol*. 2001 Feb;56(1):27-36. doi: 10.2143/A.C.56.1.2005590. PMID: 11315121. Exclusion Code: X4.
287. Menotti A, Seccareccia F. Electrocardiographic Minnesota code findings predicting short-term mortality in asymptomatic subjects. The Italian RIFLE Pooling Project (Risk Factors and Life Expectancy). *G Ital Cardiol*. 1997 Jan;27(1):40-9. PMID: 9199942. Exclusion Code: X5.
288. Michaelides AP, Andrikopoulos GK, Antoniadou C, et al. Duration of treadmill exercise testing combined with QRS score predicts adverse cardiac outcome at long-term follow-up. *Coron Artery Dis*. 2009 Aug;20(5):337-42. doi: 10.1097/MCA.0b013e32832c4589. PMID: 19543085. Exclusion Code: X2.
289. Michaelides AP, Liakos CI, Vyssoulis GP, et al. The interplay of exercise heart rate and blood pressure as a predictor of coronary artery disease and arterial hypertension. *J Clin Hypertens (Greenwich)*. 2013 Mar;15(3):162-70. doi: 10.1111/jch.12035. PMID: 23458587. Exclusion Code: X4.
290. Milne R, Gamble G, Whitlock G, et al. Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factors. *N Z Med J*. 2003 Nov 07;116(1185):U663. PMID: 14615805. Exclusion Code: X3.
291. Minkinen M, Nieminen T, Verrier RL, et al. Impaired exercise capacity predicts sudden cardiac death in a low-risk population: enhanced specificity with heightened T-wave alternans. *Ann Med*. 2009;41(5):380-9. doi: 10.1080/07853890902802971. PMID: 19301163. Exclusion Code: X5.
292. Miyamoto A, Hayashi H, Makiyama T, et al. Risk determinants in individuals with a spontaneous type 1 Brugada ECG. *Circ J*. 2011;75(4):844-51. PMID: 21343656. Exclusion Code: X2.
293. Miyasaka Y, Barnes ME, Gersh BJ, et al. Coronary ischemic events after first atrial fibrillation: risk and survival. *Am J Med*. 2007 Apr;120(4):357-63. doi: 10.1016/j.amjmed.2006.06.042. PMID: 17398231. Exclusion Code: X2.
294. Moller CS, Haggstrom J, Zethelius B, et al. Age and follow-up time affect the prognostic value of the ECG and conventional cardiovascular risk factors for stroke in adult men. *J Epidemiol Community Health*. 2007 Aug;61(8):704-12. doi: 10.1136/jech.2006.048074. PMID: 17630370. Exclusion Code: X5.
295. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. *JAMA*. 2003 Sep 24;290(12):1600-7. doi: 10.1001/jama.290.12.1600. PMID: 14506119. Exclusion Code: X5.
296. Mora S, Redberg RF, Sharrett AR, et al. Enhanced risk assessment in asymptomatic individuals with exercise testing and

## Appendix C. Excluded Studies

297. Framingham risk scores. *Circulation*. 2005 Sep 13;112(11):1566-72. doi: 10.1161/CIRCULATIONAHA.105.542993. PMID: 16144993. Exclusion Code: X5.
298. Morin DP, Saad MN, Shams OF, et al. Relationships between the T-peak to T-end interval, ventricular tachyarrhythmia, and death in left ventricular systolic dysfunction. *Europace*. 2012 Aug;14(8):1172-9. doi: 10.1093/europace/eur426. PMID: 22277646. Exclusion Code: X2.
299. Morshedi-Meibodi A, Larson MG, Levy D, et al. Heart rate recovery after treadmill exercise testing and risk of cardiovascular disease events (The Framingham Heart Study). *Am J Cardiol*. 2002 Oct 15;90(8):848-52. PMID: 12372572. Exclusion Code: X4.
300. Moyer VA. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2012 Oct 2;157(7):512-8. doi: 10.7326/0003-4819-157-7-201210020-00514. PMID: 22847227. Exclusion Code: X7.
301. Muramoto D, Yong CM, Singh N, et al. Patterns and prognosis of all components of the J-wave pattern in multiethnic athletes and ambulatory patients. *Am Heart J*. 2014 Feb;167(2):259-66. doi: 10.1016/j.ahj.2013.10.027. PMID: 24439988. Exclusion Code: X7.
302. Muzzarelli S, Pfisterer ME, Muller-Brand J, et al. Gate-keeper to coronary angiography: comparison of exercise testing, myocardial perfusion SPECT and individually tailored approach for risk stratification. *Int J Cardiovasc Imaging*. 2010 Dec;26(8):871-9. doi: 10.1007/s10554-010-9627-y. PMID: 20411429. Exclusion Code: X2.
303. Nakamura K, Berry NC, An PG, et al. Significance of ST-segment elevation in lead aVR. *Arch Intern Med*. 2012 Mar 12;172(5):389-91. doi: 10.1001/archinternmed.2011.2224. PMID: 22412103. Exclusion Code: X7.
304. Nakamura Y, Okamura T, Higashiyama A, et al. Prognostic values of clockwise and counterclockwise rotation for cardiovascular mortality in Japanese subjects: a 24-year follow-up of the National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in the Aged, 1980-2004 (NIPPON DATA 80). *Circulation*. 2012 Mar 13;125(10):1226-33. doi: 10.1161/circulationaha.111.070045. PMID: 22308300. Exclusion Code: X4.
305. Narayanan K, Zhang L, Kim C, et al. QRS fragmentation and sudden cardiac death in the obese and overweight. *J Am Heart Assoc*. 2015 Mar;4(3):e001654. doi: 10.1161/jaha.114.001654. PMID: 25762804. Exclusion Code: X7.
306. Nehme Z, Boyle MJ, Brown T. Diagnostic accuracy of prehospital clinical prediction models to identify short-term outcomes in patients with acute coronary syndromes: a systematic review (Provisional abstract). *Journal of Emergency Medicine*. 2013;44(5):946-54.e6. PMID: DARE-12013030041. Exclusion Code: X2.
307. Nielsen JB, Kuhl JT, Pietersen A, et al. P-wave duration and the risk of atrial fibrillation: Results from the Copenhagen ECG Study. *Heart Rhythm*. 2015 Sep;12(9):1887-95. doi: 10.1016/j.hrthm.2015.04.026. PMID: 25916567. Exclusion Code: X5.
308. Niemeijer MN, Berg ME, Eijgelsheim M, et al. Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):1831-6. PMID: DARE-12014050251. Exclusion Code: X5.
309. Nieminen T, Verrier RL, Leino J, et al. Atrioventricular conduction and cardiovascular mortality: assessment of recovery PR interval is superior to pre-exercise measurement. *Heart Rhythm*. 2010 Jun;7(6):796-801. doi: 10.1016/j.hrthm.2010.02.029. PMID: 20188862. Exclusion Code: X2.
310. Noseworthy PA, Peloso GM, Hwang SJ, et al. QT interval and long-term mortality risk in the Framingham Heart Study. *Ann Noninvasive Electrocardiol*. 2012 Oct;17(4):340-8. doi: 10.1111/j.1542-474X.2012.00535.x. PMID: 23094880. Exclusion Code: X4.
311. Ofoma U, He F, Shaffer ML, et al. Premature cardiac contractions and risk of incident ischemic stroke. *J Am Heart Assoc*. 2012 Oct;1(5):e002519. doi: 10.1161/jaha.112.002519. PMID: 23316293. Exclusion Code: X5.
312. Ofstad AP, Gullestad L, Orvik E, et al. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2

## Appendix C. Excluded Studies

- diabetes: the prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study. *Cardiovasc Diabetol*. 2013;12:126. doi: 10.1186/1475-2840-12-126. PMID: 23987834. Exclusion Code: X2.
312. Ogliaari G, Mahinrad S, Stott DJ, et al. Resting heart rate, heart rate variability and functional decline in old age. *Cmaj*. 2015 Oct 20;187(15):E442-9. doi: 10.1503/cmaj.150462. PMID: 26323697. Exclusion Code: X2.
313. Ohtomo K, Shigeeda T, Hirose A, et al. Silent myocardial ischaemia in patients with diabetic retinopathy. *Acta Ophthalmol*. 2014 Sep;92(6):e492-3. doi: 10.1111/aos.12362. PMID: 24698540. Exclusion Code: X4.
314. Okin PM, Anderson KM, Levy D, et al. Heart rate adjustment of exercise-induced ST segment depression. Improved risk stratification in the Framingham Offspring Study. *Circulation*. 1991 Mar;83(3):866-74. PMID: 1999037. Exclusion Code: X5.
315. Okin PM, Grandits G, Rautaharju PM, et al. Prognostic value of heart rate adjustment of exercise-induced ST segment depression in the multiple risk factor intervention trial. *J Am Coll Cardiol*. 1996 May;27(6):1437-43. PMID: 8626955. Exclusion Code: X5.
316. Okin PM, Hille DA, Kjeldsen SE, et al. Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. *Blood Press*. 2014 Apr;23(2):71-80. doi: 10.3109/08037051.2013.791414. PMID: 23721506. Exclusion Code: X2.
317. Okin PM, Kjeldsen SE, Julius S, et al. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. *Am J Cardiol*. 2012 Mar 1;109(5):699-704. doi: 10.1016/j.amjcard.2011.10.026. PMID: 22154318. Exclusion Code: X5.
318. Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. *Eur Heart J*. 2010 Sep;31(18):2271-9. doi: 10.1093/eurheartj/ehq225. PMID: 20601389. Exclusion Code: X5.
319. Okin PM, Oikarinen L, Viitasalo M, et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). *Circulation*. 2009 Apr 14;119(14):1883-91. doi: 10.1161/circulationaha.108.812313. PMID: 19332468. Exclusion Code: X5.
320. Okin PM, Oikarinen L, Viitasalo M, et al. Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. *Eur J Heart Fail*. 2011 Apr;13(4):384-91. doi: 10.1093/eurjhf/hfq224. PMID: 21239405. Exclusion Code: X5.
321. Oliveira RB, Myers J, Araujo CG, et al. Maximal exercise oxygen pulse as a predictor of mortality among male veterans referred for exercise testing. *Eur J Cardiovasc Prev Rehabil*. 2009 Jun;16(3):358-64. doi: 10.1097/HJR.0b013e3283292fe8. PMID: 19357518. Exclusion Code: X3.
322. Olson KA, Viera AJ, Soliman EZ, et al. Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. *Eur Heart J*. 2011 Dec;32(24):3098-106. doi: 10.1093/eurheartj/ehr264. PMID: 21785106. Exclusion Code: X5.
323. O'Neal WT, Shah AJ, Efirid JT, et al. Subclinical myocardial injury identified by cardiac infarction/injury score and the risk of mortality in men and women free of cardiovascular disease. *Am J Cardiol*. 2014 Oct 1;114(7):1018-23. doi: 10.1016/j.amjcard.2014.06.032. PMID: 25129878. Exclusion Code: X5.
324. O'Neal WT, Wang YG, Wu HT, et al. Electrocardiographic J Wave and Cardiovascular Outcomes in the General Population (from the Atherosclerosis Risk In Communities Study). *Am J Cardiol*. 2016 Sep 15;118(6):811-5. doi: 10.1016/j.amjcard.2016.06.047. PMID: 27596326. Exclusion Code: X5.
325. Orford JL, Sesso HD, Stedman M, et al. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. *Am Heart J*. 2002 Jul;144(1):95-100. PMID: 12094194. Exclusion Code: X3.
326. Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. *Eur Heart J*. 2013 Feb;34(5):389-97. doi:

## Appendix C. Excluded Studies

- 10.1093/eurheartj/ehs174. PMID: 22947612. Exclusion Code: X3.
327. Ota C, Shiono SN, Fujino Y, et al. Prevalence and Prognostic Value of Early Repolarization in Low Risk Surgical Patients. *Biomed Res Int*. 2015;2015:309260. doi: 10.1155/2015/309260. PMID: 26266254. Exclusion Code: X4.
328. Ozgur ES, Nayci SA, Ozge C, et al. An integrated index combined by dynamic hyperinflation and exercise capacity in the prediction of morbidity and mortality in COPD. *Respir Care*. 2012 Sep;57(9):1452-9. doi: 10.4187/respcare.01440. PMID: 22348294. Exclusion Code: X4.
329. Paisible AL, Chang CC, So-Armah KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. *J Acquir Immune Defic Syndr*. 2015 Feb 1;68(2):209-16. doi: 10.1097/qai.0000000000000419. PMID: 25588033. Exclusion Code: X3.
330. Palmerini T, Dangas G, Mehran R, et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. *Circ Cardiovasc Interv*. 2011 Dec 1;4(6):577-84. doi: 10.1161/circinterventions.111.963884. PMID: 22028471. Exclusion Code: X2.
331. Parikh NI, Gona P, Larson MG, et al. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study. *Circulation*. 2009 Mar 10;119(9):1203-10. doi: 10.1161/circulationaha.108.825364. PMID: 19237656. Exclusion Code: X5.
332. Park JI, Shin SY, Park SK, et al. Usefulness of the integrated scoring model of treadmill tests to predict myocardial ischemia and silent myocardial ischemia in community-dwelling adults (from the Rancho Bernardo study). *Am J Cardiol*. 2015 Apr 15;115(8):1049-55. doi: 10.1016/j.amjcard.2015.01.536. PMID: 25728643. Exclusion Code: X5.
333. Park YM, Sui X, Liu J, et al. The effect of cardiorespiratory fitness on age-related lipids and lipoproteins. *J Am Coll Cardiol*. 2015 May 19;65(19):2091-100. doi: 10.1016/j.jacc.2015.03.517. PMID: 25975472. Exclusion Code: X5.
334. Pataky Z, Golay A, Laville M, et al. Fasting insulin at baseline influences the number of cardiometabolic risk factors and R-R interval at 3 years in a healthy population: the RISC Study. *Diabetes Metab*. 2013 Sep;39(4):330-6. doi: 10.1016/j.diabet.2013.05.008. PMID: 23876398. Exclusion Code: X5.
335. Payne CJ, Payne AR, Gibson SC, et al. Is there still a role for preoperative 12-lead electrocardiography? *World J Surg*. 2011 Dec;35(12):2611-6. doi: 10.1007/s00268-011-1289-y. PMID: 21989644. Exclusion Code: X2.
336. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. *Ann Intern Med*. 2009 Jan 20;150(2):65-72. PMID: 19153409. Exclusion Code: X3.
337. Peel JB, Sui X, Matthews CE, et al. Cardiorespiratory fitness and digestive cancer mortality: findings from the aerobics center longitudinal study. *Cancer Epidemiol Biomarkers Prev*. 2009 Apr;18(4):1111-7. doi: 10.1158/1055-9965.epi-08-0846. PMID: 19293313. Exclusion Code: X5.
338. Perelshtein Brezinov O, Kivity S, Segev S, et al. Gender-Related Cardiovascular Risk in Healthy Middle-Aged Adults. *Am J Cardiol*. 2016 Dec 01;118(11):1669-73. doi: 10.1016/j.amjcard.2016.08.045. PMID: 27737731. Exclusion Code: X4.
339. Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the group for syncope study in the emergency room (GESINUR). *Heart Rhythm*. 2014 Nov;11(11):2035-44. doi: 10.1016/j.hrthm.2014.06.037. PMID: 24993462. Exclusion Code: X2.
340. Perino AC, Soofi M, Singh N, et al. The long-term prognostic value of the Q wave criteria for prior myocardial infarction recommended in the universal definition of myocardial infarction. *J Electrocardiol*. 2015 Sep-Oct;48(5):798-802. doi: 10.1016/j.jelectrocard.2015.07.004. PMID: 26233646. Exclusion Code: X4.
341. Peters RK, Cady LD, Jr., Bischoff DP, et al. Physical fitness and subsequent myocardial infarction in healthy workers. *JAMA*. 1983 Jun 10;249(22):3052-6. PMID: 6854827. Exclusion Code: X5.
342. Pfister R, Cairns R, Erdmann E, et al. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the

## Appendix C. Excluded Studies

- PROactive study. *Diabet Med*. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x. PMID: 21388447. Exclusion Code: X2.
343. Pittaras AM, Faselis C, Doumas M, et al. Heart rate at rest, exercise capacity, and mortality risk in veterans. *Am J Cardiol*. 2013 Nov 15;112(10):1605-9. doi: 10.1016/j.amjcard.2013.07.042. PMID: 24035162. Exclusion Code: X2.
344. Pontone G, Andreini D, Bartorelli AL, et al. A long-term prognostic value of CT angiography and exercise ECG in patients with suspected CAD. *JACC Cardiovasc Imaging*. 2013 Jun;6(6):641-50. doi: 10.1016/j.jcmg.2013.01.015. PMID: 23764093. Exclusion Code: X2.
345. Porthan K, Viitasalo M, Jula A, et al. Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. *Heart Rhythm*. 2009 Aug;6(8):1202-8, 8.e1. doi: 10.1016/j.hrthm.2009.05.006. PMID: 19632634. Exclusion Code: X5.
346. Prineas RJ, Grandits G, Rautaharju PM, et al. Long-term prognostic significance of isolated minor electrocardiographic T-wave abnormalities in middle-aged men free of clinical cardiovascular disease (The Multiple Risk Factor Intervention Trial [MRFIT]). *Am J Cardiol*. 2002 Dec 15;90(12):1391-5. PMID: 12480053. Exclusion Code: X5.
347. Prineas RJ, Rautaharju PM, Grandits G, et al. Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the multiple risk factor intervention trial. *J Electrocardiol*. 2001 Apr;34(2):91-101. PMID: 11320456. Exclusion Code: X5.
348. Puddu PE, Menotti A, Tolonen H, et al. Determinants of 40-year all-cause mortality in the European cohorts of the Seven Countries Study. *Eur J Epidemiol*. 2011 Aug;26(8):595-608. doi: 10.1007/s10654-011-9600-7. PMID: 21713523. Exclusion Code: X5.
349. Qureshi W, Shah AJ, Salahuddin T, et al. Long-term mortality risk in individuals with atrial or ventricular premature complexes (results from the Third National Health and Nutrition Examination Survey). *Am J Cardiol*. 2014 Jul 1;114(1):59-64. doi: 10.1016/j.amjcard.2014.04.005. PMID: 24819898. Exclusion Code: X5.
350. Qureshi WT, Alirhayim Z, Blaha MJ, et al. Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project. *Circulation*. 2015 May 26;131(21):1827-34. doi: 10.1161/circulationaha.114.014833. PMID: 25904645. Exclusion Code: X2.
351. Rafique AM, Biner S, Ray I, et al. Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis. *Am J Cardiol*. 2009 Oct 1;104(7):972-7. doi: 10.1016/j.amjcard.2009.05.044. PMID: 19766766. Exclusion Code: X2.
352. Rai M, Baker WL, Parker MW, et al. Meta-analysis of optimal risk stratification in patients >65 years of age. *Am J Cardiol*. 2012 Oct 15;110(8):1092-9. doi: 10.1016/j.amjcard.2012.05.048. PMID: 22795509. Exclusion Code: X7.
353. Rangel MO, O'Neal WT, Soliman EZ. Usefulness of the Electrocardiographic P-Wave Axis as a Predictor of Atrial Fibrillation. *Am J Cardiol*. 2016 Jan 1;117(1):100-4. doi: 10.1016/j.amjcard.2015.10.013. PMID: 26552511. Exclusion Code: X2.
354. Rassi CH, Churchill TW, Tavares CA, et al. Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics. *Cardiovasc Diabetol*. 2016 Feb 09;15:28. doi: 10.1186/s12933-016-0334-4. PMID: 26861208. Exclusion Code: X4.
355. Rautaharju PM, Ge S, Nelson JC, et al. Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study). *Am J Cardiol*. 2006 Feb 1;97(3):309-15. doi: 10.1016/j.amjcard.2005.08.046. PMID: 16442387. Exclusion Code: X5.
356. Rautaharju PM, Kooperberg C, Larson JC, et al. Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women's Health Initiative. *Circulation*. 2006 Jan 31;113(4):473-80. doi: 10.1161/CIRCULATIONAHA.104.496091. PMID: 16449726. Exclusion Code: X5.
357. Rautaharju PM, Kooperberg C, Larson JC, et al. Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women:

## Appendix C. Excluded Studies

- the Women's Health Initiative. *Circulation*. 2006 Jan 31;113(4):481-9. doi: 10.1161/CIRCULATIONAHA.105.537415. PMID: 16449727. Exclusion Code: X5.
358. Rautaharju PM, Prineas RJ, Eifler WJ, et al. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. *J Am Coll Cardiol*. 1986 Jul;8(1):1-10. PMID: 3711503. Exclusion Code: X5.
359. Rautaharju PM, Zhang ZM, Haisty WK, Jr., et al. Electrocardiographic predictors of incident heart failure in men and women free from manifest cardiovascular disease (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol*. 2013 Sep 15;112(6):843-9. doi: 10.1016/j.amjcard.2013.05.011. PMID: 23768456. Exclusion Code: X4.
360. Rautaharju PM, Zhang ZM, Vitolins M, et al. Electrocardiographic repolarization-related variables as predictors of coronary heart disease death in the women's health initiative study. *J Am Heart Assoc*. 2014 Aug;3(4)doi: 10.1161/jaha.114.001005. PMID: 25074699. Exclusion Code: X5.
361. Rautaharju PM, Zhang ZM, Warren J, et al. Electrocardiographic predictors of coronary heart disease and sudden cardiac deaths in men and women free from cardiovascular disease in the Atherosclerosis Risk in Communities study. *J Am Heart Assoc*. 2013 Jun;2(3):e000061. doi: 10.1161/jaha.113.000061. PMID: 23723252. Exclusion Code: X4.
362. Ravera M, Cannavo R, Noberasco G, et al. High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. *J Hypertens*. 2014 Jun;32(6):1245-54. doi: 10.1097/hjh.000000000000177. PMID: 24751593. Exclusion Code: X3.
363. Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. *Methods Inf Med*. 2007;46(1):43-9. PMID: 17224979. Exclusion Code: X3.
364. Rich JD, Chen S, Ward RP. Comparison of high risk stress myocardial perfusion imaging findings in men with rapid versus prolonged recovery of ST-segment depression after exercise stress testing. *Am J Cardiol*. 2010 May 15;105(10):1361-4. doi: 10.1016/j.amjcard.2009.12.061. PMID: 20451679. Exclusion Code: X3.
365. Rich JD, Thenappan T, Freed B, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. *Int J Cardiol*. 2013 Aug 10;167(3):669-76. doi: 10.1016/j.ijcard.2012.03.071. PMID: 22459397. Exclusion Code: X4.
366. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. 2007 Feb 14;297(6):611-9. doi: 10.1001/jama.297.6.611. PMID: 17299196. Exclusion Code: X3.
367. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. *Circulation*. 2008 Nov 25;118(22):2243-51, 4p following 51. doi: 10.1161/CIRCULATIONAHA.108.814251. PMID: 18997194. Exclusion Code: X3.
368. Rizk DV, Gutierrez O, Levitan EB, et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. *Nephrol Dial Transplant*. 2012 Sep;27(9):3482-8. doi: 10.1093/ndt/gfr684. PMID: 22167594. Exclusion Code: X2.
369. Rodrigues TC, Ehrlich J, Hunter CM, et al. Reduced heart rate variability predicts progression of coronary artery calcification in adults with type 1 diabetes and controls without diabetes. *Diabetes Technol Ther*. 2010 Dec;12(12):963-9. doi: 10.1089/dia.2010.0070. PMID: 21128843. Exclusion Code: X5.
370. Rollin A, Maury P, Kee F, et al. Isolated negative T waves in the general population is a powerful predicting factor of cardiac mortality and coronary heart disease. *Int J Cardiol*. 2016 Jan 15;203:318-24. doi: 10.1016/j.ijcard.2015.10.118. PMID: 26523363. Exclusion Code: X5.
371. Rosengarten JA, Scott PA, Morgan JM. Fragmented QRS for the prediction of sudden cardiac death: a meta-analysis (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):epub. PMID: DARE-12014061825. Exclusion Code: X5.
372. Rowin EJ, Maron BJ, Appelbaum E, et al. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. *Am J Cardiol*. 2012 Oct

## Appendix C. Excluded Studies

- 1;110(7):1027-32. doi: 10.1016/j.amjcard.2012.05.035. PMID: 22809754. Exclusion Code: X2.
373. Rutter MK, Wahid ST, McComb JM, et al. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. *J Am Coll Cardiol*. 2002 Jul 3;40(1):56-61. PMID: 12103256. Exclusion Code: X5.
374. Rywik TM, O'Connor FC, Gittings NS, et al. Role of nondiagnostic exercise-induced ST-segment abnormalities in predicting future coronary events in asymptomatic volunteers. *Circulation*. 2002 Nov 26;106(22):2787-92. PMID: 12451004. Exclusion Code: X5.
375. Rywik TM, Zink RC, Gittings NS, et al. Independent prognostic significance of ischemic ST-segment response limited to recovery from treadmill exercise in asymptomatic subjects. *Circulation*. 1998 Jun 2;97(21):2117-22. PMID: 9626171. Exclusion Code: X5.
376. Saguner AM, Ganahl S, Baldinger SH, et al. Usefulness of electrocardiographic parameters for risk prediction in arrhythmogenic right ventricular dysplasia. *Am J Cardiol*. 2014 May 15;113(10):1728-34. doi: 10.1016/j.amjcard.2014.02.031. PMID: 24792740. Exclusion Code: X2.
377. Salles GF, Cardoso CR, Fiszman R, et al. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. *Am Heart J*. 2010 May;159(5):833-40. doi: 10.1016/j.ahj.2010.02.012. PMID: 20435193. Exclusion Code: X2.
378. Salles GF, Cardoso CR, Fonseca LL, et al. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. *Am J Hypertens*. 2013 Feb;26(2):218-26. doi: 10.1093/ajh/hps004. PMID: 23382406. Exclusion Code: X2.
379. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study. *J Hypertens*. 2009 May;27(5):1094-101. doi: 10.1097/HJH.0b013e32832720b3. PMID: 19390353. Exclusion Code: X2.
380. Santhanakrishnan R, Wang N, Larson MG, et al. Racial Differences in Electrocardiographic Characteristics and Prognostic Significance in Whites Versus Asians. *J Am Heart Assoc*. 2016 Mar 25;5(3):e002956. doi: 10.1161/jaha.115.002956. PMID: 27016575. Exclusion Code: X5.
381. Savonen KP, Kiviniemi V, Laaksonen DE, et al. Two-minute heart rate recovery after cycle ergometer exercise and all-cause mortality in middle-aged men. *J Intern Med*. 2011 Dec;270(6):589-96. doi: 10.1111/j.1365-2796.2011.02434.x. PMID: 21801244. Exclusion Code: X4.
382. Savonen KP, Lakka TA, Laukkanen JA, et al. Effectiveness of workload at the heart rate of 100 beats/min in predicting cardiovascular mortality in men aged 42, 48, 54, or 60 years at baseline. *Am J Cardiol*. 2007 Aug 15;100(4):563-8. doi: 10.1016/j.amjcard.2007.03.061. PMID: 17697806. Exclusion Code: X5.
383. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. *Jama*. 2012 Sep 5;308(9):890-6. doi: 10.1001/2012.jama.11089. PMID: 22948699. Exclusion Code: X2.
384. Scheltens T, Verschuren WM, Boshuizen HC, et al. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. *Eur J Cardiovasc Prev Rehabil*. 2008 Oct;15(5):562-6. doi: 10.1097/HJR.0b013e3283063a65. PMID: 18756178. Exclusion Code: X3.
385. Schinkel AF, Boiten HJ, van der Sijde JN, et al. Prediction of 9-year cardiovascular outcomes by myocardial perfusion imaging in patients with normal exercise electrocardiographic testing. *Eur Heart J Cardiovasc Imaging*. 2012 Nov;13(11):900-4. doi: 10.1093/ehjci/jes104. PMID: 22588207. Exclusion Code: X2.
386. Schinkel AF, Elhendy A, van Domburg RT, et al. Prognostic significance of QRS duration in patients with suspected coronary artery disease referred for noninvasive evaluation of myocardial ischemia. *Am J Cardiol*. 2009 Dec 1;104(11):1490-3. doi: 10.1016/j.amjcard.2009.07.012. PMID: 19932780. Exclusion Code: X5.
387. Schlegel TT, Kulecz WB, Feiveson AH, et al. Accuracy of advanced versus strictly conventional 12-lead ECG for detection and screening of coronary artery disease, left ventricular hypertrophy and left ventricular systolic dysfunction. *BMC Cardiovasc*



## Appendix C. Excluded Studies

- Disord.* 2010;10:28. doi: 10.1186/1471-2261-10-28. PMID: 20565702. Exclusion Code: X3.
388. Schmidt C, Bergstrom G. Apolipoprotein B/apolipoprotein A-I ratio and apolipoprotein B: long-term predictors of myocardial infarction in initially healthy middle-aged men--a 13-year follow-up. *Angiology.* 2014 Nov;65(10):901-5. doi: 10.1177/0003319713511849. PMID: 24277914. Exclusion Code: X3.
389. Schnabel RB, Rienstra M, Sullivan LM, et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. *Eur J Heart Fail.* 2013 Aug;15(8):843-9. doi: 10.1093/eurjhf/hft041. PMID: 23594831. Exclusion Code: X2.
390. Scholte AJ, Schuijf JD, Kharagjitsingh AV, et al. Prevalence and predictors of an abnormal stress myocardial perfusion study in asymptomatic patients with type 2 diabetes mellitus. *Eur J Nucl Med Mol Imaging.* 2009 Apr;36(4):567-75. doi: 10.1007/s00259-008-0967-y. PMID: 18985347. Exclusion Code: X3.
391. Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). *Am J Cardiol.* 2009 Apr 1;103(7):897-901. doi: 10.1016/j.amjcard.2008.12.018. PMID: 19327412. Exclusion Code: X2.
392. Schroder K, Wegscheider K, Wenger NK, et al. Resting electrocardiogram predicts mortality in postmenopausal women with coronary heart disease or with risk factors for coronary heart disease. *Eur J Prev Cardiol.* 2014 Jun;21(6):749-57. doi: 10.1177/2047487312454022. PMID: 22752417. Exclusion Code: X2.
393. Schultz MG, Otahal P, Cleland VJ, et al. Exercise-induced hypertension, cardiovascular events, and mortality in patients undergoing exercise stress testing: a systematic review and meta-analysis. *Am J Hypertens.* 2013 Mar;26(3):357-66. doi: 10.1093/ajh/hps053. PMID: 23382486. Exclusion Code: X7.
394. Scott AC, Bilesky J, Lamanna A, et al. Limited utility of exercise stress testing in the evaluation of suspected acute coronary syndrome in patients aged less than 40 years with intermediate risk features. *Emerg Med Australas.* 2014 Apr;26(2):170-6. doi: 10.1111/1742-6723.12222. PMID: 24708007. Exclusion Code: X2.
395. Seicean S, Strohl KP, Seicean A, et al. Sleep disordered breathing as a risk of cardiac events in subjects with diabetes mellitus and normal exercise echocardiographic findings. *Am J Cardiol.* 2013 Apr 15;111(8):1214-20. doi: 10.1016/j.amjcard.2012.12.053. PMID: 23415514. Exclusion Code: X2.
396. Sellers MB, Divers J, Lu L, et al. Prevalence and determinants of electrocardiographic abnormalities in African Americans with type 2 diabetes. *J Epidemiol Glob Health.* 2014 Dec;4(4):289-96. doi: 10.1016/j.jegh.2014.04.003. PMID: 25455646. Exclusion Code: X5.
397. Shah B, Bangalore S, Gianos E, et al. Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. *Am Heart J.* 2014 Apr;167(4):480-8.e1. doi: 10.1016/j.ahj.2013.12.019. PMID: 24655696. Exclusion Code: X7.
398. Shah SA, Kambur T, Chan C, et al. Relation of short-term heart rate variability to incident heart failure (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol.* 2013 Aug 15;112(4):533-40. doi: 10.1016/j.amjcard.2013.04.018. PMID: 23683953. Exclusion Code: X4.
399. Shah SF, Meo SA. Usefulness of standard treadmill stress testing in women. *J Pak Med Assoc.* 2009 Apr;59(4):197-200. PMID: 19402276. Exclusion Code: X2.
400. Shaw LJ, Min JK, Budoff M, et al. Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study. *J Am Coll Cardiol.* 2009 Sep 29;54(14):1258-67. doi: 10.1016/j.jacc.2009.07.018. PMID: 19778667. Exclusion Code: X3.
401. Shaw LJ, Wilson PW, Hachamovitch R, et al. Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT. *JACC Cardiovasc Imaging.* 2010 Nov;3(11):1139-48. doi: 10.1016/j.jcmg.2010.09.008. PMID: 21071002. Exclusion Code: X3.
402. Shaya GE, Al-Mallah MH, Hung RK, et al. High Exercise Capacity Attenuates the Risk of Early Mortality After a First Myocardial Infarction: The Henry Ford Exercise Testing

## Appendix C. Excluded Studies

- (FIT) Project. *Mayo Clin Proc.* 2016 Feb;91(2):129-39. doi: 10.1016/j.mayocp.2015.11.012. PMID: 26848000. Exclusion Code: X2.
403. Shibasaki K, Ogawa S, Yamada S, et al. Association of decreased sympathetic nervous activity with mortality of older adults in long-term care. *Geriatr Gerontol Int.* 2014 Jan;14(1):159-66. doi: 10.1111/ggi.12074. PMID: 23879364. Exclusion Code: X2.
404. Shin SY, Park JI, Park SK, et al. Utility of graded exercise tolerance tests for prediction of cardiovascular mortality in old age: The Rancho Bernardo Study. *Int J Cardiol.* 2015 Feb 15;181:323-7. doi: 10.1016/j.ijcard.2014.12.026. PMID: 25544200. Exclusion Code: X5.
405. Shiraishi J, Sawada T, Kimura S, et al. Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study. *Circ J.* 2011;75(4):806-14. PMID: 21436597. Exclusion Code: X2.
406. Sigurdsson E, Sigfusson N, Sigvaldason H, et al. Silent ST-T changes in an epidemiologic cohort study--a marker of hypertension or coronary heart disease, or both: the Reykjavik study. *J Am Coll Cardiol.* 1996 Apr;27(5):1140-7. doi: 10.1016/0735-1097(95)00614-1. PMID: 8609333. Exclusion Code: X5.
407. Silventoinen K, Pankow J, Lindstrom J, et al. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. *Eur J Cardiovasc Prev Rehabil.* 2005 Oct;12(5):451-8. PMID: 16210931. Exclusion Code: X3.
408. Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycosylated hemoglobin improve the prediction of coronary heart disease events? *Arch Intern Med.* 2008 Jun 9;168(11):1209-16. doi: 10.1001/archinte.168.11.1209. PMID: 18541829. Exclusion Code: X3.
409. Simms AD, Weston CF, West RM, et al. Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study. *Eur Heart J Acute Cardiovasc Care.* 2015 Jun;4(3):241-53. doi: 10.1177/2048872614548602. PMID: 25228048. Exclusion Code: X2.
410. Simons LA, Simons J, Friedlander Y, et al. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. *Med J Aust.* 2003 Feb 3;178(3):113-6. PMID: 12558481. Exclusion Code: X3.
411. Sinner MF, Reinhard W, Muller M, et al. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/KORA). *PLoS Med.* 2010 Jul;7(7):e1000314. doi: 10.1371/journal.pmed.1000314. PMID: 20668657. Exclusion Code: X5.
412. Siscovick DS, Ekelund LG, Johnson JL, et al. Sensitivity of exercise electrocardiography for acute cardiac events during moderate and strenuous physical activity. The Lipid Research Clinics Coronary Primary Prevention Trial. *Arch Intern Med.* 1991 Feb;151(2):325-30. PMID: 1992960. Exclusion Code: X4.
413. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. *Circulation.* 2012 Nov 20;126(21):2465-72. doi: 10.1161/circulationaha.112.110460. PMID: 23091065. Exclusion Code: X2.
414. Skretteberg PT, Grundvold I, Kjeldsen SE, et al. HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men. *Atherosclerosis.* 2012 Jan;220(1):250-6. doi: 10.1016/j.atherosclerosis.2011.10.009. PMID: 22062589. Exclusion Code: X3.
415. Slattery ML, Jacobs DR, Jr. Physical fitness and cardiovascular disease mortality. The US Railroad Study. *Am J Epidemiol.* 1988 Mar;127(3):571-80. PMID: 3341361. Exclusion Code: X5.
416. Smetana P, Schmidt A, Zabel M, et al. Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components. *J Electrocardiol.* 2011 May-Jun;44(3):301-8. doi: 10.1016/j.jelectrocard.2011.03.004. PMID: 21511064. Exclusion Code: X2.
417. Smith JG, Platonov PG, Hedblad B, et al. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk

## Appendix C. Excluded Studies

- factors and diagnostic validity. *Eur J Epidemiol.* 2010 Feb;25(2):95-102. doi: 10.1007/s10654-009-9404-1. PMID: 19936945. Exclusion Code: X5.
418. Snoek JA, Jongman JK, Brandon T, et al. Performance of the Lausanne questionnaire and the 2010 European Society of Cardiology criteria for ECG interpretation in athletes. *Eur J Prev Cardiol.* 2015 Mar;22(3):397-405. doi: 10.1177/2047487313506827. PMID: 24057687. Exclusion Code: X5.
419. Soliman EZ, Cammarata M, Li Y. Explaining the inconsistent associations of PR interval with mortality: the length of P-duration contribution to the length of PR interval. *Heart Rhythm.* 2014 Jan;11(1):93-8. doi: 10.1016/j.hrthm.2013.10.003. PMID: 24096163. Exclusion Code: X2.
420. Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24h electrocardiographic recording. *Europace.* 2010 Feb;12(2):261-5. doi: 10.1093/europace/eup344. PMID: 19887457. Exclusion Code: X2.
421. Soliman EZ, Howard G, Cushman M, et al. Prolongation of QTc and risk of stroke: The REGARDS (REasons for Geographic and Racial Differences in Stroke) study. *J Am Coll Cardiol.* 2012 Apr 17;59(16):1460-7. doi: 10.1016/j.jacc.2012.01.025. PMID: 22497826. Exclusion Code: X2.
422. Soliman EZ, Howard G, Meschia JF, et al. Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Stroke.* 2011 Oct;42(10):2950-3. doi: 10.1161/strokeaha.111.621367. PMID: 21817138. Exclusion Code: X5.
423. Soliman EZ, Lopez F, O'Neal WT, et al. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation.* 2015 May 26;131(21):1843-50. doi: 10.1161/circulationaha.114.014145. PMID: 25918127. Exclusion Code: X4.
424. Soliman EZ, Prineas RJ. Early repolarization and sudden cardiac death. *South Med J.* 2009 Jan;102(1):110-1. doi: 10.1097/SMJ.0b013e31818f8be44. PMID: 19077760. Exclusion Code: X7.
425. Soliman EZ, Shah AJ, Boerkercher A, et al. Inter-relationship between electrocardiographic left ventricular hypertrophy and QT prolongation as predictors of increased risk of mortality in the general population. *Circ Arrhythm Electrophysiol.* 2014 Jun;7(3):400-6. doi: 10.1161/circep.113.001396. PMID: 24762807. Exclusion Code: X5.
426. Soliman EZ, Zhang ZM, Chen LY, et al. Usefulness of Maintaining a Normal Electrocardiogram Over Time for Predicting Cardiovascular Health. *Am J Cardiol.* 2017 Jan 15;119(2):249-55. doi: 10.1016/j.amjcard.2016.09.051. PMID: 28126148. Exclusion Code: X2.
427. Soofi M, Jain NA, Myers J, et al. A New 12-Lead ECG Prognostic Score. *Ann Noninvasive Electrocardiol.* 2015 Nov;20(6):554-60. doi: 10.1111/anec.12261. PMID: 25640186. Exclusion Code: X4.
428. Stacey RB, Leaverton PE, Schocken DD, et al. Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. *Am Heart J.* 2015 Nov;170(5):923-8. doi: 10.1016/j.ahj.2015.08.003. PMID: 26542500. Exclusion Code: X3.
429. Stavrakis S, Patel N, Te C, et al. Development and validation of a prognostic index for risk stratification of patients with early repolarization. *Ann Noninvasive Electrocardiol.* 2012 Oct;17(4):361-71. doi: 10.1111/j.1542-474X.2012.00533.x. PMID: 23094882. Exclusion Code: X7.
430. Stefanini GG, Kalesan B, Pilgrim T, et al. Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. *JACC Cardiovasc Interv.* 2012 Mar;5(3):301-10. doi: 10.1016/j.jcin.2011.11.011. PMID: 22440496. Exclusion Code: X2.
431. Stein PK, Barzilay JI, Chaves PH, et al. Heart rate variability and its changes over 5 years in older adults. *Age Ageing.* 2009 Mar;38(2):212-8. doi: 10.1093/ageing/afn292. PMID: 19147739. Exclusion Code: X3.
432. Stein R, Nguyen P, Abella J, et al. Prevalence and prognostic significance of exercise-induced right bundle branch block. *Am J Cardiol.* 2010 Mar 1;105(5):677-80. doi: 10.1016/j.amjcard.2009.10.050. PMID: 20185016. Exclusion Code: X2.

## Appendix C. Excluded Studies

433. Stein R, Sallam K, Adhikarla C, et al. Natural history of early repolarization in the inferior leads. *Ann Noninvasive Electrocardiol.* 2012 Oct;17(4):331-9. doi: 10.1111/j.1542-474X.2012.00537.x. PMID: 23094879. Exclusion Code: X7.
434. Stephens JW, Ambler G, Vallance P, et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? *Eur J Cardiovasc Prev Rehabil.* 2004 Dec;11(6):521-8. PMID: 15580065. Exclusion Code: X3.
435. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? *Diabetes Care.* 2004 Nov;27(11):2676-81. PMID: 15505004. Exclusion Code: X3.
436. Stewart RA, Young AA, Anderson C, et al. Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk. *Heart.* 2011 Nov;97(21):1766-70. doi: 10.1136/heartjnl-2011-300297. PMID: 21835757. Exclusion Code: X5.
437. Stiles MC, Seaquist ER, Yale JF, et al. Is silent myocardial infarction more common in women with type 2 diabetes than in men? *J Diabetes Complications.* 2012 Mar-Apr;26(2):118-22. doi: 10.1016/j.jdiacomp.2012.02.002. PMID: 22446034. Exclusion Code: X5.
438. Strom Moller C, Zethelius B, Sundstrom J, et al. Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up. *Heart.* 2007 Sep;93(9):1104-10. doi: 10.1136/hrt.2006.109116. PMID: 17483125. Exclusion Code: X10.
439. Suadicani P, Hein HO, Gyntelberg F. Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study. *Metab Syndr Relat Disord.* 2010 Jun;8(3):215-22. doi: 10.1089/met.2009.0072. PMID: 20156073. Exclusion Code: X5.
440. Suh B, Park S, Shin DW, et al. Early repolarization is associated with significant coronary artery stenosis in asymptomatic adults. *Atherosclerosis.* 2016 Feb;245:50-3. doi: 10.1016/j.atherosclerosis.2015.11.026. PMID: 26694693. Exclusion Code: X5.
441. Sui X, LaMonte MJ, Blair SN. Cardiorespiratory fitness as a predictor of nonfatal cardiovascular events in asymptomatic women and men. *Am J Epidemiol.* 2007 Jun 15;165(12):1413-23. doi: 10.1093/aje/kwm031. PMID: 17406007. Exclusion Code: X5.
442. Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. *Hypertens Res.* 2001 Nov;24(6):685-9. PMID: 11768728. Exclusion Code: X3.
443. Suka M, Sugimori H, Yoshida K. Validity of the Framingham risk model applied to Japanese men. *Methods Inf Med.* 2002;41(3):213-5. PMID: 12162145. Exclusion Code: X3.
444. Sun Z, Ng KH. Diagnostic value of coronary CT angiography with prospective ECG-gating in the diagnosis of coronary artery disease: a systematic review and meta-analysis (Provisional abstract). *International Journal of Cardiovascular Imaging.* 2012;28(8):2109-19. PMID: DARE-12013001989. Exclusion Code: X3.
445. Sung J, Cho SJ, Choe YH, et al. Relationship between aerobic fitness and progression of coronary atherosclerosis. *Heart Vessels.* 2016 Sep;31(9):1418-23. doi: 10.1007/s00380-015-0745-2. PMID: 26400860. Exclusion Code: X5.
446. Sutherland SE, Gazes PC, Keil JE, et al. Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. *Circulation.* 1993 Dec;88(6):2685-92. PMID: 8252679. Exclusion Code: X5.
447. Suvisaari J, Perala J, Saarni SI, et al. Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population. *Psychiatry Res.* 2010 Jan 30;175(1-2):126-32. doi: 10.1016/j.psychres.2008.07.021. PMID: 19926142. Exclusion Code: X2.
448. Svart K, Lehtinen R, Nieminen T, et al. Exercise electrocardiography detection of coronary artery disease by ST-segment depression/heart rate hysteresis in women: the Finnish Cardiovascular Study. *Int J Cardiol.* 2010 Apr 15;140(2):182-8. doi: 10.1016/j.ijcard.2008.11.038. PMID: 19068271. Exclusion Code: X4.
449. Tait J, Ashton T. Critical left main coronary artery stenosis identified by colour Doppler

## Appendix C. Excluded Studies

- screening during pre-exercise stress echocardiogram. *Can J Cardiol*. 2011 May-Jun;27(3):390.e13-4. doi: 10.1016/j.cjca.2010.12.055. PMID: 21601777. Exclusion Code: X7.
450. Takase B, Masaki N, Hattori H, et al. Usefulness of automatic QT dispersion measurement for detecting exercise-induced myocardial ischemia. *Anadolu Kardiyol Derg*. 2009 Jun;9(3):189-95. PMID: 19520652. Exclusion Code: X2.
451. Teodorescu C, Reinier K, Uy-Evanado A, et al. Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs. *Heart Rhythm*. 2013 Aug;10(8):1153-8. doi: 10.1016/j.hrthm.2013.05.009. PMID: 23680897. Exclusion Code: X2.
452. Teodorescu C, Reinier K, Uy-Evanado A, et al. Prolonged QRS duration on the resting ECG is associated with sudden death risk in coronary disease, independent of prolonged ventricular repolarization. *Heart Rhythm*. 2011 Oct;8(10):1562-7. doi: 10.1016/j.hrthm.2011.06.011. PMID: 21699869. Exclusion Code: X2.
453. Tereshchenko LG, Shah AJ, Li Y, et al. Electrocardiographic deep terminal negativity of the P wave in V1 and risk of mortality: the National Health and Nutrition Examination Survey III. *J Cardiovasc Electrophysiol*. 2014 Nov;25(11):1242-8. doi: 10.1111/jce.12453. PMID: 24837486. Exclusion Code: X4.
454. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. *N Engl J Med*. 2009 Dec 24;361(26):2529-37. doi: 10.1056/NEJMoa0907589. PMID: 19917913. Exclusion Code: X5.
455. Tikkanen JT, Huikuri HV. Early repolarization ECG pattern in the Finnish general population. *J Electrocardiol*. 2013 Sep-Oct;46(5):439-41. doi: 10.1016/j.jelectrocard.2013.06.012. PMID: 23871658. Exclusion Code: X7.
456. Tikkanen JT, Junttila MJ, Anttonen O, et al. Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome. *Circulation*. 2011 Jun 14;123(23):2666-73. doi: 10.1161/circulationaha.110.014068. PMID: 21632493. Exclusion Code: X5.
457. Tohidi M, Hadaegh F, Harati H, et al. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. *Int J Cardiol*. 2009 Mar 6;132(3):369-74. doi: 10.1016/j.ijcard.2007.11.085. PMID: 18242731. Exclusion Code: X3.
458. Tota-Maharaj R, Blaha MJ, Blankstein R, et al. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. *Mayo Clin Proc*. 2014 Oct;89(10):1350-9. doi: 10.1016/j.mayocp.2014.05.017. PMID: 25236430. Exclusion Code: X3.
459. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol*. 2015 May;38(5):285-92. doi: 10.1002/clc.22387. PMID: 25873476. Exclusion Code: X4.
460. Uberoi A, Sallam K, Perez M, et al. Prognostic implications of Q waves and T-wave inversion associated with early repolarization. *Mayo Clin Proc*. 2012 Jul;87(7):614-9. doi: 10.1016/j.mayocp.2012.04.009. PMID: 22766081. Exclusion Code: X7.
461. Ulmer H, Kollerits B, Kelleher C, et al. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. *Eur J Cardiovasc Prev Rehabil*. 2005 Oct;12(5):433-41. PMID: 16210929. Exclusion Code: X3.
462. Uthamalingam S, Zheng H, Leavitt M, et al. Exercise-induced ST-segment elevation in ECG lead aVR is a useful indicator of significant left main or ostial LAD coronary artery stenosis. *JACC Cardiovasc Imaging*. 2011 Feb;4(2):176-86. doi: 10.1016/j.jcmg.2010.11.014. PMID: 21329903. Exclusion Code: X2.
463. Vaara S, Nieminen MS, Lokki ML, et al. Cohort Profile: the Corogene study. *Int J Epidemiol*. 2012 Oct;41(5):1265-71. doi: 10.1093/ije/dyr090. PMID: 21642350. Exclusion Code: X2.
464. Vaidya D, Yanek LR, Moy TF, et al. Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. *Am J*

## Appendix C. Excluded Studies

465. *Cardiol.* 2007 Nov 1;100(9):1410-5. doi: 10.1016/j.amjcard.2007.06.031. PMID: 17950799. Exclusion Code: X3.
466. Vakil KP, Malhotra S, Sawada S, et al. Waist circumference and metabolic syndrome: the risk for silent coronary artery disease in males. *Metab Syndr Relat Disord.* 2012 Jun;10(3):225-31. doi: 10.1089/met.2011.0099. PMID: 22324791. Exclusion Code: X7.
467. van Noord C, Sturkenboom MC, Straus SM, et al. Serum glucose and insulin are associated with QTc and RR intervals in nondiabetic elderly. *Eur J Endocrinol.* 2010 Feb;162(2):241-8. doi: 10.1530/eje-09-0878. PMID: 19897609. Exclusion Code: X5.
468. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012 Feb;141(2 Suppl):e637S-68S. doi: 10.1378/chest.11-2306. PMID: 22315274. Exclusion Code: X7.
469. Vepsäläinen T, Laakso M, Lehto S, et al. Prolonged P wave duration predicts stroke mortality among type 2 diabetic patients with prevalent non-major macrovascular disease. *BMC Cardiovasc Disord.* 2014;14:168. doi: 10.1186/1471-2261-14-168. PMID: 25425321. Exclusion Code: X5.
470. Verdecchia P, Reboldi G, Di Pasquale G, et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). *Am J Cardiol.* 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. PMID: 24359765. Exclusion Code: X2.
471. Vergnaud AC, Bertrais S, Galan P, et al. Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort. *Prev Med.* 2008 Jul;47(1):61-5. doi: 10.1016/j.ypmed.2008.02.023. PMID: 18456313. Exclusion Code: X3.
472. Vinsonneau U, Pangnarind-Heinz V, Paleiron N, et al. Evolution of Early Repolarization Patterns after 5 Years in a Military Population at Low Cardiovascular Risk and Practical Implications in Military Medical Expertise. *Ann Noninvasive Electrocardiol.* 2015 Sep;20(5):420-5. doi: 10.1111/anec.12231. PMID: 25393741. Exclusion Code: X5.
473. Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation.* 2005 Jul 26;112(4):572-7. doi: 10.1161/CIRCULATIONAHA.104.488916. PMID: 16009800. Exclusion Code: X3.
474. von Ziegler F, Greif M, Tittus J, et al. Distribution of coronary calcifications in patients with suspected coronary heart disease. *Am Heart J.* 2014 Apr;167(4):568-75. doi: 10.1016/j.ahj.2013.12.011. PMID: 24655707. Exclusion Code: X2.
475. Waks JW, Sitlani CM, Soliman EZ, et al. Global Electric Heterogeneity Risk Score for Prediction of Sudden Cardiac Death in the General Population: The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. *Circulation.* 2016 Jun 07;133(23):2222-34. doi: 10.1161/circulationaha.116.021306. PMID: 27081116. Exclusion Code: X4.
476. Waks JW, Soliman EZ, Henriksen CA, et al. Beat-to-beat spatiotemporal variability in the T vector is associated with sudden cardiac death in participants without left ventricular hypertrophy: the Atherosclerosis Risk in Communities (ARIC) Study. *J Am Heart Assoc.* 2015 Jan;4(1):e001357. doi: 10.1161/jaha.114.001357. PMID: 25600143. Exclusion Code: X3.
477. Walsh JA, 3rd, Ilkhanoff L, Soliman EZ, et al. Natural history of the early repolarization pattern in a biracial cohort: CARDIA (Coronary Artery Risk Development in Young Adults) Study. *J Am Coll Cardiol.* 2013 Feb 26;61(8):863-9. doi: 10.1016/j.jacc.2012.11.053. PMID: 23428218. Exclusion Code: X4.
478. Walsh JA, 3rd, Soliman EZ, Ilkhanoff L, et al. Prognostic value of frontal QRS-T angle in patients without clinical evidence of cardiovascular disease (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol.* 2013 Dec 15;112(12):1880-4. doi: 10.1016/j.amjcard.2013.08.017. PMID: 24063831. Exclusion Code: X4.
479. Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people? *Med J Aust.* 2005 Jan 17;182(2):66-9. PMID: 15651963. Exclusion Code: X3.
479. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart

## Appendix C. Excluded Studies

- disease, stroke, and type 2 diabetes mellitus. *Arch Intern Med.* 2005 Dec 12; 26;165(22):2644-50. doi: 10.1001/archinte.165.22.2644. PMID: 16344423. Exclusion Code: X3.
480. Watanabe H, Makita N, Tanabe N, et al. Electrocardiographic abnormalities and risk of complete atrioventricular block. *Int J Cardiol.* 2012 Mar 22;155(3):462-4. doi: 10.1016/j.ijcard.2011.12.028. PMID: 22225759. Exclusion Code: X5.
481. Waure C, Cadeddu C, Gualano MR, et al. Telemedicine for the reduction of myocardial infarction mortality: a systematic review and a meta-analysis of published studies (Structured abstract). *Telemedicine and e-Health.* 2012; 18(5):323-8. PMID: DARE-12012049125. Exclusion Code: X2.
482. Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. *J Am Coll Cardiol.* 2007 Jul 17;50(3):217-24. doi: 10.1016/j.jacc.2007.03.037. PMID: 17631213. Exclusion Code: X3.
483. Welsh P, Doolin O, Willeit P, et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. *Eur Heart J.* 2013 Feb;34(6):443-50. doi: 10.1093/eurheartj/ehs239. PMID: 22942340. Exclusion Code: X3.
484. Wen L, Sun ML, An P, et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol.* 2014 Nov 1;114(9):1420-5. doi: 10.1016/j.amjcard.2014.07.079. PMID: 25217453. Exclusion Code: X2.
485. Wenger NK, Mischke JM, Schroeder R, et al. Electrocardiograms of menopausal women with coronary heart disease or at increased risk for its occurrence. *Am J Cardiol.* 2010 Dec 1;106(11):1580-7. doi: 10.1016/j.amjcard.2010.07.032. PMID: 21094358. Exclusion Code: X7.
486. Whang W, Peacock J, Soliman EZ, et al. Relations between depressive symptoms, anxiety, and T Wave abnormalities in subjects without clinically-apparent cardiovascular disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *Am J Cardiol.* 2014 Dec 15;114(12):1917-22. doi: 10.1016/j.amjcard.2014.09.034. PMID: 25438922. Exclusion Code: X5.
487. Wilcox JE, Rosenberg J, Vallakati A, et al. Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. *Am J Cardiol.* 2011 Dec 15;108(12):1760-6. doi: 10.1016/j.amjcard.2011.07.050. PMID: 21907948. Exclusion Code: X2.
488. Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. *Circulation.* 2008 Jul 8;118(2):124-30. doi: 10.1161/CIRCULATIONAHA.108.772962. PMID: 18591432. Exclusion Code: X3.
489. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation.* 1998 May 12;97(18):1837-47. PMID: 9603539. Exclusion Code: X3.
490. Wirawan IM, Aldington S, Griffiths RF, et al. Cardiovascular investigations of airline pilots with excessive cardiovascular risk. *Aviat Space Environ Med.* 2013 Jun;84(6):608-12. PMID: 23745289. Exclusion Code: X4.
491. Woodward M, Brindle P, Tunstall-Pedoe H, et al. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart.* 2007 Feb;93(2):172-6. doi: 10.1136/hrt.2006.108167. PMID: 17090561. Exclusion Code: X3.
492. Worthington JM, Gattellari M, Leung DY. 'Where there's smoke ...': are premature ventricular complexes a new risk factor for stroke? *Stroke.* 2010 Apr;41(4):572-3. doi: 10.1161/strokeaha.109.574426. PMID: 20167909. Exclusion Code: X7.
493. Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. *Circulation.* 2006 Nov 21;114(21):2217-25. doi: 10.1161/CIRCULATIONAHA.105.607499. PMID: 17088464. Exclusion Code: X3.
494. Wu YT, Chien CL, Wang SY, et al. Gender differences in myocardial perfusion defect in asymptomatic postmenopausal women and men with and without diabetes mellitus. *J Womens Health (Larchmt).* 2013 May;22(5):439-44. doi: 10.1089/jwh.2012.4055. PMID: 23600438. Exclusion Code: X4.
495. Xanthakis V, Enserro DM, Murabito JM, et al. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular

## Appendix C. Excluded Studies

- disease in the Framingham Offspring Study. *Circulation*. 2014 Nov 4;130(19):1676-83. doi: 10.1161/circulationaha.114.009273. PMID: 25274000. Exclusion Code: X3.
496. Yanagisawa S, Miki K, Yasuda N, et al. The prognostic value of treadmill exercise testing in very elderly patients: heart rate recovery as a predictor of mortality in octogenarians. *Europace*. 2011 Jan;13(1):114-20. doi: 10.1093/europace/euq422. PMID: 21084358. Exclusion Code: X2.
497. Yang X, So WY, Kong AP, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. *Diabetes Care*. 2007 Jan;30(1):65-70. doi: 10.2337/dc06-1273. PMID: 17192335. Exclusion Code: X3.
498. Yang X, So WY, Kong AP, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. *Am J Cardiol*. 2008 Mar 1;101(5):596-601. doi: 10.1016/j.amjcard.2007.10.019. PMID: 18308005. Exclusion Code: X3.
499. Yoo WS, Kim HJ, Kim D, et al. Early detection of asymptomatic coronary artery disease in patients with type 2 diabetes mellitus. *Korean J Intern Med*. 2009 Sep;24(3):183-9. doi: 10.3904/kjim.2009.24.3.183. PMID: 19721853. Exclusion Code: X5.
500. Zhang Y, Agnoletti D, Iaria P, et al. Gender difference in cardiovascular risk factors in the elderly with cardiovascular disease in the last stage of lifespan: the PROTEGER study. *Int J Cardiol*. 2012 Feb 23;155(1):144-8. doi: 10.1016/j.ijcard.2011.09.073. PMID: 22000269. Exclusion Code: X2.
501. Zhang Y, Post WS, Dalal D, et al. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. *Arch Intern Med*. 2011 Oct 24;171(19):1727-33. doi: 10.1001/archinternmed.2011.433. PMID: 22025428. Exclusion Code: X5.
502. Zhang Y, Protogerou AD, Iaria P, et al. Prognosis in the hospitalized very elderly: the PROTEGER study. *Int J Cardiol*. 2013 Oct 3;168(3):2714-9. doi: 10.1016/j.ijcard.2013.03.021. PMID: 23578896. Exclusion Code: X2.
503. Zhang ZM, Prineas RJ, Case D, et al. Gender differences between the Minnesota code and Novacode electrocardiographic prognostication of coronary heart disease in the cardiovascular health study. *Am J Cardiol*. 2011 Mar 15;107(6):817-20.e1. doi: 10.1016/j.amjcard.2010.11.004. PMID: 21247534. Exclusion Code: X5.
504. Zhang ZM, Prineas RJ, Soliman EZ, et al. Prognostic significance of serial Q/ST-T changes by the Minnesota Code and Novacode in the Atherosclerosis Risk in Communities (ARIC) study. *Eur J Prev Cardiol*. 2012 Dec;19(6):1430-6. doi: 10.1177/1741826711426091. PMID: 21997257. Exclusion Code: X5.
505. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Bundle branch blocks and the risk of mortality in the Atherosclerosis Risk in Communities study. *J Cardiovasc Med (Hagerstown)*. 2016 Jun;17(6):411-7. doi: 10.2459/jcm.0000000000000235. PMID: 25575277. Exclusion Code: X5.
506. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2016 May 31;133(22):2141-8. doi: 10.1161/circulationaha.115.021177. PMID: 27185168. Exclusion Code: X5.
507. Zulqarnain MA, Qureshi WT, O'Neal WT, et al. Risk of Mortality Associated With QT and JT Intervals at Different Levels of QRS Duration (from the Third National Health and Nutrition Examination Survey). *Am J Cardiol*. 2015 Jul 1;116(1):74-8. doi: 10.1016/j.amjcard.2015.03.038. PMID: 25929581. Exclusion Code: X5.



**Appendix D Table 1. Quality Assessment of Randomized, Controlled Trials (KQs 1 and 3): Part 1**

First Author, Year Trial Name	Was randomization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported intervention fidelity?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition? No. (%)	What was the differential attrition? No. (%)	Did the study have differential attrition or overall high attrition raising concern for bias?
Lievre, 2011 <sup>47</sup> DYNAMIT	Yes	Yes	Yes	NR	NR	7 (1.1%) mortality 16 (2.5%) primary composite outcome	16 (1.2)	No
Turrini, 2015 <sup>48</sup> and Turrini, 2009 <sup>49</sup> DADDY-D	Yes	Yes	Yes	17/20 (85%) with positive exercise test underwent angiography	Yes, 44 (17%) in the no screening group had non-protocol exercise testing (but unclear if those were indicated because of incident symptoms)	NR	NR	Unclear

**Abbreviations:** DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; KQ=key question; No, number; NR=not reported.

**Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (KQs 1 and 3): Part 2**

First Author, Year Trial Name	Were outcome measurements equal, valid and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
Lievre, 2011 <sup>47</sup> DYNAMIT	Yes	No	No	Yes	Unclear (3.5 years)	None (complete case analysis)	Yes	Fair	Trial stopped early because of trouble recruiting (randomized 631 of the planned 3,000). Not clear that 3.5 years of follow up is sufficient. Applicability: high risk population of diabetics with 2 risk factors (urinary albumin excretion above a threshold, hypertension, hyperlipidemia, PAD, history of TIA, tobacco consumption, and family history of premature CVD); Table 1 shows 14% with PAD, 4–5% with history of TIA; patients referred to a diabetes specialist in a hospital. Study left subsequent investigations after stress test to judgment of cardiologists (no protocol; pragmatic approach for decisions about e.g., angiography or not, various treatments).
Turrini, 2015 <sup>48</sup> and Turrini, 2009 <sup>49</sup> DADDY-D	Yes	No	No	NR	Unclear (3.6 years)	NR Complete case	Yes	Fair	Study did not reach sample size goal (aimed for 364 per group and got about 260); not clear that 3.6 years of follow up is sufficient; amount of missing data NR (flow diagram may indicate no missing data though); masking of outcome assessors NR. Applicability: setting was 2 diabetes outpatient clinics, and participants had to have a normal ECG to get into the study.

**Abbreviations:** CVD=cardiovascular disease; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; ECG=electrocardiogram; KQ=key question; NR=not reported; PAD=peripheral artery disease; TIA=transient ischemic attack.

**Appendix D Table 3. Quality Assessment of Randomized, Controlled Trials: Additional Questions for Studies Reporting Harms (KQ 3)**

First Author, Year Trial Name	Were harms prespecified and defined?	Were ascertainment techniques for harms adequately described?	Were ascertainment techniques for harms equal, valid, and reliable?	Was duration of follow up adequate for harms assessment?	Quality Rating	Comments
Turrini, 2015 <sup>48</sup> and Turrini, 2009 <sup>49</sup> DADDY-D	Yes for post- procedure MI. No for other potential harms.	No	Unclear	Yes	Fair (for MI) but poor for other harms	Study reports that one patient had an MI 3 days after a revascularization procedure and that there were no other harms/events for those who underwent revascularization; limited assessment of harms and no mention of, for example, postintervention hematomas or infections. Other than MI, no methods on how harms were defined or measured, if they were measured at all.

**Abbreviations:** DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; KQ=key question; MI=myocardial infarction.

**Appendix D Table 4. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 1**

<b>First Author, Year</b>	<b>Does study sample adequately capture the population of interest (participant eligibility and recruitment)?</b>	<b>Was there selective inclusion of participants in the model based on data availability?</b>	<b>If participants are from a treatment RCT, is treatment accounted for?</b>	<b>Enrolled consecutive patients or a random sample?</b>	<b>Were selection criteria clearly described?</b>	<b>Is a valid and reliable definition and method for measurement of the outcomes reported?</b>	<b>Was the same outcome definition (and method for measurement) used in all patients?</b>	<b>Were the outcomes assessed without knowledge of the candidate predictors (i.e., blinded)?</b>	<b>Is a valid and reliable definition and method for measurement and classification of candidate predictor(s) (ECG and risk factors) reported?</b>
Aktas, 2004 <sup>59</sup>	Yes, no CVD and asymptomatic (but executive physical participants may not be representative)	NR	NA	Yes	Yes	Yes	Yes	NR	Yes
Auer, 2012 <sup>55</sup>	Yes	Yes (but little missing data)	NA	Yes	Yes	Yes	Yes	Yes	Yes
Badheka, 2013 <sup>53</sup>	Somewhat unclear; NHANES III sample; symptoms not assessed; just under 10% with CAD	Yes	NA	Complex, nonrandom, multistage stratified sample design (NHANES III)	Yes	Yes	Yes	Unknown	Yes
Badheka, 2013 <sup>54</sup>	Yes	Yes for discrimination and calibration. No for NRI calculations; those excluded 5% with missing data).	NA	Complex, nonrandom multistage stratified sample design	Yes	Yes	Yes	Unknown	Yes

**Appendix D Table 4. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 1**

First Author, Year	Does study sample adequately capture the population of interest (participant eligibility and recruitment)?	Was there selective inclusion of participants in the model based on data availability?	If participants are from a treatment RCT, is treatment accounted for?	Enrolled consecutive patients or a random sample?	Were selection criteria clearly described?	Is a valid and reliable definition and method for measurement of the outcomes reported?	Was the same outcome definition (and method for measurement) used in all patients?	Were the outcomes assessed without knowledge of the candidate predictors (i.e., blinded)?	Is a valid and reliable definition and method for measurement and classification of candidate predictor(s) (ECG and risk factors) reported?
Chang, 2015 <sup>45</sup>	Uncertain, possibly not, see comments	No (although unclear if the 4% without adequate follow up were included in analyses)	NA	Unknown	No, "clinically indicated reasons" for CACS and stress SPECT not defined except for the 16% with atypical chest pain	Yes	Yes	Yes	Yes for most risk factors and ECG/ETT. No, cholesterol and blood pressure were not available, and conservative values were imputed based on history of hypertension or hyperlipidemia.
Cournot, 2006 <sup>60</sup>	Yes, regarding asymptomatic status, but they were self-referred or referred by PCPs and cardiologists to a preventive cardiology unit	Yes	NA	Yes	Yes	Uncertain (questionnaire or phone call to patients and physicians for initial ascertainment)	Yes	Unknown	Yes
Cournot, 2009 <sup>56</sup>	Yes, regarding asymptomatic status, but they were self-referred (20%) or referred by PCPs (27%) or other providers to a preventive cardiology unit	Yes (but little missing data)	NA	No (referrals and from media)	Yes	Uncertain (questionnaire or phone call to patients and physicians)	Yes	Unknown	Yes

**Appendix D Table 4. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 1**

First Author, Year	Does study sample adequately capture the population of interest (participant eligibility and recruitment)?	Was there selective inclusion of participants in the model based on data availability?	If participants are from a treatment RCT, is treatment accounted for?	Enrolled consecutive patients or a random sample?	Were selection criteria clearly described?	Is a valid and reliable definition and method for measurement of the outcomes reported?	Was the same outcome definition (and method for measurement) used in all patients?	Were the outcomes assessed without knowledge of the candidate predictors (i.e., blinded)?	Is a valid and reliable definition and method for measurement and classification of candidate predictor(s) (ECG and risk factors) reported?
Denes, 2007 <sup>58</sup>	Yes (but only females with intact uterus in WHI)	Yes (<10% of the larger sample had measured cholesterol data allowing calculation of FRS)	Yes	No	Yes	Yes for CVD; unclear whether inclusion of silent MI from ECGs within the CHD composite outcome is valid and reliable	Yes	Unknown	Yes
Eriksen, 2004 <sup>62</sup>	Yes	Unknown (full sample, survey 1), yes (survey 2)	NA	Yes	Yes	Yes	Yes	Unknown	Yes
Folsom, 2003 <sup>63</sup>	Yes	Yes	NA	Yes	Yes	Yes	Yes	Unknown	Yes
Ishikawa, 2015 <sup>50</sup>	Yes	Yes	NA	Yes	Yes	Yes	Yes	Unknown	Yes
Jorgensen, 2014 <sup>52</sup>	Yes	Yes	NA	Yes	Yes	Yes	Yes	Unknown	Yes
Shah, 2016 <sup>7</sup>	Probably; NHANES I and III samples; symptoms not assessed, but self-reported CVD excluded	Yes (3,640/4,192 with ECG data for derivation cohort, NHANES I; 6,329/6,927 with ECG for validation cohort (III))	NA	Complex, nonrandom, multistage, stratified sample (NHANES I and III)	Yes	Yes	Yes	Unknown	Yes

**Appendix D Table 4. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 1**

First Author, Year	Does study sample adequately capture the population of interest (participant eligibility and recruitment)?	Was there selective inclusion of participants in the model based on data availability?	If participants are from a treatment RCT, is treatment accounted for?	Enrolled consecutive patients or a random sample?	Were selection criteria clearly described?	Is a valid and reliable definition and method for measurement of the outcomes reported?	Was the same outcome definition (and method for measurement) used in all patients?	Were the outcomes assessed without knowledge of the candidate predictors (i.e., blinded)?	Is a valid and reliable definition and method for measurement and classification of candidate predictor(s) (ECG and risk factors) reported?
Strom Moller, 2007 <sup>61</sup>	Population-based, but uncertain how many people with prior ASCVD or symptoms were included	Yes	NA	Yes	Yes	Yes	Yes	Unknown	Yes
Tereshchenko, 2014 <sup>51</sup>	Yes, but uncertain how many had CVD at baseline depending on overlap or lack thereof for those with history of CAD, MI, HF, and stroke (could be as low as 5% or as high as 14%)	Yes	NA	Yes	Yes	Yes	Yes	Unknown	Yes

**Abbreviations:** ASCVD=arteriosclerotic cardiovascular disease; CACS=coronary artery calcium score; CAD=coronary artery disease; CVD=cardiovascular disease; ECG=electrocardiogram; ETT=exercise treadmill test; FRS=Framingham Risk Score; KQ=key question; HF=heart failure; NA=not applicable; NHANES=National Health and Nutrition Examination Survey; NRI=Net reclassification index or improvement; PCP=primary care physician; RCT=randomized, controlled trial; SPECT=single-photon emission computed tomography; WHI=Women’s Health Initiative.

**Appendix D Table 5. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 2**

First Author, Year	Were predictors assessed blinded for the outcome and for each other (if relevant)?	How was the predictor of interest (ECG) handled in the modeling?	Number of (%) Participants With Missing Data (Include Predictors and Outcomes)	Did the study have high attrition raising concern for bias?	How was missing data handled?	Were multiple measures of performance used (e.g., global fit, discrimination, calibration, net reclassification)?	Were both calibration and discrimination measures reported? Were confidence intervals reported?	Were a priori cut points used for classification measures (e.g., sensitivity, specificity, predictive values, NRI)?	Was a bias-corrected NRI used? This applies only to studies presenting NRI for a specific risk strata?
Aktas, 2004 <sup>59</sup>	NR	Categorized	NR	NR	NR	No	Discrimination only reported, no CIs	NA	NA
Auer, 2012 <sup>55</sup>	Yes	Categorized	For main analyses, excluded those with missing data on traditional risk factors (n=41, <2%); for secondary analyses of people with follow up ECGs at 4 years, excluded 424 (24%) with missing follow up ECGs	No	Complete-case analysis	Yes	Calibration: p-values  Discrimination with CIs	Yes	Yes
Badheka, 2013 <sup>53</sup>	Unknown	Categorized	62 (<1%) missing mortality (n=4) or ST-T data (n=58)	No	Complete-case analysis (related to ST-T and mortality; some multiple imputation used for other variables)	Yes	Both reported, with CIs only for discrimination (also given for NRI)	Yes	NA
Badheka, 2013 <sup>54</sup>	Unknown	Categorized (ECG abnormalities absent vs. present)	5% (breakdown NR)	No	Multiple imputation	Yes	Both reported, CI only reported for discrimination	Yes	NA



**Appendix D Table 5. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 2**

First Author, Year	Were predictors assessed blinded for the outcome and for each other (if relevant)?	How was the predictor of interest (ECG) handled in the modeling?	Number of (%) Participants With Missing Data (Include Predictors and Outcomes)	Did the study have high attrition raising concern for bias?	How was missing data handled?	Were multiple measures of performance used (e.g., global fit, discrimination, calibration, net reclassification)?	Were both calibration and discrimination measures reported? Were confidence intervals reported?	Were a priori cut points used for classification measures (e.g., sensitivity, specificity, predictive values, NRI)?	Was a bias-corrected NRI used? This applies only to studies presenting NRI for a specific risk strata?
Chang, 2015 <sup>45</sup>	Yes	Categorized (ETT showing presence or absence of ischemia; i.e., high or low risk)	4% missing follow up for outcomes; 100% missing cholesterol and blood pressure numbers; NR for other predictors	No, not for lost to follow up (but concern for missing data on some predictors)	Imputation for cholesterol and blood pressure based on history of diagnosis of hypertension or hyperlipidemia; unclear for missing outcome data (likely complete case analysis)	Yes	Both reported, no CIs (p-values given)	Yes	Unknown
Cournot, 2006 <sup>60</sup>	Unknown	Categorized	Lost to follow up n=138 (11%); missing predictors unknown	No	Complete-case analysis	No	Calibration reported without CIs; discrimination not reported	Cut point used and reported but not a priori (was based on median FRS score)	NA
Cournot, 2009 <sup>56</sup>	Unknown	Categorized	87 (3.4%)	No	Complete-case analysis	Yes	Both reported, no CIs	Unclear (cut point reported, but unclear if a priori decision)	NA
Denes, 2007 <sup>58</sup>	Unknown	Categorized (normal, minor abnormalities, or major abnormalities)	91% (breakdown NR) for the only eligible results (Figure 3 and the related text)	Unknown (for the sample of interest to us)	Complete-case analysis	No (only discrimination)	Discrimination only reported, with CIs	NA	NA

**Appendix D Table 5. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 2**

First Author, Year	Were predictors assessed blinded for the outcome and for each other (if relevant)?	How was the predictor of interest (ECG) handled in the modeling?	Number of (%) Participants With Missing Data (Include Predictors and Outcomes)	Did the study have high attrition raising concern for bias?	How was missing data handled?	Were multiple measures of performance used (e.g., global fit, discrimination, calibration, net reclassification)?	Were both calibration and discrimination measures reported? Were confidence intervals reported?	Were a priori cut points used for classification measures (e.g., sensitivity, specificity, predictive values, NRI)?	Was a bias-corrected NRI used? This applies only to studies presenting NRI for a specific risk strata?
Erikssen, 2004 <sup>62</sup>	Unknown	Categorized	Not reported (survey 1); for survey 2 586/2,014 (29%) not included	Not reported	Not reported	No	Calibration reported without CIs (number of predicted and observed events); discrimination not reported	Yes	NA
Folsom, 2003 <sup>63</sup>	Unknown	Categorized	11%	No	Complete-case analysis	Yes	Both reported, no CIs	Unknown	NA
Ishikawa, 2015 <sup>50</sup>	Yes	Categorized and continuous (both were done in separate models)	Overall <14%; No ECG (n=1,285), Incomplete data (n=5) No follow up data (n=84)	No	Complete-case analysis	Yes	Neither reported	Yes	NA
Jorgensen, 2014 <sup>52</sup>	Unknown	Categorized	NR	Unknown	Other (complete-case analysis except that missing HDLs imputed by setting to mean of remaining participants)	Yes	Discrimination only reported, with CIs	No, NRI cut points for risk categories were based on the data	NA
Shah, 2016 <sup>57</sup>	Unknown	Some variables categorized and some continuous	641 (6%) missing ECG data NR for outcomes	No	Complete-case analysis	Yes	Both reported, with CIs for discrimination only	Yes	NA

**Appendix D Table 5. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 2**

First Author, Year	Were predictors assessed blinded for the outcome and for each other (if relevant)?	How was the predictor of interest (ECG) handled in the modeling?	Number of (%) Participants With Missing Data (Include Predictors and Outcomes)	Did the study have high attrition raising concern for bias?	How was missing data handled?	Were multiple measures of performance used (e.g., global fit, discrimination, calibration, net reclassification)?	Were both calibration and discrimination measures reported? Were confidence intervals reported?	Were a priori cut points used for classification measures (e.g., sensitivity, specificity, predictive values, NRI)?	Was a bias-corrected NRI used? This applies only to studies presenting NRI for a specific risk strata?
Strom Moller, 2007 <sup>61</sup>	Yes for the outcome, NR for each other	Categorized	For the 70-year-old cohort, 1,139/2,239 (51%) had ECGs and were included (1,139/1,681, 68%, of those who had been invited)	Yes	Complete case	No	Discrimination only reported, no CIs (data only for the subgroup who had follow up ECGs at age 70)	NA	NA
Tereshchenko, 2014 <sup>51</sup>	Unknown	Categorized	2.6%	No	Complete-case analysis	Yes	Neither reported for eligible comparisons	Yes	Unknown

**Abbreviations:** CI=confidence interval, ECG=electrocardiogram; ETT=exercise treadmill test; FRS=Framingham Risk Score; HDL=high-density lipoprotein cholesterol; KQ=key question; NA=not applicable; NR=not reported; NRI=net reclassification improvement.

**Appendix D Table 6. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 3**

First Author, Year	If net reclassification was assessed, were appropriate clinical thresholds used to reclassify risk?	Method used for testing model performance: development dataset only or separate external validation?	In what way was the population a separate external validation from the FRS or PCE?	Was the FRS or PCE recalibrated in the population before ECG was added to the model?	Quality	Comments
Aktas, 2004 <sup>59</sup>	NA	Developmental dataset only with respect to SCORE + exercise ECG models (for models with SCORE alone, could be considered external validation)	Entirely different population (but NA because did not use FRS or PCS; used SCORE)	NA (did not use FRS or PCS for the parts eligible for our evaluation; used SCORE)	Fair	Provides limited information relevant to our questions (just some discrimination statistics without CIs); masking NR, amount and handling of missing data NR; mean follow up of only 8 years (less than desired for 10-year risk prediction). Population referred for executive physical.
Auer, 2012 <sup>55</sup>	Yes	Developmental dataset only (no split of data)	NA	Yes	Good	Applicability to older patients, ages 70–79 years at baseline; good internal validity but developmental dataset and no validation set; did not use FRS because it has not been validated in adults over age 75, but adjusted for traditional risk factors included in FRS and diabetes; used 7.5% to 15% risk thresholds over 7.5 years (attempting to correspond with 10–20% 10-year risk); mean follow up was 6.4 years
Badheka, 2013 <sup>53</sup>	Used FRS 5%–20% for intermediate risk category (not 7.5% or 10%)	Developmental dataset	Entirely different population (NHANES III)	Unknown (but seems that it was not)	Fair	Unclear proportion of population with symptoms; masking not reported; used 5%–20% for intermediate risk category
Badheka, 2013 <sup>54</sup>	Yes	Developmental dataset only (no split of data)	Entirely different population (used NHANES)	Unknown	Fair	

**Appendix D Table 6. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 3**

First Author, Year	If net reclassification was assessed, were appropriate clinical thresholds used to reclassify risk?	Method used for testing model performance: development dataset only or separate external validation?	In what way was the population a separate external validation from the FRS or PCE?	Was the FRS or PCE recalibrated in the population before ECG was added to the model?	Quality	Comments
Chang, 2015 <sup>45</sup>	Used <6% vs. 6–20% vs. >20% (not 7.5% or 10%)	Developmental dataset only	Entirely different population (but NA because did not use original FRS coefficients)	Yes (unable to use original FRS coefficients because of missing blood pressure and cholesterol values)	Fair	Moderate concern that the population may have limited applicability to our question; men and women with no history of CAD who had coronary artery calcium and stress SPECT performed for “clinically indicated reasons”; 16.5% with atypical chest pain and unclear how many had other symptoms; risk of misclassification due to imputing unavailable/missing data for all cholesterol and blood pressure measurements based on prior diagnoses of hypertension and hyperlipidemia (measurements were not available so they calculated FRS using conservative imputations; page 135); did not use current clinical thresholds for reclassification; follow up was 6.9 years; this is a derivation study without external validation. Calibration NR, p-values for discrimination.
Cournot, 2006 <sup>60</sup>	NA	Developmental dataset with respect to FRS + exercise ECG models; for models with FRS alone, could be considered external validation of FRS	Entirely different population	No	Fair	Masking of outcome assessors and assessors of relevant exposures NR; uncertain validity of outcome assessment procedures (relied primarily on questionnaire and phone calls for initial ascertainment); calibration reported, but without CIs, and reclassification and discrimination NR; duration of follow up mean 6 years. Perhaps limited applicability of the selected population that included many referrals.

**Appendix D Table 6. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 3**

First Author, Year	If net reclassification was assessed, were appropriate clinical thresholds used to reclassify risk?	Method used for testing model performance: development dataset only or separate external validation?	In what way was the population a separate external validation from the FRS or PCE?	Was the FRS or PCE recalibrated in the population before ECG was added to the model?	Quality	Comments
Cournot, 2009 <sup>56</sup>	NA	Developmental dataset with respect to FRS + exercise ECG models; for models with FRS alone, could be considered external validation of FRS	Entirely different population	No	Fair	Masking of outcome assessors and assessors of relevant exposures NR; uncertain validity of outcome assessment procedures (relied primarily on questionnaire and phone calls for initial ascertainment); some measures of discrimination and calibration reported, but without CIs, and reclassification NR; duration of follow up median 6 years. The relevant models also included femoral bruit in addition to adding exercise ECG. Perhaps limited applicability of the selected population that included many referrals
Denes, 2007 <sup>58</sup>	NA	Developmental dataset only (no split of data)	Entirely different population (used WHI)	No	Fair	High proportion of missing data for the analyses eligible for our questions; less than 10% of the sample was included in the analyses eligible for our questions (due to lack of measured cholesterol information for most participants); complete-case analysis; only reports C-statistic
Erikssen, 2004 <sup>62</sup>	NA	Developmental dataset only	NA	NA	Fair	Masking of outcome assessors NR, lack of multiple measures (calibration only; did not report discrimination or reclassification), missing data NR
Folsom, 2003 <sup>63</sup>	NA	Developmental dataset only	Entirely different population (ARIC)	NA (did not use FRS or PCE)	Fair	Masking NR; developmental set only; unclear if cut points for LVH were defined a priori; reclassification NR
Ishikawa, 2015 <sup>50</sup>	No, used <2.5%, 2.5–5%, >5%	Development dataset only	NA	NA (did not use FRS or PCE; used model with traditional risk factors plus heart rate and alcohol use as base model)	Fair	Base model included alcohol use and heart rate in addition to traditional risk factors; unclear why these particular clinical thresholds were chosen (<2.5%, 2.5–5%, >5%). Unknown if predictors were assessed blinded for outcomes; ECG QTc (predictor) determined by hand.

**Appendix D Table 6. Quality Ratings for Studies Reporting Reclassification, Calibration, and Discrimination (KQ 2): Part 3**

First Author, Year	If net reclassification was assessed, were appropriate clinical thresholds used to reclassify risk?	Method used for testing model performance: development dataset only or separate external validation?	In what way was the population a separate external validation from the FRS or PCE?	Was the FRS or PCE recalibrated in the population before ECG was added to the model?	Quality	Comments
Jorgensen, 2014 <sup>52</sup>	No, used cut points determined by the data (low risk: <8.9%; intermediate risk: 8.9%–14.9; high risk: >14.9%). <sup>a</sup>	Developmental dataset only	Entirely different population (but NA because did not use FRS or PCE)	NA, used different base model with conventional risk factors	Fair	NRI cut points for risk categories were based on the data; calibration NR; unknown masking; amount of missing ECG data NR
Shah, 2016 <sup>57</sup>	Used 1%, 5%, and 10% based on recommendation by the European Society of Cardiology for lipid management	Developmental dataset (NHANES I) and validation (NHANES III)	Entirely different population	Yes and no (appears that they ran analyses both ways)	Fair	Masking NR; some uncertainty about symptom status of participants
Strom Moller, 2007 <sup>61</sup>	NA	Developmental dataset	NA	NA	Poor	Very high attrition. Study started at age 50. The only eligible analysis/outcome is the part where they report discrimination (ROC curve) for FRS (traditional risk factors) vs. FRS + ECG indicating ischemia for a subgroup of the cohort who had repeated ECGs (20 years later) at age 70 (n=1,139 of the 2,239, 51%); they had 12-year follow up after age 70. No similar analyses provided for the full cohort of 2,239 participants. Also, unclear selection criteria; unclear what proportion of the population had prior CVD or symptoms at baseline for the 50-year-old initial cohort or for the 70-year-old subgroup.
Tereshchenko, 2014 <sup>51</sup>	Used <5%, 5–<20% and ≥20% (not 10% or 7.5%)	Developmental dataset only	Entirely different population (used ARIC)	Yes (FRSs were not directly used due to possible issues of the applicability to different ethnic groups; the authors adjusted for race)	Fair	Did not report calibration or discrimination for eligible comparison (ECG finding+traditional risk factors vs. traditional risk factors alone); unclear masking; did not use 10% or 7.5% threshold in classifications of risk groups

<sup>a</sup> Supplement table 2 reported different risk categories for categorical NRI – low risk < 23.8%, intermediate 23.8–35%, high >35%

**Abbreviations:** ARIC=Atherosclerosis Risk in Communities study; CAD=coronary artery disease; CI=confidence interval; CVD=cardiovascular disease; ECG=electrocardiogram; KQ=key question; LVH=left ventricular hypertrophy; NA=not applicable; NHANES=National Health and Nutrition Examination Survey; NR=not reported; PCE=pooled cohort equation; RCT=randomized, controlled trial; ROC=receiver operating characteristic; SCORE=Systematic COronary Risk Evaluation; SPECT=single-photon emission computed tomography; WHI=Women’s Health Initiative.

**Appendix E Table 1. Results of Included Randomized, Controlled Trials Reporting Health Outcomes (KQ 1)**

First Author, Year Trial Name	G1 (N) G2 (N)	All-Cause Mortality G1 N (%) G2 N (%) HR (95% CI)	CV Mortality G1 N (%) G2 N (%) HR (95% CI)	MI G1 N (%) G2 N (%) HR (95% CI)	Heart Failure G1 N (%) G2 N (%) HR (95% CI)	Stroke G1 N (%) G2 N (%) HR (95% CI)	Other CV Events G1 N (%) G2 N (%) HR (95% CI)	Composite CV Outcome G1 N (%) G2 N (%) HR (95% CI)
Lievre, 2011 <sup>47</sup> DYNAMIT	Screened (316) Not screened (315)	15 (4.7) 13 (4.1) NR, NS	NR	4 (1.3) 8 (2.5) NR, NS	Hospitalized cardiac failure: 5 (1.6) 4 (1.3) NR, NS	9 (2.8) 4 (1.3) NR, NS	Revascularization 18 (5.7) 21 (6.7) p=0.61	Main endpoint <sup>a</sup> 28 (8.9) 26 (8.3) 1.00 (0.59 to 1.71) Coronary events <sup>b</sup> 13 (4.1) 15 (4.8) 0.77 (0.37 to 1.63)
Turrini et al, 2015 <sup>48</sup> DADDY-D	Screened (262) Not screened (258)	NR by group. Total of 19 deaths reported (6 cardiac and 13 non-cardiac)	All 1 (0.4) 5 (1.9) 0.197 (0.023 to 1.683) Female 0/53 (0) 3/51 (5.9) NA, p=0.077	Non-fatal MI: All 11 (4.2) 12 (4.7) 0.908 (0.400 to 2.057) Female 5/53 (9.4) 1/51 (2) 4.916 (0.573 to 42.142)	All 2 (0.8) 7 (2.7) 0.273 (0.57 to 1.314) Female 0/53 (0) 3/51 (5.9) NA, p 0.065	NR by group. Total of 7 strokes	NR	Cardiac events (primary outcome; composite of nonfatal MI or cardiac death) All 12 (4.6) 14 (5.4) 0.849 (0.393 to 1.837) Female 5/53 (9.4) 3/51 (5.9) 1.653 (0.395 to 6.928)



**Appendix E Table 1. Results of Included Randomized, Controlled Trials Reporting Health Outcomes (KQ 1)**

First Author, Year Trial Name	G1 (N) G2 (N)	All-Cause Mortality G1 N (%) G2 N (%) HR (95% CI)	CV Mortality G1 N (%) G2 N (%) HR (95% CI)	MI G1 N (%) G2 N (%) HR (95% CI)	Heart Failure G1 N (%) G2 N (%) HR (95% CI)	Stroke G1 N (%) G2 N (%) HR (95% CI)	Other CV Events G1 N (%) G2 N (%) HR (95% CI)	Composite CV Outcome G1 N (%) G2 N (%) HR (95% CI)
Turrini et al, 2015 <sup>48</sup> DADDY-D (continued)			<i>Male</i> 1/209 (0.5) 2/207 (1) 0.497 (0.045 to 5.483) <i>≥60 years</i> 0/182 (0) 4/181 (2.2) NA, p=0.044 <i>&lt;60 years</i> 1/80 (1.3) 1/77 (1.3) 0.993 (0.062 to 15.87) <i>CV risk<sub>≥20</sub></i> 1/115 (0.9) 2/112 (1.8) 0.494 (0.045 to 5.443) <i>CV risk&lt;20</i> 0/147 (0) 3/146 (2.1) NA, p=0.08	<i>Male</i> 6/209 (2.9) 11/207 (5.3) 0.535 (0.198 to 1.446) <i>≥60 years</i> 7/182 (3.8) 8/181 (4.4)0.859 (0.311 to 2.370) <i>&lt;60 years</i> 4/80 (5) 4/77 (5.2) 0.999 (0.249 to 3.981) <i>CV risk<sub>≥20</sub></i> 4/115 (3.5) 6/112 (5.4) 0.656 (0.185 to 2.325) <i>CV risk&lt;20</i> 7/147 (4.8) 6/146 (4.1) 1.176 (0.393 to 3.505)	<i>Male</i> 2/209 (1) 4/207 (1.9) 0.485 (0.89 to 2.647) <i>≥60 years</i> 2/182 (1.1) 4/181 (2.2) 0.476 (0.087 to 2.599) <i>&lt;60 years</i> 0/80 (0) 3/77 (3.9) NA, p 0.08 <i>CV risk<sub>≥20</sub></i> 2/115 (1.7) 2/112 (1.8) 0.961 (0.135 to 6.822) <i>CV risk&lt;20</i> 0/147 (0) 5/146 (3.4) NA, p=0.022			<i>Male</i> 7/209 (3.3) 11/207 (5.3) 0.625 (0.242 to 1.614) <i>≥60 years</i> 7/182 (3.8) 10/181 (5.5) 0.687 (0.261 to 1.805) <i>&lt;60 years</i> 5/80 (6.3) 4/77 (5.2) 1.264 (0.339 to 4.707) <i>CV risk<sub>≥20</sub></i> 5/115 (4.3) 6/112 (5.4) 0.822 (0.251 to 2.692) <i>CV risk&lt;20</i> 7/147 (4.8) 8/146 (5.5) 0.879 (0.318 to 2.426)

<sup>a</sup> Composite endpoint of death from all causes, nonfatal MI, nonfatal stroke, or heart failure requiring hospitalization or emergency service intervention.

<sup>b</sup> Defined as fatal or nonfatal MI, hospitalized unstable angina, or heart failure requiring hospitalization or emergency service intervention.

**Abbreviations:** CI=confidence interval; CV=cardiovascular; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; KQ=key question; G=group; HR=hazard ratio; MI=myocardial infarction; N=sample size; NA=not applicable; NR=not reported; NS=not significant.

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Auer, 2012 <sup>55</sup> Fair	CHD events <sup>a</sup>	Total: 351 (16.0)  CHD deaths: 96 (4.4) Acute MIs: 101 (4.6) Hospitalizations for angina or coronary revascularization: 154 (7.0)	Base model: CVRF Harrell C index Calibration NRI Adjusted clinical NRI IDI Base model: FRS NRI IDI	1. CVRF model (used FRS variables) <sup>b</sup> 2. CVRF + any ECG abnormality 3. FRS model 4. FRS + any ECG abnormality	Harrell C Index (95% CI) CVRF model: 0.58 (0.53–0.62) CVRF + ECG: 0.60 (0.56–0.65)	Hosmer-Lemeshow chi-square CVRF model: 67.6 CVRF + ECG: 87.9 Likelihood ratio: p≤0.00005  Goodness of fit p value CVRF model: 0.03 CVRF model + ECG: 0.01	CVRF + ECG vs. CVRF Overall sample NRI: 7.4% (3.1%–19.0%) Event NRI: -0.9% Nonevent NRI: 8.3% Adjusted clinical NRI 6.7% (95% CI, 1.2% to 19.3%) IDI: 0.99% (0.32%–2.15%) For the Intermediate Risk Category: NRI 13.6%  FRS + ECG vs. FRS NRI 5.7% (-0.4%–11.8%) IDI: 1.03% (0.56%–1.50%)  Reclassification with Addition of ECG For those who experience a CHD event <7.5%, no change: 4 <7.5% to 7.5-<15%: 2 <7.5% to ≥15%: 0 Total: 6  7.5-<15.0% to <7.5%: 7 7.5-<15.0%, no change: 91 7.5-<15% to ≥15%: 27 Total: 125  ≥15.0% to <7.5%: 0 ≥15.0% to 7.5-<15.0%: 25 ≥15%, no change: 195 Total: 220  For those who do not experience a CHD event <7.5%, no change: 74 <7.5% to 7.5-<15%: 17 <7.5% to ≥15%: 0  Total: 91 7.5-<15.0% to <7.5%: 129 7.5-<15.0%, no change: 678 7.5-<15% to ≥15%: 149 Total: 956

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Auer, 2012 <sup>55</sup> Fair (continued)							<p>≥15.0% to &lt;7.5%: 0</p> <p>≥15.0% to 7.5-&lt;15.0%: 189</p> <p>≥15%, no change: 605</p> <p>Total: 794</p>
Badheka, 2013 <sup>54</sup> Fair	CV mortality  All-cause mortality	CV mortality: 739 (12.3)  All-cause mortality: 1,824 (30.3)	AUC IDI Calibration NRI	Model A: FRS <sup>c</sup>  Model B: FRS + ECG abnormalities	C-statistic Model A: 0.851 (0.836–0.865) Model B: 0.852 (0.838–0.866) p=0.05	Hosmer-Lemeshow chi-square Model A: 15.14 p=0.05 Model B: 10.98 p=0.2  Goodness of fit Likelihood ratio test: p=0.001  Bayesian information criterion Model A: 3360.54 Model B: 3358.28	<p>Overall NRI: 3.6%, p=0.0001; NRI for Those w with Events: 3.0% p=0.03 NRI for Those w without Events: NRI: 0.6% p=0.11 Absolute IDI: 0.0001, p&lt;0.001 For the Intermediate Risk Category: NRI 13.2%</p> <p>Reclassification with Addition of ECG Abnormalities For Those w with Events &lt;5%, no change: 92 &lt;5% to 5-10%: 11 &lt;5% to 10–20%: 0 &lt;5% to &gt;20%: 0 Total: 103</p> <p>5-10% to &lt;5%: 4 5-10%, no change: 98 5-10% to 10–20%: 26 5-10% to &gt;20%: 0 Total: 128</p> <p>10-20% to &lt;5%: 0 10-20% to 5–10%: 14 10-20%, no change: 205 10-20% to &gt;20%: 21 Total: 240</p> <p>&gt;20% to &lt;5%: 0 &gt;20% to 5-10%: 0 &gt;20% to 10–20%: 19 &gt;20%, no change: 208 Total: 227</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Badheka, 2013 <sup>54</sup> Fair (continued)							<p>Risk Reclassified Higher from Each Category                      For Those with Events                      &lt;5%: 11 (10.7%)                      5% to &lt;10%: 26 (20.3%)                      10% to &lt;20%: 21 (8.8%)                      &gt;20%: NA                      Total: 58 (8.3%)</p> <p>Risk Reclassified Lower from Each Category                      For Those with Events                      &lt;5%: NA                      5% to &lt;10%: 4 (3%)                      10% to &lt;20%: 14 (5.8%)                      ≥20%: 19 (8.4%)                      Total: 37 (5.3%)</p> <p>For Those with no Events                      &lt;5%, no change: 3209                      &lt;5% to 5–10%: 79                      &lt;5% to 10–20%: 0                      &lt;5% to &gt;20%: 0                      Total: 3,288</p> <p>5-10% to &lt;5%: 104                      5-10%, no change: 702                      5-10% to 10–20%: 53                      5-10% to &gt;20%: 0                      Total: 859</p> <p>10-20% to &lt;5%: 0                      10-20% to 5–10%: 65                      10-20%, no change: 512                      10-20% to &gt;20%: 37                      Total: 614</p> <p>&gt;20% to &lt;5%: 0                      &gt;20% to 5–10%: 0                      &gt;20% to 10–20%: 31                      &gt;20%, no change: 239                      Total: 270</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Badheka, 2013 <sup>54</sup> Fair (continued)							<p>Risk Reclassified Higher</p> <p>No Events</p> <p>&lt;5%: 79 (2.4%)</p> <p>5% to &lt;10%: 53 (6.2%)</p> <p>10% to &lt;20%: 37 (6.0%)</p> <p>&gt;20%: NA</p> <p>Total: 169 (3.4%)</p> <p>Risk Reclassified Lower</p> <p>No Events</p> <p>&lt;5%: NA</p> <p>5% to &lt;10%: 104 (12.1%)</p> <p>10% to &lt;20%: 65 (10.6%)</p> <p>≥20%: 31 (11.5%)</p> <p>Total: 200 (4.0%)</p> <p>Intermediate Risk Cohort:</p> <p>NRI: 13.24%</p> <p>137 (2.4%) and 187 (3.3%) were reclassified to higher and lower risk groups, respectively</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Badheka, 2013 <sup>53</sup> Fair	Cardiovascular (CV) mortality	1,226 (15.5)	C-statistic AUROC Calibration Reclassification IDI NRI	Model A: FRS only  Model B: FRS plus the variable T-wave amplitude in lead aVR	C-statistic Model A: 0.832 (0.822–0.841) Model B: 0.838 (0.828–0.848) p<0.01  AUROC Model A: 0.812 (0.800–0.824) Model B: 0.820 (0.807–0.832) p<0.01	Hosmer-Lemeshow chi-square Model A: 13.7 Model B: 16.7  Goodness of fit Likelihood ratio test: p<0.01  Bayesian information criterion Model A: 5240.0 Model B: 5172.2	Overall NRI: 0.07 (0.05–0.09) p<0.01 Reclassification of subjects with events: 2.7% p<0.01 Reclassification of subjects without events: 2.3% p<0.01 Absolute IDI 0.012 (0.009–0.015), p<0.01 Relative IDI 0.11  Participants with CVD disease events <5%, no change: 53 <5% to 5–<10%: 11 <5% to 10–<20%: 0 <5% to >20%: 0 Total: 64  5–<10% to <5%: 6 5–<10%, no change: 50 5–<10% to 10–<20%: 22 5–<10% to >20%: 0 Total: 78  10–<20% to <5%: 0 10–<20% to 5–<10%: 13 10–<20%, no change: 148 10–<20% to >20%: 60 Total: 221  >20% to <5%: 0 >20% to 5–<10%: 0 >20% to 10–<20%: 42 >20%, no change: 754 Total: 796

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Badheka, 2013 <sup>53</sup> Fair (continued)							<p>Participants with CVD disease events reclassified as higher risk from each category                      &lt;5%: 11                      5%–&lt;10%: 22                      10%–&lt;20%: 60                      &gt;20%: NA                      Total: 93</p> <p>Participants with CVD disease events reclassified as lower risk from each category                      &lt;5%: NA                      5%–&lt;10%: 6                      10%–&lt;20%: 13                      &gt;20%: 42                      Total: 61</p> <p>Participants without CVD disease events                      &lt;5%, no change: 2,426                      &lt;5% to 5–&lt;10%: 135                      &lt;5% to 10–&lt;20%: 0                      &lt;5% to &gt;20%: 0                      Total: 2,561</p> <p>5–&lt;10% to &lt;5%: 221                      5–&lt;10%, no change: 764                      5–&lt;10% to 10–&lt;20%: 158                      5–&lt;10% to &gt;20%: 0                      Total: 1,143</p> <p>10–&lt;20% to &lt;5%: 0                      10–&lt;20% to 5–&lt;10%: 216                      10–&lt;20%, no change: 898                      10–&lt;20% to &gt;20%: 152                      Total: 1,266</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Badheka, 2013 <sup>53</sup> Fair (continued)							<p>&gt;20% to &lt;5%: 0 &gt;20% to 5-&lt;10%: 0 &gt;20% to 10-&lt;20%: 158 &gt;20%, no change: 12,22 Total: 1,380</p> <p>Participants without CVD disease events reclassified as higher risk from each category &lt;5%: 135 5%-&lt;10%: 158 10%-&lt;20%: 152 &gt;20%: NA Total: 445</p> <p>Participants without CVD disease events reclassified as low er risk from each category &lt;5%: NA 5%-&lt;10%: 221 10%-&lt;20%: 216 &gt;20%: 158 Total: 595</p> <p>Intermediate risk cohort (5% to &lt;20% risk): 60 (20%) of subjects with events and 219 (9.1%) of subjects without events were reclassified appropriately to higher and low er risk categories, respectively</p>
Denes, 2007 <sup>58</sup> Fair	Incident coronary heart disease (CHD) <sup>d</sup>  Incident cardiovascular disease events <sup>e</sup>	CHD events: 246 (1.7)  CVD events: 595 (4)	AUC Calibration/ overall performance	FRS  FRS + ECG abnormality	AUROC (95% CI) FRS for CHD: 0.69 (0.61-0.86) FRS + ECG abnormality for CHD: 0.74 (0.66-0.90) FRS for CVD: 0.68 (0.62-0.77) FRS + ECG abnormality for CVD: 0.70 (0.65-0.79)	Likelihood ratio chi square test FRS + ECG abnormality CHD: p=0.004 CVD: p=0.02	NR



**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Folsom, 2003 <sup>63</sup> Fair	CHD events <sup>f</sup>	Total: 954 (6.8)  Among 707 women with diabetes: 99 (14.0) Among 6,526 women without diabetes: 211 (3.2) Among 566 men with diabetes: 129 (22.8) Among 4,946 men without diabetes: 515 (10.4)	AUROC Calibration	Basic model  Basic + LVH model	AUROC <i>Basic Model</i> Women with diabetes: 0.711 Women without diabetes: 0.777 Men with diabetes: 0.680 Men without diabetes: 0.679  <i>Basic + LVH Model (yes/no)</i> Women with diabetes: 0.709 Women without diabetes: 0.777 Men with diabetes: 0.681 Men without diabetes: 0.679	NR	NR

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Ishikawa, 2015 <sup>50</sup> Fair	Stroke events	Total: 375 (3.5) Cerebral hemorrhages: 85 (0.8) Ischemic strokes: 242 (2.3) Subarachnoid hemorrhages: 47 (0.4) Unknown cause: 1	NRI IDI	Traditional cardiovascular risk factor model <sup>h</sup> (model)  Model with ECG-LVH without QTc interval  Model with ECG-LVH with QTc interval  Model without QTc interval (as a continuous variable)  Model with QTc interval (as a continuous variable)  Model without ECG-LVH  Model with ECG-LVH  Model without ECG-LVH or QTc interval  Model with ECG-LVH and QTc interval	NR	NR	IDI The model with and without QTc Interval (as a continuous variable) IDI= 0.292, p=0.80  The model with and without ECG-LVH IDI= 0.004, p=0.75  The model with and without ECG-LVH and/or QTc interval IDI=0.006, p=0.63  NRI, Frequency (Percentage) The model with and without QTc Interval (as a continuous variable) Categorical NRI= 0.026, p<0.001 Event NRI 1.35% Nonevent NRI 1.22%  <i>Reclassification of subjects with stroke events using the model with QTc interval</i> <2.5% to <2.5%: 41 (91.1) <2.5% to 2.5–5.0%: 2 (3.4) <2.5% to >5.0%: 0 (0.0) Total: 43  2.5–5.0% to <2.5%: 4 (8.9) 2.5–5.0% to 2.5–5.0%: 51 (87.9) 2.5–5.0% to >5.0%: 11 (5.7) Total: 66  >5.0% to <2.5%: 0 (0.0) >5.0% to 2.5–5.0%: 5 (8.6) >5.0% to >5.0%: 183 (94.3) Total: 188

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Ishikawa, 2015 <sup>50</sup> Fair (continued)							<p><i>Reclassification of subjects without stroke events using the model with QTc interval</i></p> <p>&lt;2.5% to &lt;2.5%: 4,401 (95.5)                      &lt;2.5% to 2.5–5.0%: 162 (9.2)                      &lt;2.5% to &gt;5.0%: 2 (0.1)                      Total: 4,565</p> <p>2.5–5.0% to &lt;2.5%: 205 (4.5)                      2.5–5.0% to 2.5–5.0%: 1,384 (78.2)                      2.5–5.0% to &gt;5.0%: 165 (9.3)                      Total: 1,754</p> <p>&gt;5.0% to &lt;2.5%: 0 (0.0)                      &gt;5.0% to 2.5–5.0%: 224 (12.7)                      &gt;5.0% to &gt;5.0%: 1,613 (90.6)                      Total: 1,837</p> <p>The model with and without ECG-LVH                      Categorical NRI= 0.020, p&lt;0.001                      Event NRI 1.01%                      Nonevent NRI 1.01%</p> <p><i>Reclassification of subjects with stroke events using the model with ECG-LVH</i></p> <p>&lt;2.5% to &lt;2.5%: 41 (95.3)                      &lt;2.5% to 2.5–5.0%: 2 (3.2)                      &lt;2.5% to &gt;5.0%: 0 (0.0)                      Total: 43 (14.5)</p> <p>2.5–5.0% to &lt;2.5%: 2 (4.7)                      2.5–5.0% to 2.5–5.0%: 56 (88.9)                      2.5–5.0% to &gt;5.0%: 8 (4.2)                      Total: 66 (22.2)</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Ishikawa, 2015 <sup>50</sup> Fair (continued)							<p>&gt;5.0% to &lt;2.5%: 0 (0.0)                      &gt;5.0% to 2.5–5.0%: 5 (7.9)                      &gt;5.0% to &gt;5.0%: 183 (95.8)                      Total: 188 (63.3)</p> <p><i>Reclassification of subjects without stroke events using the model with ECG-LVH</i></p> <p>&lt;2.5% to &lt;2.5%: 4,495 (97.6)                      &lt;2.5% to 2.5–5.0%: 70 (4.0)                      &lt;2.5% to &gt;5.0%: 0 (0.0)                      Total: 4,565 (56.0)</p> <p>2.5–5.0% to &lt;2.5%: 110 (2.4)                      2.5–5.0% to 2.5–5.0%: 1,551 (88.3)                      2.5–5.0% to &gt;5.0%: 93 (5.2)                      Total: 1,754 (21.5)</p> <p>&gt;5.0% to &lt;2.5%: 0 (0.0)                      &gt;5.0% to 2.5–5.0%: 135 (7.7)                      &gt;5.0% to &gt;5.0%: 1,702 (94.8)                      Total: 1,837 (22.5)</p> <p>The model with and without ECG-LVH and/or QTc interval                      Categorical NRI=0.035, p&lt;0.001</p> <p><i>Reclassification of subjects with stroke events using the model with ECG-LVH and QTc interval</i></p> <p>&lt;2.5% to &lt;2.5%: 40 (87.0)                      &lt;2.5% to 2.5–5.0%: 3 (5.5)                      &lt;2.5% to &gt;5.0%: 0 (0.0)</p> <p>Total: 43 (14.5)                      2.5–5.0% to &lt;2.5%: 6 (13.0)                      2.5–5.0% to 2.5–5.0%: 44 (80.0)                      2.5–5.0% to &gt;5.0%: 16 (8.2)                      Total: 66 (22.2)</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Ishikawa, 2015 <sup>50</sup> Fair (continued)							<p>&gt;5.0% to &lt;2.5%: 0 (0.0)                      &gt;5.0% to 2.5–5.0%: 8 (14.5)                      &gt;5.0% to &gt;5.0%: 180 (91.8)                      Total: 188 (63.3)</p> <p><i>Reclassification of subjects without stroke events using the model with ECG-LVH and QTc interval</i></p> <p>&lt;2.5% to &lt;2.5%: 4403 (94.8)                      &lt;2.5% to 2.5–5.0%: 157 (9.0)                      &lt;2.5% to &gt;5.0%: 5 (0.3)                      Total: 4,565 (56.0)</p> <p>2.5–5.0% to &lt;2.5%: 242 (5.2)                      2.5–5.0% to 2.5–5.0%: 1,316 (75.9)                      2.5–5.0% to &gt;5.0%: 196 (11.0)                      Total: 1,754 (21.5)</p> <p>&gt;5.0% to &lt;2.5%: 0 (0.0)                      &gt;5.0% to 2.5–5.0%: 262 (15.1)                      &gt;5.0% to &gt;5.0%: 1,575 (88.7)                      Total: 1,837 (22.5)</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair	Fatal CVD events  Fatal or Nonfatal CVD events (combined)  All-cause mortality	Fatal CVD events: 2,236 (32.0)  Fatal or nonfatal CVD events: 3,849 (55.0)  All-cause mortality: 5,626 (80.5)  For sample with ≥10 years follow up (used to calculate discrimination and reclassification outcomes): Fatal CVD events: 837 (17) Fatal or nonfatal CVD events: 2,092 (38.6) All-cause mortality: 2,225 (32.2)	C-statistic Continuous NRI Categorical NRI	Conventional risk factors  Conventional risk factors and major/minor ECG changes	Any ECG changes C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723) Conventional risk factors and ECG changes: 0.719 (0.702–0.737) p<0.001 Conventional risk factors and ECG changes with increasing severity: 0.719 (0.702–0.736) p<0.001 C-Index for Fatal or Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663) Conventional risk factors and ECG changes as present or not: 0.660 (0.648–0.672) p<0.001 Conventional risk factors and ECG changes with increasing severity: 0.660 (0.648–0.671) p<0.001  C-Index for all-cause mortality Conventional risk factors: 0.652 (0.640–0.664)	NR	Any ECG changes Continuous NRI for fatal CVD events Conventional risk factors and ECG changes as present or not: 42.3 (34.7–50.0) p<0.001 Conventional risk factors and ECG changes with increasing severity: 42.3 (34.7–50.0) p<0.001  Categorical NRI for fatal CVD events Conventional risk factors and ECG changes as present or not: 7.1 (3.6–10.6) p<0.001 Conventional risk factors and ECG changes with increasing severity: 7.2 (3.7–10.7) p<0.001  Continuous NRI for Fatal or Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 29.1 (23.6–34.7) p<0.001 Conventional risk factors and ECG changes with increasing severity: 29.2 (23.7–34.8) p<0.001  Categorical NRI for Fatal or Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 3.8 (1.4–6.3) p<0.001

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Conventional risk factors and ECG changes: 0.656 (0.645–0.668) p&lt;0.001</p> <p>Conventional risk factors and ECG changes with increasing severity: 0.656 (0.645–0.668) p&lt;0.001</p> <p>C-Index for Fatal CVD Events (From Table 3, model validation)</p> <p>Conventional risk factors: 0.705 (0.703–0.707) Adjusted for optimism: 0.706</p> <p>Conventional risk factors and ECG changes: 0.719 (0.717–0.721) Adjusted for optimism: 0.720 p&lt;0.001</p> <p>Fatal or Nonfatal CVD Events (From Table 3, validation)</p> <p>Conventional risk factors: 0.651 (0.649–0.653) Adjusted for optimism: 0.652</p> <p>Conventional risk factors and ECG changes: 0.660 (0.658–0.662)</p>		<p>Conventional risk factors and ECG changes with increasing severity: 4.2 (1.8–6.7) p&lt;0.001</p> <p>Continuous NRI for All-Cause Mortality Conventional Risk Factors and ECG Changes as Present or Not: 22.7 (17.5–27.8) p&lt;0.001</p> <p>Categorical NRI for All-Cause Mortality Conventional Risk Factors and ECG Changes as Present or Not: 1.9 (0.1–3.6) p&lt;0.001</p> <p>Conventional Risk Factors and ECG Changes for Fatal CVD Events (From Table 3, validation)</p> <p>Continuous NRI: 42.3 (42.0–42.4) Adjusted for optimism: 42.3 p&lt;0.001</p> <p>Categorical NRI: 7.1 (6.7–9.0) Adjusted for optimism: 8.6 p&lt;0.001</p> <p>Conventional Risk Factors and ECG Changes for Fatal or Nonfatal CVD Events (From Table 3, validation)</p> <p>Continuous NRI: 29.2 (28.4–29.2)</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Adjusted for optimism: 0.660 p&lt;0.001</p> <p>T wave changes C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723) Conventional risk factors and ECG change: 0.716 (0.699–0.734) p&lt;0.001</p> <p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663) Conventional risk factors and ECG change: 0.658 (0.647–0.670) p&lt;0.001</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.656 (0.644–0.668) p&lt;0.01</p>		<p>Adjusted for optimism: 29.2 p&lt;0.001 Categorical NRI: 4.2 (3.5–5.6) Adjusted for optimism: 4.7 p&lt;0.001</p> <p>T wave changes Continuous NRI for Fatal CVD Events Conventional Risk Factors and ECG Changes as Present or Not: 29.2 (21.5–36.8) p&lt;0.001</p> <p>Categorical NRI for Fatal CVD Events Conventional Risk Factors and ECG Changes as Present or Not: 5.4 (2.2–8.6) p&lt;0.01</p> <p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 20.3 (14.7–25.9) p&lt;0.001</p> <p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 2.7 (0.6–4.8) p&lt;0.05</p>



**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Ventricular conduction delay C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723) Conventional risk factors and ECG change: 0.708 (0.690–0.726) p&gt;0.05</p> <p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663) Conventional risk factors and ECG change: 0.655 (0.643–0.667) p&gt;0.05</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.653 (0.642–0.665) p&gt;0.05</p> <p>LVH C-Index for Fatal CVD Events</p>		<p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 16.5 (11.4–21.7) p&lt;0.001</p> <p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 1.3 (-0.3–3.0) p&gt;0.05</p> <p>Ventricular conduction delay Continuous NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 2.8 (-4.9–10.4) p&gt;0.05</p> <p>Categorical NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 1.1 (0.1–2.1) p&lt;0.05</p> <p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 5.5 (-0.1–11.1) p&gt;0.05</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Conventional risk factors: 0.705 (0.687–0.723)</p> <p>Conventional risk factors and ECG change: 0.706 (0.688–0.724) p&gt;0.05</p> <p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663) Conventional risk factors and ECG change: 0.651 (0.639–0.663) p&gt;0.05</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.653 (0.641–0.665) p&gt;0.05</p> <p>Q waves C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723)</p>		<p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 0.0 (-1.1–1.2) p&gt;0.05</p> <p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 3.2 (-2.0–8.4) p&gt;0.05</p> <p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 0.2 (-0.5–1.0) p&gt;0.05</p> <p>LVH Continuous NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 12.1 (4.5–19.8) p&lt;0.01</p> <p>Categorical NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 2.7 (1.0–4.4) p&lt;0.01</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Conventional risk factors and ECG change: 0.709 (0.691–0.727) p&lt;0.05</p> <p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663) Conventional risk factors and ECG change: 0.655 (0.643–0.667) p&lt;0.01</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.654 (0.643–0.666) p&lt;0.05</p> <p>ST depressions C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723) Conventional risk factors and ECG change: 0.714 (0.697–0.732) p&lt;0.001</p>		<p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 6.7 (1.1–12.3) p&lt;0.05</p> <p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: -1.1 (-2.3–0.1) p&gt;0.05</p> <p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 7.0 (1.8–12.1) p&lt;0.01</p> <p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 0.7 (-0.2–1.7) p&gt;0.05</p> <p>Q waves Continuous NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 5.3 (-0.02–12.9) p&gt;0.05</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663)</p> <p>Conventional risk factors and ECG change: 0.660 (0.648–0.672) p&lt;0.001</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.656 (0.644–0.667) p&lt;0.01</p> <p>Resting heart Rate C-Index for Fatal CVD Events Conventional risk factors: 0.705 (0.687–0.723) Conventional risk factors and ECG change: 0.709 (0.691–0.727) p&lt;0.001</p> <p>C-Index for Fatal and Nonfatal CVD Events Conventional risk factors: 0.651 (0.639–0.663)</p>		<p>Categorical NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 1.9 (0.7–3.1) p&lt;0.01</p> <p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 3.9 (-1.6–9.5) p&gt;0.05</p> <p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 0.7 (-0.2–1.8) p&gt;0.05</p> <p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 4.7 (-0.4–9.9) p&gt;0.05</p> <p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 0.7 (0.0–1.4) p&lt;0.05</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)					<p>Conventional risk factors and ECG change: 0.652 (0.640–0.664) p&gt;0.05</p> <p>C-Index for All-Cause Mortality Conventional risk factors: 0.652 (0.640–0.664) Conventional risk factors and ECG change: 0.661 (0.649–0.672) p&lt;0.001</p>		<p>ST depressions Continuous NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 18.0 (10.4–25.6) p&lt;0.001</p> <p>Categorical NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 3.1 (0.7–5.4) p&lt;0.01</p> <p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 14.7 (9.1–20.3) p&lt;0.001</p> <p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 2.2 (0.4–4.1) p&lt;0.01</p> <p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 11.1 (6.0–16.3) p&lt;0.001</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Jorgensen, 2014 <sup>52</sup> Fair (continued)							<p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 1.5 (0.3–2.8) p&lt;0.01</p> <p>Resting heart Rate Continuous NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 14.1 (6.4–21.7) p&lt;0.001</p> <p>Categorical NRI for Fatal CVD Events Conventional risk factors and ECG changes as present or not: 0.9 (-1.8–3.7) p&gt;0.05</p> <p>Continuous NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: 7.3 (1.8–12.9) p&lt;0.05</p> <p>Categorical NRI for Fatal and Nonfatal CVD Events Conventional risk factors and ECG changes as present or not: -0.2 (-1.4–1.0) p&gt;0.05</p> <p>Continuous NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 21.4 (16.2–26.6) p&lt;0.001</p> <p>Categorical NRI for All-Cause Mortality Conventional risk factors and ECG changes as present or not: 3.7 (1.6–5.7) p&lt;0.001</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Shah, 2016 <sup>57</sup> Fair	Primary: CVD death  Secondary outcomes: 10-year ischemic heart disease (IHD) death and all-cause death	Derivation cohort: CVD death: 574 (15.8)  Validation cohort: CVD death: 282 (4.4) Fatal IHD: 166 (2.6) All-cause death: 810 (12.8)	C-statistic IDI Calibration (only for base models) Reclassification NRI	NHANES ECG risk score model  FRS model  FRS model + ECG risk equation  PCE model  PCE model + ECG risk equation	C-statistic (95% CI)  <i>NHANES ECG risk score model</i> Fatal IHD: 0.80 (0.77–0.83) Fatal CVD: 0.79 (0.76–0.81) All-cause death: 0.75 (0.73–0.77)  <i>FRS model</i> Fatal IHD: 0.79 (0.76–0.82) Fatal CVD: 0.76 (0.73–0.78) All-cause death: 0.71 (0.69–0.73)	Hosmer-Lemeshow chi-square values  NHANES ECG risk score model IHD Death: 185 CVD Death: 281 Death: 600  FRS model IHD Death: 175 CVD Death: 237 Death: 458  Pooled cohort model (ACC-AHA) IHD Death: 152 CVD Death: 222 Death: 447	NRI, Total (Event NRI; Nonevent NRI), % FRS model <i>Categorical NRI</i> Fatal IHD: 24 (17; 7) Fatal CVD: 25 (12; 13) All-cause death: 30 (11; 19) <i>Continuous NRI</i> Fatal IHD: 57 (22; 35) Fatal CVD: 56 (21; 35) All-cause death: 53 (20; 33)  ACC-AHA pooled cohort equation model <i>Categorical NRI</i> Fatal IHD: 14 (9; 5) Fatal CVD: 25 (11; 14) All-cause death: 19 (7; 12)

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Shah, 2016 <sup>57</sup> Fair (continued)				FRS variables model  FRS variables model + ECG risk equation	<p><i>FRS model + ECG risk equation</i> Fatal IHD: 0.82 (0.79–0.85) Fatal CVD: 0.80 (0.77–0.82) All-cause death: 0.75 (0.74–0.77)</p> <p><i>Difference between FRS model and FRS model + ECG risk equation</i> Fatal IHD: 0.03 (0.01–0.05) Fatal CVD: 0.04 (0.02–0.06) All-cause death: 0.04 (0.03–0.05)</p> <p><i>PCE model</i> Fatal IHD: 0.80 (0.77–0.83) Fatal CVD: 0.76 (0.73–0.78) All-cause death: 0.73 (0.71–0.75)</p> <p><i>PCE model + ECG risk equation</i> Fatal IHD: 0.82 (0.79–0.84) Fatal CVD: 0.80 (0.78–0.83) All-cause death: 0.76 (0.74–0.77)</p>	Calibration statistics for the NHANES ECG risk score for CVD death were adequate with p=0.08 in the derivation cohort and p=0.22 in the validation cohort.	<p><i>Continuous NRI</i> Fatal IHD: 41 (17; 24) Fatal CVD: 54 (20; 34) All-cause death: 35 (18; 17)</p> <p><i>Framingham variables model Categorical NRI</i> Fatal IHD: 4 (3; 1) Fatal CVD: 11 (7; 4) All-cause death: 10 (6; 4)</p> <p><i>Continuous NRI</i> Fatal IHD: 37 (9; 28) Fatal CVD: 35 (7; 28) All-cause death: 33 (8; 25)</p> <p><i>IDI, %</i> <i>FRS model Absolute IDI</i> Fatal IHD: 1.0 Fatal CVD: 1.6 All-cause death: 2.6</p> <p><i>Relative IDI</i> Fatal IHD: 25 Fatal CVD: 35 All-cause death: 38</p> <p><i>ACC-AHA pooled cohort equation model Absolute IDI</i> Fatal IHD: 0.7 Fatal CVD: 2.0 All-cause death: 1.9</p> <p><i>Relative IDI</i> Fatal IHD: 19 Fatal CVD: 47 All-cause death: 25</p>



**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Shah, 2016 <sup>57</sup> Fair (continued)					<p><i>Difference between PCE model and PCE model + ECG risk equation</i>                      Fatal IHD: 0.02 (0.01–0.03)                      Fatal CVD: 0.04 (0.03–0.06)                      All-cause death: 0.03 (0.02–0.03) 19</p> <p><i>FRS variables model</i>                      Fatal IHD: 0.83 (0.81–0.85)                      Fatal CVD: 0.81 (0.79–0.84)                      All-cause death: 0.78 (0.76–0.80)</p> <p><i>FRS variables model + ECG risk equation</i>                      Fatal IHD: 0.84 (0.82–0.87)                      Fatal CVD: 0.82 (0.80–0.85)                      All-cause death: 0.79 (0.77–0.82)</p> <p><i>Difference between Framingham variables model and Framingham variables model + ECG risk equation</i>                      Fatal IHD: 0.01 (0.01–0.02)                      Fatal CVD: 0.01 (0.01–0.02)                      All-cause death: 0.01 (0.01–0.02)</p>		<p>Framingham variables model  <i>Absolute IDI</i>                      Fatal IHD: 0.2                      Fatal CVD: 0.8                      All-cause death: 2.0  <i>Relative IDI</i>                      Fatal IHD: 7                      Fatal CVD: 13                      All-cause death: 8</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Tereshchenko 2014 <sup>51</sup> Fair	Sudden cardiac death	SCD: 311 (2.0)	Reclassification NRI	Modified FRS <sup>i</sup> +DTNPV1 vs. modified FRS	NR	NR	<p>DTNPV discrimination ability NRI estimate=0.028, p=0.06 Event NRI: 0.028 (2.8%) Nonevent NRI: 0.0002 (0.02%)</p> <p>Appropriately reclassified participants with SCD outcome into the higher risk categories: 3.4% appropriately reclassified into a higher risk group, 0.3% reclassified into a higher risk group inappropriately.</p> <p>Reclassification with addition of DTNPV1 for those with SCD events &lt;5%, no change:135 &lt;5% to 5–20%: 3 (2.2%) &lt;5% to ≥20%: 0 Total: 138</p> <p>5%–20% to &lt;5%:1 (2.6%) 5%–20%, no change: 34 5%–20% to ≥20%: 3 (7.8%) Total: 38</p> <p>≥20% to &lt;5%:0 ≥20% to 5-20%: 0 ≥20%, no change: 3 Total: 3</p> <p>Classification based on modified FRS+ DTNPV1, Total &lt;5%:136 5–20%: 37 ≥20%: 6 Total: 179</p> <p>Reclassification for those without SCD events &lt;5%, no change &lt;5%: 12,298 &lt;5% to 5–20%: 27 (0.22%) &lt;5% to ≥20%: 0 Total: 12,325</p>

**Appendix E Table 2. Results of Included Studies for KQ 2 That Evaluated Resting ECG**

First Author, Year; Quality	Outcome(s)	N (%) With Outcome(s)	Outcome Measures	Models	Discrimination	Calibration	Reclassification
Tereshchenko, 2014 <sup>51</sup> Fair (continued)							5%–20% to <5%:35 (6.6%) 5%–20%, no change: 485 5%–20% to ≥20%: 7 (1.3%) Total: 527  ≥20% to <5%:0 ≥20% to 5–20%: 1 (5.6%) ≥20%, no change: 17 Total: 18  Classification based on modified FRS+ DTNPV1, Total <5%:12333 5–20%: 513 ≥20%: 24 Total: 12,870

<sup>a</sup> Adjudicated CHD events including hard CHD Events (acute MI and CHD deaths) and soft CHD events (hospitalization for angina and coronary revascularization).

<sup>b</sup> FRS variables were age, sex, total and high-density lipoprotein cholesterol, systolic blood pressure, smoking.

<sup>c</sup> FRS model included age, sex, systolic blood pressure, smoking history, serum cholesterol level, and serum high density lipoprotein level.

<sup>d</sup> CHD defined as acute MI necessitating overnight hospitalizations, silent MI identified on serial ECGs, or death due to CHD.

<sup>e</sup> CVD end points included CHD (CHD death and nonfatal MI), coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty and stroke.

<sup>f</sup> A CHD event was defined as a validated definite or probable hospitalized myocardial infarction, a definite CHD death, an unrecognized myocardial infarction defined by ARIC ECG readings, or coronary revascularization.

<sup>g</sup> Model included age, race, total & HDL cholesterol, systolic blood pressure, use of antihypertensive medication, and smoking status

<sup>h</sup> Model included age, sex, body mass index, current smoking, alcohol intake >20 g/d, systolic blood pressure, antihypertensive medication use, diabetes mellitus, hyperlipidemia, and heart rate.

<sup>i</sup> Modified FRS in this used the CHD Framingham risk score with age, gender, SBP, DM, HDL and total cholesterol, smoking, and BP-lowering therapy; they note that calculated FRS scores were not directly used due to possible issues of the applicability to different ethnic groups and were adjusted for race

**Abbreviations:** ACC=American College of Cardiology AHA=American Heart Association; AUC=area under the curve; AUROC=area under the receiver operating characteristic curve; CHD=coronary heart disease; CI=confidence interval; CV=cardiovascular; CVD=cardiovascular disease; CVRF=cardiovascular risk factors; ECG=electrocardiogram; DTNPV1=Deep Terminal Negativity of the P Wave in VI ; FRS=Framingham Risk Score; IDI=integrated discrimination improvement; IHD=ischemic heart disease; KQ=key question; LVH= left ventricular hypertrophy; MI=myocardial infarction; NA=not applicable; NHANES=National Health and Nutrition Examination Survey; NRI=net reclassification improvement; PCE=pooled cohort equation; QTc=corrected QT interval; SCD=sudden cardiac death.

**Appendix E Table 3. Number and Percentage of Exercise ECGs With Abnormalities in Studies Included for KQ 2**

First Author, Year	Sample Size	n (%) with Abnormalities	ECG Findings Evaluated	Source of Patients	Country
Aktas, 2004 <sup>59</sup>	3,554	371 (10.4%) had ischemic ST-segment changes 549 (15.4%) had abnormal based on functional capacity or HR recovery	Exercise ECG according to Bruce (or modified Bruce) protocol; ischemic ST abnormality using a 12-lead, symptom-limited exercise ECG	Consecutive participants presenting for an executive physical. Self-referred.	U.S.
Chang, 2015 <sup>45</sup>	988 (946 with follow up)	116/946 (12.3%) with follow up had ischemic exercise ECG; 75% with >8 METs; 22% 5-8 METs; <5 METs	Exercise ECG according to Bruce protocol; stress-induced ischemia identified via ECG during symptom-limited exercise treadmill testing; METs and DTS	People who had both CACS and stress SPECT for clinically indicated reasons at the Heart and Vascular Center	U.S.
Cournot, 2006 <sup>60</sup>	1,051	89 (8.5%) had positive exercise test	Symptom-limited exercise ECG	Consecutive asymptomatic people self-referred or referred by PCPs and cardiologists for evaluation of risk factors and routine screening	France
Cournot, 2009 <sup>56</sup>	2,709	163 (6.4%) had positive exercise test	A positive exercise test <sup>9</sup> during a symptom-limited exercise ECG with orthogonal and V <sub>1</sub> to V <sub>6</sub> leads	Apparently healthy asymptomatic people self-referred (20%) or referred by PCPs (27%) or other providers to a preventive cardiology unit	France
Erikssen, 2004 <sup>62</sup>	Assessment 1 (1972–1975): 2,014 Assessment 2 (1980–1982): 1,428	205 (10.2%) positive exercise test 238 (16.7%) positive exercise test	Resting ECG and a symptom-limited bicycle exercise ECG test	Apparently healthy males ages 40–60 years recruited from five governmental agencies who participated in a cardiovascular risk assessment	Norway

**Abbreviations:** CACS=coronary artery calcium score; DTS=Duke treadmill score; ECG=electrocardiogram; HR=hazard ratio; METs=metabolic equivalents; PCPs=primary care physicians; SPECT=Single Photon Emission Computed Tomography; U.S.=United States.

**Appendix E Table 4. Number and Percentage of Resting ECGs With Abnormalities in Studies Included for KQ 2**

First Author, Year	Sample Size	n (%) With Abnormalities	ECG Findings Evaluated	Source of Patients	Country
Auer et al, 2012 <sup>55</sup>	2,192	782 (36%) any abnormality 506 (23%) major 276 (13%) minor 1,410 (64%) no abnormality	Major <sup>a</sup> and minor <sup>b</sup> 12-lead ECG abnormalities classified using the Minnesota Coding System	Population-based cohort assessing body composition, long-term conditions, and incident mobility limitation in an older adult cohort (1997–1998)	U.S.
Badheka et al, 2013 <sup>54</sup>	6,025	3,291 (54.6%) had any ECG abnormalities	Major and Minor 12-lead ECG abnormalities classified using Minnesota Code <sup>d</sup>	Population-based survey to collect information on the health and nutrition of U.S. households (1988–1994)	U.S.
Badheka et al, 2013 <sup>53</sup>	7,928	1,919 (24.2%) ST-segment elevation (>8 mV) in aVR; 1,459 (18.4%) T-wave amplitude 0.1 mV or greater in aVR	12-lead ECG ST-T wave abnormalities in lead aVR classified by the Minnesota Code	Population-based survey to collect information on the health and nutrition of U.S. households (1988–1994)	U.S.
Denes, 2007 <sup>58</sup>	1,264 <sup>c</sup>	Data only reported for the larger WHI sample of 14,749: 910 (6.2%) major 4,095 (27.8%) minor 9,744 (66.1%) none	Major, <sup>e</sup> minor, <sup>f</sup> and incident <sup>g</sup> 12-lead ECG changes using the Novacode criteria	Population-based study on common causes of morbidity/ mortality among postmenopausal women (1993–1998)	U.S.
Folsom, 2003 <sup>63</sup>	14,054	NR	LVH using a 12-lead ECG and the Cornell score	Population-based study of 4 U.S. communities (1987–1989)	U.S.
Ishikawa, 2015 <sup>50</sup>	10,643	162 (1.5%) had prolonged QTc intervals	Prolonged corrected QT (QTc) intervals <sup>i</sup> and LVH <sup>j</sup> on 12-lead ECG	Government-sponsored screening to clarify the risk factors for cardio/cerebrovascular diseases in the general population (1992-1995)	Japan
Jorgensen, 2014 <sup>52</sup>	6,991 <sup>g</sup>	2,140 (30.6%) any ECG abnormalities 1,163 (16.6%) major 353 (5.0%) intermediate 624 (8.9%) minor	Major and Minor 12-lead ECG abnormalities classified using Minnesota Code; also reported outcomes for some single ECG changes <sup>m</sup>	The Copenhagen City Heart Study (1976–1978)	Denmark
Shah, 2016 <sup>57</sup>	9,969 (derivation: 3,640, validation: 6,329)	NR (reported mean and SD for the variables in the ECG Risk Score)	ECG Risk Score including frontal T axis, corrected QT interval, T axis, heart rate, age, sex, age*sex interaction term (selected from major <sup>o</sup> and minor <sup>p</sup> abnormalities)	Population-based survey to collect information on health and nutrition; NHANES I (1971–1975) and NHANES III (1988–1994)	U.S.
Tereshchenko, 2014 <sup>51</sup>	15,375 <sup>k</sup>	167 (1.1%) had the specific DTNPV1 abnormality	Resting 12-lead, P wave morphology (specifically DTNPV1 <sup>l</sup> )	Population-based study of 4 U.S. communities (1987–1989)	U.S.

**Abbreviations:** DTNPVI=Deep Terminal Negativity of the P Wave in VI; ECG=electrocardiogram; LVH=left ventricular hypertrophy; NHANES=National Health and Nutrition Examination Survey; NR=not reported; QTc=corrected QT interval; SD=standard deviation; U.S.=United States; WHI=Women’s Health Initiative.

**Appendix E Table 5. Results of Included Randomized, Controlled Trials Reporting Harms (KQ 3)**

First Author, Year Trial Name	G1 (N) G2 (N)	Mortality Due to Screening G1 N (%) G2 N (%) HR (95% CI)	Arrhythmia G1 N (%) G2 N (%) HR (95% CI)	CV Events Due to Screening G1 N (%) G2 N (%) HR (95% CI)	Injuries G1 N (%) G2 N (%) HR (95% CI)	Anxiety G1 N (%) G2 N (%) HR (95% CI)	Labeling G1 N (%) G2 N (%) HR (95% CI)	Harms of Subsequent Procedures/ Interventions G1 N (%) G2 N (%) HR (95% CI)
Lievre et al, 2011 <sup>47</sup> DYNAMIT	Screened (316) Not screened (315)	NR (all-cause mortality described in KQ 1)	NR	NR	NR	NR	NR	NR (number of revascularizations reported in KQ 1, but NR whether any resulted in harms; 18 vs. 21)
Turrini et al, 2015 <sup>48</sup> DADDY-D	Screened (262) Not screened (258)	NR (all-cause mortality described in KQ 1)	NR	NR	NR	NR	NR	20/262 (7.6%) patients who underwent ETT had a positive result. Of those, 17 underwent coronary angiography. It was positive for critical stenosis in 12/17 (70.6%), and all 12 underwent revascularization procedures (7 percutaneous and 5 surgery). One patient having percutaneous revascularization had an acute MI (nonfatal) 3 days after the procedure.

**Abbreviations:** CI=confidence interval; CV=cardiovascular; DADDY-D=Does coronary Atherosclerosis Deserve to be Diagnosed earlyY in Diabetic patients; DYNAMIT=Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; ETT=exercise treadmill test; G=group; HR=hazard ratio; KQ=key question; MI=myocardial infarction; N=sample size; NR=not reported.

## References

1. Chou R, High Value Care Task Force of the American College of P. Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians. *Ann Intern Med.* 2015 Mar 17;162(6):438-47. doi: 10.7326/M14-1225. PMID: 25775317.
2. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2014 Feb 4;63(4):380-406. doi: 10.1016/j.jacc.2013.11.009. PMID: 24355759.
3. American Academy of Family Physicians. Annual EKGs for Low-risk Patients. 2012. <http://www.aafp.org/patient-care/clinical-recommendations/all/cw-ekg.html>. Accessed 18 Nov, 2015.
4. Lim LS, Haq N, Mahmood S, et al. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. *Am J Prev Med.* 2011 Mar;40(3):381 e1-10. doi: 10.1016/j.amepre.2010.11.021. PMID: 21335273.
5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2010 Dec 14;56(25):e50-103. doi: 10.1016/j.jacc.2010.09.001. PMID: 21144964.
6. Lauer M, Froelicher ES, Williams M, et al. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. *Circulation.* 2005 Aug 2;112(5):771-6. doi: 10.1161/CIRCULATIONAHA.105.166543. PMID: 15998671.
7. National Heart, Lung, and Blood Institute. 2013 Report on the Assessment of Cardiovascular Risk: Full Work Group Report Supplement: National Heart, Lung, and Blood Institute; 2013.
8. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014 Jul 01;63(25 Pt B):2935-59. doi: 10.1016/j.jacc.2013.11.005. PMID: 24239921.
9. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation.* 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. PMID: 18212285.
10. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol.* 2013 Feb;29(2):151-67. doi: 10.1016/j.cjca.2012.11.032. PMID: 23351925.
11. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ.* 2008 Jun 28;336(7659):1475-82. doi: 10.1136/bmj.39609.449676.25. PMID: 18573856.
12. National Institute for Health and Care Excellence. Lipid Modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. United Kingdom: National Institute for Health and Care Excellence; 2014.
13. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. *Circulation.* 2008 Nov 25;118(22):2243-51, 4p following 51. doi: 10.1161/CIRCULATIONAHA.108.814251. PMID: 18997194.
14. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA.* 2007 Feb 14;297(6):611-9. doi: 10.1001/jama.297.6.611. PMID: 17299196.
15. Woodward M, Brindle P, Tunstall-Pedoe H, et al. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart.* 2007 Feb;93(2):172-6. doi: 10.1136/hrt.2006.108167. PMID: 17090561.
16. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2007.
17. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. *J Clin Epidemiol.* 2003 Sep;56(9):880-90. PMID: 14505774.

## References

18. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*. 2003 Jun;24(11):987-1003. PMID: 12788299.
19. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. PMID: 22555213.
20. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. *Circulation*. 2002 Jan 22;105(3):310-5. PMID: 11804985.
21. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002 Dec 17;106(25):3143-421. PMID: 12485966.
22. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. *Am Heart J*. 1991 Jan;121(1 Pt 2):293-8. PMID: 1985385.
23. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. *Circulation*. 1991 Jan;83(1):356-62. PMID: 1984895.
24. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998 May 12;97(18):1837-47. PMID: 9603539.
25. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. *Stroke*. 1991 Mar;22(3):312-8. PMID: 2003301.
26. U. S. Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. Rockville, MD: U. S. Preventive Services Task Force; November 2016. <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer>
27. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2 Suppl):e637S-68S. doi: 10.1378/chest.11-2306. PMID: 22315274.
28. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011 Feb;42(2):517-84. doi: 10.1161/STR.0b013e3181fcb238. PMID: 21127304.
29. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care*. 2010 Jun;33(6):1395-402. doi: 10.2337/dc10-0555. PMID: 20508233.
30. U. S. Preventive Services Task Force. Final Update Summary: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. Rockville, MD: U.S. Preventive Services Task Force; November 2016. <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/statin-use-in-adults-preventive-medication1>
31. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. PMID: 24222016.
32. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. United Kingdom: National Institute for Health and Care Excellence; 2016. <https://www.nice.org.uk/Guidance/CG181>. Accessed May 30, 2017.
33. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. *Circulation*. 2011 Mar 22;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. PMID: 21325087.
34. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. *Circulation*. 2017 Apr 11;135(15):e867-e84. doi: 10.1161/CIR.0000000000000482. PMID: 28289069.



## References

35. National Institute for Health and Care Excellence. Do Not Do Recommendation. United Kingdom: National Institute for Health and Care Excellence; 2017. <https://www.nice.org.uk/donotdo/do-not-offer-omega-3-fatty-acid-compounds-for-the-prevention-of-cvd-to-any-of-the-following-people-who-are-being-treated-for-primary-prevention-people-who-are-being-treated-for-secondary-prevention-people-with-ckd-people-with-type-1-diabetes-people-with-t>. Accessed May 31, 2017.
36. George MG, Tong X, Sonnenfeld N, et al. Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008. *MMWR Suppl.* 2012 Jun 15;61(2):11-8. PMID: 22695458.
37. Mainous AG, Tanner RJ, Shorr RI, et al. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. *J Am Heart Assoc.* 2014 Jul 14;3(4)doi: 10.1161/JAHA.114.000989. PMID: 25023071.
38. Malayala SV, Raza A. Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men. *Int J Clin Pract.* 2016 Nov;70(11):898-906. doi: 10.1111/ijcp.12869. PMID: 27619938.
39. Fiscella K, Winters PC, Mendoza M, et al. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease? *J Gen Intern Med.* 2015 Feb;30(2):155-60. doi: 10.1007/s11606-014-2985-8. PMID: 25092016.
40. Kumar A, Fonarow GC, Eagle KA, et al. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. *Crit Pathw Cardiol.* 2009 Sep;8(3):104-11. doi: 10.1097/HPC.0b013e3181b8395d. PMID: 19726929.
41. Noto TJ, Jr., Johnson LW, Krone R, et al. Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). *Cathet Cardiovasc Diagn.* 1991 Oct;24(2):75-83. PMID: 1742788.
42. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med.* 2010 Mar 11;362(10):886-95. doi: 10.1056/NEJMoa0907272. PMID: 20220183.
43. Schulman-Marcus J, Feldman DN, Rao SV, et al. Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery: A Report From the National Cardiovascular Data Registry CathPCI Registry. *JAMA Intern Med.* 2016 May 01;176(5):611-8. doi: 10.1001/jamainternmed.2016.0259. PMID: 27018942.
44. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *New England Journal of Medicine.* 2004 Dec 30;351(27):2795-804. doi: DOI 10.1056/NEJMoa041905. PMID: WOS:000226004300004.
45. Chang SM, Nabi F, Xu J, et al. Value of CACS compared with ETT and myocardial perfusion imaging for predicting long-term cardiac outcome in asymptomatic and symptomatic patients at low risk for coronary disease: clinical implications in a multimodality imaging world. *JACC Cardiovasc Imaging.* 2015 Feb;8(2):134-44. doi: 10.1016/j.jcmg.2014.11.008. PMID: 25677886.
46. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001 Apr;20(3 Suppl):21-35. PMID: 11306229.
47. Lievre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. *Trials.* 2011;12:23. doi: 10.1186/1745-6215-12-23. PMID: 21269454.
48. Turrini F, Scarlini S, Mannucci C, et al. Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease. *Eur J Intern Med.* 2015 Jul;26(6):407-13. doi: 10.1016/j.ejim.2015.05.006. PMID: 26058988.
49. Turrini F, Messori R, Giovanardi P, et al. Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacological/behavioural treatment of traditional risk factors. DADDY-D Trial (Does coronary Atherosclerosis Deserve to be Diagnosed and treated early in Diabetics?). *Trials*; 2009. p. 119.
50. Ishikawa J, Ishikawa S, Kario K. Prolonged corrected QT interval is predictive of future stroke events even in subjects without ECG-diagnosed left ventricular hypertrophy. *Hypertension.* 2015 Mar;65(3):554-60. doi: 10.1161/hypertensionaha.114.04722. PMID: 25534703.
51. Tereshchenko LG, Henriksen CA, Sotoodehnia N, et al. Electrocardiographic deep terminal negativity of the P wave in V(1) and risk of sudden cardiac death: the Atherosclerosis Risk in Communities (ARIC) study. *J Am Heart Assoc.* 2014 Dec;3(6):e001387. doi: 10.1161/jaha.114.001387. PMID: 25416036.

## References

52. Jorgensen PG, Jensen JS, Marott JL, et al. Electrocardiographic changes improve risk prediction in asymptomatic persons age 65 years or above without cardiovascular disease. *J Am Coll Cardiol*. 2014 Sep 2;64(9):898-906. doi: 10.1016/j.jacc.2014.05.050. PMID: 25169175.
53. Badheka AO, Patel NJ, Grover PM, et al. ST-T wave abnormality in lead aVR and reclassification of cardiovascular risk (from the National Health and Nutrition Examination Survey-III). *Am J Cardiol*. 2013 Sep 15;112(6):805-10. doi: 10.1016/j.amjcard.2013.04.058. PMID: 23764245.
54. Badheka AO, Patel N, Tuliani TA, et al. Electrocardiographic abnormalities and reclassification of cardiovascular risk: insights from NHANES-III. *Am J Med*. 2013 Apr;126(4):319-26.e2. doi: 10.1016/j.amjmed.2012.10.020. PMID: 23415052.
55. Auer R, Bauer DC, Marques-Vidal P, et al. Association of major and minor ECG abnormalities with coronary heart disease events. *JAMA*. 2012 Apr 11;307(14):1497-505. doi: 10.1001/jama.2012.434. PMID: 22496264.
56. Cournot M, Taraszkiwicz D, Cambou JP, et al. Additional prognostic value of physical examination, exercise testing, and arterial ultrasonography for coronary risk assessment in primary prevention. *Am Heart J*. 2009 Nov;158(5):845-51. doi: 10.1016/j.ahj.2009.08.017. PMID: 19853707.
57. Shah AJ, Vaccarino V, Janssens AC, et al. An electrocardiogram-based risk equation for incident cardiovascular disease from the National Health and Nutrition Examination Survey. *JAMA Cardiol*. 2016 Aug 3;doi: 10.1001/jamacardio.2016.2173. PMID: 27487404.
58. Denes P, Larsen JC, Lloyd-Jones DM, et al. Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. *JAMA*. 2007 Mar 7;297(9):978-85. doi: 10.1001/jama.297.9.978. PMID: 17341712.
59. Aktas MK, Ozduran V, Pothier CE, et al. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. *JAMA*. 2004 Sep 22;292(12):1462-8. doi: 10.1001/jama.292.12.1462. PMID: 15383517.
60. Cournot M, Taraszkiwicz D, Galinier M, et al. Is exercise testing useful to improve the prediction of coronary events in asymptomatic subjects? *Eur J Cardiovasc Prev Rehabil*. 2006 Feb;13(1):37-44. PMID: 16449862.
61. Strom Moller C, Zethelius B, Sundstrom J, et al. Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up. *Heart*. 2007 Sep;93(9):1104-10. doi: 10.1136/hrt.2006.109116. PMID: 17483125.
62. Erikssen G, Bodegard J, Bjornholt JV, et al. Exercise testing of healthy men in a new perspective: from diagnosis to prognosis. *Eur Heart J*. 2004 Jun;25(11):978-86. doi: 10.1016/j.ehj.2004.04.009. PMID: 15172470.
63. Folsom AR, Chambless LE, Duncan BB, et al. Prediction of coronary heart disease in middle-aged adults with diabetes. *Diabetes Care*. 2003 Oct;26(10):2777-84. PMID: 14514579.